{"PMC7222138": [["IntroductionVentilator-associated pneumonia (VAP) is one of the most common infections in the intensive care unit (ICU) [1, 2].", [["Ventilator-associated pneumonia", "DISEASE", 12, 43], ["VAP", "DISEASE", 45, 48], ["infections", "DISEASE", 76, 86], ["pneumonia", "PROBLEM", 34, 43], ["VAP", "PROBLEM", 45, 48], ["pneumonia", "OBSERVATION", 34, 43], ["most common", "OBSERVATION_MODIFIER", 64, 75], ["infections", "OBSERVATION", 76, 86]]], ["The disease represents a diagnostic and management dilemma to clinicians [3] and is associated with significant mortality in patients [4].", [["patients", "ORGANISM", 125, 133], ["patients", "SPECIES", 125, 133], ["The disease", "PROBLEM", 0, 11], ["disease", "OBSERVATION", 4, 11]]], ["Acinetobacter strains, once considered a low-category pathogen, have become an important etiology of VAP in ICUs worldwide [5, 6].", [["VAP", "DISEASE", 101, 104], ["Acinetobacter strains", "ORGANISM", 0, 21], ["Acinetobacter strains", "PROBLEM", 0, 21], ["a low-category pathogen", "PROBLEM", 39, 62], ["VAP", "PROBLEM", 101, 104], ["VAP", "OBSERVATION", 101, 104]]], ["Patients with serious comorbidities that need mechanical ventilation can become infected with antibiotic-resistant Acinetobacter spp., representing a therapeutic challenge [7, 8].", [["Acinetobacter spp.", "DISEASE", 115, 133], ["Patients", "ORGANISM", 0, 8], ["Acinetobacter spp.", "ORGANISM", 115, 133], ["Patients", "SPECIES", 0, 8], ["Acinetobacter spp.", "SPECIES", 115, 133], ["Acinetobacter spp.", "SPECIES", 115, 133], ["serious comorbidities", "PROBLEM", 14, 35], ["mechanical ventilation", "TREATMENT", 46, 68], ["antibiotic", "TREATMENT", 94, 104], ["resistant Acinetobacter spp.", "PROBLEM", 105, 133], ["a therapeutic challenge", "TREATMENT", 148, 171]]], ["There is a paucity of information on VAP due to Acinetobacter spp.", [["VAP", "DISEASE", 37, 40], ["Acinetobacter spp", "DISEASE", 48, 65], ["Acinetobacter spp", "ORGANISM", 48, 65], ["VAP", "PROBLEM", 37, 40], ["Acinetobacter spp", "PROBLEM", 48, 65]]], ["Thus, we performed this prospective-observational multicenter study, and described the course, prognostic factors, and outcomes of VAP due to Acinetobacter spp.Data collection and procedures ::: MethodsThe same questionnaire was used throughout all participant centers and the data input was made available to centers through the internet.", [["VAP", "DISEASE", 131, 134], ["Acinetobacter spp", "DISEASE", 142, 159], ["Acinetobacter spp", "ORGANISM", 142, 159], ["observational multicenter study", "TEST", 36, 67], ["VAP", "PROBLEM", 131, 134], ["Acinetobacter spp", "PROBLEM", 142, 159], ["Methods", "TREATMENT", 195, 202]]], ["The patients enrolled in the study were regularly evaluated by the consulting infectious disease physician at the time of pneumonia suspicion/diagnosis, when antibiotic susceptibility testing (AST) results were available, at 72 h, at the 7th day, and finally at the 28th day of follow-up.", [["infectious disease", "DISEASE", 78, 96], ["pneumonia", "DISEASE", 122, 131], ["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["the study", "TEST", 25, 34], ["pneumonia", "PROBLEM", 122, 131], ["antibiotic susceptibility testing", "TEST", 158, 191], ["AST", "TEST", 193, 196], ["pneumonia", "OBSERVATION", 122, 131]]], ["All antibiotics were prescribed by an infectious disease physician.", [["All antibiotics", "TREATMENT", 0, 15]]], ["The decision to start or modify antimicrobial chemotherapy was made by infectious disease clinicians.", [["infectious disease", "DISEASE", 71, 89], ["antimicrobial chemotherapy", "TREATMENT", 32, 58]]], ["There was no policy for clinicians to choose antimicrobials in the study protocol.Inclusion criteria ::: Methods", [["antimicrobials", "TREATMENT", 45, 59], ["the study protocol", "TEST", 63, 81], ["Methods", "TREATMENT", 105, 112], ["no", "UNCERTAINTY", 10, 12]]]], "6450de33d673aaaeef75fc898f74ca3e9caec89d": [["O n September 28, 2014, a 42-year-old Liberian man was admitted to a Texas hospital and quickly placed in isolation with a presumptive diagnosis of Ebola virus disease (EVD), a diagnosis that was subsequently confirmed.", [["Ebola virus disease", "DISEASE", 148, 167], ["EVD", "DISEASE", 169, 172], ["man", "ORGANISM", 47, 50], ["Ebola virus", "ORGANISM", 148, 159], ["man", "SPECIES", 47, 50], ["Ebola virus", "SPECIES", 148, 159], ["Ebola virus", "SPECIES", 148, 159], ["Ebola virus disease", "PROBLEM", 148, 167], ["Ebola virus disease", "OBSERVATION", 148, 167]]], ["When caring for him, staff were advised to use personal protective equipment as recommended by the Centers for Disease Control and Prevention.", [["personal protective equipment", "TREATMENT", 47, 76], ["Disease Control", "TREATMENT", 111, 126]]], ["Unfortunately, the patient died on October 8, and 2 nurses who had cared for him contracted EVD (1).", [["EVD", "DISEASE", 92, 95], ["patient", "ORGANISM", 19, 26], ["patient", "SPECIES", 19, 26]]], ["This failure of infection control contributed to the public spread of panic, served as a wake-up call to the public health community, and helped convince the Centers for Disease Control and Prevention that EVD should be treated only in specialized hospitals with highly trained personnel (2) .", [["infection", "DISEASE", 16, 25], ["panic", "DISEASE", 70, 75], ["This failure of infection control", "PROBLEM", 0, 33], ["panic", "PROBLEM", 70, 75], ["Disease Control", "TREATMENT", 170, 185], ["EVD", "TREATMENT", 206, 209], ["infection", "OBSERVATION", 16, 25]]]], "0a01f5cf1c5cdc2711bcef74315dc54a6e143df0": [["IntroductionMorbidity and mortality in human immunodeficiency virus 1 (HIV)-infected individuals have significantly decreased due to the effective long-term combination antiretroviral therapy (cART) [1] .", [["IntroductionMorbidity", "DISEASE", 0, 21], ["human immunodeficiency virus 1 (HIV)-infected", "DISEASE", 39, 84], ["human immunodeficiency virus 1", "ORGANISM", 39, 69], ["HIV", "ORGANISM", 71, 74], ["individuals", "ORGANISM", 85, 96], ["human immunodeficiency virus 1 (HIV", "SPECIES", 39, 74], ["human immunodeficiency virus 1", "SPECIES", 39, 69], ["HIV", "SPECIES", 71, 74], ["IntroductionMorbidity", "TREATMENT", 0, 21], ["human immunodeficiency virus", "PROBLEM", 39, 67], ["HIV", "PROBLEM", 71, 74], ["infected individuals", "PROBLEM", 76, 96], ["the effective long-term combination antiretroviral therapy", "TREATMENT", 133, 191], ["decreased", "OBSERVATION_MODIFIER", 116, 125]]], ["New complications have however emerged as key issues within this population.", [["New complications", "PROBLEM", 0, 17], ["complications", "OBSERVATION", 4, 17]]], ["HIV/ Hepatitis C virus (HCV) co-infection, for instance, affects more than 30% of HIVinfected patients in developed countries.", [["HIV/ Hepatitis C virus (HCV) co-infection", "DISEASE", 0, 41], ["HIV/", "ORGANISM", 0, 4], ["Hepatitis C virus", "ORGANISM", 5, 22], ["HCV", "ORGANISM", 24, 27], ["patients", "ORGANISM", 94, 102], ["HIV", "SPECIES", 0, 3], ["Hepatitis C virus", "SPECIES", 5, 22], ["patients", "SPECIES", 94, 102], ["HIV", "SPECIES", 0, 3], ["Hepatitis C virus", "SPECIES", 5, 22], ["HCV", "SPECIES", 24, 27], ["HIV", "PROBLEM", 0, 3], ["Hepatitis C virus (HCV) co-infection", "PROBLEM", 5, 41], ["Hepatitis", "OBSERVATION", 5, 14]]], ["Although the impact of HCV on HIV disease progression is minimal, it is known that HIV accelerates HCV-related liver disease [2, 3] .", [["liver", "ANATOMY", 111, 116], ["HIV disease", "DISEASE", 30, 41], ["liver disease", "DISEASE", 111, 124], ["HCV", "ORGANISM", 23, 26], ["HIV", "ORGANISM", 30, 33], ["HIV", "ORGANISM", 83, 86], ["HCV", "ORGANISM", 99, 102], ["liver", "ORGAN", 111, 116], ["HIV", "SPECIES", 30, 33], ["HIV", "SPECIES", 83, 86], ["HCV", "SPECIES", 23, 26], ["HIV", "SPECIES", 30, 33], ["HIV", "SPECIES", 83, 86], ["HCV", "SPECIES", 99, 102], ["HCV", "PROBLEM", 23, 26], ["HIV disease progression", "PROBLEM", 30, 53], ["HIV accelerates HCV", "PROBLEM", 83, 102], ["liver disease", "PROBLEM", 111, 124], ["HCV", "OBSERVATION", 23, 26], ["minimal", "OBSERVATION_MODIFIER", 57, 64], ["HCV", "OBSERVATION", 99, 102], ["liver", "ANATOMY", 111, 116], ["disease", "OBSERVATION", 117, 124]]], ["The effects of HIV on HCV infection include higher rate of viral persistence and increased HCV viral loads (VL).", [["HCV infection", "DISEASE", 22, 35], ["HIV", "ORGANISM", 15, 18], ["HCV", "ORGANISM", 22, 25], ["HIV", "SPECIES", 15, 18], ["HIV", "SPECIES", 15, 18], ["HCV", "SPECIES", 22, 25], ["HCV", "SPECIES", 91, 94], ["HIV", "PROBLEM", 15, 18], ["HCV infection", "PROBLEM", 22, 35], ["viral persistence", "PROBLEM", 59, 76], ["increased HCV viral loads", "PROBLEM", 81, 106], ["HCV", "OBSERVATION_MODIFIER", 22, 25], ["infection", "OBSERVATION", 26, 35], ["viral persistence", "OBSERVATION", 59, 76], ["increased", "OBSERVATION_MODIFIER", 81, 90], ["HCV viral loads", "OBSERVATION", 91, 106]]], ["Studies have shown that HCV-associated liver diseases such as fibrosis, cirrhosis and end stage liver disease (ESLD) are accelerated in HIV-infected individuals [4] [5] [6] [7] .", [["liver", "ANATOMY", 39, 44], ["liver", "ANATOMY", 96, 101], ["liver diseases", "DISEASE", 39, 53], ["fibrosis", "DISEASE", 62, 70], ["cirrhosis", "DISEASE", 72, 81], ["end stage liver disease", "DISEASE", 86, 109], ["ESLD", "DISEASE", 111, 115], ["HIV-infected", "DISEASE", 136, 148], ["HCV", "ORGANISM", 24, 27], ["liver", "ORGAN", 39, 44], ["liver", "ORGAN", 96, 101], ["HIV", "ORGANISM", 136, 139], ["[4] [5] [6] [7]", "SIMPLE_CHEMICAL", 161, 176], ["HIV", "SPECIES", 136, 139], ["HCV", "SPECIES", 24, 27], ["HIV", "SPECIES", 136, 139], ["Studies", "TEST", 0, 7], ["HCV", "PROBLEM", 24, 27], ["liver diseases", "PROBLEM", 39, 53], ["fibrosis", "PROBLEM", 62, 70], ["cirrhosis", "PROBLEM", 72, 81], ["end stage liver disease", "PROBLEM", 86, 109], ["ESLD)", "PROBLEM", 111, 116], ["infected individuals", "PROBLEM", 140, 160], ["HCV", "OBSERVATION", 24, 27], ["liver", "ANATOMY", 39, 44], ["diseases", "OBSERVATION", 45, 53], ["fibrosis", "OBSERVATION", 62, 70], ["cirrhosis", "OBSERVATION", 72, 81], ["end stage", "OBSERVATION_MODIFIER", 86, 95], ["liver", "ANATOMY", 96, 101], ["disease", "OBSERVATION", 102, 109]]], ["The mechanisms underlying rapid liver disease progression in HIV/HCV co-infected patients are likely multifactorial and are presently not completely understood.IntroductionHepatic fibrosis results from the deposition of scar tissue and may lead to cirrhosis.", [["liver", "ANATOMY", 32, 37], ["Hepatic", "ANATOMY", 172, 179], ["scar tissue", "ANATOMY", 220, 231], ["liver disease", "DISEASE", 32, 45], ["HIV/HCV co-infected", "DISEASE", 61, 80], ["Hepatic fibrosis", "DISEASE", 172, 188], ["cirrhosis", "DISEASE", 248, 257], ["liver", "ORGAN", 32, 37], ["HIV/HCV", "ORGANISM", 61, 68], ["patients", "ORGANISM", 81, 89], ["Hepatic", "ORGAN", 172, 179], ["scar tissue", "TISSUE", 220, 231], ["HIV", "SPECIES", 61, 64], ["patients", "SPECIES", 81, 89], ["HIV", "SPECIES", 61, 64], ["HCV", "SPECIES", 65, 68], ["rapid liver disease progression", "PROBLEM", 26, 57], ["HIV/HCV co-infected patients", "PROBLEM", 61, 89], ["IntroductionHepatic fibrosis", "PROBLEM", 160, 188], ["scar tissue", "PROBLEM", 220, 231], ["cirrhosis", "PROBLEM", 248, 257], ["rapid", "OBSERVATION_MODIFIER", 26, 31], ["liver", "ANATOMY", 32, 37], ["disease", "OBSERVATION", 38, 45], ["likely", "UNCERTAINTY", 94, 100], ["Hepatic", "ANATOMY", 172, 179], ["fibrosis", "OBSERVATION", 180, 188], ["deposition", "OBSERVATION_MODIFIER", 206, 216], ["scar tissue", "OBSERVATION", 220, 231], ["may lead to", "UNCERTAINTY", 236, 247], ["cirrhosis", "OBSERVATION", 248, 257]]], ["It is characterized by distortion of the liver architecture and the major determinant of morbidity and mortality in the patients with liver disease [8] .", [["liver", "ANATOMY", 41, 46], ["liver", "ANATOMY", 134, 139], ["distortion of the liver architecture", "DISEASE", 23, 59], ["liver disease", "DISEASE", 134, 147], ["liver", "ORGAN", 41, 46], ["patients", "ORGANISM", 120, 128], ["liver", "ORGAN", 134, 139], ["patients", "SPECIES", 120, 128], ["distortion of the liver architecture", "PROBLEM", 23, 59], ["liver disease", "PROBLEM", 134, 147], ["distortion", "OBSERVATION", 23, 33], ["liver", "ANATOMY", 41, 46], ["morbidity", "OBSERVATION", 89, 98], ["liver", "ANATOMY", 134, 139], ["disease", "OBSERVATION", 140, 147]]], ["In many countries the degree of hepatic fibrosis is the principal determinant to access highly efficacious HCV treatment, known as direct acting antivirals [9] .", [["hepatic", "ANATOMY", 32, 39], ["hepatic fibrosis", "DISEASE", 32, 48], ["hepatic", "ORGAN", 32, 39], ["HCV", "SPECIES", 107, 110], ["hepatic fibrosis", "PROBLEM", 32, 48], ["HCV treatment", "TREATMENT", 107, 120], ["direct acting antivirals", "TREATMENT", 131, 155], ["hepatic", "ANATOMY", 32, 39], ["fibrosis", "OBSERVATION", 40, 48]]], ["Liver biopsy remains the gold standard for staging HCV-associated liver disease [10, 11] .", [["Liver", "ANATOMY", 0, 5], ["liver", "ANATOMY", 66, 71], ["liver disease", "DISEASE", 66, 79], ["Liver", "ORGAN", 0, 5], ["HCV", "ORGANISM", 51, 54], ["liver", "ORGAN", 66, 71], ["HCV", "SPECIES", 51, 54], ["Liver biopsy", "TEST", 0, 12], ["staging HCV", "TEST", 43, 54], ["liver disease", "PROBLEM", 66, 79], ["biopsy", "OBSERVATION", 6, 12], ["liver", "ANATOMY", 66, 71], ["disease", "OBSERVATION", 72, 79]]], ["However, liver biopsy can result in serious complications, is costly and not feasible to repeat serially, and is subject to sampling error [12] .", [["liver", "ANATOMY", 9, 14], ["liver", "ORGAN", 9, 14], ["liver biopsy", "TEST", 9, 21], ["serious complications", "PROBLEM", 36, 57], ["liver", "ANATOMY", 9, 14], ["biopsy", "OBSERVATION", 15, 21]]], ["These problems have prompted a search for non-invasive methods for liver fibrosis staging such as Fibroscan, a transient elastography technology which is based on the assessment of liver stiffness [13] .", [["liver", "ANATOMY", 67, 72], ["liver", "ANATOMY", 181, 186], ["fibrosis", "DISEASE", 73, 81], ["liver stiffness", "DISEASE", 181, 196], ["liver", "ORGAN", 67, 72], ["liver", "ORGAN", 181, 186], ["non-invasive methods", "TEST", 42, 62], ["liver fibrosis staging", "PROBLEM", 67, 89], ["Fibroscan", "TEST", 98, 107], ["a transient elastography technology", "TEST", 109, 144], ["the assessment", "TEST", 163, 177], ["liver stiffness", "PROBLEM", 181, 196], ["liver", "ANATOMY", 67, 72], ["fibrosis", "OBSERVATION", 73, 81], ["liver", "ANATOMY", 181, 186]]], ["Several factors can limit this examination such as morbid obesity, ascites, and small intercostal spaces and better result are shown in patients with severe fibrosis [8, 14] .", [["ascites", "ANATOMY", 67, 74], ["small intercostal spaces", "ANATOMY", 80, 104], ["obesity", "DISEASE", 58, 65], ["ascites", "DISEASE", 67, 74], ["fibrosis", "DISEASE", 157, 165], ["intercostal", "MULTI-TISSUE_STRUCTURE", 86, 97], ["patients", "ORGANISM", 136, 144], ["patients", "SPECIES", 136, 144], ["this examination", "TEST", 26, 42], ["morbid obesity", "PROBLEM", 51, 65], ["ascites", "PROBLEM", 67, 74], ["small intercostal spaces", "PROBLEM", 80, 104], ["severe fibrosis", "PROBLEM", 150, 165], ["ascites", "OBSERVATION", 67, 74], ["small", "OBSERVATION_MODIFIER", 80, 85], ["intercostal", "ANATOMY", 86, 97], ["severe", "OBSERVATION_MODIFIER", 150, 156], ["fibrosis", "OBSERVATION", 157, 165]]], ["Safe, reliable and simple alternatives are needed to diagnose and monitor fibrosis caused by HCV infection.IntroductionProteomic fingerprinting is a diagnostic concept based on the idea that disease states are often associated with distinctive configurations of circulating proteins.", [["fibrosis", "DISEASE", 74, 82], ["HCV infection", "DISEASE", 93, 106], ["HCV", "ORGANISM", 93, 96], ["circulating proteins", "PROTEIN", 262, 282], ["HCV", "SPECIES", 93, 96], ["fibrosis", "PROBLEM", 74, 82], ["HCV infection", "PROBLEM", 93, 106], ["circulating proteins", "PROBLEM", 262, 282], ["fibrosis", "OBSERVATION", 74, 82], ["HCV", "OBSERVATION_MODIFIER", 93, 96], ["infection", "OBSERVATION", 97, 106], ["disease", "OBSERVATION", 191, 198], ["circulating proteins", "OBSERVATION", 262, 282]]], ["Analysis of combinations of several biomarkers offers the possibility of enhanced diagnostic accuracy compared to individual biomarkers that have limited diagnostic sensitivities and specificities.", [["several biomarkers", "TEST", 28, 46], ["enhanced diagnostic accuracy", "PROBLEM", 73, 101], ["individual biomarkers", "TEST", 114, 135]]], ["Surfaceenhanced laser desorption ionization-time-of-flight mass spectrometry (SELDI-TOF MS) offers high-throughput protein profiling of native biological specimens.", [["specimens", "ANATOMY", 154, 163], ["Surfaceenhanced laser desorption ionization", "TEST", 0, 43], ["flight mass spectrometry", "TEST", 52, 76], ["SELDI", "TEST", 78, 83]]], ["This platform has been successfully used as a discovery tool for biomarkers associated with inflammation [15] , cancers [16] [17] [18] and human infectious diseases [19] [20] [21] [22] .", [["cancers", "ANATOMY", 112, 119], ["inflammation", "DISEASE", 92, 104], ["cancers", "DISEASE", 112, 119], ["[16] [17] [18]", "CHEMICAL", 120, 134], ["infectious diseases", "DISEASE", 145, 164], ["cancers [16] [17] [18]", "SIMPLE_CHEMICAL", 112, 134], ["human", "ORGANISM", 139, 144], ["[19] [20] [21] [22]", "SIMPLE_CHEMICAL", 165, 184], ["human", "SPECIES", 139, 144], ["human", "SPECIES", 139, 144], ["inflammation", "PROBLEM", 92, 104], ["cancers", "PROBLEM", 112, 119], ["human infectious diseases", "PROBLEM", 139, 164]]], ["SELDI-TOF MS serum profiling has accurately distinguished patients with different stages of liver disease, specifically those associated with HCV infections ranging from chronic hepatitis to HCV-associated hepatocellular carcinoma (HCC) [23] .IntroductionTo this end, we compared serum proteome profiles at different stages of fibrosis in HIV/ HCV co-and HCV mono-infected patients using SELDI-TOF MS. Our aim was to identify a proteomic fingerprint that could be used to develop a diagnostic test to detect and stage liver fibrosis in HIV/HCV co-infected individuals.", [["serum", "ANATOMY", 13, 18], ["liver", "ANATOMY", 92, 97], ["hepatocellular carcinoma", "ANATOMY", 206, 230], ["HCC", "ANATOMY", 232, 235], ["serum", "ANATOMY", 280, 285], ["liver", "ANATOMY", 518, 523], ["liver disease", "DISEASE", 92, 105], ["HCV infections", "DISEASE", 142, 156], ["chronic hepatitis", "DISEASE", 170, 187], ["HCV-associated hepatocellular carcinoma", "DISEASE", 191, 230], ["HCC", "DISEASE", 232, 235], ["fibrosis", "DISEASE", 327, 335], ["HIV/ HCV co-and HCV mono-infected", "DISEASE", 339, 372], ["liver fibrosis", "DISEASE", 518, 532], ["HIV/HCV co-infected", "DISEASE", 536, 555], ["serum", "ORGANISM_SUBSTANCE", 13, 18], ["patients", "ORGANISM", 58, 66], ["liver", "ORGAN", 92, 97], ["HCV", "ORGANISM", 142, 145], ["HCV", "ORGANISM", 191, 194], ["hepatocellular carcinoma", "CANCER", 206, 230], ["HCC", "CANCER", 232, 235], ["serum", "ORGANISM_SUBSTANCE", 280, 285], ["HIV/ HCV co", "ORGANISM", 339, 350], ["HCV mono", "ORGANISM", 355, 363], ["patients", "ORGANISM", 373, 381], ["liver", "ORGAN", 518, 523], ["HIV/HCV", "ORGANISM", 536, 543], ["patients", "SPECIES", 58, 66], ["HIV", "SPECIES", 339, 342], ["patients", "SPECIES", 373, 381], ["HIV", "SPECIES", 536, 539], ["HCV", "SPECIES", 142, 145], ["HCV", "SPECIES", 191, 194], ["HIV", "SPECIES", 339, 342], ["HCV", "SPECIES", 344, 347], ["HCV", "SPECIES", 355, 358], ["HIV", "SPECIES", 536, 539], ["HCV", "SPECIES", 540, 543], ["SELDI", "TEST", 0, 5], ["serum profiling", "TEST", 13, 28], ["liver disease", "PROBLEM", 92, 105], ["HCV infections", "PROBLEM", 142, 156], ["chronic hepatitis", "PROBLEM", 170, 187], ["HCV", "PROBLEM", 191, 194], ["hepatocellular carcinoma", "PROBLEM", 206, 230], ["serum proteome profiles", "TEST", 280, 303], ["fibrosis", "PROBLEM", 327, 335], ["HIV", "PROBLEM", 339, 342], ["HCV co", "PROBLEM", 344, 350], ["HCV mono", "PROBLEM", 355, 363], ["a proteomic fingerprint", "TEST", 426, 449], ["a diagnostic test", "TEST", 480, 497], ["stage liver fibrosis", "PROBLEM", 512, 532], ["HIV", "PROBLEM", 536, 539], ["HCV co-infected individuals", "PROBLEM", 540, 567], ["liver", "ANATOMY", 92, 97], ["disease", "OBSERVATION", 98, 105], ["chronic", "OBSERVATION_MODIFIER", 170, 177], ["hepatitis", "OBSERVATION", 178, 187], ["HCV", "OBSERVATION", 191, 194], ["hepatocellular", "ANATOMY", 206, 220], ["carcinoma", "OBSERVATION", 221, 230], ["fibrosis", "OBSERVATION", 327, 335], ["liver", "ANATOMY", 518, 523], ["fibrosis", "OBSERVATION", 524, 532]]], ["We report a SELDI-TOF MS-based alternative assay that can achieve high sensitivity and specificity for the detection of fibrosis in the patients with HIV/HCN co-infection.Study design, setting and populationThe Canadian Co-infection Cohort Study (CCC, CIHR Canadian HIV Trials Network (CTN222)) is a prospective multicentre study recruiting HIV/HCV co-infected patients from 18 centres across Canada since 2003 with approval by participating research ethics boards described in details elsewhere [24] .", [["fibrosis", "DISEASE", 120, 128], ["HIV/HCN co-infection", "DISEASE", 150, 170], ["HIV/HCV co-infected", "DISEASE", 341, 360], ["patients", "ORGANISM", 136, 144], ["HIV/HCN", "ORGANISM", 150, 157], ["HIV", "ORGANISM", 341, 344], ["HCV", "ORGANISM", 345, 348], ["patients", "ORGANISM", 361, 369], ["patients", "SPECIES", 136, 144], ["HIV", "SPECIES", 150, 153], ["patients", "SPECIES", 361, 369], ["HIV", "SPECIES", 150, 153], ["HIV", "SPECIES", 341, 344], ["HCV", "SPECIES", 345, 348], ["fibrosis", "PROBLEM", 120, 128], ["HIV/HCN co-infection", "PROBLEM", 150, 170], ["Study design", "TEST", 171, 183], ["a prospective multicentre study", "TEST", 298, 329], ["fibrosis", "OBSERVATION", 120, 128], ["co-infection", "OBSERVATION", 158, 170]]], ["As of October 2011, 1090 patients were enrolled.", [["patients", "ORGANISM", 25, 33], ["patients", "SPECIES", 25, 33]]], ["For this analysis participants were selected based on the availability of a serum specimen within one year of liver biopsy.", [["serum specimen", "ANATOMY", 76, 90], ["liver", "ANATOMY", 110, 115], ["participants", "ORGANISM", 18, 30], ["serum specimen", "ORGANISM_SUBSTANCE", 76, 90], ["liver biopsy", "MULTI-TISSUE_STRUCTURE", 110, 122], ["participants", "SPECIES", 18, 30], ["this analysis", "TEST", 4, 17], ["a serum specimen", "TEST", 74, 90], ["liver biopsy", "TEST", 110, 122], ["liver", "ANATOMY", 110, 115], ["biopsy", "OBSERVATION", 116, 122]]], ["HCV mono-infected patients undergoing liver biopsies were prospectively recruited from 3 sites participating in the CCC and serum samples were obtained within a year of liver biopsy.", [["liver biopsies", "ANATOMY", 38, 52], ["serum samples", "ANATOMY", 124, 137], ["liver", "ANATOMY", 169, 174], ["HCV", "ORGANISM", 0, 3], ["patients", "ORGANISM", 18, 26], ["liver biopsies", "CANCER", 38, 52], ["serum samples", "ORGANISM_SUBSTANCE", 124, 137], ["liver biopsy", "MULTI-TISSUE_STRUCTURE", 169, 181], ["patients", "SPECIES", 18, 26], ["HCV", "SPECIES", 0, 3], ["liver biopsies", "TEST", 38, 52], ["the CCC and serum samples", "TEST", 112, 137], ["liver biopsy", "TEST", 169, 181], ["liver", "ANATOMY", 38, 43], ["biopsies", "OBSERVATION", 44, 52], ["liver", "ANATOMY", 169, 174], ["biopsy", "OBSERVATION", 175, 181]]], ["A total of 151 individuals were studied, including 68 HCV mono-infected and 83 HIV/HCV co-infected subjects.", [["HCV mono-infected", "DISEASE", 54, 71], ["HIV/HCV co-infected", "DISEASE", 79, 98], ["individuals", "ORGANISM", 15, 26], ["HCV", "ORGANISM", 54, 57], ["HIV/HCV", "ORGANISM", 79, 86], ["subjects", "ORGANISM", 99, 107], ["HIV", "SPECIES", 79, 82], ["HCV", "SPECIES", 54, 57], ["HIV", "SPECIES", 79, 82], ["HCV", "SPECIES", 83, 86], ["HCV mono-infected and 83 HIV/HCV co-infected subjects", "PROBLEM", 54, 107]]], ["Patients at each of the 4 stages of fibrosis stage: F0-1 (F1), F2, F3, F4/ESLD (F4), as determined by liver biopsy, were selected for this analysis.Serum fractionationSerum proteins were fractionated prior to the SELDI-TOF MS analysis as described [20] .", [["liver biopsy", "ANATOMY", 102, 114], ["Serum", "ANATOMY", 148, 153], ["fibrosis", "DISEASE", 36, 44], ["Patients", "ORGANISM", 0, 8], ["liver biopsy", "MULTI-TISSUE_STRUCTURE", 102, 114], ["Serum", "ORGANISM_SUBSTANCE", 148, 153], ["Serum fractionationSerum proteins", "PROTEIN", 148, 181], ["Patients", "SPECIES", 0, 8], ["fibrosis stage", "PROBLEM", 36, 50], ["liver biopsy", "TEST", 102, 114], ["this analysis", "TEST", 134, 147], ["Serum fractionationSerum proteins", "TEST", 148, 181], ["the SELDI", "TEST", 209, 218], ["TOF MS analysis", "TEST", 219, 234], ["fibrosis", "OBSERVATION", 36, 44], ["ESLD", "OBSERVATION", 74, 78], ["liver", "ANATOMY", 102, 107], ["biopsy", "OBSERVATION", 108, 114]]], ["Briefly, samples were fractionated on re-hydrated Q HyperD F beads by pH into 6 fractions using Bio-Rad (Hercules, CA) serum fractionation kit following manufacturer's instructions.", [["samples", "ANATOMY", 9, 16], ["serum", "ANATOMY", 119, 124], ["serum", "ORGANISM_SUBSTANCE", 119, 124], ["Bio", "TEST", 96, 99], ["Hercules", "TEST", 105, 113], ["serum fractionation", "TEST", 119, 138]]], ["All of the steps of protein fractionation including binding and washing were performed on a BioMek 2000 laboratory automation workstation (Beckman Coulter, Fullerton, CA) with an integrated microplate shaker (MicroMix; Diagnostic Products Company, Los Angeles, CA) that holds an array bioprocessor (Bio-Rad).", [["protein fractionation", "TREATMENT", 20, 41], ["an integrated microplate shaker", "TREATMENT", 176, 207], ["an array bioprocessor", "TREATMENT", 276, 297]]], ["Serum fractions were stored at -20\u02daC until analyzed.", [["Serum fractions", "ANATOMY", 0, 15], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["Serum fractions", "TEST", 0, 15]]], ["For quality control purposes, commercial human reference sera from healthy donors (Valley Biomedical, Winchester, VA) and duplicates were included in all the test runs.ProteinChip binding and mass spectrometry analysisSamples were randomized within and across arrays with blank spots included as negative controls and applied to three types of ProteinChip arrays: weak cation exchange (CM10), immobilized metal affinity capture (IMAC30) and hydrophobic/reverse-phase (H50) (all from Bio-Rad).", [["sera", "ANATOMY", 57, 61], ["human", "ORGANISM", 41, 46], ["sera", "ORGANISM_SUBSTANCE", 57, 61], ["cation", "SIMPLE_CHEMICAL", 369, 375], ["CM10", "SIMPLE_CHEMICAL", 386, 390], ["human", "SPECIES", 41, 46], ["human", "SPECIES", 41, 46], ["the test runs", "TEST", 154, 167], ["ProteinChip binding", "PROBLEM", 168, 187], ["mass spectrometry analysisSamples", "TEST", 192, 225], ["blank spots", "TEST", 272, 283], ["ProteinChip arrays", "TREATMENT", 344, 362], ["weak cation exchange", "TREATMENT", 364, 384], ["immobilized metal affinity capture", "TREATMENT", 393, 427], ["IMAC30", "TEST", 429, 435], ["hydrophobic/reverse-phase", "TREATMENT", 441, 466], ["mass", "OBSERVATION", 192, 196]]], ["Arrays were prepared as previously described [25] and analyzed in a ProteinChip biology system reader (series PCS 4000) using the ProteinChip software version 3.5 (Bio-Rad).", [["series PCS", "TEST", 103, 113], ["the ProteinChip software version", "TEST", 126, 158]]], ["In a preliminary study (data not shown), a few samples from each group were bound onto a CM10 ProteinChip array and all the 6 fractions were analyzed.", [["samples", "ANATOMY", 47, 54], ["a preliminary study", "TEST", 3, 22], ["a few samples", "TEST", 41, 54], ["a CM10 ProteinChip array", "TEST", 87, 111]]], ["The fractions yielding the most satisfactory results (i.e. the most differentiating biomarkers) were selected for SELDI-TOF MS analysis: fractions 1 (pH 9 and flow through), 3 (pH 5) and 6 (organic) for analysis on CM10 arrays.", [["SELDI", "TEST", 114, 119], ["fractions", "TEST", 137, 146], ["pH", "TEST", 150, 152], ["pH", "TEST", 177, 179], ["analysis", "TEST", 203, 211], ["CM10 arrays", "TREATMENT", 215, 226]]], ["Optimization experiments with IMAC30 and H50 arrays led to similar results.", [["IMAC30 and H50 arrays", "DNA", 30, 51], ["IMAC30 and H50 arrays", "TREATMENT", 30, 51]]], ["Therefore, to minimize the cost and time of analysis fractions 2, 4 and 5 were not subjected to the MS analysis.ProteinChip binding and mass spectrometry analysisEach spot was read at low-and high-energy laser intensities.", [["analysis fractions", "TEST", 44, 62], ["the MS analysis", "TEST", 96, 111], ["ProteinChip binding", "TEST", 112, 131], ["mass spectrometry analysis", "TEST", 136, 162], ["Each spot", "TEST", 162, 171], ["mass", "OBSERVATION", 136, 140]]], ["Using external calibration standards (bovine insulin, 5,733.6 Da; ubiquitin, 8,564.84 Da; cytochrome c, 12,230.9 Da; \u03b2lactoglobulin, 18,363.3 Da; horseradish peroxidase, 43,240 Da; and IgG, 147,300 Da), all spectra were subjected to mass calibration based on the settings used to collect the data.", [["bovine", "ORGANISM", 38, 44], ["insulin", "GENE_OR_GENE_PRODUCT", 45, 52], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 66, 75], ["cytochrome c", "GENE_OR_GENE_PRODUCT", 90, 102], ["\u03b2lactoglobulin", "GENE_OR_GENE_PRODUCT", 117, 131], ["horseradish peroxidase", "GENE_OR_GENE_PRODUCT", 146, 168], ["bovine insulin", "PROTEIN", 38, 52], ["ubiquitin", "PROTEIN", 66, 75], ["cytochrome c", "PROTEIN", 90, 102], ["\u03b2lactoglobulin", "PROTEIN", 117, 131], ["horseradish peroxidase", "PROTEIN", 146, 168], ["43,240 Da", "PROTEIN", 170, 179], ["IgG", "PROTEIN", 185, 188], ["bovine", "SPECIES", 38, 44], ["horseradish", "SPECIES", 146, 157], ["external calibration standards (bovine insulin", "TREATMENT", 6, 52], ["\u03b2lactoglobulin", "TEST", 117, 131], ["mass calibration", "TEST", 233, 249], ["the data", "TEST", 288, 296]]], ["The baseline was subtracted using a setting of 15 times the expected peak width.", [["peak", "OBSERVATION_MODIFIER", 69, 73], ["width", "OBSERVATION_MODIFIER", 74, 79]]], ["All data were normalized by total ion current for either low intensity (2 to 100 kDa) or high intensity (10 to 200 kDa) using an external coefficient of 0.2.", [["All data", "TEST", 0, 8], ["low intensity", "PROBLEM", 57, 70], ["high intensity", "PROBLEM", 89, 103], ["an external coefficient", "TEST", 126, 149], ["low intensity", "OBSERVATION_MODIFIER", 57, 70]]], ["Spectra with normalization factors of more than double the mean were deleted.", [["normalization factors", "PROBLEM", 13, 34]]], ["Analyses were performed in two steps.", [["Analyses", "TEST", 0, 8]]], ["First, automated peak detection was applied, using cluster features of Biomarker Wizard software (Bio-Rad).", [["automated peak detection", "TEST", 7, 31], ["Biomarker", "TEST", 71, 80]]], ["Cluster with p values <0.05 (Mann-Whitney U test) were visually inspected, followed by manual peak relabeling.", [["p values", "TEST", 13, 21], ["Whitney U test", "TEST", 34, 48], ["manual peak relabeling", "TEST", 87, 109]]], ["After relabeling, exact p values for differences in average peak intensity between two groups were calculated (Wilcoxon exact test): 1) negative population with F1 (no/mild fibrosis), 2) positive population with F3-F4 (significant fibrosis).", [["fibrosis", "DISEASE", 173, 181], ["fibrosis", "DISEASE", 231, 239], ["F3", "PROTEIN", 212, 214], ["exact p values", "TEST", 18, 32], ["Wilcoxon exact test", "TEST", 111, 130], ["mild fibrosis", "PROBLEM", 168, 181], ["positive population", "PROBLEM", 187, 206], ["F3", "TEST", 212, 214], ["significant fibrosis)", "PROBLEM", 219, 240], ["mild", "OBSERVATION_MODIFIER", 168, 172], ["fibrosis", "OBSERVATION", 173, 181], ["significant", "OBSERVATION_MODIFIER", 219, 230], ["fibrosis", "OBSERVATION", 231, 239]]], ["Peaks with p values < 0.05 and receiver operating characteristic (ROC) values > 0.75 or < 0.25 were considered as potential biomarkers.", [["p values", "TEST", 11, 19], ["ROC) values", "TEST", 66, 77]]], ["Biomarker Pattern software (Bio-Rad) analysis was applied to the cleaned cluster data.", [["Biomarker Pattern software", "TEST", 0, 26], ["Bio-Rad) analysis", "TEST", 28, 45]]], ["The CART procedure seeks to minimize a cost function that balances prediction errors in either sense and the total number of biomarkers used.", [["The CART procedure", "TREATMENT", 0, 18], ["a cost function", "TREATMENT", 37, 52]]], ["Similar analysis was performed to find discriminator peaks between the four stages of fibrosis (F0-1, F2, F3 and F4).Protein identificationTwo samples that showed highest intensity in SELDI-TOF MS analysis for each biomarker were selected as positive samples and two with the lowest intensity were selected as negative controls.", [["samples", "ANATOMY", 143, 150], ["samples", "ANATOMY", 251, 258], ["fibrosis", "DISEASE", 86, 94], ["Similar analysis", "TEST", 0, 16], ["fibrosis", "PROBLEM", 86, 94], ["F0", "TEST", 96, 98], ["Protein identification", "TEST", 117, 139], ["Two samples", "TEST", 139, 150], ["highest intensity", "PROBLEM", 163, 180], ["SELDI", "TEST", 184, 189], ["TOF MS analysis", "TEST", 190, 205], ["each biomarker", "TEST", 210, 224], ["four stages", "OBSERVATION_MODIFIER", 71, 82], ["fibrosis", "OBSERVATION", 86, 94], ["highest", "OBSERVATION_MODIFIER", 163, 170], ["intensity", "OBSERVATION_MODIFIER", 171, 180]]], ["Enriched fractions were purified in a NuPAGE precast gel (Invitrogen Life Technologies, Carlsbad, CA) (180 V, 50 min, Tris buffer pH 8.2), stained with Colloidal Blue (Invitrogen) and the bands of interest were excised for in-gel digestion based on a protocol previously described [26] .", [["fractions", "ANATOMY", 9, 18], ["Colloidal Blue", "SIMPLE_CHEMICAL", 152, 166], ["Enriched fractions", "PROBLEM", 0, 18], ["a NuPAGE precast gel", "TREATMENT", 36, 56], ["CA", "TEST", 98, 100], ["Tris buffer pH", "TEST", 118, 132], ["Colloidal Blue", "TREATMENT", 152, 166], ["a protocol", "TREATMENT", 249, 259], ["Colloidal Blue", "OBSERVATION", 152, 166]]], ["Briefly, gel-bound proteins were denatured using dithiothreitol (10 mM in 100 mM ammonium bicarbonate, 25\u02daC, 30 min), alkylated with 2-iodoacetamide (55 mM in 100 mM ammonium bicarbonate, 25\u02daC, 30 min) and digested by trypsin (13 ng/ml in 10 mM ammonium bicarbonate with 10% acetonitrile, 37\u02daC) overnight.", [["dithiothreitol", "CHEMICAL", 49, 63], ["ammonium bicarbonate", "CHEMICAL", 81, 101], ["25\u02daC", "CHEMICAL", 103, 107], ["2-iodoacetamide", "CHEMICAL", 133, 148], ["ammonium bicarbonate", "CHEMICAL", 166, 186], ["25\u02daC", "CHEMICAL", 188, 192], ["ammonium bicarbonate", "CHEMICAL", 245, 265], ["acetonitrile", "CHEMICAL", 275, 287], ["37\u02daC", "CHEMICAL", 289, 293], ["dithiothreitol", "CHEMICAL", 49, 63], ["ammonium bicarbonate", "CHEMICAL", 81, 101], ["2-iodoacetamide", "CHEMICAL", 133, 148], ["ammonium bicarbonate", "CHEMICAL", 166, 186], ["ammonium bicarbonate", "CHEMICAL", 245, 265], ["acetonitrile", "CHEMICAL", 275, 287], ["dithiothreitol", "SIMPLE_CHEMICAL", 49, 63], ["ammonium bicarbonate", "SIMPLE_CHEMICAL", 81, 101], ["2-iodoacetamide", "SIMPLE_CHEMICAL", 133, 148], ["ammonium bicarbonate", "SIMPLE_CHEMICAL", 166, 186], ["trypsin", "SIMPLE_CHEMICAL", 218, 225], ["ammonium bicarbonate", "SIMPLE_CHEMICAL", 245, 265], ["acetonitrile", "SIMPLE_CHEMICAL", 275, 287], ["gel-bound proteins", "PROTEIN", 9, 27], ["trypsin", "PROTEIN", 218, 225], ["dithiothreitol", "TREATMENT", 49, 63], ["100 mM ammonium bicarbonate", "TREATMENT", 74, 101], ["iodoacetamide", "TREATMENT", 135, 148], ["100 mM ammonium bicarbonate", "TREATMENT", 159, 186], ["10 mM ammonium bicarbonate", "TREATMENT", 239, 265], ["10% acetonitrile", "TREATMENT", 271, 287]]], ["Tryptic digests were extracted with 50:25:15:10 formic acid/acetonitrile/isopropanol/water (2 times) and 100% acetonitrile (2 times) and vacuum dried.", [["50:25:15:10 formic acid/acetonitrile/isopropanol", "CHEMICAL", 36, 84], ["acetonitrile", "CHEMICAL", 110, 122], ["formic acid", "CHEMICAL", 48, 59], ["acetonitrile", "CHEMICAL", 60, 72], ["isopropanol", "CHEMICAL", 73, 84], ["acetonitrile", "CHEMICAL", 110, 122], ["15:10 formic acid", "SIMPLE_CHEMICAL", 42, 59], ["acetonitrile", "SIMPLE_CHEMICAL", 60, 72], ["isopropanol", "SIMPLE_CHEMICAL", 73, 84], ["Tryptic digests", "PROBLEM", 0, 15], ["formic acid/acetonitrile", "TREATMENT", 48, 72], ["isopropanol/water", "TREATMENT", 73, 90], ["100% acetonitrile", "TREATMENT", 105, 122], ["vacuum dried", "TREATMENT", 137, 149]]], ["Dried peptide samples were re-suspended in 0.1% trifluoroacetic acid (TFA), sonicated for 10 min and desalted with C18 reverse-phase ZipTip according to the manufacturer's protocol (Millipore, Billerica, MA).", [["samples", "ANATOMY", 14, 21], ["trifluoroacetic acid", "CHEMICAL", 48, 68], ["TFA", "CHEMICAL", 70, 73], ["trifluoroacetic acid", "CHEMICAL", 48, 68], ["TFA", "CHEMICAL", 70, 73], ["trifluoroacetic acid", "SIMPLE_CHEMICAL", 48, 68], ["TFA", "SIMPLE_CHEMICAL", 70, 73], ["ZipTip", "SIMPLE_CHEMICAL", 133, 139], ["Dried peptide samples", "TEST", 0, 21], ["0.1% trifluoroacetic acid (TFA", "TREATMENT", 43, 73], ["C18 reverse-phase ZipTip", "TREATMENT", 115, 139], ["the manufacturer's protocol", "TREATMENT", 153, 180]]], ["Samples were eluted in 4 \u03bcL of \u03b1-cyano-4-hydroxycinnamic acid (CHCA) matrix (10 mg/mL in 50:50 acetonitrile/0.1% TFA in water).", [["Samples", "ANATOMY", 0, 7], ["\u03b1-cyano-4-hydroxycinnamic acid", "CHEMICAL", 31, 61], ["CHCA", "CHEMICAL", 63, 67], ["50:50 acetonitrile", "CHEMICAL", 89, 107], ["TFA", "CHEMICAL", 113, 116], ["\u03b1-cyano-4-hydroxycinnamic acid", "CHEMICAL", 31, 61], ["CHCA", "CHEMICAL", 63, 67], ["acetonitrile", "CHEMICAL", 95, 107], ["TFA", "CHEMICAL", 113, 116], ["\u03b1-cyano-4-hydroxycinnamic acid", "SIMPLE_CHEMICAL", 31, 61], ["CHCA", "SIMPLE_CHEMICAL", 63, 67], ["TFA", "SIMPLE_CHEMICAL", 113, 116], ["Samples", "TEST", 0, 7], ["\u03b1-cyano", "TEST", 31, 38], ["hydroxycinnamic acid (CHCA) matrix", "TREATMENT", 41, 75], ["acetonitrile", "TREATMENT", 95, 107]]], ["The solution was directly spotted onto a 384-well AB OptiTOF stainless steel plate (AB Sciex, Framingham, MA) and allowed to dry at room temperature.Protein identificationMatrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) data were acquired on a 4800 Plus MALDI TOF/TOF Analyzer (AB Sciex) with the 4000 Series Explorer v3.5.3 software.", [["The solution", "TREATMENT", 0, 12], ["well AB OptiTOF stainless steel plate", "TREATMENT", 45, 82], ["Protein identificationMatrix", "TEST", 149, 177], ["assisted laser desorption ionization", "TREATMENT", 178, 214], ["flight mass spectrometry", "TEST", 223, 247], ["MALDI TOF", "TEST", 297, 306]]], ["Internal calibration was carried out using des-Arg-1-bradykinin (monoisotopic mass 904.4681), angiotensin I (1296.6853), glu 1 -fibrinopeptide B (1570.6774), adrenocorticotropic hormone (ACTH) fragments [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] (2093.0867), (2465.1989) and (3657.9294).", [["des-Arg-1-bradykinin", "CHEMICAL", 43, 63], ["angiotensin", "CHEMICAL", 94, 105], ["bradykinin", "CHEMICAL", 53, 63], ["des-Arg-1-bradykinin", "SIMPLE_CHEMICAL", 43, 63], ["angiotensin I", "GENE_OR_GENE_PRODUCT", 94, 107], ["fibrinopeptide B", "GENE_OR_GENE_PRODUCT", 128, 144], ["adrenocorticotropic hormone", "GENE_OR_GENE_PRODUCT", 158, 185], ["ACTH", "SIMPLE_CHEMICAL", 187, 191], ["[1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17]", "SIMPLE_CHEMICAL", 203, 278], ["Internal calibration", "TEST", 0, 20], ["des", "TEST", 43, 46], ["Arg", "TEST", 47, 50], ["monoisotopic mass", "TEST", 65, 82], ["angiotensin I", "TEST", 94, 107], ["glu", "TEST", 121, 124], ["fibrinopeptide B", "TEST", 128, 144], ["adrenocorticotropic hormone (ACTH) fragments", "TEST", 158, 202]]], ["In the positive-ion reflector mode, MS data were collected over a mass range of 800-4000 Da using a fixed laser intensity of 3200 nJ for 1000 shots/spectrum, with a uniformly random spot search pattern.", [["MS data", "TEST", 36, 43], ["a uniformly random spot search pattern", "PROBLEM", 163, 201]]], ["In each MS spectrum, the 20 most abundant MS peaks were selected for MS/MS using an acquisition method that excluded ions with S/N less than 20.", [["MS/MS", "PROBLEM", 69, 74], ["an acquisition method", "TEST", 81, 102], ["S/N", "TEST", 127, 130]]], ["The precursor ions with the strongest S/N were acquired first using a 1 kV MS/MS operating mode in which the relative precursor mass window was set at 50 and the metastable suppression enabled.", [["The precursor ions", "PROBLEM", 0, 18], ["a 1 kV MS/MS operating mode", "TREATMENT", 68, 95], ["the relative precursor mass window", "TREATMENT", 105, 139], ["ions", "OBSERVATION_MODIFIER", 14, 18], ["mass window", "OBSERVATION", 128, 139], ["metastable suppression", "OBSERVATION", 162, 184]]], ["MS/MS acquisition of selected precursors was set to 2000 shots per spectrum with 50 shots per sub-spectrum using a fixed laser intensity of 4200 nJ.Protein identificationProtein identification was performed with ProteinPilot 4.0.8 software using the Paragon algorithm (AB Sciex).", [["selected precursors", "PROBLEM", 21, 40], ["a fixed laser intensity", "TREATMENT", 113, 136], ["Protein identification", "TEST", 148, 170], ["Protein identification", "TEST", 170, 192], ["ProteinPilot", "TREATMENT", 212, 224], ["the Paragon algorithm", "TREATMENT", 246, 267]]], ["Peptides present in positive samples but absent in the negative samples were selected.", [["samples", "ANATOMY", 29, 36], ["samples", "ANATOMY", 64, 71], ["samples", "CANCER", 64, 71], ["positive samples", "PROBLEM", 20, 36], ["positive samples", "OBSERVATION_MODIFIER", 20, 36]]], ["MS/MS data were searched against the UniProtKB/Swiss-Prot database (downloaded on March 7, 2017) for Homo sapiens, HCV and HIV.", [["Homo sapiens", "DISEASE", 101, 113], ["HCV and HIV", "DISEASE", 115, 126], ["Homo sapiens", "ORGANISM", 101, 113], ["HCV", "ORGANISM", 115, 118], ["HIV", "ORGANISM", 123, 126], ["Homo sapiens", "SPECIES", 101, 113], ["HIV", "SPECIES", 123, 126], ["Homo sapiens", "SPECIES", 101, 113], ["HCV", "SPECIES", 115, 118], ["HIV", "SPECIES", 123, 126], ["MS/MS data", "TEST", 0, 10], ["Homo sapiens", "PROBLEM", 101, 113], ["HCV", "PROBLEM", 115, 118], ["HIV", "PROBLEM", 123, 126]]], ["Trypsin was selected as the digestion enzyme.", [["Trypsin", "CHEMICAL", 0, 7], ["Trypsin", "GENE_OR_GENE_PRODUCT", 0, 7], ["digestion enzyme", "PROTEIN", 28, 44], ["Trypsin", "TREATMENT", 0, 7], ["the digestion enzyme", "TEST", 24, 44]]], ["Other search parameters included cysteine alkylation by iodoacetamide, gelbased thorough ID with a focus on biological modifications.", [["cysteine", "CHEMICAL", 33, 41], ["iodoacetamide", "CHEMICAL", 56, 69], ["cysteine", "CHEMICAL", 33, 41], ["iodoacetamide", "CHEMICAL", 56, 69], ["cysteine", "AMINO_ACID", 33, 41], ["iodoacetamide", "SIMPLE_CHEMICAL", 56, 69], ["cysteine alkylation", "TREATMENT", 33, 52], ["iodoacetamide", "TREATMENT", 56, 69], ["biological modifications", "TREATMENT", 108, 132]]], ["The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE [27] partner repository with the dataset identifier PXD009007.ResultsDemographic and clinical characteristics of the study population are shown in Table 1 .", [["The mass spectrometry proteomics", "TEST", 0, 32], ["the study population", "TEST", 219, 239]]], ["Coinfected and mono-infected patients were similar in most respects, except there was a higher proportion reporting recent alcohol use (63% vs. 38%) and fewer women (16% vs. 31%) among co-infected patients.", [["alcohol", "CHEMICAL", 123, 130], ["alcohol", "CHEMICAL", 123, 130], ["patients", "ORGANISM", 29, 37], ["alcohol", "SIMPLE_CHEMICAL", 123, 130], ["women", "ORGANISM", 159, 164], ["patients", "ORGANISM", 197, 205], ["patients", "SPECIES", 29, 37], ["women", "SPECIES", 159, 164], ["patients", "SPECIES", 197, 205], ["mono-infected", "OBSERVATION_MODIFIER", 15, 28]]], ["Co-infected individuals were generally younger (mean 45.4 years) compared to mono-infected (mean 49.6 years) and had been HCV-infected for a shorter period of time (16.5 vs. 20.7 years).", [["HCV-infected", "DISEASE", 122, 134], ["individuals", "ORGANISM", 12, 23], ["HCV", "ORGANISM", 122, 125], ["HCV", "SPECIES", 122, 125], ["HCV", "PROBLEM", 122, 125], ["HCV", "OBSERVATION", 122, 125], ["infected", "OBSERVATION", 126, 134]]], ["These last differences would have been expected knowing the accelerated progression of fibrosis in co-infected patients [2, 3] .", [["fibrosis", "DISEASE", 87, 95], ["patients", "ORGANISM", 111, 119], ["patients", "SPECIES", 111, 119], ["fibrosis", "PROBLEM", 87, 95], ["accelerated", "OBSERVATION_MODIFIER", 60, 71], ["progression", "OBSERVATION_MODIFIER", 72, 83], ["fibrosis", "OBSERVATION", 87, 95], ["co-infected", "OBSERVATION_MODIFIER", 99, 110]]], ["Each group was divided into four categories according to liver biopsy score: F1 (n = 50), F2 (n = 49), F3 (n = 50) and F4 (n = 22) based on the Batts-Ludwig scoring system.", [["liver", "ANATOMY", 57, 62], ["liver biopsy", "MULTI-TISSUE_STRUCTURE", 57, 69], ["liver biopsy score", "TEST", 57, 75], ["F3", "TEST", 103, 105], ["F4", "TEST", 119, 121], ["the Batts", "TEST", 140, 149], ["liver", "ANATOMY", 57, 62]]], ["The characteristics according to fibrosis score are also shown in Table 1 .Comparison of SELDI-TOF MS spectra in HIV/HCV-co infection and HCV mono-infection cohortsThe SELDI-TOF MS approach was applied to samples from 151 patients.", [["samples", "ANATOMY", 205, 212], ["fibrosis", "DISEASE", 33, 41], ["HIV/HCV-co infection", "DISEASE", 113, 133], ["HIV/HCV", "ORGANISM", 113, 120], ["HCV", "ORGANISM", 138, 141], ["patients", "ORGANISM", 222, 230], ["patients", "SPECIES", 222, 230], ["HIV/HCV", "SPECIES", 113, 120], ["HCV", "SPECIES", 138, 141], ["fibrosis score", "PROBLEM", 33, 47], ["SELDI", "TEST", 89, 94], ["HIV", "PROBLEM", 113, 116], ["HCV", "PROBLEM", 117, 120], ["co infection", "PROBLEM", 121, 133], ["HCV mono-infection cohorts", "PROBLEM", 138, 164], ["The SELDI-TOF MS approach", "TREATMENT", 164, 189], ["fibrosis", "OBSERVATION", 33, 41]]], ["Due to the difference in parameters (age and duration of HCV infection) between HCV mono-infected and HIV/ HCV co-infected individuals, the spectra of each group were analyzed separately.", [["HCV infection", "DISEASE", 57, 70], ["HCV mono-infected and HIV/ HCV co-infected", "DISEASE", 80, 122], ["HCV", "ORGANISM", 57, 60], ["HCV", "ORGANISM", 80, 83], ["HIV/ HCV co", "ORGANISM", 102, 113], ["individuals", "ORGANISM", 123, 134], ["HIV", "SPECIES", 102, 105], ["HCV", "SPECIES", 57, 60], ["HCV", "SPECIES", 80, 83], ["HIV", "SPECIES", 102, 105], ["HCV", "SPECIES", 107, 110], ["the difference in parameters", "PROBLEM", 7, 35], ["HCV infection", "PROBLEM", 57, 70], ["HCV mono-infected", "PROBLEM", 80, 97], ["HIV/ HCV co", "PROBLEM", 102, 113], ["infected individuals", "PROBLEM", 114, 134]]], ["Most biomarker programs focus on a single disease and have a dichotomous pattern (i.e. either positive or negative).", [["a single disease", "PROBLEM", 33, 49], ["a dichotomous pattern", "PROBLEM", 59, 80]]], ["Our primary comparison was non-fibrotic patients (F1) to more advanced fibrotic patients (F3-F4) .", [["patients", "ORGANISM", 40, 48], ["patients", "ORGANISM", 80, 88], ["patients", "SPECIES", 40, 48], ["patients", "SPECIES", 80, 88], ["advanced", "OBSERVATION_MODIFIER", 62, 70], ["fibrotic", "OBSERVATION_MODIFIER", 71, 79]]], ["Due to the relatively small number of samples in F4 group we pooled F3 and F4 groups together for analysis.", [["samples", "ANATOMY", 38, 45], ["analysis", "TEST", 98, 106], ["relatively", "OBSERVATION_MODIFIER", 11, 21], ["small", "OBSERVATION_MODIFIER", 22, 27], ["number", "OBSERVATION_MODIFIER", 28, 34]]], ["Using Biomarker Wizard software, sixteen potential biomarkers with significant intensity difference and good area under curve (AUC) from ROC curve analysis were identified ( Table 2 ).", [["sixteen potential biomarkers", "TEST", 33, 61], ["significant intensity difference", "PROBLEM", 67, 99], ["AUC", "TEST", 127, 130], ["ROC curve analysis", "TEST", 137, 155], ["significant", "OBSERVATION_MODIFIER", 67, 78], ["intensity", "OBSERVATION_MODIFIER", 79, 88], ["good", "OBSERVATION_MODIFIER", 104, 108]]], ["Six of these individual biomarkers were down-regulated in the group with advanced fibrosis, while eight were up-regulated with moderate changes between the two groups (1.33 to 2.55-fold).", [["fibrosis", "DISEASE", 82, 90], ["these individual biomarkers", "TEST", 7, 34], ["advanced fibrosis", "PROBLEM", 73, 90], ["moderate changes between the two groups", "PROBLEM", 127, 166], ["advanced", "OBSERVATION_MODIFIER", 73, 81], ["fibrosis", "OBSERVATION", 82, 90], ["moderate", "OBSERVATION_MODIFIER", 127, 135]]], ["When we tested the ability of these 14 biomarkers to differentiate patients with regards to their stage of liver fibrosis (F1, F2, F3 and F4), 8 out of 14 had significant intensity differences with a p value < 0.01.", [["liver", "ANATOMY", 107, 112], ["liver fibrosis", "DISEASE", 107, 121], ["patients", "ORGANISM", 67, 75], ["liver", "ORGAN", 107, 112], ["patients", "SPECIES", 67, 75], ["these 14 biomarkers", "TEST", 30, 49], ["liver fibrosis", "PROBLEM", 107, 121], ["significant intensity differences", "PROBLEM", 159, 192], ["a p value", "TEST", 198, 207], ["liver", "ANATOMY", 107, 112], ["fibrosis", "OBSERVATION", 113, 121], ["significant", "OBSERVATION_MODIFIER", 159, 170], ["intensity", "OBSERVATION_MODIFIER", 171, 180]]], ["The three biomarkers demonstrating the most significant difference in expression (6.4, 9.3 and 66.6 k(m/z)) are shown in Fig 1.", [["The three biomarkers", "TEST", 0, 20], ["expression", "TEST", 70, 80], ["most", "OBSERVATION_MODIFIER", 39, 43], ["significant", "OBSERVATION_MODIFIER", 44, 55], ["difference", "OBSERVATION_MODIFIER", 56, 66]]], ["The cumulative data illustrate how changes in multiple protein biomarkers can be used as \"fingerprints\" reflective of a particular disease state.", [["The cumulative data", "TEST", 0, 19], ["multiple protein biomarkers", "TEST", 46, 73], ["a particular disease state", "PROBLEM", 118, 144]]], ["Similar analysis was performed with HCV mono-infected samples.", [["samples", "ANATOMY", 54, 61], ["HCV mono-infected", "DISEASE", 36, 53], ["HCV", "ORGANISM", 36, 39], ["HCV", "SPECIES", 36, 39], ["Similar analysis", "TEST", 0, 16], ["HCV mono", "TEST", 36, 44], ["infected samples", "PROBLEM", 45, 61]]], ["Fourteen classifiers with significant intensity differences between F1 and F3-4 were identified (S1 Table) .", [["F3", "DNA", 75, 77], ["significant intensity differences", "PROBLEM", 26, 59], ["significant", "OBSERVATION_MODIFIER", 26, 37], ["intensity", "OBSERVATION_MODIFIER", 38, 47]]], ["Representative SELDI-MS spectra of the identified biomarkers can be found under S1 Fig. SELDI -TOF MS peak values are available in S1 File.Comparison of SELDI-TOF MS spectra in HIV/HCV-co infection and HCV mono-infection cohortsTo select biomarkers with the greatest discriminatory power to distinguish between nonfibrotic (F1) and fibrotic patients (F2-3-4), the biomarker pattern recognition software was used to generate random training and test data sets and candidate decision trees.", [["HIV/HCV-co infection", "DISEASE", 177, 197], ["HIV/HCV", "ORGANISM", 177, 184], ["HCV", "ORGANISM", 202, 205], ["patients", "ORGANISM", 341, 349], ["patients", "SPECIES", 341, 349], ["HIV/HCV", "SPECIES", 177, 184], ["HCV", "SPECIES", 202, 205], ["SELDI -TOF MS peak values", "TEST", 88, 113], ["SELDI", "TEST", 153, 158], ["HIV", "PROBLEM", 177, 180], ["HCV", "PROBLEM", 181, 184], ["co infection", "PROBLEM", 185, 197], ["HCV mono-infection cohorts", "PROBLEM", 202, 228], ["F2", "TEST", 351, 353], ["random training", "TEST", 424, 439], ["test data sets", "TEST", 444, 458], ["fibrotic", "OBSERVATION_MODIFIER", 332, 340]]], ["In coinfected patients, 4 biomarkers (8.1, 8.9, 13.8 and 22.8 k(m/z)) served as the main splitters with the highest individual predictive rates and were used to build an algorithm.", [["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22], ["4 biomarkers", "TEST", 24, 36], ["k(m/z)", "TEST", 62, 68], ["an algorithm", "TEST", 167, 179]]], ["A representative decision tree that achieved 90.6% sensitivity and 73.3% specificity is presented in Fig 2.", [["sensitivity", "TEST", 51, 62]]], ["This Mass-over-charge (m/z) value, mean signal intensity, and area-under-curve (AUC) for selected individuals differentially expressed peptides/proteins between hepatic fibrosis 0-1 (F1), fibrosis 2 (F2), fibrosis 3 (F3) and ESLD or fibrosis 4 (F4) patients.Fig 2.", [["hepatic", "ANATOMY", 161, 168], ["hepatic fibrosis", "DISEASE", 161, 177], ["fibrosis", "DISEASE", 188, 196], ["fibrosis", "DISEASE", 205, 213], ["fibrosis", "DISEASE", 233, 241], ["patients", "ORGANISM", 249, 257], ["patients", "SPECIES", 249, 257], ["This Mass-over-charge (m/z) value", "TEST", 0, 33], ["mean signal intensity", "PROBLEM", 35, 56], ["area-under-curve (AUC", "TEST", 62, 83], ["selected individuals differentially expressed peptides/proteins between hepatic fibrosis", "PROBLEM", 89, 177], ["fibrosis", "PROBLEM", 188, 196], ["fibrosis", "PROBLEM", 205, 213], ["ESLD", "PROBLEM", 225, 229], ["fibrosis", "PROBLEM", 233, 241], ["intensity", "OBSERVATION_MODIFIER", 47, 56], ["hepatic", "ANATOMY", 161, 168], ["fibrosis", "OBSERVATION", 169, 177], ["fibrosis", "OBSERVATION", 188, 196], ["fibrosis", "OBSERVATION", 205, 213], ["ESLD", "OBSERVATION", 225, 229], ["fibrosis", "OBSERVATION", 233, 241]]], ["Decision tree to differentiate non-fibrotic individuals (F1) from individuals with significant fibrosis (F2 and above) in HIV/HCV co-infection.Biomarker pattern based on CART analysis was used to generate candidate diagnostic algorithms.", [["fibrosis", "DISEASE", 95, 103], ["HIV/HCV co-infection", "DISEASE", 122, 142], ["HIV/HCV", "ORGANISM", 122, 129], ["HIV", "SPECIES", 122, 125], ["HIV", "SPECIES", 122, 125], ["HCV", "SPECIES", 126, 129], ["non-fibrotic individuals", "PROBLEM", 31, 55], ["significant fibrosis", "PROBLEM", 83, 103], ["HIV/HCV co-infection", "PROBLEM", 122, 142], ["Biomarker pattern", "TEST", 143, 160], ["CART analysis", "TEST", 170, 183], ["diagnostic algorithms", "TEST", 215, 236], ["significant", "OBSERVATION_MODIFIER", 83, 94], ["fibrosis", "OBSERVATION", 95, 103], ["HCV co-infection", "OBSERVATION", 126, 142]]], ["The numbers on the root node, the descendant nodes and the terminal nodes represent the mass values in followed by the intensity value.", [["root node", "ANATOMY", 19, 28], ["descendant nodes", "ANATOMY", 34, 50], ["terminal nodes", "ANATOMY", 59, 73], ["root node", "MULTI-TISSUE_STRUCTURE", 19, 28], ["descendant nodes", "MULTI-TISSUE_STRUCTURE", 34, 50], ["terminal nodes", "MULTI-TISSUE_STRUCTURE", 59, 73], ["the mass values", "PROBLEM", 84, 99], ["the intensity value", "TEST", 115, 134], ["numbers", "OBSERVATION_MODIFIER", 4, 11], ["root", "ANATOMY", 19, 23], ["node", "OBSERVATION", 24, 28], ["descendant", "OBSERVATION_MODIFIER", 34, 44], ["nodes", "OBSERVATION", 45, 50], ["terminal", "OBSERVATION_MODIFIER", 59, 67], ["nodes", "OBSERVATION", 68, 73], ["mass", "OBSERVATION", 88, 92], ["intensity", "OBSERVATION_MODIFIER", 119, 128]]], ["Non-fibrotic individuals = Class 1, individuals with significant fibrosis = Class 2.Fig 2.", [["fibrosis", "DISEASE", 65, 73], ["Non-fibrotic individuals", "PROBLEM", 0, 24], ["significant fibrosis", "PROBLEM", 53, 73], ["significant", "OBSERVATION_MODIFIER", 53, 64], ["fibrosis", "OBSERVATION", 65, 73]]], ["Decision tree to differentiate non-fibrotic individuals (F1) from individuals with significant fibrosis (F2 and above) in HIV/HCV co-infection.algorithm was able to correctly diagnose 77/83 individuals (92.8%).", [["fibrosis", "DISEASE", 95, 103], ["HIV/HCV co-infection", "DISEASE", 122, 142], ["HIV/HCV", "ORGANISM", 122, 129], ["HIV", "SPECIES", 122, 125], ["HIV", "SPECIES", 122, 125], ["HCV", "SPECIES", 126, 129], ["non-fibrotic individuals", "PROBLEM", 31, 55], ["significant fibrosis", "PROBLEM", 83, 103], ["HIV/HCV co-infection", "PROBLEM", 122, 142], ["significant", "OBSERVATION_MODIFIER", 83, 94], ["fibrosis", "OBSERVATION", 95, 103], ["HCV co-infection", "OBSERVATION", 126, 142]]], ["However, when the same algorithm was applied to the HCV mono-infected samples, we obtained an accuracy of only 53% (35/64), 50% sensitivity and 55% specificity (data not shown).", [["samples", "ANATOMY", 70, 77], ["HCV", "ORGANISM", 52, 55], ["HCV", "SPECIES", 52, 55], ["an accuracy", "TEST", 91, 102]]], ["To evaluate the possible influence of HIV disease activity on these biomarkers, we assessed the correlation between these biomarkers and the markers of HIV progression (HIV RNA and CD4 counts (Fig 3A) and were highly correlated with one another (Fig 3B) .", [["HIV", "ORGANISM", 38, 41], ["HIV", "ORGANISM", 152, 155], ["CD4", "GENE_OR_GENE_PRODUCT", 181, 184], ["HIV RNA", "RNA", 169, 176], ["CD4", "PROTEIN", 181, 184], ["HIV", "SPECIES", 38, 41], ["HIV", "SPECIES", 152, 155], ["HIV", "SPECIES", 169, 172], ["HIV disease activity", "PROBLEM", 38, 58], ["these biomarkers", "TEST", 62, 78], ["these biomarkers", "TEST", 116, 132], ["HIV progression", "PROBLEM", 152, 167], ["HIV RNA", "TEST", 169, 176], ["CD4 counts", "TEST", 181, 191], ["HIV", "OBSERVATION", 38, 41]]], ["However, unlike the biomarkers specific to co-infection, we were not able to obtain good decision trees with these biomarkers (data not shown).Biomarker identificationPresumptive identifications were based on peptides present in the positive samples and absent in negative samples.", [["samples", "ANATOMY", 242, 249], ["samples", "ANATOMY", 273, 280], ["co-infection", "DISEASE", 43, 55], ["the biomarkers", "TEST", 16, 30], ["co-infection", "PROBLEM", 43, 55], ["these biomarkers", "TEST", 109, 125], ["Biomarker identification", "TEST", 143, 167], ["peptides", "TEST", 209, 217], ["the positive samples", "TEST", 229, 249]]], ["Serum fractionations were run on sodium dodecyl sulfate-denaturing polyacrylamide gel electrophoresis (SDS-PAGE).", [["Serum", "ANATOMY", 0, 5], ["sodium dodecyl sulfate", "CHEMICAL", 33, 55], ["sodium dodecyl sulfate", "CHEMICAL", 33, 55], ["polyacrylamide", "CHEMICAL", 67, 81], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["sodium dodecyl sulfate", "SIMPLE_CHEMICAL", 33, 55], ["Serum fractionations", "TEST", 0, 20], ["sodium dodecyl sulfate", "TREATMENT", 33, 55], ["denaturing polyacrylamide gel electrophoresis", "TREATMENT", 56, 101]]], ["Selected bands were cut with their negative control.", [["Selected bands", "TREATMENT", 0, 14]]], ["Table 3 summarizes the biomarkers identified by MALDI-TOF MS when comparing positive and negative samples.Biomarker identificationAll candidate biomarkers were of host origin and included: immunoglobulin (Ig) kappa chain constant (C) region (13.8 k(m/z)), haptoglobin (46.8 k(m/z)) and its alpha chain (18.4 k (m/z)), a possible truncated form of apolipoprotein A1 (ApoA1 (22.8 k(m/z)), plasminogen (84.6 k(m/z)) and serotransferrin (78.8 k(m/z)).", [["samples", "ANATOMY", 98, 105], ["serotransferrin", "CHEMICAL", 417, 432], ["immunoglobulin (Ig) kappa", "GENE_OR_GENE_PRODUCT", 189, 214], ["haptoglobin", "GENE_OR_GENE_PRODUCT", 256, 267], ["alpha chain", "GENE_OR_GENE_PRODUCT", 290, 301], ["apolipoprotein A1", "GENE_OR_GENE_PRODUCT", 347, 364], ["ApoA1", "GENE_OR_GENE_PRODUCT", 366, 371], ["plasminogen", "GENE_OR_GENE_PRODUCT", 387, 398], ["serotransferrin", "SIMPLE_CHEMICAL", 417, 432], ["immunoglobulin (Ig) kappa chain constant (C) region", "PROTEIN", 189, 240], ["haptoglobin", "PROTEIN", 256, 267], ["alpha chain", "PROTEIN", 290, 301], ["apolipoprotein A1", "PROTEIN", 347, 364], ["ApoA1", "PROTEIN", 366, 371], ["plasminogen", "PROTEIN", 387, 398], ["the biomarkers", "TEST", 19, 33], ["Biomarker identification", "TEST", 106, 130], ["All candidate biomarkers", "TEST", 130, 154], ["immunoglobulin (Ig", "TREATMENT", 189, 207], ["k(m/z", "TEST", 247, 252], ["haptoglobin", "TEST", 256, 267], ["k(m/z", "TEST", 274, 279], ["its alpha chain", "TEST", 286, 301], ["k (m/z", "TEST", 308, 314], ["apolipoprotein", "TEST", 347, 361], ["ApoA1", "TEST", 366, 371], ["k", "TEST", 378, 379], ["plasminogen", "TEST", 387, 398], ["k", "TEST", 405, 406], ["serotransferrin", "TEST", 417, 432]]], ["Using the marker pattern recognition software, we tried to establish a decision tree using only these clusters to distinguish between fibrotic patients (F2, 3 and 4) and healthy individuals (F1) with co-infection.", [["co-infection", "DISEASE", 200, 212], ["patients", "ORGANISM", 143, 151], ["patients", "SPECIES", 143, 151], ["co-infection", "PROBLEM", 200, 212], ["fibrotic", "OBSERVATION_MODIFIER", 134, 142], ["co-infection", "OBSERVATION", 200, 212]]], ["We obtained a 3-node algorithm using biomarkers at 13.8, 18.4 and 78.8 k(m/z).", [["a 3-node algorithm", "TEST", 12, 30], ["biomarkers", "TEST", 37, 47]]], ["This algorithm was able to correctly diagnose 64/83 (77.1%) individuals and had a sensitivity and specificity of 86.8% and 60.0% respectively (Fig 4) .", [["a sensitivity", "TEST", 80, 93], ["specificity", "TEST", 98, 109], ["Fig", "TEST", 143, 146]]], ["A second analysis was performed with all 151 individuals and using these same known biomarkers and we obtained similar results with an efficiency of 77.4% (117/151) with a sensitivity of 81.1% and specificity of 70.0%.", [["A second analysis", "TEST", 0, 17], ["an efficiency", "TEST", 132, 145], ["a sensitivity", "TEST", 170, 183], ["specificity", "TEST", 197, 208]]], ["However, this algorithm had four nodes using the biomarkers at 18.4, 46.8, 78.8 and 84.6 k(m/z) (Fig 5) .DiscussionTo date, new biomarkers for fibrosis have been sought primarily by using differential twodimensional gel electrophoresis (2D-GE) separations of tissues or serum together with mass spectrometry for protein identification [28, 29] .", [["tissues", "ANATOMY", 259, 266], ["serum", "ANATOMY", 270, 275], ["fibrosis", "DISEASE", 143, 151], ["tissues", "TISSUE", 259, 266], ["serum", "ORGANISM_SUBSTANCE", 270, 275], ["this algorithm", "TEST", 9, 23], ["the biomarkers", "TEST", 45, 59], ["k", "TEST", 89, 90], ["new biomarkers", "TEST", 124, 138], ["fibrosis", "PROBLEM", 143, 151], ["differential twodimensional gel electrophoresis", "TREATMENT", 188, 235], ["2D-GE) separations of tissues", "TREATMENT", 237, 266], ["mass spectrometry", "TEST", 290, 307], ["protein identification", "TEST", 312, 334], ["nodes", "OBSERVATION", 33, 38], ["fibrosis", "OBSERVATION", 143, 151], ["tissues", "ANATOMY", 259, 266]]], ["Proteomic analysis of plasma or serum derived from HCV-infected subjects is an emerging technique for the identification of biomarkers indicative of disease progression and severity [23, [30] [31] [32] [33] .", [["plasma", "ANATOMY", 22, 28], ["serum", "ANATOMY", 32, 37], ["HCV-infected", "DISEASE", 51, 63], ["plasma", "ORGANISM_SUBSTANCE", 22, 28], ["serum", "ORGANISM_SUBSTANCE", 32, 37], ["HCV", "ORGANISM", 51, 54], ["[30] [31] [32] [33]", "SIMPLE_CHEMICAL", 187, 206], ["HCV", "SPECIES", 51, 54], ["Proteomic analysis", "TEST", 0, 18], ["plasma or serum", "TEST", 22, 37], ["HCV", "PROBLEM", 51, 54], ["disease progression", "PROBLEM", 149, 168], ["severity", "TEST", 173, 181], ["infected", "OBSERVATION", 55, 63], ["disease", "OBSERVATION", 149, 156]]], ["Using plasma samples from clinically defined patients of fibrosis progression by biopsy, we have obtained results that support the potential use of SELDI-TOF MS profiling as a tool to follow disease progression.DiscussionUsing SELDI-TOF MS we observed changes in the level of 14 plasma proteins/peptides in mono-infected and 14 in co-infected during the progress of hepatic fibrosis.", [["plasma samples", "ANATOMY", 6, 20], ["plasma", "ANATOMY", 279, 285], ["hepatic", "ANATOMY", 366, 373], ["fibrosis", "DISEASE", 57, 65], ["hepatic fibrosis", "DISEASE", 366, 382], ["plasma samples", "ORGANISM_SUBSTANCE", 6, 20], ["patients", "ORGANISM", 45, 53], ["plasma", "ORGANISM_SUBSTANCE", 279, 285], ["hepatic", "ORGAN", 366, 373], ["plasma proteins", "PROTEIN", 279, 294], ["patients", "SPECIES", 45, 53], ["plasma samples", "TEST", 6, 20], ["fibrosis progression", "PROBLEM", 57, 77], ["biopsy", "TEST", 81, 87], ["SELDI-TOF MS profiling", "TREATMENT", 148, 170], ["disease progression", "PROBLEM", 191, 210], ["plasma proteins", "TEST", 279, 294], ["peptides", "PROBLEM", 295, 303], ["hepatic fibrosis", "PROBLEM", 366, 382], ["fibrosis", "OBSERVATION", 57, 65], ["hepatic", "ANATOMY", 366, 373], ["fibrosis", "OBSERVATION", 374, 382]]], ["We obtained satisfactory decision tree with an accuracy of 92.8% to identify non-fibrotic patients compared individuals with significant fibrosis in co-infection (81.3% sensitivity and 90.6% specificity).", [["non-fibrotic", "DISEASE", 77, 89], ["fibrosis", "DISEASE", 137, 145], ["co-infection", "DISEASE", 149, 161], ["patients", "ORGANISM", 90, 98], ["patients", "SPECIES", 90, 98], ["an accuracy", "TEST", 44, 55], ["significant fibrosis in co-infection", "PROBLEM", 125, 161], ["sensitivity", "TEST", 169, 180], ["significant", "OBSERVATION_MODIFIER", 125, 136], ["fibrosis", "OBSERVATION", 137, 145], ["co-infection", "OBSERVATION", 149, 161]]], ["Some \"misclassified\" patients in our algorithm could be due to the low reliability of the biopsy- assigned disease stage categorisation.", [["patients", "ORGANISM", 21, 29], ["patients", "SPECIES", 21, 29], ["the biopsy", "TEST", 86, 96], ["disease stage categorisation", "PROBLEM", 107, 135]]], ["We need to take into consideration that our reference point was the biopsy test done within the year of the sample collection and that biopsies are subject to sampling error and inter-observer variability.", [["sample", "ANATOMY", 108, 114], ["biopsies", "CANCER", 135, 143], ["the biopsy test", "TEST", 64, 79], ["biopsies", "TEST", 135, 143], ["inter-observer variability", "TEST", 178, 204]]], ["The aspirate aminotransferase (AST) to platelet ratio index (APRI) has been validated as a surrogate marker of significant hepatic fibrosis in HIV/HCV co-infection [34] .", [["platelet", "ANATOMY", 39, 47], ["hepatic", "ANATOMY", 123, 130], ["hepatic fibrosis", "DISEASE", 123, 139], ["HIV/HCV co-infection", "DISEASE", 143, 163], ["aspirate aminotransferase", "GENE_OR_GENE_PRODUCT", 4, 29], ["AST", "SIMPLE_CHEMICAL", 31, 34], ["platelet", "CELL", 39, 47], ["hepatic", "ORGAN", 123, 130], ["HIV/HCV", "ORGANISM", 143, 150], ["aspirate aminotransferase", "PROTEIN", 4, 29], ["AST", "PROTEIN", 31, 34], ["HIV", "SPECIES", 143, 146], ["HCV", "SPECIES", 147, 150], ["The aspirate aminotransferase", "TEST", 0, 29], ["AST", "TEST", 31, 34], ["platelet ratio index", "TEST", 39, 59], ["APRI", "TEST", 61, 65], ["significant hepatic fibrosis", "PROBLEM", 111, 139], ["HIV/HCV co-infection", "PROBLEM", 143, 163], ["significant", "OBSERVATION_MODIFIER", 111, 122], ["hepatic", "ANATOMY", 123, 130], ["fibrosis", "OBSERVATION", 131, 139], ["HCV co-infection", "OBSERVATION", 147, 163]]], ["In support of this possibility, five out of eight coinfected patients \"misclassified\" by our SELDI-TOF MS biomarkers had APRI values that did not correlate with their biopsy score.DiscussionUnfortunately, we were unable to generate an algorithm that could accurately diagnose both mono-and co-infected using the same set of biomarkers.", [["patients", "ORGANISM", 61, 69], ["APRI", "PROTEIN", 121, 125], ["patients", "SPECIES", 61, 69], ["our SELDI", "TEST", 89, 98], ["APRI values", "TEST", 121, 132], ["their biopsy score", "TEST", 161, 179], ["an algorithm", "TEST", 232, 244], ["biomarkers", "TEST", 324, 334]]], ["This could be due to the biological differences between the infections.", [["infections", "DISEASE", 60, 70], ["the infections", "PROBLEM", 56, 70], ["could be due to", "UNCERTAINTY", 5, 20], ["infections", "OBSERVATION", 60, 70]]], ["Even though we observed the same phenotype (liver fibrosis), it is possible that active liver disease and its progression are different in the two populations.", [["liver", "ANATOMY", 44, 49], ["liver", "ANATOMY", 88, 93], ["liver fibrosis", "DISEASE", 44, 58], ["liver disease", "DISEASE", 88, 101], ["liver", "ORGAN", 44, 49], ["liver", "ORGAN", 88, 93], ["the same phenotype (liver fibrosis", "PROBLEM", 24, 58], ["active liver disease", "PROBLEM", 81, 101], ["liver", "ANATOMY", 44, 49], ["fibrosis", "OBSERVATION", 50, 58], ["is possible", "UNCERTAINTY", 64, 75], ["active", "OBSERVATION_MODIFIER", 81, 87], ["liver", "ANATOMY", 88, 93], ["disease", "OBSERVATION", 94, 101], ["progression", "OBSERVATION_MODIFIER", 110, 121], ["different", "OBSERVATION_MODIFIER", 126, 135], ["two", "OBSERVATION_MODIFIER", 143, 146], ["populations", "OBSERVATION_MODIFIER", 147, 158]]], ["Several studies have reported that co-infected individuals progress more rapidly to ESLD than mono infected individuals [4] [5] [6] [7] .", [["ESLD", "DISEASE", 84, 88], ["[4] [5] [6] [7]", "SIMPLE_CHEMICAL", 120, 135], ["Several studies", "TEST", 0, 15], ["co-infected individuals", "PROBLEM", 35, 58], ["ESLD than mono infected individuals", "PROBLEM", 84, 119]]], ["Therefore, it is possible that biomarkers we observed in co-infection are, in fact, markers for accelerated fibrosis.", [["co-infection", "DISEASE", 57, 69], ["fibrosis", "DISEASE", 108, 116], ["biomarkers", "TEST", 31, 41], ["co-infection", "PROBLEM", 57, 69], ["accelerated fibrosis", "PROBLEM", 96, 116], ["co-infection", "OBSERVATION", 57, 69], ["fibrosis", "OBSERVATION", 108, 116]]], ["The differences between the mono and co-infected protein fingerprint observed suggest that further analyses might shed light on underlying pathologic mechanisms for more accelerated liver fibrosis progression among HIV positive patients.", [["liver", "ANATOMY", 182, 187], ["liver fibrosis", "DISEASE", 182, 196], ["HIV positive", "DISEASE", 215, 227], ["liver", "ORGAN", 182, 187], ["patients", "ORGANISM", 228, 236], ["HIV", "SPECIES", 215, 218], ["patients", "SPECIES", 228, 236], ["HIV", "SPECIES", 215, 218], ["the mono and co-infected protein fingerprint", "PROBLEM", 24, 68], ["further analyses", "TEST", 91, 107], ["underlying pathologic mechanisms", "PROBLEM", 128, 160], ["more accelerated liver fibrosis progression", "PROBLEM", 165, 208], ["liver", "ANATOMY", 182, 187], ["fibrosis", "OBSERVATION", 188, 196]]], ["This could be achieved by carefully matching samples tested by the important covariates that determine the risk for accelerated disease in HCV.DiscussionIt is important to note that most of the biomarkers used in the algorithm in HIV/HCV coinfection, with the exception of one (22.8-k(m/z)), did not correlate with markers of HIV disease progression (e.g. HIV RNA or CD4 counts).", [["HCV", "DISEASE", 139, 142], ["HIV/HCV coinfection", "DISEASE", 230, 249], ["HCV", "ORGANISM", 139, 142], ["HIV/HCV", "ORGANISM", 230, 237], ["HIV", "ORGANISM", 326, 329], ["CD4", "GENE_OR_GENE_PRODUCT", 367, 370], ["HIV RNA", "RNA", 356, 363], ["CD4", "PROTEIN", 367, 370], ["HIV", "SPECIES", 230, 233], ["HCV", "SPECIES", 139, 142], ["HIV", "SPECIES", 230, 233], ["HCV", "SPECIES", 234, 237], ["HIV", "SPECIES", 326, 329], ["HIV", "SPECIES", 356, 359], ["accelerated disease in HCV", "PROBLEM", 116, 142], ["the biomarkers", "TEST", 190, 204], ["HIV/HCV coinfection", "PROBLEM", 230, 249], ["HIV disease progression", "PROBLEM", 326, 349], ["HIV RNA", "PROBLEM", 356, 363], ["CD4 counts", "TEST", 367, 377], ["disease", "OBSERVATION", 128, 135], ["HCV", "OBSERVATION", 139, 142], ["HCV", "OBSERVATION", 234, 237]]], ["Consequently, these biomarkers are probably related to liver fibrosis.", [["liver", "ANATOMY", 55, 60], ["liver fibrosis", "DISEASE", 55, 69], ["liver", "ORGAN", 55, 60], ["these biomarkers", "TEST", 14, 30], ["liver fibrosis", "PROBLEM", 55, 69], ["probably related to", "UNCERTAINTY", 35, 54], ["liver", "ANATOMY", 55, 60], ["fibrosis", "OBSERVATION", 61, 69]]], ["They can reflect the immune response or inflammatory environment that is present during the disease.", [["inflammatory environment", "PROBLEM", 40, 64], ["the disease", "PROBLEM", 88, 99], ["immune response", "OBSERVATION", 21, 36], ["inflammatory", "OBSERVATION_MODIFIER", 40, 52]]], ["It is important to emphasize that, even though we have detected biomarkers that can be used to stage liver fibrosis in mono-and co-infected individuals, we cannot affirm that these biomarkers are specific for HCV-induced fibrosis.", [["liver", "ANATOMY", 101, 106], ["liver fibrosis", "DISEASE", 101, 115], ["fibrosis", "DISEASE", 221, 229], ["liver", "ORGAN", 101, 106], ["individuals", "ORGANISM", 140, 151], ["HCV", "ORGANISM", 209, 212], ["HCV", "SPECIES", 209, 212], ["stage liver fibrosis in mono", "PROBLEM", 95, 123], ["co-infected individuals", "PROBLEM", 128, 151], ["these biomarkers", "TEST", 175, 191], ["HCV", "PROBLEM", 209, 212], ["fibrosis", "PROBLEM", 221, 229], ["liver", "ANATOMY", 101, 106], ["fibrosis", "OBSERVATION", 107, 115], ["fibrosis", "OBSERVATION", 221, 229]]], ["In order to establish specificity, we will need to validate our algorithms with non-HCV liver anomalies such as alcoholic liver disease, hepatitis B-induced fibrosis or HCC.", [["liver", "ANATOMY", 88, 93], ["liver", "ANATOMY", 122, 127], ["HCC", "ANATOMY", 169, 172], ["liver anomalies", "DISEASE", 88, 103], ["alcoholic liver disease", "DISEASE", 112, 135], ["hepatitis B", "DISEASE", 137, 148], ["fibrosis", "DISEASE", 157, 165], ["HCC", "DISEASE", 169, 172], ["liver", "ORGAN", 88, 93], ["liver", "ORGAN", 122, 127], ["HCC", "CANCER", 169, 172], ["non-HCV", "SPECIES", 80, 87], ["non-HCV liver anomalies", "PROBLEM", 80, 103], ["alcoholic liver disease", "PROBLEM", 112, 135], ["hepatitis B", "PROBLEM", 137, 148], ["induced fibrosis", "PROBLEM", 149, 165], ["HCC", "PROBLEM", 169, 172], ["liver", "ANATOMY", 88, 93], ["anomalies", "OBSERVATION", 94, 103], ["alcoholic", "OBSERVATION_MODIFIER", 112, 121], ["liver", "ANATOMY", 122, 127], ["disease", "OBSERVATION", 128, 135], ["hepatitis", "OBSERVATION", 137, 146], ["fibrosis", "OBSERVATION", 157, 165], ["HCC", "OBSERVATION", 169, 172]]], ["It is very likely that several of our candidate biomarkers are 'general' markers for liver damage since most are liverderived and some have already been found in liver infection [21] .", [["liver", "ANATOMY", 85, 90], ["liver", "ANATOMY", 162, 167], ["liver damage", "DISEASE", 85, 97], ["liver infection", "DISEASE", 162, 177], ["liver", "ORGAN", 85, 90], ["liver", "ORGAN", 162, 167], ["liver damage", "PROBLEM", 85, 97], ["liver infection", "PROBLEM", 162, 177], ["very likely", "UNCERTAINTY", 6, 17], ["liver", "ANATOMY", 85, 90], ["damage", "OBSERVATION", 91, 97], ["liver", "ANATOMY", 162, 167], ["infection", "OBSERVATION", 168, 177]]], ["In addition, we observed 5 biomarkers that were present in both mono and co-infection and had a good correlation between them.", [["co-infection", "DISEASE", 73, 85], ["5 biomarkers", "TEST", 25, 37], ["co-infection", "PROBLEM", 73, 85], ["co-infection", "OBSERVATION", 73, 85]]], ["This leads us to believe that there is a potential to identify biomarkers that would be able to diagnose fibrosis independent of HIV infection status.Serum biomarkers for HIV/HCV co-infectionWhile several non-invasive models utilize tests that are not routinely available, some groups have incorporated routine tests and laboratory data to assess fibrosis non-invasively [35] .", [["Serum", "ANATOMY", 150, 155], ["fibrosis", "DISEASE", 105, 113], ["HIV infection", "DISEASE", 129, 142], ["HIV/HCV co-infection", "DISEASE", 171, 191], ["fibrosis", "DISEASE", 347, 355], ["HIV", "ORGANISM", 129, 132], ["Serum", "ORGANISM_SUBSTANCE", 150, 155], ["HIV/HCV", "ORGANISM", 171, 178], ["HIV", "SPECIES", 171, 174], ["HIV", "SPECIES", 129, 132], ["HIV", "SPECIES", 171, 174], ["HCV", "SPECIES", 175, 178], ["diagnose fibrosis", "PROBLEM", 96, 113], ["HIV infection status", "PROBLEM", 129, 149], ["Serum biomarkers", "TEST", 150, 166], ["HIV", "PROBLEM", 171, 174], ["HCV co-infection", "PROBLEM", 175, 191], ["tests", "TEST", 233, 238], ["routine tests", "TEST", 303, 316], ["laboratory data", "TEST", 321, 336], ["fibrosis", "PROBLEM", 347, 355], ["fibrosis", "OBSERVATION", 105, 113]]], ["We tried to improve our algorithms by adding APRI values without success [data not shown].", [["APRI", "PROTEIN", 45, 49], ["APRI values", "TEST", 45, 56]]], ["Although Fibroscan has largely replaced liver biopsy clinically it still has poor overall specificity and lack of sensitivity in the middle stages of fibrosis.", [["liver biopsy", "ANATOMY", 40, 52], ["fibrosis", "DISEASE", 150, 158], ["liver biopsy", "MULTI-TISSUE_STRUCTURE", 40, 52], ["Fibroscan", "TEST", 9, 18], ["liver biopsy", "TEST", 40, 52], ["fibrosis", "PROBLEM", 150, 158], ["Fibroscan", "OBSERVATION", 9, 18], ["liver", "ANATOMY", 40, 45], ["biopsy", "OBSERVATION", 46, 52], ["middle stages", "OBSERVATION_MODIFIER", 133, 146], ["fibrosis", "OBSERVATION", 150, 158]]], ["It might be of interest to evaluate the potential of incorporating Fibroscan to improve the accuracy of our diagnostic algorithms particularly for distinguishing the middle stages of fibrosis.Serum biomarkers for HIV/HCV co-infectionIn the emerging field of MS-based protein profiling of body fluids, the profile itself can be used to diagnose disease.", [["Serum", "ANATOMY", 192, 197], ["body fluids", "ANATOMY", 288, 299], ["fibrosis", "DISEASE", 183, 191], ["HIV/HCV co-infection", "DISEASE", 213, 233], ["Fibroscan", "SIMPLE_CHEMICAL", 67, 76], ["Serum", "ORGANISM_SUBSTANCE", 192, 197], ["HIV/HCV", "ORGANISM", 213, 220], ["body", "ORGANISM_SUBDIVISION", 288, 292], ["HIV", "SPECIES", 213, 216], ["HIV", "SPECIES", 213, 216], ["HCV", "SPECIES", 217, 220], ["incorporating Fibroscan", "TEST", 53, 76], ["our diagnostic algorithms", "TEST", 104, 129], ["fibrosis", "PROBLEM", 183, 191], ["Serum biomarkers", "TEST", 192, 208], ["HIV", "PROBLEM", 213, 216], ["HCV co-infection", "PROBLEM", 217, 233], ["body fluids", "TREATMENT", 288, 299], ["diagnose disease", "PROBLEM", 335, 351], ["middle stages", "OBSERVATION_MODIFIER", 166, 179], ["fibrosis", "OBSERVATION", 183, 191]]], ["Extending its use does not depend on identification of the proteins in the discriminating peaks.", [["the proteins", "TEST", 55, 67]]], ["However, protein identification is still possible, and adds biological relevance to the findings.", [["protein identification", "TEST", 9, 31]]], ["We were able to identify, Ig kappa chain C region, haptoglobin, a Serum biomarkers for HIV/HCV co-infection Decision tree to differentiate non-fibrotic individuals (F1) from individuals with significant fibrosis (F2 and above) in HCV-infected individuals using known biomarkers.", [["Serum", "ANATOMY", 66, 71], ["fibrosis", "DISEASE", 203, 211], ["HCV-infected", "DISEASE", 230, 242], ["Ig kappa chain C", "GENE_OR_GENE_PRODUCT", 26, 42], ["haptoglobin", "GENE_OR_GENE_PRODUCT", 51, 62], ["Serum", "ORGANISM_SUBSTANCE", 66, 71], ["HIV/HCV", "ORGANISM", 87, 94], ["HCV", "ORGANISM", 230, 233], ["individuals", "ORGANISM", 243, 254], ["Ig kappa chain C region", "PROTEIN", 26, 49], ["haptoglobin", "PROTEIN", 51, 62], ["HIV", "SPECIES", 87, 90], ["HIV", "SPECIES", 87, 90], ["HCV", "SPECIES", 91, 94], ["HCV", "SPECIES", 230, 233], ["Ig kappa chain C region", "PROBLEM", 26, 49], ["haptoglobin", "TEST", 51, 62], ["a Serum biomarkers", "TEST", 64, 82], ["HIV", "PROBLEM", 87, 90], ["HCV co-infection", "PROBLEM", 91, 107], ["non-fibrotic individuals", "PROBLEM", 139, 163], ["significant fibrosis", "PROBLEM", 191, 211], ["HCV", "PROBLEM", 230, 233], ["infected individuals", "PROBLEM", 234, 254], ["known biomarkers", "TEST", 261, 277], ["significant", "OBSERVATION_MODIFIER", 191, 202], ["fibrosis", "OBSERVATION", 203, 211], ["infected", "OBSERVATION", 234, 242]]], ["A biomarker pattern based on CART analysis was used to generate candidate diagnostic algorithms.", [["A biomarker pattern", "TEST", 0, 19], ["CART analysis", "TEST", 29, 42], ["diagnostic algorithms", "TEST", 74, 95]]], ["The numbers in the root node, the descendant nodes and the terminal nodes represent mass values (Cxxxxxx) followed by intensity values.", [["root node", "ANATOMY", 19, 28], ["descendant nodes", "ANATOMY", 34, 50], ["terminal nodes", "ANATOMY", 59, 73], ["root node", "MULTI-TISSUE_STRUCTURE", 19, 28], ["descendant nodes", "MULTI-TISSUE_STRUCTURE", 34, 50], ["terminal nodes", "MULTI-TISSUE_STRUCTURE", 59, 73], ["mass values", "PROBLEM", 84, 95], ["intensity values", "TEST", 118, 134], ["numbers", "OBSERVATION_MODIFIER", 4, 11], ["root", "OBSERVATION_MODIFIER", 19, 23], ["node", "OBSERVATION", 24, 28], ["descendant", "OBSERVATION_MODIFIER", 34, 44], ["nodes", "OBSERVATION", 45, 50], ["terminal", "OBSERVATION_MODIFIER", 59, 67], ["nodes", "OBSERVATION", 68, 73], ["mass", "OBSERVATION", 84, 88]]], ["Class 1: non-fibrotic individuals, Class 2: individuals with significant fibrosis. truncated form of ApoA1 and plasminogen.", [["fibrosis", "DISEASE", 73, 81], ["individuals", "ORGANISM", 44, 55], ["ApoA1", "GENE_OR_GENE_PRODUCT", 101, 106], ["plasminogen", "GENE_OR_GENE_PRODUCT", 111, 122], ["ApoA1", "PROTEIN", 101, 106], ["plasminogen", "PROTEIN", 111, 122], ["significant fibrosis", "PROBLEM", 61, 81], ["ApoA1 and plasminogen", "TREATMENT", 101, 122], ["significant", "OBSERVATION_MODIFIER", 61, 72], ["fibrosis", "OBSERVATION", 73, 81]]], ["It is interesting to observe that most of these proteins have already being identified as biomarkers for fibrosis.", [["fibrosis", "DISEASE", 105, 113], ["fibrosis", "PROBLEM", 105, 113], ["fibrosis", "OBSERVATION", 105, 113]]], ["For example, the Fibrotest is based on haptoglobin, alpha-2 macroglobulin, gamma globulin, ApoA1, gamma glutamyl transferase and total bilirubin measurement in serum specimens [36] .", [["serum specimens", "ANATOMY", 160, 175], ["bilirubin", "CHEMICAL", 135, 144], ["glutamyl", "CHEMICAL", 104, 112], ["bilirubin", "CHEMICAL", 135, 144], ["haptoglobin", "GENE_OR_GENE_PRODUCT", 39, 50], ["alpha-2 macroglobulin", "GENE_OR_GENE_PRODUCT", 52, 73], ["gamma globulin", "GENE_OR_GENE_PRODUCT", 75, 89], ["ApoA1", "GENE_OR_GENE_PRODUCT", 91, 96], ["gamma glutamyl transferase", "GENE_OR_GENE_PRODUCT", 98, 124], ["bilirubin", "SIMPLE_CHEMICAL", 135, 144], ["serum", "ORGANISM_SUBSTANCE", 160, 165], ["haptoglobin", "PROTEIN", 39, 50], ["alpha-2 macroglobulin", "PROTEIN", 52, 73], ["gamma globulin", "PROTEIN", 75, 89], ["ApoA1", "PROTEIN", 91, 96], ["gamma glutamyl transferase", "PROTEIN", 98, 124], ["the Fibrotest", "TEST", 13, 26], ["haptoglobin", "TEST", 39, 50], ["alpha", "TEST", 52, 57], ["macroglobulin", "TEST", 60, 73], ["gamma globulin", "TEST", 75, 89], ["ApoA1", "TEST", 91, 96], ["gamma glutamyl transferase", "TEST", 98, 124], ["total bilirubin measurement", "TEST", 129, 156], ["serum specimens", "TEST", 160, 175]]], ["Ig kappa C region is known to be a good biomarker for inflammation and malignancy [37] , it is a predictor of non-Hodgkin's lymphoma in patients with HIV [38] and patients with HCV [39] .", [["non-Hodgkin's lymphoma", "ANATOMY", 110, 132], ["inflammation", "DISEASE", 54, 66], ["malignancy", "DISEASE", 71, 81], ["non-Hodgkin's lymphoma", "DISEASE", 110, 132], ["Ig kappa C", "GENE_OR_GENE_PRODUCT", 0, 10], ["non-Hodgkin's lymphoma", "CANCER", 110, 132], ["patients", "ORGANISM", 136, 144], ["patients", "ORGANISM", 163, 171], ["Ig kappa C region", "DNA", 0, 17], ["patients", "SPECIES", 136, 144], ["HIV", "SPECIES", 150, 153], ["patients", "SPECIES", 163, 171], ["HIV", "SPECIES", 150, 153], ["HCV", "SPECIES", 177, 180], ["Ig kappa C region", "PROBLEM", 0, 17], ["inflammation", "PROBLEM", 54, 66], ["malignancy", "PROBLEM", 71, 81], ["non-Hodgkin's lymphoma", "PROBLEM", 110, 132], ["HIV", "PROBLEM", 150, 153], ["HCV", "PROBLEM", 177, 180], ["known to be", "UNCERTAINTY", 21, 32], ["inflammation", "OBSERVATION", 54, 66], ["malignancy", "OBSERVATION", 71, 81], ["non-Hodgkin's lymphoma", "OBSERVATION", 110, 132]]], ["Our data demonstrate that using SELDI-TOF MS technology we could stage discrete levels of liver fibrosis as changes of intensity of these biomarkers are detected.", [["liver", "ANATOMY", 90, 95], ["fibrosis", "DISEASE", 96, 104], ["liver", "ORGAN", 90, 95], ["Our data", "TEST", 0, 8], ["SELDI-TOF MS technology", "TREATMENT", 32, 55], ["liver fibrosis", "PROBLEM", 90, 104], ["these biomarkers", "TEST", 132, 148], ["liver", "ANATOMY", 90, 95], ["fibrosis", "OBSERVATION", 96, 104]]], ["Even when we used peaks from already known markers, we weren't able to obtain an optimal algorithm compare to the unidentified peaks.Serum biomarkers for HIV/HCV co-infectionThe sera used in our study were fractionated without prior depletion of the most abundant serum proteins.", [["Serum", "ANATOMY", 133, 138], ["sera", "ANATOMY", 178, 182], ["serum", "ANATOMY", 264, 269], ["HIV/HCV co-infection", "DISEASE", 154, 174], ["Serum", "ORGANISM_SUBSTANCE", 133, 138], ["HIV/HCV", "ORGANISM", 154, 161], ["sera", "ORGANISM_SUBSTANCE", 178, 182], ["serum", "ORGANISM_SUBSTANCE", 264, 269], ["serum proteins", "PROTEIN", 264, 278], ["HIV", "SPECIES", 154, 157], ["HIV", "SPECIES", 154, 157], ["HCV", "SPECIES", 158, 161], ["an optimal algorithm", "TEST", 78, 98], ["Serum biomarkers", "TEST", 133, 149], ["HIV", "PROBLEM", 154, 157], ["HCV co-infection", "PROBLEM", 158, 174], ["The sera", "TEST", 174, 182], ["our study", "TEST", 191, 200], ["prior depletion", "PROBLEM", 227, 242], ["the most abundant serum proteins", "PROBLEM", 246, 278]]], ["High-abundance proteins can mask the presence of lower-abundance proteins of either host or virus origin in MS studies.", [["High-abundance proteins", "PROTEIN", 0, 23], ["lower-abundance proteins", "PROTEIN", 49, 73], ["High-abundance proteins", "PROBLEM", 0, 23], ["lower-abundance proteins", "PROBLEM", 49, 73], ["MS studies", "TEST", 108, 118], ["lower", "OBSERVATION_MODIFIER", 49, 54]]], ["Some of the identified biomarkers proved to be fragments of full length of abundant proteins.", [["abundant proteins", "PROTEIN", 75, 92], ["abundant proteins", "PROBLEM", 75, 92], ["full length", "OBSERVATION_MODIFIER", 60, 71], ["abundant", "OBSERVATION_MODIFIER", 75, 83], ["proteins", "OBSERVATION", 84, 92]]], ["These fragments may be products of the natural course of protein degradation or associated with the extent and/or type of infection.", [["fragments", "ANATOMY", 6, 15], ["infection", "DISEASE", 122, 131], ["These fragments", "PROBLEM", 0, 15], ["protein degradation", "PROBLEM", 57, 76], ["infection", "PROBLEM", 122, 131], ["fragments", "OBSERVATION", 6, 15], ["may be", "UNCERTAINTY", 16, 22], ["natural", "OBSERVATION_MODIFIER", 39, 46], ["course", "OBSERVATION_MODIFIER", 47, 53], ["protein degradation", "OBSERVATION", 57, 76], ["infection", "OBSERVATION", 122, 131]]], ["The identification of a viral derived plasma biomarker could greatly enhance the specificity of our assay.Serum biomarkers for HIV/HCV co-infectionOther biomarkers have been identified in HIV/HCV mono and co-infected individuals such as POTE ankyrin domain family, member E, histidine-rich glycoprotein, fibronectin and complement C3 [40] .", [["plasma", "ANATOMY", 38, 44], ["Serum", "ANATOMY", 106, 111], ["HIV/HCV mono and co-infected", "DISEASE", 188, 216], ["histidine", "CHEMICAL", 275, 284], ["plasma", "ORGANISM_SUBSTANCE", 38, 44], ["Serum", "ORGANISM_SUBSTANCE", 106, 111], ["HIV/HCV", "ORGANISM", 127, 134], ["HIV/HCV mono", "ORGANISM", 188, 200], ["ankyrin", "GENE_OR_GENE_PRODUCT", 242, 249], ["histidine-rich glycoprotein", "GENE_OR_GENE_PRODUCT", 275, 302], ["fibronectin", "GENE_OR_GENE_PRODUCT", 304, 315], ["complement C3", "GENE_OR_GENE_PRODUCT", 320, 333], ["POTE ankyrin domain family", "PROTEIN", 237, 263], ["member E", "PROTEIN", 265, 273], ["histidine-rich glycoprotein", "PROTEIN", 275, 302], ["fibronectin", "PROTEIN", 304, 315], ["complement C3", "PROTEIN", 320, 333], ["HIV", "SPECIES", 188, 191], ["HIV", "SPECIES", 127, 130], ["HCV", "SPECIES", 131, 134], ["HIV", "SPECIES", 188, 191], ["HCV", "SPECIES", 192, 195], ["a viral derived plasma biomarker", "TEST", 22, 54], ["our assay", "TEST", 96, 105], ["Serum biomarkers", "TEST", 106, 122], ["HIV", "PROBLEM", 127, 130], ["HCV co-infectionOther biomarkers", "PROBLEM", 131, 163], ["HIV/HCV mono", "PROBLEM", 188, 200], ["co-infected individuals", "PROBLEM", 205, 228], ["histidine-rich glycoprotein", "TREATMENT", 275, 302], ["fibronectin and complement C3", "TREATMENT", 304, 333], ["viral", "OBSERVATION", 24, 29]]], ["As some have similar mass as the biomarkers we discovered by SELDI-TOF MS, it would be of interest to confirm these using immunocapture assay.", [["similar mass", "PROBLEM", 13, 25], ["the biomarkers", "TEST", 29, 43], ["immunocapture assay", "TEST", 122, 141], ["similar", "OBSERVATION_MODIFIER", 13, 20], ["mass", "OBSERVATION", 21, 25]]], ["In addition, Yang et al [41] found complement C4-a and inter-alpha-trypsin inhibition to heavy chain H4, as biomarker candidates for predicting hepatic fibrosis using Isobaric Tags for Relative and Absolute Quantitation (iTRAQ) and differential gel electrophoresis (DIGE).", [["hepatic", "ANATOMY", 144, 151], ["hepatic fibrosis", "DISEASE", 144, 160], ["inter-alpha-trypsin", "GENE_OR_GENE_PRODUCT", 55, 74], ["heavy chain H4", "GENE_OR_GENE_PRODUCT", 89, 103], ["hepatic", "ORGAN", 144, 151], ["complement C4", "PROTEIN", 35, 48], ["inter-alpha", "PROTEIN", 55, 66], ["trypsin", "PROTEIN", 67, 74], ["heavy chain H4", "PROTEIN", 89, 103], ["complement C4", "TEST", 35, 48], ["inter-alpha-trypsin inhibition", "TREATMENT", 55, 85], ["heavy chain H4", "PROBLEM", 89, 103], ["hepatic fibrosis", "PROBLEM", 144, 160], ["Isobaric Tags", "TEST", 167, 180], ["Absolute Quantitation", "TEST", 198, 219], ["differential gel electrophoresis", "TEST", 232, 264], ["hepatic", "ANATOMY", 144, 151], ["fibrosis", "OBSERVATION", 152, 160]]], ["The authors also found ApoA1, Ig kappa chain C region, haptoglobin and others as potential biomarker candidates.", [["ApoA1", "GENE_OR_GENE_PRODUCT", 23, 28], ["Ig kappa chain C", "GENE_OR_GENE_PRODUCT", 30, 46], ["haptoglobin", "GENE_OR_GENE_PRODUCT", 55, 66], ["ApoA1", "PROTEIN", 23, 28], ["Ig kappa chain C region", "PROTEIN", 30, 53], ["haptoglobin", "PROTEIN", 55, 66], ["ApoA1", "TEST", 23, 28], ["Ig kappa chain C region", "PROBLEM", 30, 53], ["haptoglobin", "TEST", 55, 66]]], ["However, this study only included pooled serum samples of 24 people with chronic HCV and 6 non-infected individuals.", [["serum samples", "ANATOMY", 41, 54], ["HCV", "DISEASE", 81, 84], ["serum samples", "ORGANISM_SUBSTANCE", 41, 54], ["people", "ORGANISM", 61, 67], ["people", "SPECIES", 61, 67], ["HCV", "SPECIES", 81, 84], ["this study", "TEST", 9, 19], ["pooled serum samples", "TEST", 34, 54], ["chronic HCV", "PROBLEM", 73, 84], ["6 non-infected individuals", "PROBLEM", 89, 115], ["chronic", "OBSERVATION_MODIFIER", 73, 80], ["HCV", "OBSERVATION", 81, 84]]], ["Using SELDI-TOF MS serum profiling, Schwelgle et al [23] found 4 biomarkers (5.8, 8.9, 9.5 and 11.7 k(m/z)) that helped differentiate between healthy controls and HCC patients.", [["serum", "ANATOMY", 19, 24], ["HCC", "ANATOMY", 163, 166], ["HCC", "DISEASE", 163, 166], ["serum", "ORGANISM_SUBSTANCE", 19, 24], ["HCC", "CANCER", 163, 166], ["patients", "ORGANISM", 167, 175], ["patients", "SPECIES", 167, 175], ["SELDI", "TEST", 6, 11], ["serum profiling", "TEST", 19, 34], ["biomarkers", "TEST", 65, 75], ["k(m/z)", "TEST", 100, 106], ["HCC", "OBSERVATION", 163, 166]]], ["In this study, they did not fractionate samples but they concentrated on low-mass proteins that have a metal-binding affinity.", [["samples", "ANATOMY", 40, 47], ["low-mass proteins", "PROTEIN", 73, 90], ["this study", "TEST", 3, 13], ["low-mass proteins", "PROBLEM", 73, 90]]], ["Our study differs significantly in that we only tested HCV infected individuals, we looked at high-and low-mass proteins after fractionation of the samples and we used 3 different types of ProteinChips (metal binding, weak cation exchange, and hydrophobic/reverse-phase).Serum biomarkers for HIV/HCV co-infectionUnlike previous studies using SELDI-TOF MS to diagnose a disease or infection, we aimed to evaluate the progression of a disease and not a dichotomous \"positive\" and \"negative\" outcome.", [["samples", "ANATOMY", 148, 155], ["Serum", "ANATOMY", 271, 276], ["HCV infected", "DISEASE", 55, 67], ["HIV/HCV co-infection", "DISEASE", 292, 312], ["infection", "DISEASE", 380, 389], ["HCV", "ORGANISM", 55, 58], ["ProteinChips", "SIMPLE_CHEMICAL", 189, 201], ["cation", "SIMPLE_CHEMICAL", 223, 229], ["Serum", "ORGANISM_SUBSTANCE", 271, 276], ["HIV/HCV", "ORGANISM", 292, 299], ["HIV", "SPECIES", 292, 295], ["HCV", "SPECIES", 55, 58], ["HIV", "SPECIES", 292, 295], ["HCV", "SPECIES", 296, 299], ["Our study", "TEST", 0, 9], ["HCV infected individuals", "PROBLEM", 55, 79], ["low-mass proteins", "PROBLEM", 103, 120], ["the samples", "TEST", 144, 155], ["ProteinChips (metal binding", "TREATMENT", 189, 216], ["weak cation exchange", "TREATMENT", 218, 238], ["hydrophobic/reverse-phase", "TREATMENT", 244, 269], ["Serum biomarkers", "TEST", 271, 287], ["HIV", "PROBLEM", 292, 295], ["HCV co-infection", "PROBLEM", 296, 312], ["previous studies", "TEST", 319, 335], ["SELDI", "TEST", 342, 347], ["a disease", "PROBLEM", 367, 376], ["infection", "PROBLEM", 380, 389], ["a disease", "PROBLEM", 431, 440], ["a dichotomous \"positive\"", "PROBLEM", 449, 473], ["disease", "OBSERVATION", 369, 376], ["infection", "OBSERVATION", 380, 389], ["disease", "OBSERVATION", 433, 440]]], ["As expected we did not observe either absence or presence of specific biomarkers/peaks but rather a gradual difference in plasma levels of certain peptides/proteins at the different stages of liver fibrosis.", [["plasma", "ANATOMY", 122, 128], ["liver", "ANATOMY", 192, 197], ["liver fibrosis", "DISEASE", 192, 206], ["plasma", "ORGANISM_SUBSTANCE", 122, 128], ["liver", "ORGAN", 192, 197], ["specific biomarkers/peaks", "PROBLEM", 61, 86], ["a gradual difference", "PROBLEM", 98, 118], ["plasma levels", "TEST", 122, 135], ["certain peptides/proteins", "PROBLEM", 139, 164], ["liver fibrosis", "PROBLEM", 192, 206], ["gradual", "OBSERVATION_MODIFIER", 100, 107], ["different stages", "OBSERVATION_MODIFIER", 172, 188], ["liver", "ANATOMY", 192, 197], ["fibrosis", "OBSERVATION", 198, 206]]], ["It would be interesting to see if by scaling each biomarker and adding to obtain a score, we could accomplish a better correlation with the stage of liver fibrosis in these patients.", [["liver", "ANATOMY", 149, 154], ["liver fibrosis", "DISEASE", 149, 163], ["liver", "ORGAN", 149, 154], ["patients", "ORGANISM", 173, 181], ["patients", "SPECIES", 173, 181], ["liver fibrosis", "PROBLEM", 149, 163], ["liver", "ANATOMY", 149, 154], ["fibrosis", "OBSERVATION", 155, 163]]], ["The CCC study has enrolled co-infected individuals since 2003.", [["The CCC study", "TEST", 0, 13], ["enrolled co-infected individuals", "PROBLEM", 18, 50]]], ["We are in the process of studying longitudinal changes of these biomarkers in co-infected individuals during the progression of fibrosis.", [["fibrosis", "DISEASE", 128, 136], ["these biomarkers", "TEST", 58, 74], ["fibrosis", "PROBLEM", 128, 136], ["progression", "OBSERVATION_MODIFIER", 113, 124], ["fibrosis", "OBSERVATION", 128, 136]]], ["In addition, we wonder if these biomarkers may vary after treatment of HCV infection as it has been shown with other markers [42, 43] .Serum biomarkers for HIV/HCV co-infectionNon-invasive measures of liver fibrosis are gaining acceptance for long-term evaluation of hepatic complication in HIV/HCV co-infection [44] .", [["Serum", "ANATOMY", 135, 140], ["liver", "ANATOMY", 201, 206], ["hepatic", "ANATOMY", 267, 274], ["HCV infection", "DISEASE", 71, 84], ["HIV/HCV co-infection", "DISEASE", 156, 176], ["liver fibrosis", "DISEASE", 201, 215], ["hepatic complication", "DISEASE", 267, 287], ["HIV/HCV co-infection", "DISEASE", 291, 311], ["HCV", "ORGANISM", 71, 74], ["Serum", "ORGANISM_SUBSTANCE", 135, 140], ["HIV/HCV", "ORGANISM", 156, 163], ["liver", "ORGAN", 201, 206], ["hepatic", "ORGAN", 267, 274], ["HIV/HCV", "ORGANISM", 291, 298], ["HIV", "SPECIES", 156, 159], ["HIV", "SPECIES", 291, 294], ["HCV", "SPECIES", 71, 74], ["HIV", "SPECIES", 156, 159], ["HCV", "SPECIES", 160, 163], ["HIV", "SPECIES", 291, 294], ["HCV", "SPECIES", 295, 298], ["these biomarkers", "TEST", 26, 42], ["HCV infection", "PROBLEM", 71, 84], ["Serum biomarkers", "TEST", 135, 151], ["HIV", "PROBLEM", 156, 159], ["HCV co-infection", "PROBLEM", 160, 176], ["liver fibrosis", "PROBLEM", 201, 215], ["long-term evaluation", "TEST", 243, 263], ["hepatic complication", "PROBLEM", 267, 287], ["HIV", "PROBLEM", 291, 294], ["HCV co-infection", "PROBLEM", 295, 311], ["HCV", "OBSERVATION", 71, 74], ["liver", "ANATOMY", 201, 206], ["fibrosis", "OBSERVATION", 207, 215], ["hepatic", "ANATOMY", 267, 274], ["complication", "OBSERVATION", 275, 287]]], ["We have investigated the serum proteome profile of HIV/HCV co-infected and HCV mono-infected patients by SELDI-TOF MS. The identification of the biomarkers may also give unique insight into the complex and prolonged host-virus interactions that lead to liver fibrosis.Serum biomarkers for HIV/HCV co-infectionSupporting information S1 Table.", [["serum", "ANATOMY", 25, 30], ["liver", "ANATOMY", 253, 258], ["Serum", "ANATOMY", 268, 273], ["HIV/HCV co-infected", "DISEASE", 51, 70], ["HCV mono-infected", "DISEASE", 75, 92], ["liver fibrosis", "DISEASE", 253, 267], ["HIV/HCV co-infection", "DISEASE", 289, 309], ["serum", "ORGANISM_SUBSTANCE", 25, 30], ["HIV/HCV", "ORGANISM", 51, 58], ["HCV mono", "ORGANISM", 75, 83], ["patients", "ORGANISM", 93, 101], ["liver", "ORGAN", 253, 258], ["Serum", "ORGANISM_SUBSTANCE", 268, 273], ["HIV/HCV", "ORGANISM", 289, 296], ["HIV", "SPECIES", 51, 54], ["patients", "SPECIES", 93, 101], ["HIV", "SPECIES", 289, 292], ["HIV", "SPECIES", 51, 54], ["HCV", "SPECIES", 55, 58], ["HCV", "SPECIES", 75, 78], ["HIV", "SPECIES", 289, 292], ["HCV", "SPECIES", 293, 296], ["the serum proteome profile", "TEST", 21, 47], ["HIV", "PROBLEM", 51, 54], ["HCV co-infected", "PROBLEM", 55, 70], ["HCV mono", "PROBLEM", 75, 83], ["the biomarkers", "TEST", 141, 155], ["the complex and prolonged host-virus interactions", "PROBLEM", 190, 239], ["liver fibrosis", "PROBLEM", 253, 267], ["Serum biomarkers", "TEST", 268, 284], ["HIV", "PROBLEM", 289, 292], ["HCV co-infection", "PROBLEM", 293, 309], ["liver", "ANATOMY", 253, 258], ["fibrosis", "OBSERVATION", 259, 267]]]], "PMC7115499": [["IntroductionInfluenza is one of the respiratory pathogens that can cause serious health problems in both mortality and morbidity worldwide.", [["Influenza", "DISEASE", 12, 21], ["IntroductionInfluenza", "PROBLEM", 0, 21], ["the respiratory pathogens", "PROBLEM", 32, 57], ["serious health problems", "PROBLEM", 73, 96]]], ["However, unspecific presenting symptoms of influenza, absence of timely laboratory tests in clinical practice and frequent secondary bacterial pneumonia make it difficult to estimate the disease burden of influenza directly from the clinical diagnosed cases [1], [2].", [["influenza", "DISEASE", 43, 52], ["pneumonia", "DISEASE", 143, 152], ["influenza", "DISEASE", 205, 214], ["unspecific presenting symptoms", "PROBLEM", 9, 39], ["influenza", "PROBLEM", 43, 52], ["laboratory tests", "TEST", 72, 88], ["frequent secondary bacterial pneumonia", "PROBLEM", 114, 152], ["the disease burden", "PROBLEM", 183, 201], ["influenza", "PROBLEM", 205, 214], ["bacterial", "OBSERVATION_MODIFIER", 133, 142], ["pneumonia", "OBSERVATION", 143, 152]]], ["It is therefore necessary to assess influenza associated excess mortality or hospitalization by statistical modeling and use the estimate as a measurement for severity of influenza epidemics [3].", [["influenza", "DISEASE", 36, 45], ["influenza", "DISEASE", 171, 180], ["influenza", "PROBLEM", 36, 45], ["influenza epidemics", "PROBLEM", 171, 190]]], ["Some studies reported that the disease burden of influenza was nearly equivalent across some temperate countries [4], but others noticed that effects of influenza occasionally exhibited disparities between geographical areas even in the same influenza season [5].", [["influenza", "DISEASE", 49, 58], ["influenza", "DISEASE", 153, 162], ["influenza", "DISEASE", 242, 251], ["Some studies", "TEST", 0, 12], ["the disease burden", "PROBLEM", 27, 45], ["influenza", "PROBLEM", 49, 58], ["influenza", "PROBLEM", 153, 162], ["influenza", "OBSERVATION", 49, 58]]], ["It has been proposed that socioeconomic factors and various circulating virus strains could play an important role in determining the severity of influenza epidemics [5], [6], [7].", [["influenza", "DISEASE", 146, 155], ["socioeconomic factors", "PROBLEM", 26, 47], ["various circulating virus strains", "PROBLEM", 52, 85], ["influenza epidemics", "PROBLEM", 146, 165]]], ["Some environmental factors that are critical for survival and transmission of viruses, such as temperature and humidity, could also be involved as effect modifiers [8].", [["Some environmental factors", "PROBLEM", 0, 26], ["viruses", "PROBLEM", 78, 85]]], ["However, geographical variations in influenza associated disease burden in the tropics and subtropics have not been explored.IntroductionA recent large-scale phylogenetic study postulated that novel influenza viruses first emerge in the tropics and subsequently spread into the temperate when environmental factors favor virus transmissions [9].", [["influenza", "DISEASE", 36, 45], ["influenza viruses", "DISEASE", 199, 216], ["influenza viruses", "ORGANISM", 199, 216], ["geographical variations", "PROBLEM", 9, 32], ["influenza associated disease burden", "PROBLEM", 36, 71], ["scale phylogenetic study", "TEST", 152, 176], ["novel influenza viruses", "PROBLEM", 193, 216], ["virus transmissions", "PROBLEM", 321, 340], ["geographical", "OBSERVATION_MODIFIER", 9, 21], ["variations", "OBSERVATION_MODIFIER", 22, 32], ["influenza", "OBSERVATION", 36, 45], ["large", "OBSERVATION_MODIFIER", 146, 151]]], ["Particularly, East and Southeast Asian countries are proposed as the potential reservoirs for dormant influenza viruses, although the mechanism remains unclear [10].", [["influenza viruses", "DISEASE", 102, 119], ["influenza viruses", "ORGANISM", 102, 119], ["dormant influenza viruses", "PROBLEM", 94, 119]]], ["Unfortunately, there are few disease burden studies in this region to provide the evidence for or against the postulation, largely due to a lack of data from well-designed long-standing surveillance.", [["few disease burden studies", "PROBLEM", 25, 51], ["long-standing surveillance", "TEST", 172, 198], ["few", "OBSERVATION_MODIFIER", 25, 28], ["disease", "OBSERVATION", 29, 36]]], ["This situation was further complicated by the unpredictable influenza seasonality in these regions.IntroductionIn this study we applied a standardized modeling strategy to three metropolitan cities in East and Southeast Asia: Guangzhou, Hong Kong and Singapore, all of which have well-organized surveillance networks for influenza for several years.", [["influenza", "DISEASE", 321, 330], ["the unpredictable influenza seasonality in these regions", "PROBLEM", 42, 98], ["this study", "TEST", 114, 124], ["a standardized modeling strategy", "TREATMENT", 136, 168], ["influenza", "PROBLEM", 321, 330], ["unpredictable", "OBSERVATION_MODIFIER", 46, 59], ["influenza", "OBSERVATION", 60, 69]]], ["Guangzhou and Hong Kong, both located at southern China, share a similar subtropical climate with a mean temperature around 23 \u00b0C, but the latter is more economically developed with a higher GDP per capita of $27,762 in Hong Kong as compared with that of $9235 in Guangzhou in 2006 [11], [12].", [["GDP", "CHEMICAL", 191, 194], ["GDP", "CHEMICAL", 191, 194], ["GDP", "SIMPLE_CHEMICAL", 191, 194], ["a mean temperature", "TEST", 98, 116]]], ["The socioeconomic level of Singapore is comparable to Hong Kong, with a GDP per capita of $31,622 in 2006 [13].", [["GDP", "CHEMICAL", 72, 75]]], ["The difference and similarity between these cities, in terms of socioeconomic status and environmental factors, provide us a good opportunity to explore the factors that may affect the disparity or similarity across geographical areas.Influenza surveillance data ::: MethodsThe influenza virology data in Guangzhou, Hong Kong and Singapore during 2004\u20132006 were obtained from the Guang Dong Provincial Center for Disease Control and Prevention (GDCDC), the Hong Kong Department of Health (DH) and the Singapore Ministry of Health (MOH), respectively.", [["Influenza", "DISEASE", 235, 244], ["Methods", "TREATMENT", 267, 274], ["Disease Control", "TREATMENT", 413, 428]]], ["The nasopharyngeal aspirate specimens were collected from the outpatients or inpatients presenting influenza-like illness (ILI) symptoms of fever (\u226538 \u00b0C), cough or sore throat and then were tested for influenza by direct immunofluorescence or cell culture.", [["nasopharyngeal aspirate specimens", "ANATOMY", 4, 37], ["cell", "ANATOMY", 244, 248], ["influenza-like illness", "DISEASE", 99, 121], ["ILI", "DISEASE", 123, 126], ["fever", "DISEASE", 140, 145], ["cough", "DISEASE", 156, 161], ["sore throat", "DISEASE", 165, 176], ["influenza", "DISEASE", 202, 211], ["nasopharyngeal aspirate specimens", "CANCER", 4, 37], ["outpatients", "ORGANISM", 62, 73], ["cell", "CELL", 244, 248], ["outpatients", "SPECIES", 62, 73], ["inpatients", "SPECIES", 77, 87], ["The nasopharyngeal aspirate specimens", "TEST", 0, 37], ["influenza", "PROBLEM", 99, 108], ["symptoms", "PROBLEM", 128, 136], ["fever", "PROBLEM", 140, 145], ["cough", "PROBLEM", 156, 161], ["sore throat", "PROBLEM", 165, 176], ["influenza", "PROBLEM", 202, 211], ["direct immunofluorescence", "TEST", 215, 240], ["cell culture", "TEST", 244, 256], ["nasopharyngeal", "ANATOMY", 4, 18]]], ["Positive samples were later typed or subtyped into A/H3N2, A/H1N1 and B by haemagglutination inhibition (HI) test with strain-specific antiserum provided by the World Health Organization (WHO).Mortality and meteorology data ::: MethodsMortality data for each city were obtained from Hong Kong Census and Statistics Department (coded according to the International Classification of Diseases Tenth Revision, ICD-10), Guangzhou Department of Health (coded in ICD-10) and Singapore Registry of Births and Deaths (coded in ICD-9), respectively.", [["samples", "ANATOMY", 9, 16], ["A/H3N2", "ORGANISM", 51, 57], ["A/H1N1", "ORGANISM", 59, 65], ["B", "CELL", 70, 71], ["antiserum", "ORGANISM_SUBSTANCE", 135, 144], ["A/H3N2", "SPECIES", 51, 57], ["A/H1N1", "SPECIES", 59, 65], ["A/H3N2", "TEST", 51, 57], ["H1N1", "PROBLEM", 61, 65], ["haemagglutination inhibition", "TEST", 75, 103], ["strain", "PROBLEM", 119, 125], ["Diseases Tenth Revision", "TREATMENT", 382, 405], ["ICD", "TREATMENT", 407, 410]]], ["We aggregated the weekly numbers of deaths with underlying cause of cardiorespiratory diseases (CRD, ICD-9 390-519; ICD-10 I00-I99, J00-J99), pneumonia and influenza (P&I, ICD-9 480-487; ICD-10 J10-J18), chronic obstructive pulmonary diseases (COPD, ICD-9 490-496; ICD-10 J40-J47), ischemic heart diseases (IHD, ICD-9 410-414; ICD-10 I20-I25) and all causes (ICD-9 001-999; ICD-10 A00-T99).", [["pulmonary", "ANATOMY", 224, 233], ["heart", "ANATOMY", 291, 296], ["deaths", "DISEASE", 36, 42], ["cardiorespiratory diseases", "DISEASE", 68, 94], ["CRD", "DISEASE", 96, 99], ["pneumonia", "DISEASE", 142, 151], ["influenza", "DISEASE", 156, 165], ["chronic obstructive pulmonary diseases", "DISEASE", 204, 242], ["COPD", "DISEASE", 244, 248], ["ischemic heart diseases", "DISEASE", 282, 305], ["IHD", "DISEASE", 307, 310], ["pulmonary", "ORGAN", 224, 233], ["heart", "ORGAN", 291, 296], ["cardiorespiratory diseases", "PROBLEM", 68, 94], ["ICD", "TEST", 101, 104], ["ICD", "TEST", 116, 119], ["J00", "TEST", 132, 135], ["pneumonia", "PROBLEM", 142, 151], ["influenza", "PROBLEM", 156, 165], ["ICD", "TEST", 172, 175], ["ICD", "TEST", 187, 190], ["chronic obstructive pulmonary diseases", "PROBLEM", 204, 242], ["COPD", "PROBLEM", 244, 248], ["ICD", "TEST", 250, 253], ["ICD", "TEST", 265, 268], ["ischemic heart diseases", "PROBLEM", 282, 305], ["IHD", "PROBLEM", 307, 310], ["ICD", "TEST", 312, 315], ["ICD", "TEST", 327, 330], ["ICD", "TEST", 359, 362], ["ICD", "TEST", 374, 377], ["cardiorespiratory diseases", "OBSERVATION", 68, 94], ["pneumonia", "OBSERVATION", 142, 151], ["influenza", "OBSERVATION", 156, 165], ["chronic", "OBSERVATION_MODIFIER", 204, 211], ["obstructive", "OBSERVATION_MODIFIER", 212, 223], ["pulmonary", "ANATOMY", 224, 233], ["diseases", "OBSERVATION", 234, 242], ["COPD", "OBSERVATION", 244, 248], ["ischemic", "OBSERVATION_MODIFIER", 282, 290], ["heart", "ANATOMY", 291, 296], ["diseases", "OBSERVATION", 297, 305]]], ["We obtained the weekly mean temperature and humidity for three cities, from the National Meteorological Information Center in China, Hong Kong Observatory and Singapore National Environment Agency, respectively.Modeling influenza effects ::: MethodsWe fitted a Poisson regression model to weekly numbers of mortality with the aim to assess the percentage of excess mortality associated with increased influenza activity in the population, as described in our previous studies [14], [15].", [["Modeling influenza effects", "PROBLEM", 211, 237], ["Methods", "TREATMENT", 242, 249], ["excess mortality", "PROBLEM", 358, 374], ["increased influenza activity", "PROBLEM", 391, 419], ["influenza", "OBSERVATION", 220, 229], ["increased", "OBSERVATION_MODIFIER", 391, 400], ["influenza activity", "OBSERVATION", 401, 419]]], ["Briefly, long-term trends and seasonal patterns of mortality counts, as well as weekly average temperature and relative humidity, were added as confounders into the core models with their natural cubic spline smoothing functions.", [["long-term trends", "PROBLEM", 9, 25], ["mortality counts", "TEST", 51, 67], ["relative humidity", "TREATMENT", 111, 128], ["long-term", "OBSERVATION_MODIFIER", 9, 18]]], ["Both temperature and humidity have been found to affect influenza virus transmission [8] and also been associated with mortality in previous studies [16], [17].", [["influenza virus transmission", "DISEASE", 56, 84], ["influenza virus", "ORGANISM", 56, 71], ["influenza virus", "SPECIES", 56, 71], ["influenza virus", "SPECIES", 56, 71], ["humidity", "TREATMENT", 21, 29], ["influenza virus transmission", "PROBLEM", 56, 84], ["previous studies", "TEST", 132, 148]]], ["A typical form of core model islog(Yt)=ns(t)+ns(tempt)+ns(humdt)where Yt denotes the death numbers at week t; ns(t), ns(tempt) and ns(humdt) denote the natural spline smoothing functions of time, temperature and relative humidity, respectively.", [["death", "DISEASE", 85, 90], ["Yt", "PROTEIN", 70, 72], ["ns(tempt)", "TREATMENT", 117, 126], ["ns(humdt)", "TREATMENT", 131, 140]]], ["Auto-regressive terms in the residuals may be added to remove significant autocorrelations of residuals in first four weeks, so that time varying confounding could be adequately controlled.", [["significant autocorrelations of residuals", "PROBLEM", 62, 103], ["residuals", "OBSERVATION", 94, 103]]], ["The weekly proportions of specimens positive for specific influenza types/subtypes (named as influenza proportions, flut) were simultaneously entered into the core model, to estimate influenza effects:log(Yt)=ns(t)+ns(tempt)+ns(humdt)+flut", [["specimens", "ANATOMY", 26, 35], ["specimens", "TEST", 26, 35], ["specific influenza types/subtypes", "PROBLEM", 49, 82], ["ns", "TEST", 215, 217], ["flut", "ANATOMY", 235, 239]]]], "PMC7151928": [["Types ::: Overview of Hematopoietic stem cell transplantationHematopoietic stem cell transplantation is classified as autologous, allogeneic, or syngeneic.", [["Hematopoietic stem cell", "ANATOMY", 22, 45], ["Hematopoietic stem cell", "ANATOMY", 61, 84], ["Hematopoietic stem cell", "CELL", 22, 45], ["Hematopoietic stem cell", "CELL", 61, 84], ["syngeneic", "CANCER", 145, 154], ["Hematopoietic stem cell transplantation", "TREATMENT", 22, 61], ["Hematopoietic stem cell transplantation", "TREATMENT", 61, 100], ["autologous, allogeneic", "TREATMENT", 118, 140], ["syngeneic", "PROBLEM", 145, 154], ["Hematopoietic stem cell transplantation", "OBSERVATION", 22, 61], ["Hematopoietic", "OBSERVATION", 61, 74], ["stem cell transplantation", "OBSERVATION", 75, 100]]], ["In autologous HSCT, patients receive their own hematopoietic stem cells.", [["hematopoietic stem cells", "ANATOMY", 47, 71], ["patients", "ORGANISM", 20, 28], ["hematopoietic stem cells", "CELL", 47, 71], ["hematopoietic stem cells", "CELL_TYPE", 47, 71], ["patients", "SPECIES", 20, 28], ["their own hematopoietic stem cells", "TREATMENT", 37, 71], ["autologous HSCT", "OBSERVATION", 3, 18], ["hematopoietic stem cells", "OBSERVATION", 47, 71]]], ["In allogeneic HSCT, patients receive hematopoietic stem cells from a nonidentical sibling or unrelated matched donor.", [["hematopoietic stem cells", "ANATOMY", 37, 61], ["patients", "ORGANISM", 20, 28], ["hematopoietic stem cells", "CELL", 37, 61], ["hematopoietic stem cells", "CELL_TYPE", 37, 61], ["patients", "SPECIES", 20, 28], ["allogeneic HSCT", "TREATMENT", 3, 18], ["hematopoietic stem cells", "TREATMENT", 37, 61], ["unrelated matched donor", "PROBLEM", 93, 116], ["allogeneic HSCT", "OBSERVATION", 3, 18], ["hematopoietic stem cells", "OBSERVATION", 37, 61]]], ["In syngeneic HSCT, patients receive hematopoietic stem cells from a genetically identical twin.", [["hematopoietic stem cells", "ANATOMY", 36, 60], ["patients", "ORGANISM", 19, 27], ["hematopoietic stem cells", "CELL", 36, 60], ["hematopoietic stem cells", "CELL_TYPE", 36, 60], ["patients", "SPECIES", 19, 27], ["hematopoietic stem cells", "TREATMENT", 36, 60], ["syngeneic HSCT", "OBSERVATION", 3, 17], ["hematopoietic stem cells", "OBSERVATION", 36, 60]]], ["The source of the donor hematopoietic stem cells can be bone marrow, peripheral blood, or umbilical cord blood.", [["hematopoietic stem cells", "ANATOMY", 24, 48], ["bone marrow", "ANATOMY", 56, 67], ["peripheral blood", "ANATOMY", 69, 85], ["umbilical cord blood", "ANATOMY", 90, 110], ["hematopoietic stem cells", "CELL", 24, 48], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 56, 67], ["peripheral blood", "ORGANISM_SUBSTANCE", 69, 85], ["cord blood", "ORGANISM_SUBSTANCE", 100, 110], ["donor hematopoietic stem cells", "CELL_TYPE", 18, 48], ["the donor hematopoietic stem cells", "PROBLEM", 14, 48], ["bone marrow", "PROBLEM", 56, 67], ["peripheral blood, or umbilical cord blood", "PROBLEM", 69, 110], ["donor hematopoietic stem cells", "OBSERVATION", 18, 48], ["bone marrow", "OBSERVATION", 56, 67], ["peripheral", "ANATOMY_MODIFIER", 69, 79], ["blood", "ANATOMY", 80, 85], ["umbilical cord", "ANATOMY", 90, 104]]], ["Because autologous and syngeneic transplants involve stem cells that are immunologically identical to the recipient, reactions between graft and host are avoided.", [["stem cells", "ANATOMY", 53, 63], ["graft", "ANATOMY", 135, 140], ["stem cells", "CELL", 53, 63], ["graft", "TISSUE", 135, 140], ["stem cells", "CELL_TYPE", 53, 63], ["autologous and syngeneic transplants", "TREATMENT", 8, 44], ["stem cells", "PROBLEM", 53, 63], ["graft", "TREATMENT", 135, 140], ["syngeneic transplants", "OBSERVATION", 23, 44], ["stem cells", "OBSERVATION", 53, 63], ["graft", "OBSERVATION", 135, 140]]], ["In allogeneic transplants, mismatch between donor and recipient human leukocyte antigens (HLAs) mediate graft-versus-host disease (GVHD), which may lead to allograft rejection.Types ::: Overview of Hematopoietic stem cell transplantationFactors that determine the type of transplant to be performed include the nature and stage of the underlying disease, the availability of a suitable donor, and the medical condition of the recipient.", [["graft", "ANATOMY", 104, 109], ["allograft", "ANATOMY", 156, 165], ["Hematopoietic stem cell", "ANATOMY", 198, 221], ["graft-versus-host disease", "DISEASE", 104, 129], ["GVHD", "DISEASE", 131, 135], ["human", "ORGANISM", 64, 69], ["leukocyte antigens", "GENE_OR_GENE_PRODUCT", 70, 88], ["HLAs", "GENE_OR_GENE_PRODUCT", 90, 94], ["graft", "TISSUE", 104, 109], ["allograft", "TISSUE", 156, 165], ["Hematopoietic stem cell", "CELL", 198, 221], ["recipient human leukocyte antigens", "PROTEIN", 54, 88], ["HLAs", "PROTEIN", 90, 94], ["human", "SPECIES", 64, 69], ["human", "SPECIES", 64, 69], ["allogeneic transplants", "TREATMENT", 3, 25], ["mismatch between donor and recipient human leukocyte antigens", "PROBLEM", 27, 88], ["host disease", "PROBLEM", 117, 129], ["GVHD", "PROBLEM", 131, 135], ["allograft rejection", "PROBLEM", 156, 175], ["Hematopoietic stem cell transplantation", "TREATMENT", 198, 237], ["transplant", "TREATMENT", 272, 282], ["the underlying disease", "PROBLEM", 331, 353], ["a suitable donor", "TREATMENT", 375, 391], ["the recipient", "TREATMENT", 422, 435], ["allogeneic transplants", "OBSERVATION", 3, 25], ["mismatch", "OBSERVATION", 27, 35], ["human leukocyte", "OBSERVATION", 64, 79], ["graft", "OBSERVATION", 104, 109], ["host disease", "OBSERVATION", 117, 129], ["GVHD", "OBSERVATION", 131, 135], ["may lead to", "UNCERTAINTY", 144, 155], ["allograft rejection", "OBSERVATION", 156, 175], ["Hematopoietic stem cell transplantation", "OBSERVATION", 198, 237], ["disease", "OBSERVATION", 346, 353]]], ["The advantages of allogeneic transplantation over autologous transplantation include a higher likelihood that the stem cell product is free of tumor contamination and graft-versus-host activity.Indications ::: Overview of Hematopoietic stem cell transplantationA survey from several countries found that the most common indications for HSCT are lymphoproliferative disorders (55%), leukemias (34%), solid tumors (6%), and nonmalignant disorders (5%).", [["stem cell", "ANATOMY", 114, 123], ["tumor", "ANATOMY", 143, 148], ["graft", "ANATOMY", 167, 172], ["Hematopoietic stem cell", "ANATOMY", 222, 245], ["leukemias", "ANATOMY", 382, 391], ["solid tumors", "ANATOMY", 399, 411], ["nonmalignant", "ANATOMY", 422, 434], ["tumor", "DISEASE", 143, 148], ["lymphoproliferative disorders", "DISEASE", 345, 374], ["leukemias", "DISEASE", 382, 391], ["solid tumors", "DISEASE", 399, 411], ["nonmalignant disorders", "DISEASE", 422, 444], ["stem cell", "CELL", 114, 123], ["tumor", "CANCER", 143, 148], ["graft", "TISSUE", 167, 172], ["Hematopoietic stem cell", "CELL", 222, 245], ["leukemias", "CANCER", 382, 391], ["solid tumors", "CANCER", 399, 411], ["nonmalignant disorders", "CANCER", 422, 444], ["allogeneic transplantation", "TREATMENT", 18, 44], ["autologous transplantation", "TREATMENT", 50, 76], ["the stem cell product", "PROBLEM", 110, 131], ["tumor contamination", "PROBLEM", 143, 162], ["graft", "TREATMENT", 167, 172], ["HSCT", "TEST", 336, 340], ["lymphoproliferative disorders", "PROBLEM", 345, 374], ["leukemias", "PROBLEM", 382, 391], ["solid tumors", "PROBLEM", 399, 411], ["nonmalignant disorders", "PROBLEM", 422, 444], ["allogeneic transplantation", "OBSERVATION", 18, 44], ["stem cell", "OBSERVATION", 114, 123], ["tumor", "OBSERVATION", 143, 148], ["graft", "OBSERVATION", 167, 172], ["Hematopoietic stem cell", "OBSERVATION", 222, 245], ["lymphoproliferative", "OBSERVATION", 345, 364], ["leukemias", "OBSERVATION", 382, 391], ["solid", "OBSERVATION_MODIFIER", 399, 404], ["tumors", "OBSERVATION", 405, 411], ["nonmalignant", "OBSERVATION_MODIFIER", 422, 434]]], ["The lymphoproliferative disorders included plasma cell disorder, Hodgkin disease, and non-Hodgkin lymphoma.", [["plasma cell", "ANATOMY", 43, 54], ["Hodgkin", "ANATOMY", 65, 72], ["non-Hodgkin lymphoma", "ANATOMY", 86, 106], ["lymphoproliferative disorders", "DISEASE", 4, 33], ["plasma cell disorder", "DISEASE", 43, 63], ["Hodgkin disease", "DISEASE", 65, 80], ["non-Hodgkin lymphoma", "DISEASE", 86, 106], ["plasma cell", "CELL", 43, 54], ["Hodgkin disease", "CANCER", 65, 80], ["non-Hodgkin lymphoma", "CANCER", 86, 106], ["The lymphoproliferative disorders", "PROBLEM", 0, 33], ["plasma cell disorder", "PROBLEM", 43, 63], ["Hodgkin disease", "PROBLEM", 65, 80], ["non-Hodgkin lymphoma", "PROBLEM", 86, 106], ["lymphoproliferative disorders", "OBSERVATION", 4, 33], ["plasma cell disorder", "OBSERVATION", 43, 63], ["Hodgkin disease", "OBSERVATION", 65, 80], ["non-Hodgkin lymphoma", "OBSERVATION", 86, 106]]], ["Autologous HSCT was slightly more common than allogeneic HSCT.", [["Autologous HSCT", "TEST", 0, 15], ["allogeneic HSCT", "TREATMENT", 46, 61], ["slightly", "OBSERVATION_MODIFIER", 20, 28], ["more common", "OBSERVATION_MODIFIER", 29, 40]]], ["For allogeneic HSCT, the most frequent malignant disease was acute myeloid leukemia (33%) and the most common nonmalignant disease, bone marrow failure syndrome (6%).", [["malignant disease", "ANATOMY", 39, 56], ["acute myeloid leukemia", "ANATOMY", 61, 83], ["nonmalignant", "ANATOMY", 110, 122], ["bone marrow", "ANATOMY", 132, 143], ["acute myeloid leukemia", "DISEASE", 61, 83], ["bone marrow failure syndrome", "DISEASE", 132, 160], ["malignant disease", "CANCER", 39, 56], ["acute myeloid leukemia", "CANCER", 61, 83], ["nonmalignant disease", "CANCER", 110, 130], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 132, 143], ["allogeneic HSCT", "TREATMENT", 4, 19], ["the most frequent malignant disease", "PROBLEM", 21, 56], ["acute myeloid leukemia", "PROBLEM", 61, 83], ["the most common nonmalignant disease", "PROBLEM", 94, 130], ["bone marrow failure syndrome", "PROBLEM", 132, 160], ["most frequent", "OBSERVATION_MODIFIER", 25, 38], ["malignant", "OBSERVATION_MODIFIER", 39, 48], ["disease", "OBSERVATION", 49, 56], ["acute", "OBSERVATION_MODIFIER", 61, 66], ["myeloid leukemia", "OBSERVATION", 67, 83], ["most common", "OBSERVATION_MODIFIER", 98, 109], ["nonmalignant", "OBSERVATION_MODIFIER", 110, 122], ["disease", "OBSERVATION", 123, 130], ["bone", "ANATOMY", 132, 136], ["marrow failure", "OBSERVATION", 137, 151]]], ["For autologous HSCT, the most frequent indication was for a plasma cell disorder (41%); the most common nonmalignant indications included bone marrow failure, hemoglobinopathies, immune deficiencies, inherited diseases of metabolism, and autoimmune disorders.Conditioning Regimens ::: Overview of Hematopoietic stem cell transplantationBefore undergoing HSCT, patients receive a conditioning regimen with the goals of reducing the tumor burden (with malignancy), ablating the bone marrow, and suppressing the recipient's immune system, thereby allowing engraftment of stem cells.", [["plasma cell", "ANATOMY", 60, 71], ["nonmalignant", "ANATOMY", 104, 116], ["bone marrow", "ANATOMY", 138, 149], ["Hematopoietic stem cell", "ANATOMY", 297, 320], ["tumor", "ANATOMY", 431, 436], ["bone marrow", "ANATOMY", 476, 487], ["immune system", "ANATOMY", 521, 534], ["stem cells", "ANATOMY", 568, 578], ["plasma cell disorder", "DISEASE", 60, 80], ["bone marrow failure", "DISEASE", 138, 157], ["hemoglobinopathies", "DISEASE", 159, 177], ["immune deficiencies", "DISEASE", 179, 198], ["inherited diseases of metabolism", "DISEASE", 200, 232], ["autoimmune disorders", "DISEASE", 238, 258], ["tumor", "DISEASE", 431, 436], ["malignancy", "DISEASE", 450, 460], ["plasma cell", "CELL", 60, 71], ["nonmalignant", "CANCER", 104, 116], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 138, 149], ["Hematopoietic stem cell", "CELL", 297, 320], ["patients", "ORGANISM", 360, 368], ["tumor", "CANCER", 431, 436], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 476, 487], ["immune system", "ANATOMICAL_SYSTEM", 521, 534], ["stem cells", "CELL", 568, 578], ["stem cells", "CELL_TYPE", 568, 578], ["patients", "SPECIES", 360, 368], ["autologous HSCT", "TREATMENT", 4, 19], ["a plasma cell disorder", "PROBLEM", 58, 80], ["bone marrow failure", "PROBLEM", 138, 157], ["hemoglobinopathies", "PROBLEM", 159, 177], ["immune deficiencies", "PROBLEM", 179, 198], ["inherited diseases of metabolism", "PROBLEM", 200, 232], ["autoimmune disorders", "PROBLEM", 238, 258], ["Hematopoietic stem cell transplantation", "TREATMENT", 297, 336], ["HSCT", "TREATMENT", 354, 358], ["a conditioning regimen", "TREATMENT", 377, 399], ["the tumor burden", "PROBLEM", 427, 443], ["malignancy", "PROBLEM", 450, 460], ["engraftment of stem cells", "TREATMENT", 553, 578], ["bone", "ANATOMY", 138, 142], ["marrow failure", "OBSERVATION", 143, 157], ["immune deficiencies", "OBSERVATION", 179, 198], ["autoimmune disorders", "OBSERVATION", 238, 258], ["Hematopoietic stem cell transplantation", "OBSERVATION", 297, 336], ["tumor", "OBSERVATION", 431, 436], ["bone marrow", "ANATOMY", 476, 487], ["stem cells", "OBSERVATION", 568, 578]]], ["The three regimen types are myeloablative conditioning, reduced-intensity conditioning, and nonmyeloablative conditioning.", [["The three regimen types", "TREATMENT", 0, 23], ["myeloablative conditioning", "TREATMENT", 28, 54], ["reduced-intensity conditioning", "TREATMENT", 56, 86], ["nonmyeloablative conditioning", "TREATMENT", 92, 121], ["myeloablative conditioning", "OBSERVATION", 28, 54], ["nonmyeloablative conditioning", "OBSERVATION", 92, 121]]], ["This classification is based on the duration of cytopenia and the requirement for stem cell support.", [["stem cell", "ANATOMY", 82, 91], ["cytopenia", "DISEASE", 48, 57], ["stem cell", "CELL", 82, 91], ["cytopenia", "PROBLEM", 48, 57], ["stem cell support", "TREATMENT", 82, 99], ["cytopenia", "OBSERVATION", 48, 57], ["stem cell support", "OBSERVATION", 82, 99]]], ["Myeloablative conditioning causes irreversible cytopenia, for which stem cell support is always necessary, whereas nonmyeloablative conditioning causes minimal cytopenia, for which stem cell support may not be needed.", [["stem cell", "ANATOMY", 68, 77], ["stem cell", "ANATOMY", 181, 190], ["cytopenia", "DISEASE", 47, 56], ["cytopenia", "DISEASE", 160, 169], ["stem cell", "CELL", 68, 77], ["stem cell", "CELL", 181, 190], ["Myeloablative conditioning", "TREATMENT", 0, 26], ["irreversible cytopenia", "PROBLEM", 34, 56], ["stem cell support", "TREATMENT", 68, 85], ["nonmyeloablative conditioning", "TREATMENT", 115, 144], ["minimal cytopenia", "PROBLEM", 152, 169], ["stem cell support", "TREATMENT", 181, 198], ["irreversible", "OBSERVATION_MODIFIER", 34, 46], ["cytopenia", "OBSERVATION", 47, 56], ["minimal", "OBSERVATION_MODIFIER", 152, 159], ["cytopenia", "OBSERVATION", 160, 169]]], ["Reduced-intensity conditioning causes cytopenia of variable duration, and stem cell support should be given.Conditioning Regimens ::: Overview of Hematopoietic stem cell transplantationConventional myeloablative conditioning regimens include cyclophosphamide and total-body irradiation (TBI) or busulfan.", [["stem cell", "ANATOMY", 74, 83], ["Hematopoietic stem cell", "ANATOMY", 146, 169], ["body", "ANATOMY", 269, 273], ["cytopenia", "DISEASE", 38, 47], ["cyclophosphamide", "CHEMICAL", 242, 258], ["TBI", "DISEASE", 287, 290], ["busulfan", "CHEMICAL", 295, 303], ["cyclophosphamide", "CHEMICAL", 242, 258], ["busulfan", "CHEMICAL", 295, 303], ["stem cell", "CELL", 74, 83], ["Hematopoietic stem cell", "CELL", 146, 169], ["cyclophosphamide", "SIMPLE_CHEMICAL", 242, 258], ["busulfan", "SIMPLE_CHEMICAL", 295, 303], ["Reduced-intensity conditioning", "PROBLEM", 0, 30], ["cytopenia of variable duration", "PROBLEM", 38, 68], ["stem cell support", "TREATMENT", 74, 91], ["Hematopoietic stem cell transplantation", "TREATMENT", 146, 185], ["Conventional myeloablative conditioning regimens", "TREATMENT", 185, 233], ["cyclophosphamide", "TREATMENT", 242, 258], ["total-body irradiation (TBI)", "TREATMENT", 263, 291], ["busulfan", "TREATMENT", 295, 303], ["-intensity", "OBSERVATION_MODIFIER", 7, 17], ["cytopenia", "OBSERVATION", 38, 47], ["variable duration", "OBSERVATION_MODIFIER", 51, 68], ["stem cell support", "OBSERVATION", 74, 91], ["Hematopoietic stem cell transplantation", "OBSERVATION", 146, 185]]], ["The more recent nonmyeloablative or reduced-intensity conditioning regimens have used fludarabine and reduced-dose alkylating agents or TBI.", [["fludarabine", "CHEMICAL", 86, 97], ["alkylating agents", "CHEMICAL", 115, 132], ["TBI", "DISEASE", 136, 139], ["fludarabine", "CHEMICAL", 86, 97], ["fludarabine", "SIMPLE_CHEMICAL", 86, 97], ["reduced-intensity conditioning regimens", "TREATMENT", 36, 75], ["fludarabine", "TREATMENT", 86, 97], ["reduced-dose alkylating agents", "TREATMENT", 102, 132], ["TBI", "PROBLEM", 136, 139], ["nonmyeloablative", "OBSERVATION", 16, 32], ["reduced", "OBSERVATION_MODIFIER", 36, 43], ["-intensity", "OBSERVATION_MODIFIER", 43, 53]]], ["Although these less intensive regimens do not provide a strong cytoreductive effect, they allow engraftment of the donor stem cells with a subsequent potentially beneficial graft-versus-malignancy effect.", [["stem cells", "ANATOMY", 121, 131], ["graft", "ANATOMY", 173, 178], ["malignancy", "DISEASE", 186, 196], ["donor stem cells", "CELL", 115, 131], ["graft", "TISSUE", 173, 178], ["donor stem cells", "CELL_TYPE", 115, 131], ["these less intensive regimens", "TREATMENT", 9, 38], ["a strong cytoreductive effect", "TREATMENT", 54, 83], ["the donor stem cells", "TREATMENT", 111, 131], ["beneficial graft", "TREATMENT", 162, 178], ["malignancy effect", "PROBLEM", 186, 203], ["donor stem cells", "OBSERVATION", 115, 131], ["beneficial", "OBSERVATION_MODIFIER", 162, 172], ["graft", "OBSERVATION", 173, 178], ["malignancy", "OBSERVATION", 186, 196]]], ["The nonmyeloablative or reduced-intensity conditioning regimens are associated with reduced transplant-associated morbidity and lower incidence of pulmonary complications after transplantation.Conditioning Regimens ::: Overview of Hematopoietic stem cell transplantationProphylaxis after allogeneic transplant to prevent GVHD usually involves methotrexate, cyclosporin, corticosteroids, or in vitro T cell depletion of the graft before infusion.Risk Factors for Pulmonary Disease ::: Posttransplant Pulmonary ComplicationsRelapse status at transplant and donor-recipient HLA mismatching or nonidentity are risk factors for pulmonary complications and mortality after HSCT (Box 77-1).", [["pulmonary", "ANATOMY", 147, 156], ["Hematopoietic stem cell", "ANATOMY", 231, 254], ["T cell", "ANATOMY", 399, 405], ["graft", "ANATOMY", 423, 428], ["Pulmonary", "ANATOMY", 462, 471], ["Pulmonary", "ANATOMY", 499, 508], ["pulmonary", "ANATOMY", 623, 632], ["pulmonary complications", "DISEASE", 147, 170], ["GVHD", "DISEASE", 321, 325], ["methotrexate", "CHEMICAL", 343, 355], ["cyclosporin", "CHEMICAL", 357, 368], ["Pulmonary Disease", "DISEASE", 462, 479], ["pulmonary complications", "DISEASE", 623, 646], ["methotrexate", "CHEMICAL", 343, 355], ["cyclosporin", "CHEMICAL", 357, 368], ["corticosteroids", "CHEMICAL", 370, 385], ["pulmonary", "ORGAN", 147, 156], ["Hematopoietic stem cell", "CELL", 231, 254], ["methotrexate", "SIMPLE_CHEMICAL", 343, 355], ["cyclosporin", "SIMPLE_CHEMICAL", 357, 368], ["corticosteroids", "SIMPLE_CHEMICAL", 370, 385], ["T cell", "CELL", 399, 405], ["graft", "TISSUE", 423, 428], ["Pulmonary", "ORGAN", 462, 471], ["pulmonary", "ORGAN", 623, 632], ["The nonmyeloablative", "TREATMENT", 0, 20], ["reduced-intensity conditioning regimens", "TREATMENT", 24, 63], ["reduced transplant-associated morbidity", "PROBLEM", 84, 123], ["pulmonary complications", "PROBLEM", 147, 170], ["transplantation", "TREATMENT", 177, 192], ["Hematopoietic stem cell transplantationProphylaxis", "TREATMENT", 231, 281], ["allogeneic transplant", "TREATMENT", 288, 309], ["GVHD", "PROBLEM", 321, 325], ["methotrexate", "TREATMENT", 343, 355], ["cyclosporin", "TREATMENT", 357, 368], ["corticosteroids", "TREATMENT", 370, 385], ["vitro T cell depletion of the graft", "TREATMENT", 393, 428], ["infusion", "TREATMENT", 436, 444], ["Pulmonary Disease", "PROBLEM", 462, 479], ["Posttransplant Pulmonary Complications", "PROBLEM", 484, 522], ["transplant", "TREATMENT", 540, 550], ["donor-recipient HLA mismatching", "TREATMENT", 555, 586], ["risk factors", "PROBLEM", 606, 618], ["pulmonary complications", "PROBLEM", 623, 646], ["HSCT (Box", "TEST", 667, 676], ["nonmyeloablative", "OBSERVATION", 4, 20], ["reduced", "OBSERVATION_MODIFIER", 24, 31], ["-intensity", "OBSERVATION_MODIFIER", 31, 41], ["reduced", "OBSERVATION_MODIFIER", 84, 91], ["transplant", "OBSERVATION", 92, 102], ["morbidity", "OBSERVATION", 114, 123], ["lower", "OBSERVATION_MODIFIER", 128, 133], ["pulmonary", "ANATOMY", 147, 156], ["complications", "OBSERVATION", 157, 170], ["Hematopoietic stem cell transplantation", "OBSERVATION", 231, 270], ["GVHD", "OBSERVATION", 321, 325], ["cell depletion", "OBSERVATION", 401, 415], ["graft", "OBSERVATION", 423, 428], ["Pulmonary", "ANATOMY", 462, 471], ["Disease", "OBSERVATION", 472, 479], ["Pulmonary", "ANATOMY", 499, 508], ["Complications", "OBSERVATION", 509, 522], ["pulmonary", "ANATOMY", 623, 632], ["complications", "OBSERVATION", 633, 646]]], ["Active phase of malignancy, age over 21 years, and receipt of HLA-nonidentical donor marrow are risk factors for respiratory failure after HSCT.Box 77-1Risk Factors for Pulmonary Complications After Hematopoietic Stem Cell Transplantation (HSCT)Donor-recipient human leukocyte antigen mismatchRelapse statusActive phase of malignancyAge over 21 yearsPretransplant pulmonary function abnormalitiesReduced diffusion capacityIncreased alveolar-arterial oxygen gradientRestrictive lung diseaseFEV1 <80% predictedElevated pretransplant cytokine levels (TGF-\u03b2, TGF-\u03b1, GM-CSF)Allogeneic transplantationGraft-versus-host disease and type of GVHD prophylaxisRenal disease", [["marrow", "ANATOMY", 85, 91], ["respiratory", "ANATOMY", 113, 124], ["Pulmonary", "ANATOMY", 169, 178], ["Hematopoietic Stem Cell", "ANATOMY", 199, 222], ["malignancy", "ANATOMY", 323, 333], ["pulmonary", "ANATOMY", 364, 373], ["alveolar", "ANATOMY", 432, 440], ["arterial", "ANATOMY", 441, 449], ["lung", "ANATOMY", 477, 481], ["Graft", "ANATOMY", 595, 600], ["Renal", "ANATOMY", 649, 654], ["malignancy", "DISEASE", 16, 26], ["respiratory failure", "DISEASE", 113, 132], ["malignancy", "DISEASE", 323, 333], ["pulmonary function abnormalities", "DISEASE", 364, 396], ["oxygen", "CHEMICAL", 450, 456], ["Graft-versus-host disease", "DISEASE", 595, 620], ["GVHD", "DISEASE", 633, 637], ["Renal disease", "DISEASE", 649, 662], ["oxygen", "CHEMICAL", 450, 456], ["donor marrow", "MULTI-TISSUE_STRUCTURE", 79, 91], ["human", "ORGANISM", 261, 266], ["leukocyte antigen", "GENE_OR_GENE_PRODUCT", 267, 284], ["pulmonary", "ORGAN", 364, 373], ["alveolar", "MULTI-TISSUE_STRUCTURE", 432, 440], ["arterial", "MULTI-TISSUE_STRUCTURE", 441, 449], ["oxygen", "SIMPLE_CHEMICAL", 450, 456], ["lung", "ORGAN", 477, 481], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 548, 553], ["TGF-\u03b1", "GENE_OR_GENE_PRODUCT", 555, 560], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 562, 568], ["Renal", "ORGAN", 649, 654], ["cytokine", "PROTEIN", 531, 539], ["TGF-\u03b2", "PROTEIN", 548, 553], ["TGF", "PROTEIN", 555, 558], ["human", "SPECIES", 261, 266], ["human", "SPECIES", 261, 266], ["malignancy", "PROBLEM", 16, 26], ["HLA-nonidentical donor marrow", "TREATMENT", 62, 91], ["risk factors", "PROBLEM", 96, 108], ["respiratory failure", "PROBLEM", 113, 132], ["Box", "TEST", 144, 147], ["Pulmonary Complications", "PROBLEM", 169, 192], ["Hematopoietic Stem Cell Transplantation", "TREATMENT", 199, 238], ["Donor-recipient human leukocyte antigen mismatch", "TREATMENT", 245, 293], ["malignancy", "PROBLEM", 323, 333], ["Pretransplant pulmonary function abnormalities", "PROBLEM", 350, 396], ["Reduced diffusion capacity", "PROBLEM", 396, 422], ["Increased alveolar-arterial oxygen gradient", "PROBLEM", 422, 465], ["Restrictive lung diseaseFEV1", "PROBLEM", 465, 493], ["Elevated pretransplant cytokine levels", "PROBLEM", 508, 546], ["TGF", "TEST", 548, 551], ["\u03b2", "TEST", 552, 553], ["TGF", "TEST", 555, 558], ["\u03b1", "TEST", 559, 560], ["GM", "TEST", 562, 564], ["Allogeneic transplantation", "TREATMENT", 569, 595], ["Graft-versus-host disease", "PROBLEM", 595, 620], ["GVHD prophylaxis", "TREATMENT", 633, 649], ["Renal disease", "PROBLEM", 649, 662], ["phase", "OBSERVATION_MODIFIER", 7, 12], ["malignancy", "OBSERVATION", 16, 26], ["donor marrow", "OBSERVATION", 79, 91], ["failure", "OBSERVATION", 125, 132], ["Pulmonary", "ANATOMY", 169, 178], ["Complications", "OBSERVATION", 179, 192], ["Hematopoietic Stem Cell Transplantation", "OBSERVATION", 199, 238], ["malignancy", "OBSERVATION", 323, 333], ["pulmonary", "ANATOMY", 364, 373], ["diffusion capacity", "OBSERVATION", 404, 422], ["alveolar", "ANATOMY_MODIFIER", 432, 440], ["arterial", "ANATOMY_MODIFIER", 441, 449], ["oxygen gradient", "OBSERVATION", 450, 465], ["lung", "ANATOMY", 477, 481], ["diseaseFEV1", "OBSERVATION", 482, 493], ["CSF", "ANATOMY", 565, 568], ["Allogeneic transplantation", "OBSERVATION", 569, 595], ["host disease", "OBSERVATION", 608, 620], ["GVHD prophylaxis", "OBSERVATION", 633, 649], ["disease", "OBSERVATION", 655, 662]]]], "055dd8279f848e0c60d33f73804725a0d682ec61": [["The science of epidemiology has been developed over the last 200 years, using traditional methods to describe the distribution of diseases by person, place, and time.", [["person", "SPECIES", 142, 148], ["traditional methods", "TREATMENT", 78, 97], ["diseases", "PROBLEM", 130, 138], ["diseases", "OBSERVATION", 130, 138]]], ["Technological and analytical advances can enhance traditional epidemiological methods to study the emergence, epidemiology, and transmission dynamics of viruses and associated diseases.", [["associated diseases", "PROBLEM", 165, 184]]], ["Social media are increasingly used to detect the emergence and geographic spread of viral disease outbreaks.", [["viral disease", "DISEASE", 84, 97], ["viral disease outbreaks", "PROBLEM", 84, 107], ["viral disease", "OBSERVATION", 84, 97]]], ["Large-scale population movement can be estimated using satellite imagery and mobile phone use, and fine-scale population movement can be tracked using global positioning system (GPS) loggers, allowing estimation of transmission pathways and contact patterns at different spatial scales.", [["-scale", "OBSERVATION_MODIFIER", 5, 11]]], ["Advances in genomic sequencing and bioinformatics permit more accurate determination of viral evolution and the construction of transmission networks, also at different spatial and temporal scales.", [["genomic sequencing", "TEST", 12, 30], ["viral evolution", "PROBLEM", 88, 103], ["transmission networks", "TREATMENT", 128, 149], ["viral", "OBSERVATION", 88, 93]]], ["More complex and realistic mathematical models of virus transmission within human and animal populations, including detailed agent-based models, are increasingly used to predict transmission patterns and the impact of control interventions such as vaccination and quarantine.", [["human", "ORGANISM", 76, 81], ["human", "SPECIES", 76, 81], ["human", "SPECIES", 76, 81], ["control interventions", "TREATMENT", 218, 239], ["vaccination and quarantine", "TREATMENT", 248, 274], ["complex", "OBSERVATION_MODIFIER", 5, 12]]], ["In this chapter, we will briefly review traditional epidemiological methods and then describe the new technologies with some examples of their application.HISTORYInsight into the epidemiology of viral infections long preceded the recognition and characterization of viruses as communicable agents of disease in humans and animals, extending at least as far back as the treatise of Abu Becr (Rhazes) on measles and smallpox in the tenth century.", [["viral infections", "DISEASE", 195, 211], ["measles and smallpox", "DISEASE", 402, 422], ["humans", "ORGANISM", 311, 317], ["measles", "ORGANISM", 402, 409], ["humans", "SPECIES", 311, 317], ["humans", "SPECIES", 311, 317], ["viral infections", "PROBLEM", 195, 211], ["viruses", "PROBLEM", 266, 273], ["disease in humans", "PROBLEM", 300, 317], ["measles", "PROBLEM", 402, 409], ["viral", "OBSERVATION_MODIFIER", 195, 200], ["infections", "OBSERVATION", 201, 211], ["viruses", "OBSERVATION", 266, 273], ["disease", "OBSERVATION", 300, 307]]], ["Successful efforts to alter the epidemiology of viral infections can be traced to the practice of variolation, the deliberate inoculation of infectious material from persons with smallpox (see chapter on the history of viral pathogenesis).", [["viral infections", "DISEASE", 48, 64], ["smallpox", "DISEASE", 179, 187], ["persons", "SPECIES", 166, 173], ["viral infections", "PROBLEM", 48, 64], ["variolation", "TREATMENT", 98, 109], ["infectious material", "PROBLEM", 141, 160], ["smallpox", "TREATMENT", 179, 187], ["viral pathogenesis", "PROBLEM", 219, 237], ["viral infections", "OBSERVATION", 48, 64], ["inoculation", "OBSERVATION_MODIFIER", 126, 137], ["infectious", "OBSERVATION_MODIFIER", 141, 151]]], ["Edward Jenner greatly improved the practice of variolation in 1796 using the less-virulent cowpox virus, establishing the field of vaccinology.", [["cowpox virus", "ORGANISM", 91, 103], ["virulent cowpox virus", "SPECIES", 82, 103], ["cowpox virus", "SPECIES", 91, 103], ["the less-virulent cowpox virus", "PROBLEM", 73, 103], ["improved", "OBSERVATION_MODIFIER", 22, 30], ["cowpox virus", "OBSERVATION", 91, 103]]], ["An early example of rigorous epidemiological study prior to the discovery of viruses was the work of the Danish physician Peter Panum who investigated an outbreak of measles on the Faroe Islands in 1846.", [["measles", "DISEASE", 166, 173], ["rigorous epidemiological study", "TEST", 20, 50], ["viruses", "OBSERVATION", 77, 84]]], ["Through careful documentation of clinical cases and contact histories, Panum provided evidence of the contagious nature of measles, accurate measurement of the incubation period, and demonstration of the long-term protective immunity conferred by measles.", [["measles", "DISEASE", 123, 130], ["measles", "DISEASE", 247, 254], ["the long-term protective immunity", "TREATMENT", 200, 233]]], ["The discovery of viruses as \"filterable agents\" in the late-nineteenth and early twentieth centuries greatly enhanced the study of viral epidemiology, allowing the characterization of infected individuals, risk factors for infection and disease, and transmission pathways.Traditional Epidemiological MethodsTraditional epidemiological methods measure the distribution of viral infections, diseases, and associated risk factors in populations in terms of person, place, and time using standard measures of disease frequency, study designs, and approaches to causal inference.", [["infection", "DISEASE", 223, 232], ["viral infections", "DISEASE", 371, 387], ["person", "SPECIES", 454, 460], ["viruses", "PROBLEM", 17, 24], ["filterable agents", "TREATMENT", 29, 46], ["the study", "TEST", 118, 127], ["infected individuals", "PROBLEM", 184, 204], ["infection", "PROBLEM", 223, 232], ["disease", "PROBLEM", 237, 244], ["viral infections", "PROBLEM", 371, 387], ["diseases", "PROBLEM", 389, 397], ["disease frequency", "PROBLEM", 505, 522], ["viruses", "OBSERVATION", 17, 24], ["infection", "OBSERVATION", 223, 232], ["viral infections", "OBSERVATION", 371, 387]]], ["Populations are often defined in terms of target and study populations, and individuals within study populations in terms of exposure and outcome status.", [["study populations", "TEST", 53, 70]]], ["Exposures or risk factors include demographic, social, genetic, and environmental factors, and outcomes include infection or disease.", [["infection", "DISEASE", 112, 121], ["infection", "PROBLEM", 112, 121], ["disease", "PROBLEM", 125, 132], ["infection", "OBSERVATION", 112, 121]]], ["In viral epidemiology, infection status is determined using diagnostic methods to detect viral proteins or nucleic acids, and serologic assays to measure immunologic markers of exposure to viral antigens.", [["infection", "DISEASE", 23, 32], ["viral proteins", "PROTEIN", 89, 103], ["viral antigens", "PROTEIN", 189, 203], ["infection status", "PROBLEM", 23, 39], ["diagnostic methods", "TEST", 60, 78], ["viral proteins", "PROBLEM", 89, 103], ["nucleic acids", "TEST", 107, 120], ["serologic assays", "TEST", 126, 142], ["immunologic markers", "TEST", 154, 173], ["viral antigens", "PROBLEM", 189, 203], ["viral", "OBSERVATION_MODIFIER", 3, 8], ["infection", "OBSERVATION", 23, 32]]], ["Infection status can be defined as acute, chronic, or latent.", [["Infection status", "PROBLEM", 0, 16], ["acute", "OBSERVATION_MODIFIER", 35, 40], ["chronic", "OBSERVATION_MODIFIER", 42, 49], ["latent", "OBSERVATION_MODIFIER", 54, 60]]], ["Standard measures of disease frequency include incidence, the number of new cases per period of observation (e.g., 1000 person-years), and prevalence, the number of all cases in a defined population and time period.", [["disease frequency", "PROBLEM", 21, 38], ["disease", "OBSERVATION", 21, 28]]], ["Prevalence is a function of both incidence and duration of infection and can increase despite declining incidence, as observed with the introduction of antiretroviral therapy for human immunodeficiency virus (HIV) infection in the United States.", [["infection", "DISEASE", 59, 68], ["human immunodeficiency virus (HIV) infection", "DISEASE", 179, 223], ["human immunodeficiency virus", "ORGANISM", 179, 207], ["HIV", "ORGANISM", 209, 212], ["human immunodeficiency virus (HIV", "SPECIES", 179, 212], ["human immunodeficiency virus", "SPECIES", 179, 207], ["HIV", "SPECIES", 209, 212], ["infection", "PROBLEM", 59, 68], ["antiretroviral therapy", "TREATMENT", 152, 174], ["human immunodeficiency virus", "PROBLEM", 179, 207], ["HIV) infection", "PROBLEM", 209, 223], ["infection", "OBSERVATION", 59, 68]]], ["Although the number of new cases of HIV infection declined, the prevalence of HIV infection increased as treated individuals survived longer.", [["HIV infection", "DISEASE", 36, 49], ["HIV infection", "DISEASE", 78, 91], ["HIV", "ORGANISM", 36, 39], ["HIV", "ORGANISM", 78, 81], ["HIV", "SPECIES", 36, 39], ["HIV", "SPECIES", 78, 81], ["HIV", "SPECIES", 36, 39], ["HIV", "SPECIES", 78, 81], ["HIV infection", "PROBLEM", 36, 49], ["HIV infection", "PROBLEM", 78, 91], ["new", "OBSERVATION_MODIFIER", 23, 26], ["HIV", "OBSERVATION_MODIFIER", 36, 39], ["infection", "OBSERVATION", 40, 49], ["HIV", "OBSERVATION_MODIFIER", 78, 81], ["infection", "OBSERVATION", 82, 91]]], ["Commonly used study designs include, l cross-sectional studies in which individuals are sampled or surveyed for exposure and disease status within a narrow time frame, l cohort studies in which exposed and unexposed individuals are observed over time for the onset of specified outcomes, l case-control studies in which those with and without the outcome (infection or disease) are compared on exposure status, and l clinical trials in which individuals are randomized to an exposure such as a vaccine or drug and observed for the onset of specified outcomes Appropriate study design, rigorous adherence to study protocols, and statistical methods are used to address threats to causal inference (i.e., whether observed associations between exposure and outcome are causal), such as bias and confounding.Traditional Epidemiological MethodsMuch can be learned about the epidemiology of viral infections using such traditional methods and many examples could be cited to establish the importance of these approaches, including demonstration of the mode of transmission of viruses by mosquitoes (e.g., yellow fever and West Nile viruses), the causal relationship between maternal viral infection and fetal abnormalities (e.g., rubella virus and cytomegalovirus), and the role of viruses in the etiology of cancer (e.g., Epstein-Barr and human papilloma viruses).Methods in Infectious Disease EpidemiologyThe epidemiology of communicable infectious diseases is distinguishable from the epidemiology of noncommunicable diseases in that the former must account for \"dependent happenings.\"", [["fetal", "ANATOMY", 1197, 1202], ["cancer", "ANATOMY", 1303, 1309], ["infection", "DISEASE", 356, 365], ["viral infections", "DISEASE", 885, 901], ["yellow fever", "DISEASE", 1099, 1111], ["West Nile viruses", "DISEASE", 1116, 1133], ["viral infection", "DISEASE", 1177, 1192], ["fetal abnormalities", "DISEASE", 1197, 1216], ["rubella virus and cytomegalovirus", "DISEASE", 1224, 1257], ["cancer", "DISEASE", 1303, 1309], ["Epstein-Barr and human papilloma viruses", "DISEASE", 1317, 1357], ["Infectious Disease", "DISEASE", 1370, 1388], ["infectious diseases", "DISEASE", 1434, 1453], ["noncommunicable diseases", "DISEASE", 1498, 1522], ["individuals", "ORGANISM", 72, 83], ["individuals", "ORGANISM", 216, 227], ["individuals", "ORGANISM", 442, 453], ["yellow fever", "ORGANISM", 1099, 1111], ["West Nile viruses", "ORGANISM", 1116, 1133], ["fetal", "ANATOMICAL_SYSTEM", 1197, 1202], ["rubella virus", "ORGANISM", 1224, 1237], ["cytomegalovirus", "ORGANISM", 1242, 1257], ["cancer", "CANCER", 1303, 1309], ["Epstein-Barr", "ORGANISM", 1317, 1329], ["human papilloma viruses", "ORGANISM", 1334, 1357], ["rubella virus", "SPECIES", 1224, 1237], ["human", "SPECIES", 1334, 1339], ["West Nile viruses", "SPECIES", 1116, 1133], ["rubella virus", "SPECIES", 1224, 1237], ["human papilloma viruses", "SPECIES", 1334, 1357], ["l cross-sectional studies", "TEST", 37, 62], ["disease status", "PROBLEM", 125, 139], ["l cohort studies", "TEST", 168, 184], ["infection", "PROBLEM", 356, 365], ["disease", "PROBLEM", 369, 376], ["a vaccine", "TREATMENT", 492, 501], ["study protocols", "TEST", 607, 622], ["viral infections", "PROBLEM", 885, 901], ["such traditional methods", "TREATMENT", 908, 932], ["viruses", "PROBLEM", 1070, 1077], ["yellow fever", "PROBLEM", 1099, 1111], ["West Nile viruses", "PROBLEM", 1116, 1133], ["maternal viral infection", "PROBLEM", 1168, 1192], ["fetal abnormalities", "PROBLEM", 1197, 1216], ["rubella virus", "PROBLEM", 1224, 1237], ["cytomegalovirus", "PROBLEM", 1242, 1257], ["viruses", "PROBLEM", 1276, 1283], ["cancer", "PROBLEM", 1303, 1309], ["Epstein-Barr and human papilloma viruses", "PROBLEM", 1317, 1357], ["communicable infectious diseases", "PROBLEM", 1421, 1453], ["noncommunicable diseases", "PROBLEM", 1498, 1522], ["dependent happenings", "PROBLEM", 1560, 1580], ["viral", "OBSERVATION_MODIFIER", 885, 890], ["infections", "OBSERVATION", 891, 901], ["viral", "OBSERVATION_MODIFIER", 1177, 1182], ["infection", "OBSERVATION", 1183, 1192], ["viruses", "OBSERVATION", 1276, 1283], ["cancer", "OBSERVATION", 1303, 1309], ["papilloma viruses", "OBSERVATION", 1340, 1357], ["Infectious", "OBSERVATION", 1370, 1380], ["communicable", "OBSERVATION_MODIFIER", 1421, 1433], ["infectious", "OBSERVATION", 1434, 1444]]], ["This term was introduced by Ronald Ross to capture the fact that infectious agents are transmitted between individuals or from a common source.", [["infectious agents", "TREATMENT", 65, 82], ["infectious", "OBSERVATION", 65, 75]]], ["Traditional epidemiological and statistical methods often assume disease events in a population are independent of one another.", [["disease events", "PROBLEM", 65, 79]]], ["In infectious disease epidemiology, individuals are defined in terms of susceptible, exposed, infectious, and recovered or immune.", [["infectious disease", "DISEASE", 3, 21], ["individuals", "ORGANISM", 36, 47], ["infectious", "PROBLEM", 94, 104], ["infectious", "OBSERVATION_MODIFIER", 3, 13], ["susceptible", "OBSERVATION_MODIFIER", 72, 83], ["infectious", "OBSERVATION", 94, 104]]], ["Key characteristics of viral infections that determine the frequency and timing of transmission, and thus the epidemiology, include the mode of transmission (e.g., respiratory, gastrointestinal, sexual, bloodborne, and vector-borne), whether infection is transient or persistent, and whether immunity is short or long lasting.", [["respiratory", "ANATOMY", 164, 175], ["gastrointestinal", "ANATOMY", 177, 193], ["viral infections", "DISEASE", 23, 39], ["respiratory, gastrointestinal, sexual, bloodborne, and vector-borne", "DISEASE", 164, 231], ["infection", "DISEASE", 242, 251], ["gastrointestinal", "ORGANISM_SUBDIVISION", 177, 193], ["viral infections", "PROBLEM", 23, 39], ["infection", "PROBLEM", 242, 251], ["viral", "OBSERVATION_MODIFIER", 23, 28], ["infections", "OBSERVATION", 29, 39], ["gastrointestinal", "ANATOMY", 177, 193], ["infection", "OBSERVATION", 242, 251], ["persistent", "OBSERVATION_MODIFIER", 268, 278]]], ["Temporal changes in the transmission dynamics of viral infection can be displayed with epidemic curves, by plotting the number or incidence of new infections over time to demonstrate outbreaks, seasonality, and the response to interventions.", [["viral infection", "DISEASE", 49, 64], ["infections", "DISEASE", 147, 157], ["Temporal changes", "PROBLEM", 0, 16], ["viral infection", "PROBLEM", 49, 64], ["epidemic curves", "PROBLEM", 87, 102], ["new infections", "PROBLEM", 143, 157], ["outbreaks", "PROBLEM", 183, 192], ["interventions", "TREATMENT", 227, 240], ["viral infection", "OBSERVATION", 49, 64], ["new", "OBSERVATION_MODIFIER", 143, 146], ["infections", "OBSERVATION", 147, 157], ["outbreaks", "OBSERVATION", 183, 192]]], ["Key metrics in infectious disease epidemiology that capture the dependent nature of communicable diseases include:Methods in Infectious Disease Epidemiology(1) the latent period, the average time from infection to the onset of infectiousness; (2) the infectious period, the average duration of infectiousness; (3) the generation time, the average period between infection in one individual and transmission to another; and (4) the basic reproductive number (R 0 ), the average number of new infections initiated by a single infectious individual in a completely susceptible population over the course of that individual's infectious period.Methods in Infectious Disease EpidemiologyIf R 0 is larger than one, the number of infected individuals and hence the size of the outbreak will increase.", [["communicable diseases", "DISEASE", 84, 105], ["Infectious Disease", "DISEASE", 125, 143], ["infection", "DISEASE", 201, 210], ["infection", "DISEASE", 362, 371], ["infections", "DISEASE", 491, 501], ["Infectious Disease", "DISEASE", 651, 669], ["R 0", "GENE_OR_GENE_PRODUCT", 685, 688], ["communicable diseases", "PROBLEM", 84, 105], ["infection", "PROBLEM", 201, 210], ["infectiousness", "PROBLEM", 227, 241], ["infectiousness", "PROBLEM", 294, 308], ["infection", "PROBLEM", 362, 371], ["new infections", "PROBLEM", 487, 501], ["infected individuals", "PROBLEM", 723, 743], ["infectious", "OBSERVATION", 15, 25], ["infection", "OBSERVATION", 201, 210], ["infectious", "OBSERVATION_MODIFIER", 251, 261], ["infection", "OBSERVATION", 362, 371], ["new", "OBSERVATION_MODIFIER", 487, 490], ["infections", "OBSERVATION", 491, 501], ["infectious", "OBSERVATION", 622, 632], ["Infectious", "OBSERVATION", 651, 661], ["larger", "OBSERVATION_MODIFIER", 692, 698], ["infected", "OBSERVATION", 723, 731], ["size", "OBSERVATION_MODIFIER", 758, 762], ["outbreak", "OBSERVATION_MODIFIER", 770, 778]]], ["If R 0 is smaller than one, each infectious individual infects on average less than one other individual and the number of infected individuals will decrease and the outbreak ceases.", [["R 0", "GENE_OR_GENE_PRODUCT", 3, 6], ["each infectious individual infects", "PROBLEM", 28, 62], ["infected individuals", "PROBLEM", 123, 143], ["smaller", "OBSERVATION_MODIFIER", 10, 17], ["infectious", "OBSERVATION_MODIFIER", 33, 43], ["infects", "OBSERVATION", 55, 62], ["infected", "OBSERVATION", 123, 131]]], ["The reproductive number (R) is a function not only of characteristics of the viral pathogen (e.g., mode of transmission), but also the social contact network within which it is transmitted and changes over time in response to a decreasing number of susceptible individuals and control interventions.", [["the viral pathogen", "PROBLEM", 73, 91], ["susceptible individuals", "TREATMENT", 249, 272], ["control interventions", "TREATMENT", 277, 298], ["reproductive", "OBSERVATION_MODIFIER", 4, 16], ["number", "OBSERVATION_MODIFIER", 17, 23], ["viral", "OBSERVATION_MODIFIER", 77, 82], ["pathogen", "OBSERVATION", 83, 91]]], ["An important concept related to the interdependence of transmission events is herd immunity, the protection of susceptible individuals against infection in populations with a high proportion of immune individuals because of the low probability of an infectious individual coming in contact with a susceptible individual.Methods in Infectious Disease EpidemiologyThe concepts and methods of infectious disease epidemiology provide the tools to understand changes in temporal and spatial patterns of viral infections and the impact of interventions.", [["infection", "DISEASE", 143, 152], ["Infectious Disease", "DISEASE", 331, 349], ["viral infections", "DISEASE", 498, 514], ["herd", "ORGANISM_SUBDIVISION", 78, 82], ["transmission events", "PROBLEM", 55, 74], ["susceptible individuals", "PROBLEM", 111, 134], ["infection in populations", "PROBLEM", 143, 167], ["immune individuals", "PROBLEM", 194, 212], ["an infectious individual", "PROBLEM", 247, 271], ["infectious disease epidemiology", "PROBLEM", 390, 421], ["viral infections", "PROBLEM", 498, 514], ["interventions", "TREATMENT", 533, 546], ["infection", "OBSERVATION", 143, 152], ["low probability", "OBSERVATION_MODIFIER", 228, 243], ["infectious", "OBSERVATION", 250, 260], ["Infectious", "OBSERVATION", 331, 341], ["infectious", "OBSERVATION", 390, 400], ["viral infections", "OBSERVATION", 498, 514]]], ["Traditional epidemiological methods provide powerful analytical approaches to measure associations between exposures (risk factors) and outcomes (infection or disease).", [["infection", "DISEASE", 146, 155], ["powerful analytical approaches", "TREATMENT", 44, 74], ["outcomes (infection or disease)", "PROBLEM", 136, 167]]], ["Recent technological advances enhance these methods and permit novel approaches to investigate the emergence, epidemiology, and transmission dynamics of viruses and associated diseases.SURVEILLANCEExpanded access to the Internet and social media has revolutionized outbreak detection and viral disease surveillance by providing novel sources of data in real time (Chunara, 2012) .", [["these methods", "TEST", 38, 51], ["associated diseases", "PROBLEM", 165, 184], ["viral disease surveillance", "PROBLEM", 288, 314], ["viral disease", "OBSERVATION", 288, 301]]], ["Traditional epidemiologic surveillance systems rely on standardized case definitions, with individual cases typically classified as suspected, probable, or confirmed based on the level of evidence.", [["Traditional epidemiologic surveillance systems", "TEST", 0, 46]]], ["Confirmed cases require laboratory evidence of viral infection.", [["viral infection", "DISEASE", 47, 62], ["viral infection", "PROBLEM", 47, 62], ["evidence of", "UNCERTAINTY", 35, 46], ["viral", "OBSERVATION_MODIFIER", 47, 52], ["infection", "OBSERVATION", 53, 62]]], ["Surveillance systems are either active or passive.", [["Surveillance systems", "TEST", 0, 20], ["active", "OBSERVATION_MODIFIER", 32, 38]]], ["Active surveillance involves the purposeful search for cases within populations whereas passive surveillance relies on routine reporting of cases, typically by health care workers, health care facilities, and laboratories.", [["passive surveillance", "TEST", 88, 108]]], ["Data acquired through active surveillance are often of higher quality because of better adherence to standardized case definitions and completeness of case ascertainment but are more expensive and resource intensive.", [["active surveillance", "TEST", 22, 41]]], ["However, both active and passive surveillance are prone to delays in data reporting.SURVEILLANCEThe major advantage of using the Internet and social media to monitor disease activity is that the signal can be detected without the lag associated with traditional surveillance systems.", [["passive surveillance", "TEST", 25, 45], ["disease activity", "PROBLEM", 166, 182], ["traditional surveillance systems", "TEST", 250, 282], ["active", "OBSERVATION_MODIFIER", 14, 20]]], ["Influenza is the most common viral infection for which the Internet and social media have been used for disease surveillance because of its high incidence, wide geographic distribution, discrete seasonality, short symptomatic period, and relatively specific set of signs and symptoms.", [["Influenza", "DISEASE", 0, 9], ["viral infection", "DISEASE", 29, 44], ["Influenza", "SPECIES", 0, 9], ["Influenza", "PROBLEM", 0, 9], ["viral infection", "PROBLEM", 29, 44], ["social media", "TREATMENT", 72, 84], ["disease surveillance", "TEST", 104, 124], ["short symptomatic period", "PROBLEM", 208, 232], ["signs and symptoms", "PROBLEM", 265, 283], ["most common", "OBSERVATION_MODIFIER", 17, 28], ["viral", "OBSERVATION_MODIFIER", 29, 34], ["infection", "OBSERVATION", 35, 44], ["discrete", "OBSERVATION_MODIFIER", 186, 194], ["seasonality", "OBSERVATION_MODIFIER", 195, 206]]], ["However, the Internet and social media have several limitations compared to traditional active and passive surveillance systems and complement rather than replace these methods.", [["passive surveillance systems", "TEST", 99, 127], ["these methods", "TREATMENT", 163, 176]]], ["These limitations include lack of specificity in the \"diagnosis,\" and waxing and waning interest and attention in social media independent of disease frequency.Novel Data StreamsIn 2008, the Internet company Google developed a webbased tool called Google Flu Trends, for early detection of influenza outbreaks.", [["influenza", "DISEASE", 290, 299], ["disease frequency", "PROBLEM", 142, 159], ["influenza outbreaks", "PROBLEM", 290, 309], ["influenza", "OBSERVATION", 290, 299]]], ["Google Flu Trends is based on the fact that millions of people use the Google search engine each day to obtain health-related information (Ginsberg, 2009 ).", [["people", "ORGANISM", 56, 62], ["people", "SPECIES", 56, 62]]], ["Logs of user key words for pathogens, diseases, symptoms, and treatments, as well as information on user location contained in computer Internet Protocol (IP) addresses, allow temporal and spatial analyses of trends in search terms ( Figure 1 ).", [["pathogens", "PROBLEM", 27, 36], ["diseases", "PROBLEM", 38, 46], ["symptoms", "PROBLEM", 48, 56], ["treatments", "TREATMENT", 62, 72]]], ["Early results suggested that Google Flu Trends detected regional outbreaks of influenza 7-10 days before conventional surveillance by the Centers for Disease Control and Prevention (Carneiro, 2009 ).", [["influenza", "DISEASE", 78, 87], ["influenza", "PROBLEM", 78, 87], ["Disease Control", "TREATMENT", 150, 165]]], ["However, accurate prediction was not as reliable as initially thought, and Google estimates did not closely match measured activity during the 2012-2013 influenza season.", [["influenza", "DISEASE", 153, 162]]], ["Google now reevaluates estimates using data from traditional surveillance systems (specifically those of the Centers for Disease Control and Prevention) to refine model and parameter estimates.", [["traditional surveillance systems", "TEST", 49, 81], ["Disease Control", "TREATMENT", 121, 136]]], ["These refinements more accurately capture the start of the influenza season, the time of peak influenza virus transmission, and the severity of the influenza season.", [["influenza", "DISEASE", 59, 68], ["influenza virus transmission", "DISEASE", 94, 122], ["influenza", "DISEASE", 148, 157], ["influenza virus", "ORGANISM", 94, 109], ["peak influenza virus transmission", "PROBLEM", 89, 122], ["the influenza season", "PROBLEM", 144, 164]]], ["A similar approach, called Google Dengue Trends, is used to track dengue virus infections by aggregating historical logs of anonymous online Google search queries associated with dengue, using the methods developed for Google Flu Trends.", [["Dengue", "DISEASE", 34, 40], ["dengue", "DISEASE", 66, 72], ["infections", "DISEASE", 79, 89], ["dengue", "DISEASE", 179, 185], ["dengue virus", "SPECIES", 66, 78], ["dengue virus infections", "PROBLEM", 66, 89], ["dengue", "PROBLEM", 179, 185]]], ["Early observations suggest Google queries are correlated with national-level dengue surveillance data, and this novel data source may have the potential to provide information faster than traditional surveillance systems ( Figure 2 ).Novel Data StreamsOther Internet sources are being explored to enhance viral surveillance.", [["dengue", "DISEASE", 77, 83], ["dengue surveillance data", "TEST", 77, 101], ["viral surveillance", "TEST", 305, 323]]], ["As with Google searches, the use of disease-specific queries to Wikipedia are expected to correlate with disease activity.", [["disease", "PROBLEM", 36, 43]]], ["The number of times specific influenza-related Wikipedia sites were accessed provided accurate estimates of influenza-like illnesses in the United States 2 weeks earlier than standard surveillance systems and performed better than Google Flu Trends (McIver, 2014) .Novel Data StreamsSimilarly, social media data are being evaluated for surveillance purposes.", [["influenza-like illnesses", "DISEASE", 108, 132], ["influenza", "PROBLEM", 108, 117], ["standard surveillance systems", "TEST", 175, 204], ["surveillance purposes", "TEST", 336, 357]]], ["As with Google Flu Trends, the number of tweets related to influenza activity is correlated with the number of symptomatic individuals.", [["influenza", "DISEASE", 59, 68], ["influenza activity", "PROBLEM", 59, 77], ["symptomatic individuals", "PROBLEM", 111, 134]]], ["Several published studies reported correlations between Twitter activity and reported influenza-like illnesses (Chew, 2010; Signorini, 2011 ; Figure 3 ).Novel Data StreamsLimitations to using social media, such as Twitter, to monitor disease activity are illustrated by the Ebola virus outbreak in West Africa in early 2014.", [["influenza-like illnesses", "DISEASE", 86, 110], ["Ebola virus", "DISEASE", 274, 285], ["Ebola virus", "ORGANISM", 274, 285], ["Ebola virus", "SPECIES", 274, 285], ["Ebola virus", "SPECIES", 274, 285], ["Several published studies", "TEST", 0, 25], ["influenza", "PROBLEM", 86, 95], ["social media", "TREATMENT", 192, 204], ["influenza", "OBSERVATION", 86, 95]]], ["Despite the fact that Ebola had not yet occurred in the United States, posts to Twitter on Ebola rose dramatically, likely in response to intense media coverage and fear.", [["Ebola", "DISEASE", 22, 27], ["Ebola", "DISEASE", 91, 96], ["Ebola", "ORGANISM", 22, 27], ["Ebola", "ORGANISM", 91, 96], ["Ebola", "PROBLEM", 22, 27], ["intense media coverage", "TREATMENT", 138, 160], ["fear", "PROBLEM", 165, 169], ["Ebola", "OBSERVATION", 22, 27], ["intense", "OBSERVATION_MODIFIER", 138, 145], ["media coverage", "OBSERVATION", 146, 160]]], ["Clearly, such tweets could not be interpreted to indicate Ebola disease activity in the United States.", [["Ebola disease", "DISEASE", 58, 71], ["Ebola", "ORGANISM", 58, 63]]], ["Studies reporting misleading associations, or the lack of correlation between social media and disease activity, are rarely published, providing a cautionary note.Novel Data StreamsWhile initial efforts using data from the Internet for viral disease surveillance offer promising results, concerns have been raised regarding the utility and robustness of these approaches (Lazer, 2014) .", [["viral disease", "DISEASE", 236, 249], ["Studies", "TEST", 0, 7], ["viral disease surveillance", "PROBLEM", 236, 262]]], ["Integration into existing surveillance frameworks will be necessary to maximize the utility of these data streams.Communicating Surveillance DataThe Internet allows rapid processing and communication of health-related information, including the aggregation and display of surveillance data for viral infections.", [["viral infections", "DISEASE", 294, 310], ["surveillance data", "TEST", 272, 289], ["viral infections", "PROBLEM", 294, 310]]], ["Traditional surveillance networks can be linked through the Internet to allow rapid integration and dissemination of information.", [["Traditional surveillance networks", "TREATMENT", 0, 33]]], ["Information on viral disease outbreaks available through Internet postings of health care agencies such as the World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC), as well as press reports and blogs, can provide data that are more current than traditional surveillance systems.", [["viral disease outbreaks", "DISEASE", 15, 38], ["viral disease outbreaks", "PROBLEM", 15, 38], ["Disease Control", "TREATMENT", 159, 174]]], ["Several of the most commonly used surveillance sites report animal as well as human diseases (see Sidebar 1 and Figure 4 ).VIRAL INFECTIONS IN SPACE AND TIMEMapping spatial patterns of disease and relationships with environmental variables preceded the development of modern epidemiology.", [["human", "ORGANISM", 78, 83], ["human", "SPECIES", 78, 83], ["human", "SPECIES", 78, 83], ["human diseases", "PROBLEM", 78, 92], ["VIRAL INFECTIONS IN SPACE", "PROBLEM", 123, 148], ["disease", "PROBLEM", 185, 192], ["environmental variables", "PROBLEM", 216, 239], ["INFECTIONS", "OBSERVATION", 129, 139], ["disease", "OBSERVATION", 185, 192]]], ["The classic example is John Snow's hand-drawn map of London cholera cases of 1854.", [["cholera", "DISEASE", 60, 67]]], ["However, routine mapping of health data only became commonplace in the 1990s after desktop geographic information systems became widely available.", [["routine mapping of health data", "TEST", 9, 39]]], ["Combined with satellite imagery and remotely sensed environmental and ecological data, spatial mapping of viral infections is a powerful tool for surveillance and epidemiological research.VIRAL INFECTIONS IN SPACE AND TIMESpatial epidemiology is typically used to identify and monitor areas of differential risk.", [["viral infections", "DISEASE", 106, 122], ["satellite imagery", "TEST", 14, 31], ["ecological data", "TEST", 70, 85], ["viral infections", "PROBLEM", 106, 122], ["surveillance", "TEST", 146, 158], ["epidemiological research", "TEST", 163, 187], ["VIRAL INFECTIONS IN SPACE", "PROBLEM", 188, 213], ["differential risk", "PROBLEM", 294, 311], ["viral infections", "OBSERVATION", 106, 122], ["INFECTIONS", "OBSERVATION", 194, 204]]], ["An early example was a large outbreak of St. Louis encephalitis virus infection in Houston, Texas in 1964.", [["St. Louis encephalitis virus infection", "DISEASE", 41, 79], ["St. Louis encephalitis virus", "ORGANISM", 41, 69], ["St. Louis encephalitis virus", "SPECIES", 41, 69], ["St. Louis encephalitis virus", "SPECIES", 41, 69], ["St. Louis encephalitis virus infection", "PROBLEM", 41, 79], ["large", "OBSERVATION_MODIFIER", 23, 28], ["outbreak", "OBSERVATION_MODIFIER", 29, 37]]], ["Spatial analysis showed that the outbreak was concentrated in the city center, with lower incidence at the outskirts.", [["Spatial analysis", "TEST", 0, 16], ["the outbreak", "PROBLEM", 29, 41], ["concentrated", "OBSERVATION_MODIFIER", 46, 58], ["lower", "OBSERVATION_MODIFIER", 84, 89]]], ["Further investigation revealed that the city center was associated with the lowest economic strata, unscreened windows, lack of air-conditioning and pools of standing water, factors facilitating virus transmission.VIRAL INFECTIONS IN SPACE AND TIMEInvestigation into the spatiotemporal dynamics of viral diseases at smaller spatial scales has becomeSidebar 1 Sources of information on outbreaks of viral diseasesProMED, the Program for Monitoring Emerging Diseases, is an Internet-based reporting system established in 1994 that compiles information on outbreaks of infectious diseases affecting humans, animals, and food plants.", [["viral diseases", "DISEASE", 298, 312], ["viral diseases", "DISEASE", 398, 412], ["Emerging Diseases", "DISEASE", 447, 464], ["infectious diseases", "DISEASE", 566, 585], ["humans", "ORGANISM", 596, 602], ["humans", "SPECIES", 596, 602], ["humans", "SPECIES", 596, 602], ["Further investigation", "TEST", 0, 21], ["standing water", "TREATMENT", 158, 172], ["VIRAL INFECTIONS IN SPACE", "PROBLEM", 214, 239], ["viral diseases", "PROBLEM", 298, 312], ["viral diseases", "PROBLEM", 398, 412], ["infectious diseases", "PROBLEM", 566, 585], ["INFECTIONS", "OBSERVATION", 220, 230], ["spatiotemporal", "OBSERVATION_MODIFIER", 271, 285], ["viral diseases", "OBSERVATION", 298, 312], ["smaller", "OBSERVATION_MODIFIER", 316, 323], ["viral diseases", "OBSERVATION", 398, 412], ["infectious", "OBSERVATION", 566, 576]]], ["A team of experts screen, review, and investigate reports before posting and often provide commentary.", [["experts screen", "TEST", 10, 24]]], ["Reports are distributed by email to direct subscribers and posted on the ProMED-mail Web site.", [["ProMED-mail Web site", "DNA", 73, 93]]], ["Started in 2006 by epidemiologists and software developers at Boston Children's Hospital, HealthMap monitors disease outbreaks and provides real-time surveillance of emerging public health threats, including viral infections (Figure 4) .", [["viral infections", "DISEASE", 208, 224], ["Children", "SPECIES", 69, 77], ["disease outbreaks", "PROBLEM", 109, 126], ["viral infections", "PROBLEM", 208, 224], ["viral infections", "OBSERVATION", 208, 224]]], ["HealthMap organizes and displays data on disease outbreaks and surveillance using an automated process.", [["disease outbreaks", "PROBLEM", 41, 58], ["surveillance", "TEST", 63, 75]]], ["Data sources include online news aggregators, eyewitness reports, expertcurated discussions and validated official reports.Internet ResourcesGoogle flu trends http://www.google.org/flutrends Google dengue trends http://www.google.org/denguetrends HealthMap http://healthmap.org ProMED http://www.promedmail.org possible with increasing availability of global positioning systems devices and geocoding algorithms.", [["dengue", "DISEASE", 198, 204], ["global positioning systems devices", "TREATMENT", 352, 386], ["geocoding algorithms", "TEST", 391, 411]]], ["Such studies have revealed spatial heterogeneity in the local transmission of some directly (e.g., HIV and influenza) and indirectly (e.g., dengue and chikungunya) transmitted viruses.", [["HIV and influenza) and indirectly (e.g., dengue and chikungunya) transmitted viruses", "DISEASE", 99, 183], ["HIV", "SPECIES", 99, 102], ["HIV", "SPECIES", 99, 102], ["dengue", "SPECIES", 140, 146], ["Such studies", "TEST", 0, 12], ["spatial heterogeneity", "PROBLEM", 27, 48], ["HIV", "PROBLEM", 99, 102], ["influenza", "PROBLEM", 107, 116], ["indirectly (e.g., dengue and chikungunya) transmitted viruses", "PROBLEM", 122, 183], ["spatial", "OBSERVATION_MODIFIER", 27, 34], ["heterogeneity", "OBSERVATION", 35, 48]]], ["For example, clustering analyses of the residential locations of people with dengue in Bangkok over a 5-year period showed evidence of localized transmission at distances less than 1 km (Salje, 2012; Figure 5 ).", [["dengue", "DISEASE", 77, 83], ["people", "ORGANISM", 65, 71], ["people", "SPECIES", 65, 71], ["evidence of", "UNCERTAINTY", 123, 134], ["localized", "OBSERVATION_MODIFIER", 135, 144]]], ["Analyses of data from a large population-based cohort of HIV-infected persons in Rakai District, Uganda revealed strong within-household clustering of prevalent and incident HIV cases as well clustering of prevalent cases up to 500 m (Grabowski, 2014) .", [["HIV-infected", "DISEASE", 57, 69], ["HIV", "ORGANISM", 57, 60], ["persons", "ORGANISM", 70, 77], ["HIV", "SPECIES", 57, 60], ["persons", "SPECIES", 70, 77], ["HIV", "SPECIES", 57, 60], ["HIV", "SPECIES", 174, 177], ["HIV", "PROBLEM", 57, 60], ["HIV cases", "PROBLEM", 174, 183], ["strong", "OBSERVATION_MODIFIER", 113, 119]]], ["Beyond descriptive applications, mapping spatiotemporal patterns of viral infections can provide fundamental insights into transmission dynamics at different spatial scales.", [["viral infections", "DISEASE", 68, 84], ["descriptive applications", "TREATMENT", 7, 31], ["viral infections", "PROBLEM", 68, 84], ["viral infections", "OBSERVATION", 68, 84]]], ["Traveling waves from large cities to small towns were shown to drive the spatiotemporal dynamics of measles in England and Wales (Xia, 2004) .", [["measles", "DISEASE", 100, 107], ["Traveling waves from large cities", "PROBLEM", 0, 33], ["large", "OBSERVATION_MODIFIER", 21, 26], ["small", "OBSERVATION_MODIFIER", 37, 42]]], ["The incidence of dengue hemorrhagic fever across Thailand manifested as a traveling wave emanating from Bangkok and moving radially at a speed of 148 km/month (Cummings, 2004) .Remotely Sensed DataInsight into the spatial epidemiology of viral infections and associations with environmental risk factors can be greatly enhanced when information on the spatial location of cases is combined with remotely sensed environmental data (Rodgers, 2003) .", [["dengue hemorrhagic fever", "DISEASE", 17, 41], ["viral infections", "DISEASE", 238, 254], ["dengue hemorrhagic fever", "SPECIES", 17, 41], ["dengue hemorrhagic fever", "PROBLEM", 17, 41], ["viral infections", "PROBLEM", 238, 254], ["environmental risk factors", "PROBLEM", 277, 303], ["dengue", "OBSERVATION_MODIFIER", 17, 23], ["hemorrhagic", "OBSERVATION_MODIFIER", 24, 35], ["fever", "OBSERVATION", 36, 41], ["viral infections", "OBSERVATION", 238, 254]]], ["Satellite sensors that detect reflected visible or infrared radiation provide additional information on temperature, rainfall, humidity, and vegetation among other variables, which are particularly important for the transmission dynamics of vector-borne viral infections.", [["viral infections", "DISEASE", 254, 270], ["Satellite sensors", "TEST", 0, 17], ["infrared radiation", "TREATMENT", 51, 69], ["vegetation among other variables", "PROBLEM", 141, 173], ["borne viral infections", "PROBLEM", 248, 270], ["vegetation", "OBSERVATION", 141, 151], ["viral infections", "OBSERVATION", 254, 270]]], ["Satellite data for epidemiologic analyses are provided by a number of sources such as: (1) earth-observing satellites with high spatial resolution (1-4 m) but low repeat frequencies such as Ikonos and Landsat satellites; (2) oceanographic and atmospheric satellites such as MODIS and ASTER with lower spatial resolution (0.25-1 km) that provide images of the Earth surface twice a day; and (3) geostationary weather satellites such as GEOS with large spatial resolution (1-8 km).", [["Satellite data", "TEST", 0, 14], ["epidemiologic analyses", "TEST", 19, 41], ["observing satellites", "PROBLEM", 97, 117], ["high spatial resolution", "PROBLEM", 123, 146], ["low repeat frequencies", "PROBLEM", 159, 181], ["Ikonos and Landsat satellites", "PROBLEM", 190, 219], ["oceanographic and atmospheric satellites", "PROBLEM", 225, 265], ["large", "OBSERVATION_MODIFIER", 445, 450], ["spatial", "OBSERVATION_MODIFIER", 451, 458], ["resolution", "OBSERVATION_MODIFIER", 459, 469]]], ["Risk maps display the similarity of environmental features in unsampled locations to environmental features in locations where the disease is measured to be present or absent.", [["Risk maps", "TEST", 0, 9], ["the disease", "PROBLEM", 127, 138], ["disease", "OBSERVATION", 131, 138]]], ["Spatial analysis of the initial cases of West Nile virus infection in New York City in 1999 identified a significant spatial cluster (Brownstein, 2002) .", [["West Nile virus infection", "DISEASE", 41, 66], ["West Nile virus", "ORGANISM", 41, 56], ["Nile virus", "SPECIES", 46, 56], ["West Nile virus", "SPECIES", 41, 56], ["Spatial analysis", "TEST", 0, 16], ["West Nile virus infection", "PROBLEM", 41, 66], ["significant", "OBSERVATION_MODIFIER", 105, 116], ["spatial", "OBSERVATION_MODIFIER", 117, 124], ["cluster", "OBSERVATION_MODIFIER", 125, 132]]], ["Using models incorporating measures of vegetation cover from satellite imagery, the risk of West Nile Virus could be estimated throughout the city.", [["West Nile Virus", "ORGANISM", 92, 107], ["West Nile Virus", "SPECIES", 92, 107], ["vegetation", "PROBLEM", 39, 49], ["satellite imagery", "TEST", 61, 78], ["West Nile Virus", "PROBLEM", 92, 107], ["vegetation", "OBSERVATION", 39, 49]]], ["A more recent risk map for West Nile virus in Suffolk County, New York, was generated with data on vector habitat, landscape, virus activity, and socioeconomic variables derived from publicly available data sets (Rochlin, 2011; Figure 6 ).POPULATION MOVEMENTPopulation movement plays a crucial role in the spread of viral infections.", [["viral infections", "DISEASE", 316, 332], ["West Nile virus", "ORGANISM", 27, 42], ["West Nile virus", "SPECIES", 27, 42], ["vector habitat", "TREATMENT", 99, 113], ["landscape, virus activity", "PROBLEM", 115, 140], ["socioeconomic variables", "PROBLEM", 146, 169], ["viral infections", "PROBLEM", 316, 332], ["viral", "OBSERVATION_MODIFIER", 316, 321], ["infections", "OBSERVATION", 322, 332]]], ["In the past, quantifying the contribution of movement to viral transmission dynamics at different spatial scales was challenging, due to limited data.", [["viral transmission dynamics", "PROBLEM", 57, 84]]], ["As an early example, the impact of restrictions of animal movement on transmission of foot-and-mouth disease in 2001 was estimated, using detailed contact-tracing data from farms in the United Kingdom (Shirley, 2005) .", [["foot-and-mouth disease", "DISEASE", 86, 108], ["foot", "ORGANISM_SUBDIVISION", 86, 90], ["mouth", "ORGAN", 95, 100], ["foot-and-mouth", "SPECIES", 86, 100], ["transmission of foot", "TEST", 70, 90], ["mouth disease", "PROBLEM", 95, 108], ["foot", "ANATOMY", 86, 90], ["mouth", "ANATOMY", 95, 100]]], ["However, such detailed data are rarely available for patterns of human movement.", [["human", "ORGANISM", 65, 70], ["human", "SPECIES", 65, 70], ["human", "SPECIES", 65, 70], ["such detailed data", "TEST", 9, 27]]], ["Studies have attempted to model the impact of long-range human movement on the spread of viral diseases using measures such as distance between cities, commuting rates, and data on air travel.", [["viral diseases", "DISEASE", 89, 103], ["human", "ORGANISM", 57, 62], ["human", "SPECIES", 57, 62], ["human", "SPECIES", 57, 62], ["Studies", "TEST", 0, 7], ["long-range human movement", "TREATMENT", 46, 71], ["viral diseases", "PROBLEM", 89, 103], ["viral diseases", "OBSERVATION", 89, 103]]], ["This approach has been used to explain regional and interregional spread of influenza viruses.", [["influenza viruses", "DISEASE", 76, 93], ["influenza viruses", "ORGANISM", 76, 93], ["influenza viruses", "PROBLEM", 76, 93], ["interregional", "OBSERVATION_MODIFIER", 52, 65], ["spread", "OBSERVATION_MODIFIER", 66, 72], ["influenza viruses", "OBSERVATION", 76, 93]]], ["Data on air traffic volume, distance between areas, and population sizes have been invoked to describe and predict local and regional spread of chikungunya virus in the Americas (Tatem, 2012) .Movement LoggersNew technologies have greatly enhanced the capacity to study the impact of human movement on transmission dynamics of infectious diseases.", [["chikungunya", "DISEASE", 144, 155], ["infectious diseases", "DISEASE", 327, 346], ["air traffic", "MULTI-TISSUE_STRUCTURE", 8, 19], ["chikungunya virus", "ORGANISM", 144, 161], ["human", "ORGANISM", 284, 289], ["human", "SPECIES", 284, 289], ["chikungunya virus", "SPECIES", 144, 161], ["human", "SPECIES", 284, 289], ["air traffic volume", "TEST", 8, 26], ["chikungunya virus", "PROBLEM", 144, 161], ["infectious diseases", "PROBLEM", 327, 346], ["regional", "OBSERVATION_MODIFIER", 125, 133], ["spread", "OBSERVATION_MODIFIER", 134, 140], ["chikungunya virus", "OBSERVATION", 144, 161], ["infectious", "OBSERVATION", 327, 337]]], ["Data from mobile phones and GPS loggers can be used to characterize individual movement patterns and the time spent in different locations (Figure 7) .", [["GPS loggers", "TEST", 28, 39]]], ["Individual movement patterns can be overlaid on risk maps to quantify movement to and from areas of high (sources) and low risk (sinks) as well as to estimate potential contact patterns.", [["risk maps", "TEST", 48, 57]]], ["GPS data loggers generated 2.3 million GPS data points to track the fine-scale mobility patterns of 582 residents from two neighborhoods in Iquitos, Peru, to better understand the epidemiology of viral infections (Vazquez-Prokopec, 2013) .", [["viral infections", "DISEASE", 196, 212], ["GPS data", "TEST", 0, 8], ["GPS data", "TEST", 39, 47], ["viral infections", "PROBLEM", 196, 212], ["viral infections", "OBSERVATION", 196, 212]]], ["However, potential contacts between individuals were irregular and temporally unstructured, with fewer than half of the tracked participants having a regular, predictable routine.", [["participants", "SPECIES", 128, 140], ["irregular", "OBSERVATION_MODIFIER", 53, 62]]], ["The investigators explored the potential impact of these temporally unstructured daily routines and contact patterns on the simulated spread of influenza virus.", [["influenza", "DISEASE", 144, 153], ["influenza virus", "ORGANISM", 144, 159], ["influenza virus", "SPECIES", 144, 159], ["influenza virus", "PROBLEM", 144, 159], ["influenza virus", "OBSERVATION", 144, 159]]], ["The projected outbreak size was 20% larger as a consequence of these unstructured contact patterns, in comparison to scenarios modeling temporally structured contacts.TRANSMISSION NETWORKSIn addition to identifying individual and environmental characteristics associated with temporal and spatial patterns of viral infections, transmission networks are critical drivers of the dynamics of viral infections.", [["viral infections", "DISEASE", 309, 325], ["viral infections", "DISEASE", 389, 405], ["viral infections", "PROBLEM", 309, 325], ["viral infections", "PROBLEM", 389, 405], ["projected", "OBSERVATION_MODIFIER", 4, 13], ["outbreak", "OBSERVATION_MODIFIER", 14, 22], ["size", "OBSERVATION_MODIFIER", 23, 27], ["20%", "OBSERVATION_MODIFIER", 32, 35], ["larger", "OBSERVATION_MODIFIER", 36, 42], ["viral infections", "OBSERVATION", 309, 325], ["viral infections", "OBSERVATION", 389, 405]]], ["Analysis of transmission networks defines the host contact structure within which directly transmitted viral infections spread.", [["viral infections", "DISEASE", 103, 119], ["transmitted viral infections spread", "PROBLEM", 91, 126], ["host contact structure", "OBSERVATION", 46, 68], ["viral", "OBSERVATION_MODIFIER", 103, 108], ["infections", "OBSERVATION", 109, 119]]], ["Network theory and analysis are complex subjects with a long history in mathematics and sociology, but have recently been adapted by infectious disease epidemiologists.", [["infectious disease", "DISEASE", 133, 151]]], ["The epidemiologic study of social networks is facilitated by unique study designs, including snowball sampling or respondent-driven sampling, in which study participants are asked to recruit additional participants among their social contacts.", [["social networks", "MULTI-TISSUE_STRUCTURE", 27, 42], ["participants", "SPECIES", 157, 169], ["participants", "SPECIES", 202, 214], ["The epidemiologic study", "TEST", 0, 23], ["snowball sampling", "TEST", 93, 110]]], ["Concurrent sexual partnerships amplify the spread of HIV compared with serial monogamy.", [["HIV", "DISEASE", 53, 56], ["HIV", "ORGANISM", 53, 56], ["HIV", "SPECIES", 53, 56], ["HIV", "SPECIES", 53, 56], ["HIV", "PROBLEM", 53, 56]]], ["This could partially explain the dramatic differences in the prevalence of HIV in different countries.", [["HIV", "DISEASE", 75, 78], ["HIV", "ORGANISM", 75, 78], ["HIV", "SPECIES", 75, 78], ["HIV", "PROBLEM", 75, 78], ["could partially explain", "UNCERTAINTY", 5, 28], ["dramatic", "OBSERVATION_MODIFIER", 33, 41], ["differences", "OBSERVATION_MODIFIER", 42, 53]]], ["Social networks were shown to affect transmission of the 2009 H1N1 influenza virus, and were responsible for cyclical patterns of transmission between schools, communities, and households.", [["influenza virus", "DISEASE", 67, 82], ["2009 H1N1 influenza virus", "ORGANISM", 57, 82], ["H1N1 influenza virus", "SPECIES", 62, 82], ["2009 H1N1 influenza virus", "SPECIES", 57, 82], ["the 2009 H1N1 influenza virus", "PROBLEM", 53, 82]]], ["Technological advances in quantifying contact patterns, with wearable sensors and the use of viral genetic signatures, have greatly enhanced the ability to understand complex transmission networks.Contact PatternsSelf-reported contact histories and contact tracing are the traditional epidemiological methods to define transmission networks.", [["wearable sensors", "TREATMENT", 61, 77], ["viral genetic signatures", "TEST", 93, 117], ["contact tracing", "TEST", 249, 264]]], ["Contact tracing has a long history in public health, particularly in the control of sexually transmitted diseases and tuberculosis, and is critical to the control of outbreaks of viral infections such as the Middle East respiratory syndrome coronavirus (MERS-CoV) and Ebola virus.", [["sexually transmitted diseases", "DISEASE", 84, 113], ["tuberculosis", "DISEASE", 118, 130], ["viral infections", "DISEASE", 179, 195], ["Middle East respiratory syndrome coronavirus", "DISEASE", 208, 252], ["Ebola virus", "DISEASE", 268, 279], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 208, 252], ["MERS-CoV", "ORGANISM", 254, 262], ["Ebola virus", "ORGANISM", 268, 279], ["Ebola virus", "SPECIES", 268, 279], ["Middle East respiratory syndrome coronavirus", "SPECIES", 208, 252], ["MERS-CoV", "SPECIES", 254, 262], ["Ebola virus", "SPECIES", 268, 279], ["Contact tracing", "TEST", 0, 15], ["sexually transmitted diseases", "PROBLEM", 84, 113], ["tuberculosis", "PROBLEM", 118, 130], ["viral infections", "PROBLEM", 179, 195], ["the Middle East respiratory syndrome coronavirus", "PROBLEM", 204, 252], ["Ebola virus", "PROBLEM", 268, 279], ["tuberculosis", "OBSERVATION", 118, 130], ["viral infections", "OBSERVATION", 179, 195], ["Middle", "ANATOMY_MODIFIER", 208, 214], ["respiratory syndrome", "OBSERVATION", 220, 240], ["Ebola virus", "OBSERVATION", 268, 279]]], ["To better understand the nature of human contact patterns, sensor nodes or motes have been used to characterize the frequency and duration of contacts between individuals in settings such as schools and health-care facilities.", [["sensor nodes", "ANATOMY", 59, 71], ["human", "ORGANISM", 35, 40], ["sensor nodes", "MULTI-TISSUE_STRUCTURE", 59, 71], ["human", "SPECIES", 35, 40], ["human", "SPECIES", 35, 40], ["sensor nodes", "PROBLEM", 59, 71], ["nodes", "OBSERVATION", 66, 71]]], ["These technologies offer opportunities to validate and complement data collected using questionnaires and contact diaries.Contact PatternsAs an example, investigators used wireless sensor network technology to obtain data on social contacts within 3 m for 788 high school students in the United States, enabling construction of the social network within which a respiratory pathogen could be transmitted (Salathe, 2010) .", [["respiratory pathogen", "DISEASE", 362, 382], ["social network", "MULTI-TISSUE_STRUCTURE", 332, 346], ["complement data", "TEST", 55, 70], ["a respiratory pathogen", "PROBLEM", 360, 382]]], ["The data revealed a high-density network with typical small-world properties, in which a small number of steps link any two individuals.", [["The data", "TEST", 0, 8], ["a high-density network", "PROBLEM", 18, 40], ["high", "OBSERVATION_MODIFIER", 20, 24], ["density", "OBSERVATION", 25, 32], ["typical", "OBSERVATION_MODIFIER", 46, 53], ["small", "OBSERVATION_MODIFIER", 54, 59], ["-world properties", "OBSERVATION_MODIFIER", 59, 76], ["small", "OBSERVATION_MODIFIER", 89, 94]]], ["Computer simulations of the spread of an influenza-like virus on the weighted contact graph were in good agreement with absentee data collected during the influenza season.", [["influenza", "DISEASE", 155, 164], ["influenza-like virus", "ORGANISM", 41, 61], ["an influenza-like virus", "PROBLEM", 38, 61], ["influenza", "OBSERVATION", 41, 50]]], ["Analysis of targeted immunization strategies suggested that contact network data can be employed to design targeted vaccination strategies that are significantly more effective than random vaccination.MOLECULAR EPIDEMIOLOGYAdvances in nucleic acid sequencing and bioinformatics have led to major advances in viral epidemiology.", [["nucleic acid", "CHEMICAL", 235, 247], ["targeted immunization strategies", "TREATMENT", 12, 44], ["targeted vaccination strategies", "TREATMENT", 107, 138], ["MOLECULAR EPIDEMIOLOGYAdvances in nucleic acid sequencing", "PROBLEM", 201, 258]]], ["Population (Sanger) sequencing has been the standard method for DNA sequencing but is increasingly replaced by deep sequencing in which variants within a viral swarm are distinguished.", [["DNA", "CELLULAR_COMPONENT", 64, 67], ["DNA sequencing", "TEST", 64, 78], ["deep sequencing", "TEST", 111, 126], ["a viral swarm", "PROBLEM", 152, 165], ["deep", "ANATOMY_MODIFIER", 111, 115], ["viral swarm", "OBSERVATION", 154, 165]]], ["Sequencing allows for the detection of single nucleotide polymorphisms (SNPs) and nucleotide insertions or deletions (\"indels\"), analysis of synonymous and nonsynonymous mutations, and phylogenetic analysis (see chapter on virus evolution).MOLECULAR EPIDEMIOLOGYSequencing techniques can be applied to both viral and host genomes.", [["nucleotide", "CHEMICAL", 82, 92], ["SNPs", "DNA", 72, 76], ["viral and host genomes", "DNA", 307, 329], ["the detection", "TEST", 22, 35], ["single nucleotide polymorphisms (SNPs)", "PROBLEM", 39, 77], ["nucleotide insertions", "TREATMENT", 82, 103], ["deletions (\"indels\"", "PROBLEM", 107, 126], ["synonymous and nonsynonymous mutations", "PROBLEM", 141, 179], ["phylogenetic analysis", "TEST", 185, 206], ["MOLECULAR EPIDEMIOLOGYSequencing techniques", "TREATMENT", 240, 283], ["host genomes", "OBSERVATION", 317, 329]]], ["SNPs may be associated with changes in viral pathogenesis, virulence, or drug resistance.", [["SNPs", "TREATMENT", 0, 4], ["changes in viral pathogenesis", "PROBLEM", 28, 57], ["virulence", "PROBLEM", 59, 68], ["drug resistance", "PROBLEM", 73, 88], ["may be associated with", "UNCERTAINTY", 5, 27], ["viral", "OBSERVATION", 39, 44]]], ["Molecular techniques applied to pathogens also have been fundamental to the study of the animal origins of many viral infections including HIV and MERS.", [["viral infections", "DISEASE", 112, 128], ["HIV", "ORGANISM", 139, 142], ["HIV", "SPECIES", 139, 142], ["HIV", "SPECIES", 139, 142], ["Molecular techniques", "TREATMENT", 0, 20], ["pathogens", "PROBLEM", 32, 41], ["the study", "TEST", 72, 81], ["many viral infections", "PROBLEM", 107, 128], ["HIV", "PROBLEM", 139, 142], ["many", "OBSERVATION_MODIFIER", 107, 111], ["viral", "OBSERVATION_MODIFIER", 112, 117], ["infections", "OBSERVATION", 118, 128]]], ["Phylogeographic approaches were used to trace the origins of the HIV pandemic to spillover events in central Africa (Sharp, 2010) .", [["HIV pandemic", "DISEASE", 65, 77], ["HIV", "SPECIES", 65, 68], ["Phylogeographic approaches", "TREATMENT", 0, 26], ["HIV", "OBSERVATION", 65, 68], ["central", "OBSERVATION_MODIFIER", 101, 108], ["Africa", "OBSERVATION_MODIFIER", 109, 115]]], ["More recently, sequence data were used to track the animal reservoirs of MERS-CoV associated with the 2014 outbreaks (Haagmans, 2014) , and to compare the Ebola virus strain circulating in the 2014 West Africa outbreak to strains from prior outbreaks (Gire, 2014) .MOLECULAR EPIDEMIOLOGYEpidemiologic studies that probe host genomes can be either candidate gene studies or genome-wide association studies.", [["Ebola virus", "DISEASE", 155, 166], ["MERS-CoV", "ORGANISM", 73, 81], ["Ebola virus", "ORGANISM", 155, 166], ["Ebola virus", "SPECIES", 155, 166], ["MERS-CoV", "SPECIES", 73, 81], ["Ebola virus", "SPECIES", 155, 166], ["sequence data", "TEST", 15, 28], ["CoV", "PROBLEM", 78, 81], ["the Ebola virus strain", "PROBLEM", 151, 173], ["MOLECULAR EPIDEMIOLOGYEpidemiologic studies", "TEST", 265, 308], ["gene studies", "TEST", 357, 369]]], ["The goal of these studies is to link specific changes with an increased risk of infection or disease.", [["infection", "DISEASE", 80, 89], ["these studies", "TEST", 12, 25], ["infection", "PROBLEM", 80, 89], ["disease", "PROBLEM", 93, 100], ["increased", "OBSERVATION_MODIFIER", 62, 71], ["infection", "OBSERVATION", 80, 89]]], ["As an example, a small subset of individuals who failed to acquire HIV infection despite exposure, prompted studies to determine how these individuals differed from those who acquired infection.", [["HIV infection", "DISEASE", 67, 80], ["infection", "DISEASE", 184, 193], ["HIV", "ORGANISM", 67, 70], ["individuals", "ORGANISM", 139, 150], ["HIV", "SPECIES", 67, 70], ["HIV", "SPECIES", 67, 70], ["HIV infection", "PROBLEM", 67, 80], ["studies", "TEST", 108, 115], ["infection", "PROBLEM", 184, 193], ["small", "OBSERVATION_MODIFIER", 17, 22], ["infection", "OBSERVATION", 184, 193]]], ["A 32-base-pair deletion in the human CCR5 gene, now referred to as CCR5-delta 32, accounted for the resistance of these subjects.", [["human", "ORGANISM", 31, 36], ["CCR5", "GENE_OR_GENE_PRODUCT", 37, 41], ["CCR5-delta 32", "GENE_OR_GENE_PRODUCT", 67, 80], ["32-base-pair deletion", "DNA", 2, 23], ["human CCR5 gene", "DNA", 31, 46], ["CCR5", "PROTEIN", 67, 71], ["delta 32", "DNA", 72, 80], ["human", "SPECIES", 31, 36], ["human", "SPECIES", 31, 36], ["A 32-base-pair deletion in the human CCR5 gene", "TREATMENT", 0, 46], ["CCR5-delta", "TEST", 67, 77], ["32-base", "OBSERVATION_MODIFIER", 2, 9], ["human CCR5", "ANATOMY", 31, 41]]], ["Individuals who are CCR5-delta 32 homozygotes are protected against HIV infection by CCR5tropic HIV strains, while heterozygotes have decreased disease severity.PHYLODYNAMICSInfectious disease epidemiologists are increasingly linking evolutionary, immunologic, and epidemiological processes, a field referred to as phylodynamics Voltz, 2013) .", [["HIV infection", "DISEASE", 68, 81], ["CCR5-delta 32", "GENE_OR_GENE_PRODUCT", 20, 33], ["HIV", "ORGANISM", 68, 71], ["CCR5tropic HIV", "ORGANISM", 85, 99], ["CCR5", "PROTEIN", 20, 24], ["HIV", "SPECIES", 68, 71], ["HIV", "SPECIES", 96, 99], ["HIV", "SPECIES", 68, 71], ["HIV", "SPECIES", 96, 99], ["CCR5", "TEST", 20, 24], ["HIV infection", "PROBLEM", 68, 81], ["CCR5tropic HIV strains", "PROBLEM", 85, 107], ["heterozygotes", "PROBLEM", 115, 128], ["decreased disease severity", "PROBLEM", 134, 160], ["PHYLODYNAMICSInfectious disease", "PROBLEM", 161, 192], ["decreased", "OBSERVATION_MODIFIER", 134, 143], ["disease", "OBSERVATION", 144, 151]]], ["Because of the high mutation rates of viral pathogens, particularly RNA viruses, evolutionary and epidemiological processes take place on a similar timescale (see chapter on virus evolution).", [["the high mutation rates", "PROBLEM", 11, 34], ["viral pathogens", "PROBLEM", 38, 53], ["RNA viruses", "PROBLEM", 68, 79], ["viral pathogens", "OBSERVATION", 38, 53], ["RNA viruses", "OBSERVATION", 68, 79]]], ["According to this framework, phylodynamic processes that determine the degree of viral diversity are a function of host immune selective pressures and epidemiological patterns of transmission ( Figure 8 ).PHYLODYNAMICSIntrahost phylodynamic processes begin with molecular characteristics of the virus as well as the host's permissiveness and response to infection.", [["infection", "DISEASE", 354, 363], ["phylodynamic processes", "PROBLEM", 29, 51], ["viral diversity", "PROBLEM", 81, 96], ["PHYLODYNAMICSIntrahost phylodynamic processes", "PROBLEM", 205, 250], ["the virus", "PROBLEM", 291, 300], ["infection", "PROBLEM", 354, 363], ["viral diversity", "OBSERVATION", 81, 96], ["virus", "OBSERVATION", 295, 300], ["infection", "OBSERVATION", 354, 363]]], ["For example, a single amino acid substitution in Epstein-Barr virus was shown to disrupt antigen presentation by specific human leukocyte antigen polymorphisms (Liu, 2014) .", [["amino acid", "CHEMICAL", 22, 32], ["amino acid", "CHEMICAL", 22, 32], ["amino acid", "AMINO_ACID", 22, 32], ["Epstein-Barr virus", "ORGANISM", 49, 67], ["human", "ORGANISM", 122, 127], ["leukocyte antigen", "GENE_OR_GENE_PRODUCT", 128, 145], ["human leukocyte antigen polymorphisms", "DNA", 122, 159], ["human", "SPECIES", 122, 127], ["Epstein-Barr virus", "SPECIES", 49, 67], ["human", "SPECIES", 122, 127], ["a single amino acid substitution", "TREATMENT", 13, 45], ["Barr virus", "PROBLEM", 57, 67], ["acid substitution", "OBSERVATION", 28, 45], ["Barr virus", "OBSERVATION", 57, 67]]], ["This resulted in decreased T-cell receptor recognition and successful viral immune escape.", [["T-cell", "ANATOMY", 27, 33], ["T-cell receptor", "GENE_OR_GENE_PRODUCT", 27, 42], ["T-cell receptor", "PROTEIN", 27, 42], ["decreased T-cell receptor recognition", "PROBLEM", 17, 54], ["successful viral immune escape", "PROBLEM", 59, 89], ["decreased", "OBSERVATION_MODIFIER", 17, 26], ["viral immune escape", "OBSERVATION", 70, 89]]], ["The virus must also induce an \"optimal\" host immune response to maximize transmission to new hosts.", [["The virus", "PROBLEM", 0, 9], ["virus", "OBSERVATION", 4, 9]]], ["If the virus induces a strong, proinflammatory immune response not balanced by the appropriate anti-inflammatory responses, the host may succumb to the overabundance of inflammation and cannot propagate viral transmission.", [["inflammation", "DISEASE", 169, 181], ["the virus", "PROBLEM", 3, 12], ["inflammation", "PROBLEM", 169, 181], ["virus", "OBSERVATION", 7, 12], ["inflammation", "OBSERVATION", 169, 181]]], ["Alternatively, a virus that fails to stimulate an immune response may also replicate uninhibited, overwhelming, and killing the host prior to transmission.", [["a virus", "PROBLEM", 15, 22]]], ["Selective pressures maximize replication while sustaining transmission between hosts.PHYLODYNAMICSInterhost dynamics are affected by several factors including evolutionary pressures, timescales of infection, viral latent periods, and host population structures.", [["infection", "DISEASE", 197, 206], ["Selective pressures maximize replication", "TREATMENT", 0, 40], ["evolutionary pressures", "TEST", 159, 181], ["infection", "PROBLEM", 197, 206], ["viral latent periods", "PROBLEM", 208, 228], ["pressures", "OBSERVATION_MODIFIER", 10, 19], ["pressures", "OBSERVATION_MODIFIER", 172, 181], ["infection", "OBSERVATION", 197, 206], ["viral", "OBSERVATION_MODIFIER", 208, 213], ["host population", "OBSERVATION_MODIFIER", 234, 249]]], ["Typically, only a small number of virions are transmitted between hosts, creating a genetic bottleneck that limits viral diversity.", [["virions", "ANATOMY", 34, 41], ["a small number of virions", "PROBLEM", 16, 41], ["small", "OBSERVATION_MODIFIER", 18, 23], ["number", "OBSERVATION_MODIFIER", 24, 30], ["virions", "OBSERVATION", 34, 41], ["viral diversity", "OBSERVATION", 115, 130]]], ["A virus that mutates to cause highly pathogenic disease but is not transmitted cannot propagate its pathogenicity.", [["A virus", "SPECIES", 0, 7], ["A virus", "PROBLEM", 0, 7], ["highly pathogenic disease", "PROBLEM", 30, 55], ["virus", "OBSERVATION", 2, 7], ["highly", "OBSERVATION_MODIFIER", 30, 36], ["pathogenic", "OBSERVATION_MODIFIER", 37, 47], ["disease", "OBSERVATION", 48, 55], ["pathogenicity", "OBSERVATION", 100, 113]]], ["Cross-immunity between viral strains also precludes the replication of particular viral lineages.", [["viral lineages", "CELL_TYPE", 82, 96], ["Cross-immunity", "TREATMENT", 0, 14], ["viral strains", "PROBLEM", 23, 36], ["particular viral lineages", "PROBLEM", 71, 96], ["viral strains", "OBSERVATION", 23, 36], ["viral lineages", "OBSERVATION", 82, 96]]], ["Influenza vaccine strains require annual changes due to new circulating influenza strains that have escaped immune pressures through high mutation rates and gene re-assortment.", [["Influenza", "DISEASE", 0, 9], ["Influenza vaccine strains", "TREATMENT", 0, 25], ["annual changes", "PROBLEM", 34, 48], ["new circulating influenza strains", "PROBLEM", 56, 89], ["immune pressures", "TEST", 108, 124], ["high mutation rates", "TREATMENT", 133, 152], ["gene re-assortment", "TREATMENT", 157, 175]]], ["The strong selection pressure of cross-immunity is reflected in the short branch lengths in a phylogenetic tree of influenza viruses isolated from infected individuals.", [["influenza viruses", "DISEASE", 115, 132], ["influenza viruses", "ORGANISM", 115, 132], ["the short branch lengths", "PROBLEM", 64, 88], ["influenza viruses", "PROBLEM", 115, 132], ["infected individuals", "PROBLEM", 147, 167], ["strong", "OBSERVATION_MODIFIER", 4, 10], ["selection", "OBSERVATION_MODIFIER", 11, 20], ["pressure", "OBSERVATION_MODIFIER", 21, 29], ["short", "OBSERVATION_MODIFIER", 68, 73], ["branch", "OBSERVATION_MODIFIER", 74, 80], ["lengths", "OBSERVATION_MODIFIER", 81, 88], ["phylogenetic", "OBSERVATION_MODIFIER", 94, 106], ["tree", "OBSERVATION_MODIFIER", 107, 111], ["influenza viruses", "OBSERVATION", 115, 132], ["infected", "OBSERVATION_MODIFIER", 147, 155]]], ["Thus, the selection of influenza strains for future vaccines is partly determined by cross-immunity to prior circulating strains, because influenza viral strains that circulated in the past may elicit immune protection against currently circulating strains.PHYLODYNAMICSAt the population level, phylodynamic methods have been used to estimate R 0 for HIV and hepatitis C virus, for which reporting and surveillance data are often incomplete (Volz, 2013) .", [["influenza", "DISEASE", 23, 32], ["HIV and hepatitis C", "DISEASE", 351, 370], ["influenza strains", "ORGANISM", 23, 40], ["influenza viral strains", "ORGANISM", 138, 161], ["HIV", "ORGANISM", 351, 354], ["hepatitis C virus", "ORGANISM", 359, 376], ["HIV", "SPECIES", 351, 354], ["hepatitis C virus", "SPECIES", 359, 376], ["HIV", "SPECIES", 351, 354], ["hepatitis C virus", "SPECIES", 359, 376], ["influenza strains", "PROBLEM", 23, 40], ["future vaccines", "TREATMENT", 45, 60], ["prior circulating strains", "PROBLEM", 103, 128], ["influenza viral strains", "PROBLEM", 138, 161], ["immune protection", "TREATMENT", 201, 218], ["circulating strains", "PROBLEM", 237, 256], ["phylodynamic methods", "TREATMENT", 295, 315], ["HIV", "PROBLEM", 351, 354], ["hepatitis C virus", "PROBLEM", 359, 376], ["surveillance data", "TEST", 402, 419]]], ["Phylodynamic and phylogeographic models also have been useful in reconstructing the spatial spread of viruses to reveal hidden patterns of transmission.", [["viruses", "OBSERVATION", 102, 109]]], ["For example, epidemiological and molecular studies of influenza virus transmission were compared at different spatial scales to highlight the similarities and differences between these data sources (Viboud, 2013) .", [["influenza virus transmission", "DISEASE", 54, 82], ["influenza virus", "ORGANISM", 54, 69], ["influenza virus", "SPECIES", 54, 69], ["influenza virus", "SPECIES", 54, 69], ["influenza virus transmission", "PROBLEM", 54, 82], ["influenza virus", "OBSERVATION", 54, 69]]], ["The findings were broadly consistent with large-scale studies of interregional or inter-hemispheric spread in temperate regions with multiple viral introductions resulting in epidemics followed by interepidemic periods driven by seasonal bottlenecks.", [["large-scale studies", "PROBLEM", 42, 61], ["interregional or inter-hemispheric spread in temperate regions", "PROBLEM", 65, 127], ["multiple viral introductions", "PROBLEM", 133, 161], ["epidemics", "PROBLEM", 175, 184], ["consistent with", "UNCERTAINTY", 26, 41], ["large", "OBSERVATION_MODIFIER", 42, 47], ["inter-hemispheric", "OBSERVATION_MODIFIER", 82, 99], ["spread", "OBSERVATION_MODIFIER", 100, 106], ["multiple", "OBSERVATION_MODIFIER", 133, 141], ["viral introductions", "OBSERVATION", 142, 161]]], ["However, at smaller spatial scalessuch as a country or community-epidemiological studies revealed spatially structured diffusion patterns that were not identified in molecular studies.", [["community-epidemiological studies", "TEST", 55, 88], ["spatially structured diffusion patterns", "PROBLEM", 98, 137], ["molecular studies", "TEST", 166, 183]]], ["Phylogenetic analyses of gag and env genes were used to assess the spatial dynamics of HIV transmission in rural Rakai District, Uganda, using data from a cohort of 14,594 individuals residing in 46 communities (Grabowski, 2014) .", [["HIV transmission", "DISEASE", 87, 103], ["gag", "GENE_OR_GENE_PRODUCT", 25, 28], ["env", "GENE_OR_GENE_PRODUCT", 33, 36], ["HIV", "ORGANISM", 87, 90], ["gag and env genes", "DNA", 25, 42], ["HIV", "SPECIES", 87, 90], ["Phylogenetic analyses", "TEST", 0, 21], ["gag and env genes", "PROBLEM", 25, 42], ["gag", "OBSERVATION", 25, 28], ["env genes", "OBSERVATION", 33, 42]]], ["Among Phylodynamics links evolutionary, immunologic, and epidemiologic processes to explain viral diversity, as shown here for equine influenza virus.", [["influenza virus", "DISEASE", 134, 149], ["equine influenza virus", "ORGANISM", 127, 149], ["equine influenza virus", "SPECIES", 127, 149], ["equine influenza virus", "SPECIES", 127, 149], ["epidemiologic processes", "PROBLEM", 57, 80], ["viral diversity", "PROBLEM", 92, 107], ["equine influenza virus", "PROBLEM", 127, 149], ["viral diversity", "OBSERVATION", 92, 107]]], ["For viral evolution, these processes take place on a similar timescale.", [["viral evolution", "PROBLEM", 4, 19]]], ["Within host mutations (1) result from an interplay between optimization of viral shedding, immunologic selective pressures and host pathogenicity.", [["viral shedding", "PROBLEM", 75, 89], ["immunologic selective pressures", "TEST", 91, 122], ["host pathogenicity", "PROBLEM", 127, 145], ["host pathogenicity", "OBSERVATION", 127, 145]]], ["Transmission bottlenecks and host heterogeneity (2) further determine the population genetic structure of the virus, which in turn influences and is determined by the epidemic dynamics.", [["host heterogeneity", "PROBLEM", 29, 47], ["the virus", "PROBLEM", 106, 115], ["host heterogeneity", "OBSERVATION_MODIFIER", 29, 47], ["virus", "OBSERVATION", 110, 115]]], ["Larger scale spatial dynamics at local, regional, and global levels (3) the remaining clusters, almost three-quarters involved individuals living in different communities, suggesting transmission chains frequently extend beyond local communities in rural Uganda.", [["Larger scale spatial dynamics at local, regional, and global levels", "PROBLEM", 0, 67], ["transmission chains", "PROBLEM", 183, 202], ["scale", "OBSERVATION_MODIFIER", 7, 12], ["spatial", "OBSERVATION_MODIFIER", 13, 20], ["dynamics", "OBSERVATION_MODIFIER", 21, 29], ["rural Uganda", "OBSERVATION", 249, 261]]], ["The timescale of infection is also important for viral diversity and transmission dynamics.", [["infection", "DISEASE", 17, 26], ["infection", "PROBLEM", 17, 26], ["viral diversity", "PROBLEM", 49, 64], ["timescale", "OBSERVATION_MODIFIER", 4, 13], ["infection", "OBSERVATION", 17, 26]]], ["Some viruses are capable of initiating an acute infection that is cleared within days, while other viral infections are chronic and persist for a lifetime.", [["infection", "DISEASE", 48, 57], ["viral infections", "DISEASE", 99, 115], ["Some viruses", "PROBLEM", 0, 12], ["an acute infection", "PROBLEM", 39, 57], ["other viral infections", "PROBLEM", 93, 115], ["viruses", "OBSERVATION", 5, 12], ["acute", "OBSERVATION_MODIFIER", 42, 47], ["infection", "OBSERVATION", 48, 57], ["viral", "OBSERVATION_MODIFIER", 99, 104], ["infections", "OBSERVATION", 105, 115], ["chronic", "OBSERVATION_MODIFIER", 120, 127]]], ["The duration of infection impacts how quickly a virus must be transmitted and has implications for the infectious period and the potential to be transmitted to new hosts.", [["infection", "DISEASE", 16, 25], ["infection", "PROBLEM", 16, 25], ["a virus", "PROBLEM", 46, 53], ["infection", "OBSERVATION", 16, 25], ["infectious", "OBSERVATION", 103, 113]]], ["Viruses with long latent periods create interhost phylogenetic trees with longer branch lengths.", [["Viruses", "PROBLEM", 0, 7], ["interhost", "OBSERVATION_MODIFIER", 40, 49], ["phylogenetic trees", "OBSERVATION", 50, 68], ["longer", "OBSERVATION_MODIFIER", 74, 80], ["branch", "OBSERVATION_MODIFIER", 81, 87], ["lengths", "OBSERVATION_MODIFIER", 88, 95]]], ["The long duration between infection and transmission permits accumulation of viral changes through many rounds of viral replication before transmission to the next host.", [["infection", "DISEASE", 26, 35], ["The long duration between infection", "PROBLEM", 0, 35], ["viral changes", "PROBLEM", 77, 90], ["viral replication", "TREATMENT", 114, 131], ["long duration", "OBSERVATION_MODIFIER", 4, 17], ["infection", "OBSERVATION", 26, 35], ["viral changes", "OBSERVATION", 77, 90], ["viral replication", "OBSERVATION", 114, 131]]], ["Examples include hepatitis B virus, hepatitis C virus, and human immunodeficiency virus.MATHEMATICAL MODELS OF TRANSMISSION DYNAMICSAvailability of computational resources allows widespread use and development of classic approaches to the mathematical modeling of viral transmission dynamics, such as compartmental, metapopulation and network models, to address epidemiologic questions (see chapter on mathematical methods).", [["hepatitis B", "DISEASE", 17, 28], ["hepatitis C", "DISEASE", 36, 47], ["human immunodeficiency virus", "DISEASE", 59, 87], ["hepatitis B virus", "ORGANISM", 17, 34], ["hepatitis C virus", "ORGANISM", 36, 53], ["human immunodeficiency virus", "ORGANISM", 59, 87], ["hepatitis B virus", "SPECIES", 17, 34], ["hepatitis C virus", "SPECIES", 36, 53], ["human", "SPECIES", 59, 64], ["immunodeficiency virus", "SPECIES", 65, 87], ["hepatitis B virus", "SPECIES", 17, 34], ["hepatitis C virus", "SPECIES", 36, 53], ["human immunodeficiency virus", "SPECIES", 59, 87], ["hepatitis B virus", "PROBLEM", 17, 34], ["hepatitis C virus", "PROBLEM", 36, 53], ["human immunodeficiency virus", "PROBLEM", 59, 87], ["hepatitis", "OBSERVATION", 17, 26], ["immunodeficiency virus", "OBSERVATION", 65, 87]]], ["These models have been used extensively in the study of viral dynamics and to explore the potential impact of control interventions.", [["the study", "TEST", 43, 52], ["viral dynamics", "TEST", 56, 70], ["control interventions", "TREATMENT", 110, 131]]], ["New sources of high-resolution spatial, temporal, and genetic data create opportunities for models that integrate these data with traditional epidemiological data.", [["high-resolution spatial, temporal, and genetic data", "PROBLEM", 15, 66], ["these data", "TEST", 114, 124], ["traditional epidemiological data", "TEST", 130, 162], ["high", "OBSERVATION_MODIFIER", 15, 19]]], ["Such analyses improve estimates of key transmission parameters and understanding of the mechanisms driving virus spread.Agent-Based ModelsAgent-based models (also known as individual-based models) can now be run using desktop computers, and offer advantages over more traditional mathematical models.", [["Such analyses", "TEST", 0, 13], ["Agent", "TREATMENT", 120, 125]]], ["Because each unit in a population is modeled explicitly in space and time and assigned specific attributes, agent-based models can reproduce the heterogeneity and complexity observed in the real world.", [["agent-based models", "TREATMENT", 108, 126], ["the heterogeneity", "PROBLEM", 141, 158], ["heterogeneity", "OBSERVATION", 145, 158]]], ["Agent-based models have been used to study the spread of viruses in populations as well as the evolution of viruses within and across populations.", [["Agent", "TREATMENT", 0, 5], ["viruses in populations", "PROBLEM", 57, 79], ["viruses", "PROBLEM", 108, 115], ["viruses", "OBSERVATION", 57, 64], ["viruses", "OBSERVATION", 108, 115]]], ["While agent-based models are intuitive and easy to formulate, these models are often difficult to construct due to the large number of parameters necessary to describe the behavior and interaction between individual units.", [["large", "OBSERVATION_MODIFIER", 119, 124]]], ["The Global Epidemic and Mobility Model (GLEAM) on the gleamviz platform (www.gleamviz.com), for example, contains extensive data on populations and human mobility, and allows stochastic simulation of the global spread of infectious diseases using user-defined transmission models.SYNTHESISOur understanding of the epidemiology of viral infections is being revolutionized by the integration of traditional epidemiological information with novel sources of data.SYNTHESISl Data streams from the Internet are promising sources to enhance traditional surveillance but have yet to be fully validated.SYNTHESISl Molecular data on viral genomic sequences provide unprecedented opportunities to characterize viral transmission pathways.SYNTHESISl Phylodynamic and phylogeographic models have been used to estimate R 0 , and characterize the spatial spread of viruses.SYNTHESISl Network analysis reveals hidden patterns of transmission between population subgroups that are not easy to capture with traditional epidemiological methods.SYNTHESISl Novel analytical and computational resources are playing a key role in integrating information from multiple large data banks.SYNTHESISThese more comprehensive methods improve our ability to estimate the impact of infection control measures.", [["infectious diseases", "DISEASE", 221, 240], ["viral infections", "DISEASE", 330, 346], ["infection", "DISEASE", 1251, 1260], ["human", "ORGANISM", 148, 153], ["viral genomic sequences", "DNA", 624, 647], ["human", "SPECIES", 148, 153], ["human", "SPECIES", 148, 153], ["infectious diseases", "PROBLEM", 221, 240], ["viral infections", "PROBLEM", 330, 346], ["traditional surveillance", "TEST", 535, 559], ["viral genomic sequences", "TEST", 624, 647], ["phylogeographic models", "TEST", 756, 778], ["viruses", "PROBLEM", 851, 858], ["SYNTHESISl Network analysis", "TEST", 859, 886], ["infection control measures", "TREATMENT", 1251, 1277], ["Global", "OBSERVATION_MODIFIER", 4, 10], ["Epidemic", "OBSERVATION_MODIFIER", 11, 19], ["Mobility", "OBSERVATION_MODIFIER", 24, 32], ["extensive", "OBSERVATION_MODIFIER", 114, 123], ["infectious", "OBSERVATION", 221, 231], ["viral infections", "OBSERVATION", 330, 346], ["viruses", "OBSERVATION", 851, 858], ["infection", "OBSERVATION", 1251, 1260]]], ["The combination of traditional and evolving methodologies is closing the gap between epidemiological studies and viral pathogenesis.", [["traditional and evolving methodologies", "PROBLEM", 19, 57], ["epidemiological studies", "TEST", 85, 108], ["viral pathogenesis", "PROBLEM", 113, 131], ["viral pathogenesis", "OBSERVATION", 113, 131]]], ["These developments have laid the foundation for exciting future research that will complement other approaches to the pathogenesis of viral diseases.SYNTHESISWith these evolving technologies in mind, it is timely to ask: Is the world able to control viral diseases more effectively?", [["viral diseases", "DISEASE", 134, 148], ["viral diseases", "DISEASE", 250, 264], ["viral diseases", "PROBLEM", 134, 148], ["viral diseases", "PROBLEM", 250, 264], ["viral diseases", "OBSERVATION", 134, 148]]], ["On the one hand, smallpox has been eradicated and we are on the verge of elimination of wild polioviruses.", [["smallpox", "DISEASE", 17, 25], ["smallpox", "TREATMENT", 17, 25], ["wild polioviruses", "PROBLEM", 88, 105]]], ["Furthermore, deaths of children under the age of 5 years (which are mainly due to viral and other infectious diseases) have decreased by almost 50% in the last few decades.", [["deaths", "DISEASE", 13, 19], ["viral and other infectious diseases", "DISEASE", 82, 117], ["children", "ORGANISM", 23, 31], ["children", "SPECIES", 23, 31], ["viral and other infectious diseases", "PROBLEM", 82, 117], ["infectious", "OBSERVATION", 98, 108], ["decreased", "OBSERVATION_MODIFIER", 124, 133]]], ["On the other hand, the AIDS pandemic continues to rage in low-income countries, with only a slight reduction in the annual incidence of new infections.", [["AIDS", "DISEASE", 23, 27], ["infections", "DISEASE", 140, 150], ["the AIDS pandemic", "PROBLEM", 19, 36], ["a slight reduction", "PROBLEM", 90, 108], ["new infections", "PROBLEM", 136, 150], ["slight", "OBSERVATION_MODIFIER", 92, 98], ["reduction", "OBSERVATION_MODIFIER", 99, 108], ["new", "OBSERVATION_MODIFIER", 136, 139], ["infections", "OBSERVATION", 140, 150]]], ["The United States has not done any better in reducing HIV incidence which has been unchanged for at least 20 years.", [["HIV", "ORGANISM", 54, 57], ["HIV", "SPECIES", 54, 57], ["unchanged", "OBSERVATION_MODIFIER", 83, 92]]], ["The 2014-15 Ebola pandemic in West Africa reflects the limited capacity for dealing with new and emerging viral diseases on a global basis.", [["Ebola", "DISEASE", 12, 17], ["viral diseases", "DISEASE", 106, 120], ["new and emerging viral diseases", "PROBLEM", 89, 120], ["viral", "OBSERVATION", 106, 111]]]], "34bec30ce78b4c883064be6e70f11829503a7e5f": [["IntroductionThe novel coronavirus SARS-CoV-2 coined by the World Health Organization (WHO) as COVID-19 is now declared to be pandemic, affecting 210 countries and territories (and 2 international conveyances) with over 2,026,958 confirmed infected cases worldwide, 129,100 deaths, and 494,418 recoveries as of April 15th, 2020, 15:27 GMT [6] .", [["deaths", "DISEASE", 273, 279], ["coronavirus SARS-CoV-2", "ORGANISM", 22, 44], ["coronavirus", "SPECIES", 22, 33], ["COVID", "TEST", 94, 99], ["pandemic", "PROBLEM", 125, 133]]], ["Statistically, this rate simply predicates an exponential increase in the confirmed cases, vis-\u00e0-vis March 20th 2020 figure of 269,0 0 0 inflicted cases.", [["this rate", "TEST", 15, 24], ["exponential", "OBSERVATION_MODIFIER", 46, 57], ["increase", "OBSERVATION_MODIFIER", 58, 66]]], ["Without taking into consideration the infection multiplier factor, and assuming no effective antidotes are out and distributed at this time, we can expect more than six million confirmed cases to surface on our planet by the later part of May 2020 with the death rate and other derogatory impacts to increase proportionately.IntroductionSuch an outbreak is already having a sweeping effect on every region of the globe.", [["infection", "DISEASE", 38, 47], ["death", "DISEASE", 257, 262], ["infection multiplier factor", "PROTEIN", 38, 65], ["the infection multiplier factor", "PROBLEM", 34, 65], ["effective antidotes", "TREATMENT", 83, 102], ["the death rate", "TEST", 253, 267], ["infection", "OBSERVATION", 38, 47], ["outbreak", "OBSERVATION", 345, 353], ["sweeping effect", "OBSERVATION", 374, 389], ["globe", "ANATOMY", 413, 418]]], ["Indeed, our world has yet to experience the velocity of such a virus infection and mortality rate, resulting in massive shortage of resources, job loss, and/or disruption as well as mounting and drastic economic impact on a global scale.", [["infection", "DISEASE", 69, 78], ["a virus infection", "PROBLEM", 61, 78], ["mortality rate", "TEST", 83, 97], ["massive shortage of resources", "PROBLEM", 112, 141], ["job loss", "PROBLEM", 143, 151], ["disruption", "PROBLEM", 160, 170], ["a global scale", "TREATMENT", 222, 236], ["massive", "OBSERVATION_MODIFIER", 112, 119], ["shortage", "OBSERVATION_MODIFIER", 120, 128], ["drastic", "OBSERVATION_MODIFIER", 195, 202]]], ["Nonetheless, within a single precinct, the ability to implement the right policy thinking at a timely manner will also significantly impact on the number of anticipated deaths.IntroductionOur recommendation, amid this global crisis, is to initiate a Global Pandemic Safeguard Agency, with a conceived name of IPPO: Intercontinental Pandemic Preparedness Organization to share workable solutions and higher level policy measures while each region or country is implementing their specific policies to control the spread in a timely manner.A strategic global pandemic management organizationWhile several highly respected coalitions among members from a majority of nations, such as the United Nations, Intergovernmental Economic Organisation (OECD), and WHO exist, there is however not a global arrangement endowed with a systematic infrastructure to oversee readily available but necessary medical supplies in reserve, cooperative technology, and adequate funding when dealing with an unknown pandemic such as the COVID-19 crisis.", [["deaths", "DISEASE", 169, 175], ["workable solutions", "TREATMENT", 376, 394], ["higher level policy measures", "TREATMENT", 399, 427], ["A strategic global pandemic management", "TREATMENT", 538, 576], ["a systematic infrastructure", "PROBLEM", 819, 846], ["the COVID", "TEST", 1010, 1019], ["right", "ANATOMY_MODIFIER", 68, 73]]], ["Apparently, the 7.8 billion citizens of the world are not prepared to deal with another pandemic given what we are witnessing minute-by-minute on the devastating effects of COVID-19.", [["COVID-19", "CHEMICAL", 173, 181], ["the 7.8 billion citizens", "TREATMENT", 12, 36], ["COVID", "TEST", 173, 178]]], ["This may be the god-sent wakeup call for humankind to start planning for an effective global coalition such as IPPO with a league of nations, notwithstanding the current efforts by individual countries to implement best-practice, epidemiological model-driven policies to flatten the curve of COVID-19 contagion.A strategic global pandemic management organizationAs of today, April 15th, 2020, we have yet no remedy for a confirmed COVID-19 case, although speculations abound.", [["epidemiological model", "TEST", 230, 251], ["COVID", "TEST", 292, 297], ["A strategic global pandemic management", "TREATMENT", 311, 349]]], ["Nevertheless, while the survival rates are relatively high, any healthcare system will soon cripple itself as the infection spreads without properly targeting quarantines, having the needed supplies while awaiting an effective cure.", [["infection", "DISEASE", 114, 123], ["the survival rates", "TEST", 20, 38], ["the infection", "PROBLEM", 110, 123], ["infection", "OBSERVATION", 114, 123]]], ["Aside from massively increasing the number of COVID-19 tests and contact tracing, the only working strategy at this stage has been to plank the curve via social distancing and regulated quarantines or mandated lockdown for slowing down the spread of the virus.", [["COVID", "TEST", 46, 51], ["contact tracing", "TEST", 65, 80], ["the virus", "PROBLEM", 250, 259], ["massively", "OBSERVATION_MODIFIER", 11, 20], ["increasing", "OBSERVATION_MODIFIER", 21, 31]]], ["While these strategies have proven to be somewhat useful, as we have learned from nations such as China and South Korea, there is now the possibility of a second (or even a third) wave where returning residents from affected countries continue to revive the spread as experienced in countries and special administrative regions such as Hong Kong, Singapore and even China.A strategic global pandemic management organizationChina administered the lockdown for the affected Hubei province, where the epicenter for COVID-19 outbreak, Wuhan, is located.", [["A strategic global pandemic management", "TREATMENT", 372, 410], ["COVID", "TEST", 512, 517]]], ["In Germany and South Korea, the nationwide lockdown and contact tracing were well managed and disciplined, perhaps due to their size, education, sense of nationalism, and national healthcare policies.", [["contact tracing", "TEST", 56, 71], ["size", "OBSERVATION_MODIFIER", 128, 132]]], ["An American teacher stationed in South Korea writes, \"Nationwide testing, transparent and frequent government updates, free healthcare for all affected an overall sense of community responsibility has prevented me from feeling like my world has turned upside down\" [15] .A strategic global pandemic management organizationTo date, the successes of Taiwan, Germany and South Korea have not, however, appeared to be successfully replicated to other countries, and maybe it might not even happen soon if it ever does.Virtual staffing platformOne of the key challenges we face today is the shortage of medical staff, especially doctors and nurses, to care for COVID-19 patients.", [["patients", "ORGANISM", 665, 673], ["patients", "SPECIES", 665, 673], ["Nationwide testing", "TEST", 54, 72], ["A strategic global pandemic management", "TREATMENT", 271, 309]]], ["Such a shortage will not only distress the COVID-19 patients but will also stymie the regular flow of typical patients who may need an equal or higher level of care, such as a stroke or cardiovascular patient.", [["cardiovascular", "ANATOMY", 186, 200], ["stroke", "DISEASE", 176, 182], ["patients", "ORGANISM", 52, 60], ["patients", "ORGANISM", 110, 118], ["patient", "ORGANISM", 201, 208], ["patients", "SPECIES", 52, 60], ["patients", "SPECIES", 110, 118], ["patient", "SPECIES", 201, 208], ["a stroke", "PROBLEM", 174, 182]]], ["Under this complex situation, a virtual medical staffing platform can be of great utility.Virtual staffing platformA virtual care outfit provides a simple e-health solution.", [["a virtual medical staffing platform", "TREATMENT", 30, 65], ["a simple e-health solution", "TREATMENT", 146, 172]]], ["\"Virtual Care Providers can be accessed with just the touch of a smart screen\u2026.access to health records, answers to many questions, and the option to schedule video calls with a patient's provider.", [["patient", "ORGANISM", 178, 185], ["patient", "SPECIES", 178, 185], ["a smart screen", "TEST", 63, 77]]], ["By moving these simple tasks to a virtual platform, frontline nurses can provide the best hands-on patient care unin-terrupted\u2026.(giving) your patients peace of mind and exceptional care\u2026\" [2] .Virtual staffing platformThe key here is the technology creating a virtual assistive framework, to release front-end caregivers to take care of patients who urgently need the hands-on consultation.", [["patient", "ORGANISM", 99, 106], ["patients", "ORGANISM", 142, 150], ["patients", "ORGANISM", 337, 345], ["patient", "SPECIES", 99, 106], ["patients", "SPECIES", 142, 150], ["patients", "SPECIES", 337, 345]]], ["This type of telemedicine setup, we presume, can be deployed within and even across national boundaries.", [["telemedicine setup", "TREATMENT", 13, 31]]], ["It can also be supervised by reputed international experts with many younger and less experienced practicing clinicians being engaged with patients simultaneously, thereby relieving the shortage.Virtual staffing platformEven so, there are international regulations, patient privacy factors, and other localized healthcare legalities.", [["patients", "ORGANISM", 139, 147], ["patient", "ORGANISM", 266, 273], ["patients", "SPECIES", 139, 147], ["patient", "SPECIES", 266, 273]]], ["For preserving massscale lives and also to ease the burden of calamities from the aftermath, the details of how the experts can best work with the lessthan-experts can all be negotiated for saving lives with effectiveness and efficiencies.", [["calamities", "DISEASE", 62, 72]]], ["The high-level stature of a league of nations can weigh the pros and cons of the crisis and create a cooperative agreement on privacy, credentialing, training, certification, and policymaking on a \"reserve force\" deployment protocol, in coordination with the legal framework of the organizational charter.A global telehealth infrastructureIPPO will oversee a global telehealth setting, including the selection criteria for competing vendors and cooperative partnership agreements.", [["the crisis", "PROBLEM", 77, 87], ["a \"reserve force\" deployment protocol", "TREATMENT", 195, 232], ["high", "OBSERVATION_MODIFIER", 4, 8], ["global", "OBSERVATION_MODIFIER", 307, 313]]], ["As early as 1910, the use of the telephone to reduce unnecessary physician visits and a tele-stethoscope was in operation [3] .", [["a tele-stethoscope", "TREATMENT", 86, 104]]], ["With the hyper-growth and advancements in mobile, satellite, and wireless technology, telemedicine has mutured and is now being fueled by the COVID-19 pandemic.", [["the hyper-growth", "PROBLEM", 5, 21], ["hyper", "OBSERVATION", 9, 14], ["growth", "OBSERVATION_MODIFIER", 15, 21]]], ["In 2017, remote patient monitoring (RPM), being the most prevalent e-health technology to have been implemented, occupied a 63% of total telehealth market share [1] .", [["patient", "ORGANISM", 16, 23], ["patient", "SPECIES", 16, 23], ["remote patient monitoring", "TEST", 9, 34]]], ["There are major players in the global market, and the global telemedicine market size has been valued at $24.9B in 2016 and is expected to reach $113.1B by 2025 [20] .A global telehealth infrastructureToday there are telemedicine applications for many chronic conditions, mental health, as well as emergency treatments.", [["A global telehealth infrastructure", "PROBLEM", 167, 201], ["telemedicine applications", "TREATMENT", 217, 242], ["many chronic conditions", "PROBLEM", 247, 270], ["emergency treatments", "TREATMENT", 298, 318], ["major", "OBSERVATION_MODIFIER", 10, 15], ["size", "OBSERVATION_MODIFIER", 81, 85], ["global", "OBSERVATION_MODIFIER", 169, 175], ["telehealth infrastructure", "OBSERVATION", 176, 201], ["chronic", "OBSERVATION_MODIFIER", 252, 259]]], ["If not already, progress in e-technology will soon allow a secured and matured telemedicine setup for assistive medical consultation throughout the world.", [["assistive medical consultation", "TREATMENT", 102, 132]]], ["Telemedicine has gone through a remarkable evolution in the last decade, and is becoming an increasingly important part of the American healthcare infrastructure [4] , enabling care professionals to check, diagnose, and treat patients at a distance via telecommunications technology.", [["patients", "ORGANISM", 226, 234], ["patients", "SPECIES", 226, 234], ["Telemedicine", "TREATMENT", 0, 12]]], ["With the COVID-19 pandemic, a spike in mental health crises all over the planet will soon emerge and teleconsutlation will also provide an excellentARTICLE IN PRESSJID: HLPT [m5G; May 15, 2020; 2:7 ] modality to offer urgently needed services and credibly prescribe medicine within localized guidelines in this regard.", [["the COVID", "TEST", 5, 14], ["a spike in mental health crises", "PROBLEM", 28, 59]]], ["While it may not be possible to institute a global telehealth framework for a pandemic overnight, with careful consideration, we know that it is possible and greatly beneficial to implement telemedicine services by networking existing telemedicinal infrastructures in order to save lives and provide mental health care while moderating the anticipated spike in behavioral health and emotional upheaval of would-be patients as an integral outcome of COVD-19 [19] .", [["patients", "ORGANISM", 414, 422], ["patients", "SPECIES", 414, 422], ["telemedicine services", "TREATMENT", 190, 211], ["mental health care", "TREATMENT", 300, 318], ["COVD", "TEST", 449, 453]]], ["Given that a mental health patient can be a threat to himself and others, the existence of IPPO will be an effective mechanism to share proven solutions, to implement large-scale policy thinking, and to manage and oversee a telehealth setting to be fully operational on a global scale during a pandemic.A standby emergency medical supply chain ecosystemSupply chain management (SCM) is the active and systematic flow of goods and services, and it includes all processes that transform raw materials into final products.", [["patient", "ORGANISM", 27, 34], ["patient", "SPECIES", 27, 34], ["IPPO", "TREATMENT", 91, 95], ["a pandemic", "PROBLEM", 292, 302], ["A standby emergency medical supply chain ecosystemSupply chain management", "TREATMENT", 303, 376], ["active", "OBSERVATION_MODIFIER", 390, 396]]], ["With the use of technology, optimization models, and business intelligence, SCM systems attempt to centrally control and synchronize the production, shipment, and distribution of goods and services to avoid over storage or shortage [14] .A standby emergency medical supply chain ecosystemOne of the unfortunate and severe crises we are facing during COVID-19 is the shortage of medical and personal protective equipment (PPE) supplies, including ventilators, N95 respirators, surgical gowns, gloves and masks, to name a few.", [["SCM systems", "TREATMENT", 76, 87], ["A standby emergency medical supply chain ecosystemOne", "TREATMENT", 238, 291], ["severe crises", "PROBLEM", 315, 328], ["ventilators", "TREATMENT", 446, 457], ["N95 respirators", "TREATMENT", 459, 474], ["surgical gowns", "TREATMENT", 476, 490], ["gloves and masks", "TREATMENT", 492, 508], ["severe", "OBSERVATION_MODIFIER", 315, 321], ["crises", "OBSERVATION", 322, 328], ["surgical gowns", "OBSERVATION", 476, 490]]], ["The lack of such medical supplies is the primary cause of complications during the COVID-19 treatment process as well as the high risk of exposing healthy medical professionals to the virus.", [["complications", "PROBLEM", 58, 71], ["the COVID-19 treatment process", "TREATMENT", 79, 109], ["the virus", "PROBLEM", 180, 189]]], ["In the US, many states will soon run into an extraordinary shortage of ventilators and other necessary self-protection gears within weeks, if large-scale productions are not already in full-scale operation.", [["ventilators", "TREATMENT", 71, 82], ["large-scale productions", "PROBLEM", 142, 165], ["full-scale operation", "TREATMENT", 185, 205]]], ["Unfortunately, the current SCM may be too dependent on the countries that previously massproduce and supply these items and if these countries would also need the items urgently, such supply chain would ultimately be cut off for self-preservation among the supplying countries.", [["self-preservation", "TREATMENT", 229, 246]]], ["Moreover, a country's highest level of government can always impose the \"emergency clause\" whereby all production of such PPE and other needed equipment will no longer be available for export to other countries.A standby emergency medical supply chain ecosystemAccording to the New York Times, \"The White House was set to announce a deal with Ventec Life Systems, a Washington Statebased ventilator maker, and GM on March 25 th \u2026We are fortunate that the auto manufacturer has the expertise and infrastructure to mass-produce ventilators.\" [5] noted that \"The US has about 160,0 0 0 ventilators, according to a 2018 analysis from the Johns Hopkins Center for Health Security, a number that experts have warned will not suffice if social distancing measures and other attempts to flatten the curve of the disease do not work quickly enough.\"A standby emergency medical supply chain ecosystemDr.", [["GM", "CHEMICAL", 410, 412], ["such PPE", "TREATMENT", 117, 125], ["A standby emergency medical supply chain", "TREATMENT", 211, 251], ["social distancing measures", "TREATMENT", 730, 756], ["the disease", "PROBLEM", 800, 811], ["A standby emergency medical supply chain", "TREATMENT", 840, 880], ["mass", "OBSERVATION", 513, 517]]], ["Steven Choi, the chief quality officer for the Yale School of Medicine and the Yale-New Haven Health System, said that diseases like COVID-19 will put unusual pressure on ventilator resources.", [["COVID", "TEST", 133, 138], ["ventilator resources", "TREATMENT", 171, 191]]], ["\"People need to understand, though, that a typical adult patient normally stays in the ICU only for three to four days.", [["patient", "ORGANISM", 57, 64], ["People", "SPECIES", 1, 7], ["patient", "SPECIES", 57, 64]]], ["What we're seeing in Covid-19 patients in Asia, Italy and the US is that when patients do end up being ill enough to be admitted to the ICU, they need to be intubated and remain on a ventilator for two to three weeks, which increases the demands for ICU beds and ventilators dramatically.\" [16] .", [["patients", "ORGANISM", 30, 38], ["patients", "ORGANISM", 78, 86], ["patients", "SPECIES", 30, 38], ["patients", "SPECIES", 78, 86], ["intubated", "TREATMENT", 157, 166], ["a ventilator", "TREATMENT", 181, 193], ["ICU beds", "TREATMENT", 250, 258]]], ["There is a strong possibility that the supply will be severely scarce, by May 2020, if production and supplies are not at a near equilibrium.", [["strong possibility", "UNCERTAINTY", 11, 29]]], ["Undoubtedly, for future pandemics, a large-scale standby reserve must be there if humankind is to survive.", [["a large-scale standby reserve", "TREATMENT", 35, 64]]], ["IPPO, as conceived, will contract with competing vendors from around the globe to create a stockpile of such needed medical supply surplus, which will come handy during such global-scale disasters.", [["IPPO", "CHEMICAL", 0, 4], ["medical supply surplus", "TREATMENT", 116, 138]]], ["But there are standard supplies such as the mask, self-protection devices, and even an upper respiratory complication normalizer such as a ventilator, or other innovations that can be pre-determined by healthcare professionals.Artificial Intelligence (AI) and COVID-19Artificial Intelligence (AI) is visible in every sector of our present-day society.Artificial Intelligence (AI) and COVID-19\"AI, robotics and other forms of smart automation have the potential to bring great economic benefits, contributing up to $15 trillion to global GDP by 2030 according to PwC analysis.\" [21] .Artificial Intelligence (AI) and COVID-19Keeping our focus on COVID-19, AI and automation are playing at least two major roles.RoboticsThe world is facing a dire shortage of healthcare workforce during COVID-AI 19.", [["respiratory", "ANATOMY", 93, 104], ["the mask", "TREATMENT", 40, 48], ["self-protection devices", "TREATMENT", 50, 73], ["an upper respiratory complication", "PROBLEM", 84, 117], ["a ventilator", "TREATMENT", 137, 149], ["Artificial Intelligence (AI)", "TREATMENT", 227, 255], ["COVID-19Artificial Intelligence (AI)", "TREATMENT", 260, 296], ["Artificial Intelligence (AI)", "TREATMENT", 351, 379], ["COVID", "TREATMENT", 384, 389], ["robotics", "TREATMENT", 397, 405], ["smart automation", "TREATMENT", 425, 441], ["Artificial Intelligence (AI)", "TREATMENT", 583, 611], ["COVID", "TREATMENT", 616, 621], ["COVID", "TEST", 645, 650], ["AI", "PROBLEM", 655, 657], ["upper", "ANATOMY_MODIFIER", 87, 92], ["respiratory", "ANATOMY", 93, 104], ["complication", "OBSERVATION", 105, 117]]], ["In most regions, the situation has gone from bad to worse.", [["most", "ANATOMY_MODIFIER", 3, 7], ["regions", "ANATOMY_MODIFIER", 8, 15]]], ["Furthermore, the deficit is re-calling for retired health workers such as nurses and doctors to help out.", [["the deficit", "PROBLEM", 13, 24]]], ["Many of these unsang \"heroes-on-the-floor\" are overworked, frustrated, and becoming fearful that they would be inflicting themselves and their loved-ones given that they may be frequently become unprotected and exposed.", [["unprotected", "OBSERVATION", 195, 206]]], ["We cannot afford to lose a single professional to the virus, while that remains a frequently reported event [30] .RoboticsCOVID-19 is motivating us to develop robotic systems that can be rapidly deployed with remote access by experts and essential service providers without the need to travel to front lines [31] .", [["RoboticsCOVID", "TEST", 114, 127], ["robotic systems", "TREATMENT", 159, 174]]], ["Originating from AI and automation, the technology, and the algorithms to perform frontline tasks, such as giving a flu shot, will be, if not already, available.", [["frontline tasks", "TEST", 82, 97], ["a flu shot", "TREATMENT", 114, 124]]], ["Just as with Zoom meetings, one can appreciate the role of robotics more clearly during a pandemic crisis than ever.AI algorithms for cure and diagnosisAs yet, we are waiting for an effective haven-sent vaccine against the COVID-19 virus; meanwhile, there are promising laboratory research studies, clinical trials, and biomedical experiments taking place throughout the globe.", [["COVID-19 virus", "ORGANISM", 223, 237], ["COVID-19 virus", "SPECIES", 223, 237], ["a pandemic crisis", "PROBLEM", 88, 105], ["AI algorithms", "TEST", 116, 129], ["the COVID", "TEST", 219, 228], ["clinical trials", "TREATMENT", 299, 314], ["biomedical experiments", "TREATMENT", 320, 342], ["globe", "ANATOMY", 371, 376]]], ["A new drug or vaccine to control and kill the virus will be liken to winning a humanitarian jackpot towards preventing the present and near future calamities from COVID-19.AI algorithms for cure and diagnosisAI is crucial in the race to find a vaccine.", [["A new drug or vaccine", "TREATMENT", 0, 21], ["the virus", "PROBLEM", 42, 51], ["a humanitarian jackpot", "TREATMENT", 77, 99], ["COVID", "TEST", 163, 168], ["AI algorithms", "TREATMENT", 172, 185], ["cure", "PROBLEM", 190, 194], ["a vaccine", "TREATMENT", 242, 251]]], ["AI procedures such as machine learning and deep learning can help demystify viral protein structures and probably create an agent that will induce the body to produce defensive white-blood cells and antigens.", [["body", "ANATOMY", 151, 155], ["white-blood cells", "ANATOMY", 177, 194], ["body", "ORGANISM_SUBDIVISION", 151, 155], ["white-blood cells", "CELL", 177, 194], ["defensive white-blood cells", "CELL_TYPE", 167, 194], ["antigens", "PROTEIN", 199, 207], ["AI procedures", "TREATMENT", 0, 13], ["viral protein structures", "PROBLEM", 76, 100], ["an agent", "TREATMENT", 121, 129], ["defensive white-blood cells", "PROBLEM", 167, 194]]], ["An AI tool, the artificial neural networks (ANN), is typically deployed on various large-scale samples of structured and unstructured data organized from the affected cells to predict the best possible route to kill the virus.", [["neural networks", "ANATOMY", 27, 42], ["cells", "ANATOMY", 167, 172], ["neural networks", "MULTI-TISSUE_STRUCTURE", 27, 42], ["cells", "CELL", 167, 172], ["the affected cells", "PROBLEM", 154, 172], ["the virus", "PROBLEM", 216, 225], ["virus", "OBSERVATION", 220, 225]]], ["Based on numerous successes of past AI technologies, we believe AI will be, if not already is, a principal deputy in this battlefield [11] .AI algorithms for cure and diagnosisAnother noteworthy AI initiative that has been developed by Wang & Wong at the University of Waterloo and the AI firm DarwinAI in Canada, COVID-Net was trained to identify signs of COVID-19 in chest x-rays using 5,941 images taken from 2,839 patients with various lung conditions, including bacterial infections, non-COVID-19 viral infections, and COVID-19 [9, 29] .", [["chest", "ANATOMY", 369, 374], ["lung", "ANATOMY", 440, 444], ["bacterial infections", "DISEASE", 467, 487], ["viral infections", "DISEASE", 502, 518], ["chest", "ORGAN", 369, 374], ["patients", "ORGANISM", 418, 426], ["lung", "ORGAN", 440, 444], ["patients", "SPECIES", 418, 426], ["past AI technologies", "TREATMENT", 31, 51], ["AI", "PROBLEM", 64, 66], ["AI algorithms", "TEST", 140, 153], ["COVID", "TEST", 357, 362], ["chest x-rays", "TEST", 369, 381], ["images", "TEST", 394, 400], ["various lung conditions", "PROBLEM", 432, 455], ["bacterial infections", "PROBLEM", 467, 487], ["non-COVID", "TEST", 489, 498], ["viral infections", "PROBLEM", 502, 518], ["COVID", "TEST", 524, 529], ["chest", "ANATOMY", 369, 374], ["lung", "ANATOMY", 440, 444], ["conditions", "OBSERVATION", 445, 455], ["bacterial", "OBSERVATION_MODIFIER", 467, 476], ["infections", "OBSERVATION", 477, 487]]], ["Imagine extending such applications to accelerate COVID-19 testings, enhance data-driven contact tracing, and targeted quarantines.", [["accelerate COVID", "TEST", 39, 55], ["enhance data", "TEST", 69, 81], ["contact tracing", "TEST", 89, 104]]], ["Most importantly, this type of open source initiative can further lead us to discuss AI models and the need for an intercontinental clinical dataset platform for all patients affected by COVID-19, which can be shared worldwide to ensure future isolation of returning residents will not be cause for a second or third wave of the pandemic -an essential paradigm for future pandemic preparedness initiative.Global AI patient dataset repositoryCOVID-Net uses Convolutional Neural Networks (CNNs) on chest X-rays to detect COVID-19 infections.", [["infections", "DISEASE", 528, 538], ["patients", "ORGANISM", 166, 174], ["patient", "ORGANISM", 415, 422], ["patients", "SPECIES", 166, 174], ["patient", "SPECIES", 415, 422], ["AI models", "TREATMENT", 85, 94], ["the pandemic", "PROBLEM", 325, 337], ["dataset repositoryCOVID", "TREATMENT", 423, 446], ["chest X-rays", "TEST", 496, 508], ["COVID-19 infections", "PROBLEM", 519, 538], ["chest", "ANATOMY", 496, 501], ["infections", "OBSERVATION", 528, 538]]], ["Simply put, a CNN algorithm mimics the way how human eyes extract and process visual information to recognize attributes of interest and/or differentiate one group of images from others.", [["eyes", "ANATOMY", 53, 57], ["human", "ORGANISM", 47, 52], ["eyes", "ORGAN", 53, 57], ["human", "SPECIES", 47, 52], ["human", "SPECIES", 47, 52]]], ["For example, the discriminating attributes might be a particular shape of shadow found in the Xrays of COVID-19 infected patients, compared to non-infected ones.", [["COVID-19", "ORGANISM", 103, 111], ["patients", "ORGANISM", 121, 129], ["patients", "SPECIES", 121, 129], ["shadow", "PROBLEM", 74, 80], ["the Xrays", "TEST", 90, 99], ["COVID", "TEST", 103, 108], ["particular", "OBSERVATION_MODIFIER", 54, 64], ["shape", "OBSERVATION_MODIFIER", 65, 70], ["shadow", "OBSERVATION", 74, 80], ["infected", "OBSERVATION", 112, 120]]], ["Typically, a large-scale data set is required to train the AI algorithms, such as CNN, to reach high accuracy.Global AI patient dataset repositoryCOVID-Net is a good step towards open-source datasets to fight against the invisible public enemy.", [["patient", "ORGANISM", 120, 127], ["CNN", "PROTEIN", 82, 85], ["patient", "SPECIES", 120, 127], ["large", "OBSERVATION_MODIFIER", 13, 18], ["enemy", "OBSERVATION", 238, 243]]], ["Also, the CDC has made publicly available some demographics, infection trends, frequencies, growth rates, geo-maps, and travel histories.", [["infection", "DISEASE", 61, 70], ["infection trends", "PROBLEM", 61, 77], ["growth rates", "TEST", 92, 104]]], ["To date, however, only limited clinically meaningful datasets are available about the infected, recovered, and deceased patients, as of April 14 th , 2020.", [["patients", "ORGANISM", 120, 128], ["patients", "SPECIES", 120, 128]]], ["For researchers to make significant progress in understanding and to develop effective vaccines, we need a repository of clinical data on as many COVID-19 cases as possible.", [["effective vaccines", "TREATMENT", 77, 95], ["clinical data", "TEST", 121, 134], ["many COVID", "TREATMENT", 141, 151]]], ["It would be difficult or even impossible to gain better insights into the nature, velocity, and detection of antibodies against a virus like the COVID-19 without such clinical datasets.Global AI patient dataset repositoryAI tools are good at predicting the fate of patients; for example, which patients will develop severe or even fatal symptoms.", [["patient", "ORGANISM", 195, 202], ["patients", "ORGANISM", 265, 273], ["patients", "ORGANISM", 294, 302], ["antibodies", "PROTEIN", 109, 119], ["patient", "SPECIES", 195, 202], ["patients", "SPECIES", 265, 273], ["patients", "SPECIES", 294, 302], ["antibodies", "PROBLEM", 109, 119], ["a virus", "PROBLEM", 128, 135], ["the COVID", "TEST", 141, 150], ["Global AI", "PROBLEM", 185, 194], ["severe or even fatal symptoms", "PROBLEM", 316, 345]]], ["But such prediction relies on detailed data of the patients, such as preexisting conditions, lung and heart conditions, chronic illnesses, smoking or alcoholic life-traits, active health status, medications, treatment, and lab data.", [["lung", "ANATOMY", 93, 97], ["heart", "ANATOMY", 102, 107], ["lung and heart conditions", "DISEASE", 93, 118], ["patients", "ORGANISM", 51, 59], ["lung", "ORGAN", 93, 97], ["heart", "ORGAN", 102, 107], ["patients", "SPECIES", 51, 59], ["preexisting conditions", "PROBLEM", 69, 91], ["lung and heart conditions", "PROBLEM", 93, 118], ["chronic illnesses", "PROBLEM", 120, 137], ["medications", "TREATMENT", 195, 206], ["treatment", "TREATMENT", 208, 217], ["lab data", "TEST", 223, 231], ["lung", "ANATOMY", 93, 97], ["heart", "ANATOMY", 102, 107], ["chronic", "OBSERVATION_MODIFIER", 120, 127], ["illnesses", "OBSERVATION", 128, 137]]], ["Currently, the repository of clinical data is elusive and collaborative effort s are needed to set up an intercontinental platform to fill this gap.", [["clinical data", "TEST", 29, 42]]], ["The sharable, de-identified patient records from across the globe, in our opinion, would expedite the process of finding an antidote.Global AI patient dataset repositoryPut simply, we need to establish a platform championed by IPPO (and under its custody) for such records to combat the current crisis, a platform that will serve as an essential infrastructure for future pandemics.Virtual agentsAI can be of great use in the form of virtual agents.", [["patient", "ORGANISM", 28, 35], ["patient", "ORGANISM", 143, 150], ["patient", "SPECIES", 28, 35], ["patient", "SPECIES", 143, 150], ["an antidote", "TREATMENT", 121, 132], ["the current crisis", "PROBLEM", 283, 301], ["Virtual agentsAI", "TREATMENT", 382, 398], ["virtual agents", "TREATMENT", 434, 448], ["globe", "ANATOMY", 60, 65]]], ["Specifically, AI is creating assistive virtual agents, such as chatbots.", [["assistive virtual agents", "TREATMENT", 29, 53]]], ["\"The virtual assistant can answer questions about the coronavirus and use a series of questions built on data from the Centers for Disease Control and Prevention (CDC) and other reputable sources to perform a preliminary screening for symptoms.", [["coronavirus", "ORGANISM", 54, 65], ["the coronavirus", "PROBLEM", 50, 65], ["Disease Control", "TREATMENT", 131, 146], ["a preliminary screening", "TEST", 207, 230], ["symptoms", "PROBLEM", 235, 243]]], ["Depending on what the answers are, the AI (application) can then suggest the next best steps for further testing and treatment.", [["further testing", "TEST", 97, 112], ["treatment", "TREATMENT", 117, 126]]], ["The chatbot can be added to any healthcare provider's website... for free.\" [22] .Virtual agentsWe can depict several other use scenarios for a virtual assistant when support centers and helplines are overloaded.", [["Virtual agents", "TREATMENT", 82, 96], ["support centers", "TREATMENT", 167, 182], ["overloaded", "PROBLEM", 201, 211], ["overloaded", "OBSERVATION", 201, 211]]], ["Chatbots can be designed to provide institutional directives, updated by the minutes, to a specific group of clinicians or front-liners as an agent via two-way communication capabilities.AI and COVID-19 testing policyThe use of AI models is promising for current and future health crises.", [["front-liners", "TREATMENT", 123, 135], ["AI", "TEST", 187, 189], ["COVID", "TEST", 194, 199], ["AI models", "TREATMENT", 228, 237]]], ["There is a constant flow of AI-driven clues to find a cure for the COVID-19 virus [17] .", [["AI", "SIMPLE_CHEMICAL", 28, 30], ["COVID-19 virus", "ORGANISM", 67, 81], ["COVID-19 virus", "SPECIES", 67, 81], ["a constant flow of AI", "PROBLEM", 9, 30], ["the COVID", "TEST", 63, 72], ["constant", "OBSERVATION_MODIFIER", 11, 19], ["flow", "OBSERVATION", 20, 24]]], ["We need more AI experts and expect a spike in demand for AI analysts and developers in all social sectors, including public health.", [["a spike in demand", "PROBLEM", 35, 52]]], ["An AI workforce cannot be produced overnight.", [["An AI workforce", "TREATMENT", 0, 15]]], ["The US education ecosystem does not seem to have placed adequate emphasis on, and funding for, this need thus far.AI and COVID-19 testing policyAbove all, the capacity for accelerating COVID-19 testings is critical in a pandemic.", [["AI", "TEST", 114, 116], ["COVID", "TEST", 121, 126], ["accelerating COVID", "TEST", 172, 190]]], ["Here, the rationale lies in isolating those who are infected from those who are not to stop the spread.", [["infected", "OBSERVATION", 52, 60]]], ["The need to explore possibilities for AI applications to enhance such testings cannot be overly emphasized.AI and COVID-19 testing policyThe role of the overseer agency might be to evaluate, fund, and monitor the progress of pandemic-specific applications and testing technologies from around the planet continuously, thereby ensuring that any spaces being open for public activities would be safe and secure.Concluding remarks on pandemic educationOur final remarks might not be directly related to IPPO, but education-related issues that surface as essential social ingredients to combat a pandemic as vigorous as COVID-19.Education and literacyThe word \"Pandemic\" seems to have roots in the Greek term \"pan\" meaning \"all,\" and \"demos\" meaning \"people.\"", [["roots", "ANATOMY", 681, 686], ["roots", "ORGAN", 681, 686], ["people", "ORGANISM", 747, 753], ["people", "SPECIES", 747, 753], ["AI applications", "TREATMENT", 38, 53], ["such testings", "TEST", 65, 78], ["AI", "TEST", 107, 109], ["COVID", "TEST", 114, 119], ["pandemic", "PROBLEM", 225, 233], ["testing technologies", "TEST", 260, 280], ["any spaces", "PROBLEM", 340, 350], ["public activities", "TREATMENT", 366, 383], ["COVID", "TEST", 616, 621]]], ["Today, the word \"Pandemic\" has a specific standing as an epidemic that spreads over a wide geographic area and carries the potential to affect a large proportion of people.", [["people", "ORGANISM", 165, 171], ["people", "SPECIES", 165, 171]]], ["We are not sure if there is a specific term for COVID-19 to refer to a disaster beyond a wide geographic area encompassing beyond the planet Earth.", [["COVID", "TEST", 48, 53], ["a wide geographic area", "PROBLEM", 87, 109], ["planet Earth", "OBSERVATION", 134, 146]]], ["Scientifically speaking, the characteristics of COVID-19 correlates to all people, all age groups, and all socio-economic sectors, whether rich or poor.", [["people", "ORGANISM", 75, 81], ["people", "SPECIES", 75, 81], ["COVID", "TEST", 48, 53]]], ["Furthermore, there is no global clinical data repository for the infected cases and the deceased patients, for researchers to design and test detection modeling.Education and literacyHerein lies the rationale for why the IPPO is an effective mechanism and necessary framework for all nations to move the agenda towards fighting against COVID-19, as system science dictates a solution for the entire system (world), not just a single system component or element (country).", [["patients", "ORGANISM", 97, 105], ["IPPO", "SIMPLE_CHEMICAL", 221, 225], ["patients", "SPECIES", 97, 105], ["the infected cases", "PROBLEM", 61, 79], ["test detection modeling", "TEST", 137, 160], ["no", "UNCERTAINTY", 22, 24]]], ["Imagine that an individual in a neighbouring country is inflicted with COVID-19, but is asymptomatic so that s/he may not be isolated.", [["COVID", "TEST", 71, 76]]], ["Someone travelling from the neighbour's country who happens to be near this individual will likely transport the virus to their own country, eventually causing great harm and calamities.", [["calamities", "DISEASE", 175, 185], ["great harm and calamities", "PROBLEM", 160, 185], ["great", "OBSERVATION_MODIFIER", 160, 165], ["harm", "OBSERVATION", 166, 170]]], ["This is exactly how so many countries are now in the same boat, where travellers from COVID-19 epicenters have brought the virus with them to their very own surrounding.", [["COVID", "TEST", 86, 91], ["the virus", "PROBLEM", 119, 128]]], ["In the context ofARTICLE IN PRESSJID: HLPT [m5G; May 15, 2020; 2:7 ] COVID-19, we are, indeed, our \"brother's keepers\" as any individual inflicted with COVID-19 has the likelihood of impacting on the health and well-being of all concerned.", [["COVID-19", "CHEMICAL", 152, 160]]], ["At this moment, the widely implemented strategy that seems to be somewhat useful is social distancing and a lockdown of an entire region or even a nation, on time.", [["seems to be", "UNCERTAINTY", 53, 64]]], ["It is, however, unknown if the virus will resume spreading after removing the social distancing, and at what duration?", [["the virus", "PROBLEM", 27, 36]]], ["Indeed, nations such as Singapore (and special regions such as Hong Kong) are experiencing a second wave of COVID-19 spread.", [["COVID", "TEST", 108, 113]]], ["We can only offer some practical recommendations while COVID-19 is still at an experimental and emotionally draining stage.ARTICLE IN PRESS\u2022 Education : The world of education needs to incorporate a component on a possible pandemic, at an early stage of the education continuum.", [["pandemic", "PROBLEM", 223, 231]]], ["The majority of the world population appears to have limited knowledge of a health-related, infectious epidemic and its widespread impact.", [["infectious epidemic", "PROBLEM", 92, 111], ["majority", "OBSERVATION_MODIFIER", 4, 12], ["infectious", "OBSERVATION_MODIFIER", 92, 102], ["widespread", "OBSERVATION_MODIFIER", 120, 130], ["impact", "OBSERVATION_MODIFIER", 131, 137]]], ["With COVID-19, many are being educated, and subsequently, having an appreciation of the seriousness of the issues and the impact of an pandemic. \u2022 The Business of Educational Continuity: With virtual learning technology and continuous advancements, all post-secondary institutions need to establish a standby cloud-based \"academic continuity\" paradigm.", [["COVID", "TREATMENT", 5, 10], ["the issues", "PROBLEM", 103, 113], ["an pandemic", "PROBLEM", 132, 143], ["virtual learning technology", "TREATMENT", 192, 219], ["continuous advancements", "TREATMENT", 224, 247], ["pandemic", "OBSERVATION", 135, 143]]], ["Most schools and colleges are closed, and not all institutions around the globe have an instantly deployable online learning infrastructure.", [["globe", "ANATOMY", 74, 79]]], ["The sudden pause will delay graduation, and it might be a year or two before a student completes the degree.", [["The sudden pause", "PROBLEM", 0, 16]]], ["The Department of Education notified all post-secondary institutions \"The Department is providing broad approval to institutions to use online technologies to accommodate students on a temporary basis, without going through the regular approval process of the Department in the event that an institution is otherwise required to seek Departmental approval for the use or expansion of distance learning programs\" [10] .", [["online technologies", "TREATMENT", 136, 155], ["expansion of distance learning programs", "TREATMENT", 371, 410]]], ["As we noted earlier, the potential of AI in pandemic preparedness is limitless.", [["AI", "PROBLEM", 38, 40]]], ["We strongly recommend an exposure to AI methods and models to the students, researchers, and public health officials to have an appreciation for the new world of technology and automation.", [["AI methods", "TREATMENT", 37, 47], ["automation", "TEST", 177, 187]]], ["For example, AI literacy as a required component of the STEM education in the K12 sector as well as in the higher education STEM areas should be mandated in the US.", [["the STEM education", "TREATMENT", 52, 70], ["STEM", "OBSERVATION_MODIFIER", 56, 60]]], ["AI is the fastest growing discipline in China's universities, with 180 new approved majors, up from 35 the year before.", [["fastest", "OBSERVATION_MODIFIER", 10, 17], ["growing", "OBSERVATION_MODIFIER", 18, 25]]], ["From the secondary to the post-secondary science curriculum, AI appears to be a required component [12] .", [["AI", "PROBLEM", 61, 63]]], ["Unfortunately, the US Tech Giants appear to have a limited role in combating COVID-19 with strategic innovations, thus far, although there is some news emerging on how Google and Apple are collaborating on virtually enhancing the contact tracing effort s.ARTICLE IN PRESSExperts believe that the world is already starting to face a sizable recession, amid COVID-19 pandemic [8] .", [["a sizable recession", "PROBLEM", 330, 349], ["amid COVID", "TEST", 351, 361], ["sizable", "OBSERVATION_MODIFIER", 332, 339], ["recession", "OBSERVATION", 340, 349]]], ["\"There's little doubt we're heading for a global recession or already in one, but these economists say it's more like the next Great Depression.\" [18] .", [["Depression", "DISEASE", 133, 143], ["a global recession", "PROBLEM", 40, 58], ["recession", "OBSERVATION", 49, 58]]], ["At the least, the possibility of a prolonged recession appears to be sure for heavy-hit nations.", [["a prolonged recession", "PROBLEM", 33, 54], ["possibility of", "UNCERTAINTY", 18, 32], ["prolonged", "OBSERVATION_MODIFIER", 35, 44], ["recession", "OBSERVATION", 45, 54]]], ["It is not a question of if but when.", [["not a question", "UNCERTAINTY", 6, 20]]], ["The world certainly needs a better combat strategy and ecosystem for the next one.ARTICLE IN PRESSWe suspect the process for a majority of nations to participate in a conceived IPPO will be both lengthy and complicated.", [["IPPO", "DISEASE", 177, 181]]], ["When it comes to another COVID-19, however, we do not appear to have another choice.Declaration of Competing InterestNone.", [["COVID-19", "DNA", 25, 33]]]], "0f6091029a2cc8ddd6a5c6ee18de7478b73daab2": [["INTRODUCTIONInfluenza A viruses belong to the Orthomyxoviridae family, and have a genome composed of eight segments of single-stranded, negative-sense RNA.", [["INTRODUCTIONInfluenza A viruses", "ORGANISM", 0, 31], ["Orthomyxoviridae", "GENE_OR_GENE_PRODUCT", 46, 62], ["Orthomyxoviridae family", "PROTEIN", 46, 69], ["single-stranded, negative-sense RNA", "RNA", 119, 154], ["INTRODUCTIONInfluenza A viruses", "SPECIES", 0, 31], ["sense RNA", "OBSERVATION_MODIFIER", 145, 154]]], ["Their surfaces are composed by a lipid envelope, originated from the plasmatic membrane of infected epithelial cells, and two antigenic proteins: Hemagglutinin (HA) and Neuraminidase (NA); these two antigens exhibit higher variability compared with their remaining proteins [1] .", [["plasmatic membrane", "ANATOMY", 69, 87], ["epithelial cells", "ANATOMY", 100, 116], ["plasmatic membrane", "CELLULAR_COMPONENT", 69, 87], ["epithelial cells", "CELL", 100, 116], ["Hemagglutinin", "GENE_OR_GENE_PRODUCT", 146, 159], ["HA", "GENE_OR_GENE_PRODUCT", 161, 163], ["Neuraminidase", "SIMPLE_CHEMICAL", 169, 182], ["NA", "SIMPLE_CHEMICAL", 184, 186], ["infected epithelial cells", "CELL_TYPE", 91, 116], ["antigenic proteins", "PROTEIN", 126, 144], ["Hemagglutinin", "PROTEIN", 146, 159], ["HA", "PROTEIN", 161, 163], ["Neuraminidase", "PROTEIN", 169, 182], ["a lipid envelope", "PROBLEM", 31, 47], ["infected epithelial cells", "PROBLEM", 91, 116], ["two antigenic proteins", "TEST", 122, 144], ["Hemagglutinin (HA)", "TREATMENT", 146, 164], ["Neuraminidase (NA)", "TEST", 169, 187], ["these two antigens", "TEST", 189, 207], ["higher variability", "PROBLEM", 216, 234], ["lipid envelope", "OBSERVATION", 33, 47], ["infected epithelial cells", "OBSERVATION", 91, 116]]], ["Depending on the extent of variability of two surface proteins, until now are known 16 HA (H1-H16), and 9 NA genotypes (N1-N9), respectively, which can be combined in different combinations [1, 2] .INTRODUCTIONIn early April 2009, authorities from the Mexican public health observed a high number of influenza-like illnesses in their territory, and informed about this outbreak to the regional office of the World Health Organization (WHO).", [["surface", "ANATOMY", 46, 53], ["influenza-like illnesses", "DISEASE", 300, 324], ["H1-H16", "GENE_OR_GENE_PRODUCT", 91, 97], ["surface proteins", "PROTEIN", 46, 62], ["H1", "PROTEIN", 91, 93], ["H16", "PROTEIN", 94, 97], ["two surface proteins", "TEST", 42, 62], ["influenza", "PROBLEM", 300, 309], ["influenza", "OBSERVATION", 300, 309]]], ["In mid April, the Centers for Disease Control from USA identified the new virus in two cases from California.", [["Disease Control from USA", "PROBLEM", 30, 54], ["the new virus", "PROBLEM", 66, 79], ["mid", "ANATOMY_MODIFIER", 3, 6], ["new", "OBSERVATION_MODIFIER", 70, 73], ["virus", "OBSERVATION", 74, 79]]], ["The new virus spread rapidly throughout the world, and as a consequence the WHO authorities declared the \"Pandemic (H1N1) 2009\" on June 11, 2009 [3] .", [["Pandemic", "DISEASE", 106, 114], ["The new virus spread", "PROBLEM", 0, 20], ["new", "OBSERVATION_MODIFIER", 4, 7], ["virus", "OBSERVATION", 8, 13], ["spread", "OBSERVATION_MODIFIER", 14, 20], ["rapidly", "OBSERVATION_MODIFIER", 21, 28]]], ["It is thought that the new 2009 H1N1 pandemic virus (from here, 2009 H1N1pdm) has emerged through at least four reassortment and transmission events among swine, avian and human H1N1 lineages, probably in Asia and North America [4] .", [["2009 H1N1 pandemic virus", "ORGANISM", 27, 51], ["swine", "ORGANISM", 155, 160], ["human", "ORGANISM", 172, 177], ["H1N1 pandemic virus", "SPECIES", 32, 51], ["swine", "SPECIES", 155, 160], ["human", "SPECIES", 172, 177], ["H1N1", "SPECIES", 178, 182], ["2009 H1N1 pandemic virus", "SPECIES", 27, 51], ["swine", "SPECIES", 155, 160], ["human H1N1", "SPECIES", 172, 182], ["the new 2009 H1N1 pandemic virus", "PROBLEM", 19, 51]]], ["Particularly, the HA segment of 2009 H1N1pdm was originated from American swine lineage, whereas the NA segment derived from the European swine lineage [5, 6] .", [["H1N1pdm", "DISEASE", 37, 44], ["swine", "SPECIES", 74, 79], ["swine", "SPECIES", 138, 143], ["American swine", "SPECIES", 65, 79], ["European swine", "SPECIES", 129, 143]]], ["It is believed that the ancestors of this pandemic strain remained undetected for approximately one decade due to lack of a *Address correspondence to this author at the Rio de la Plata y Lagerenza, CP 1120 Asunci\u00f3n, Paraguay; Tel: +595 21 424 520; Fax: +595 21 480 185; E-mail: emilioespinola@hotmail.com surveillance system in pigs, the historical \"mixing vessel\" for new influenza viruses.", [["vessel", "ANATOMY", 358, 364], ["influenza viruses", "DISEASE", 374, 391], ["pigs", "ORGANISM", 329, 333], ["vessel", "MULTI-TISSUE_STRUCTURE", 358, 364], ["pigs", "SPECIES", 329, 333], ["pigs", "SPECIES", 329, 333], ["this pandemic strain", "PROBLEM", 37, 57], ["new influenza viruses", "PROBLEM", 370, 391], ["vessel", "ANATOMY", 358, 364], ["influenza viruses", "OBSERVATION", 374, 391]]], ["Furthermore, the closest ancestors of the new pandemic strains emerged probably in January 2009 [4] .INTRODUCTIONThe objective of this study was to analyze a dataset of complete nucleotide (nt) sequences of HA and NA genes, in order to assess the extent of diversity among circulating 2009-2010 strains, estimate if these genes evolved through positive, negative, or neutral selection models of evolution during the pandemic phase, and analyze the worldwide percentage of detection of important amino acid mutations that could enhance the viral performance, such as transmissibility or resistance to drugs.INTRODUCTIONComplete CoDing Sequences (CDS) of HA (1701 nt) and NA (1410 nt) genes corresponding to 2009 H1N1pdm, isolated from humans, were downloaded from the Influenza Virus Resource (http://www.ncbi.nlm.nih.gov/genomes/FLU /SwineFlu.html) from the National Center for Biotechnology Information, by the year of sequence repository.", [["pandemic", "DISEASE", 46, 54], ["nucleotide", "CHEMICAL", 178, 188], ["amino acid", "CHEMICAL", 495, 505], ["nucleotide", "CHEMICAL", 178, 188], ["amino acid", "CHEMICAL", 495, 505], ["amino acid", "AMINO_ACID", 495, 505], ["humans", "ORGANISM", 734, 740], ["nucleotide (nt) sequences", "DNA", 178, 203], ["HA and NA genes", "DNA", 207, 222], ["CoDing Sequences", "DNA", 627, 643], ["CDS", "DNA", 645, 648], ["HA", "DNA", 653, 655], ["NA (1410 nt) genes", "DNA", 670, 688], ["humans", "SPECIES", 734, 740], ["humans", "SPECIES", 734, 740], ["the new pandemic strains", "PROBLEM", 38, 62], ["this study", "TEST", 130, 140], ["complete nucleotide (nt)", "TREATMENT", 169, 193], ["HA", "PROBLEM", 207, 209], ["NA genes", "TEST", 214, 222], ["the pandemic phase", "TEST", 412, 430], ["important amino acid mutations", "PROBLEM", 485, 515], ["the viral performance", "PROBLEM", 535, 556], ["drugs", "TREATMENT", 600, 605], ["HA", "PROBLEM", 653, 655], ["NA", "TEST", 670, 672]]], ["The first dataset consisted of 3765 HA and 2996 NA sequences, respectively, which were reported in the period 2009-2010.", [["3765 HA and 2996 NA sequences", "DNA", 31, 60], ["NA sequences", "TEST", 48, 60]]], ["After discarding exact duplicates in sequence using a Perl script, we obtained 2038 HA and 1273 NA sequences, respectively; these sequences were different in at least one nucleotide among all representatives.", [["nucleotide", "CHEMICAL", 171, 181], ["2038 HA and 1273 NA sequences", "DNA", 79, 108], ["a Perl script", "TEST", 52, 65], ["HA and 1273 NA sequences", "TEST", 84, 108], ["these sequences", "TEST", 124, 139]]], ["Reassortant strains were discarded, as well as incomplete CDS sequences.INTRODUCTIONNucleotide sequences were manually edited in FASTA format, using BioEdit v7.0.5 [7] , and aligned with CLUSTAL W [8] .", [["CDS sequences", "DNA", 58, 71], ["INTRODUCTIONNucleotide sequences", "DNA", 72, 104], ["Reassortant strains", "PROBLEM", 0, 19], ["incomplete CDS sequences", "TEST", 47, 71], ["INTRODUCTIONNucleotide sequences", "TREATMENT", 72, 104]]], ["Sequence information (GenBank accession number, strain, and year of isolation) for each sample used in this study are available for HA (Table S1) and NA genes (Table S2) , respectively.", [["HA (Table S1", "GENE_OR_GENE_PRODUCT", 132, 144], ["NA genes", "DNA", 150, 158], ["each sample", "TEST", 83, 94], ["this study", "TEST", 103, 113], ["HA", "PROBLEM", 132, 134]]], ["The percentages of identities were calculated by applying the formula 100 -(pairwise distance value x 100).", [["percentages", "OBSERVATION_MODIFIER", 4, 15]]], ["A graph was constructed by plotting the percentage identities in the abscissa (x axis) vs the frequency of each of the calculated pairwise identities in the ordinate (y axis).", [["A graph", "TEST", 0, 7]]], ["The graphs were prepared in the R environment, using ggplot2 package (www.r-project.org).INTRODUCTIONThe models of nucleotide substitution that best fitted each dataset were determined with MEGA v5 [9] , and were: GTR+I model for HA genes, and T92+G model for NA genes, respectively.", [["nucleotide", "CHEMICAL", 115, 125], ["nucleotide", "CHEMICAL", 115, 125], ["GTR+I", "GENE_OR_GENE_PRODUCT", 214, 219], ["T92+G", "GENE_OR_GENE_PRODUCT", 244, 249], ["HA genes", "DNA", 230, 238], ["T92", "DNA", 244, 247], ["NA genes", "DNA", 260, 268], ["ggplot2 package", "TREATMENT", 53, 68], ["nucleotide substitution", "TREATMENT", 115, 138], ["GTR+I model", "TREATMENT", 214, 225], ["HA genes", "TREATMENT", 230, 238], ["T92", "TEST", 244, 247]]], ["Phylogenetic relationships were reconstructed by the Neighbor-Joining method [10] , with the appropriate models of nucleotide substitution for each dataset (as described above) and bootstrap analysis of 1000 replicates, as incorporated in MEGA v5 [9] .", [["nucleotide", "CHEMICAL", 115, 125], ["nucleotide", "CHEMICAL", 115, 125], ["nucleotide substitution", "TREATMENT", 115, 138], ["bootstrap analysis", "TEST", 181, 199]]], ["Outgroup sequences for HA and NA genes corresponded to strain A/Puerto Rico/8/1934.INTRODUCTIONMutations in each CDS were analyzed by the method of Nei and Gojobori [11] .", [["HA", "GENE_OR_GENE_PRODUCT", 23, 25], ["HA and NA genes", "DNA", 23, 38], ["CDS", "DNA", 113, 116], ["Outgroup sequences", "TEST", 0, 18], ["HA", "PROBLEM", 23, 25], ["NA genes", "PROBLEM", 30, 38]]], ["Codon aligned sequences for each dataset were analyzed using the Perl-based SNAP program (http://www.hiv.lanl.gov/content/sequence/SNAP/SNAP.htm l) [12] in order to calculate the variability of each CDS.", [["CDS", "DNA", 199, 202]]], ["The selective pressure was measured by comparing the rate of non-synonymous nucleotide substitutions per nonsynonymous site (d N ) against that of synonymous substitutions per synonymous site (d S ).", [["nucleotide", "CHEMICAL", 76, 86], ["nucleotide", "CHEMICAL", 76, 86], ["The selective pressure", "TEST", 0, 22], ["non-synonymous nucleotide substitutions", "TREATMENT", 61, 100], ["synonymous substitutions", "PROBLEM", 147, 171], ["selective", "OBSERVATION_MODIFIER", 4, 13], ["pressure", "OBSERVATION_MODIFIER", 14, 22], ["synonymous substitutions", "OBSERVATION", 147, 171], ["synonymous site", "OBSERVATION", 176, 191]]], ["The ratio d N /d S was used as an index to assess positive selection.", [["The ratio d N /d S", "TEST", 0, 18], ["an index", "TEST", 31, 39], ["positive selection", "PROBLEM", 50, 68]]], ["A ratio d N /d S >1 means positive (diversifying) selection, =1 means neutral selection, and <1 means negative (purifying) selection.INTRODUCTIONThe analysis of pairwise identity frequencies showed high percentage of similarities among circulating 2009-2010 pandemic influenza strains (Fig. 1) .", [["influenza", "DISEASE", 267, 276], ["A ratio d N /d S", "TEST", 0, 16], ["neutral selection", "TEST", 70, 87], ["The analysis of pairwise identity frequencies", "TEST", 145, 190], ["high percentage of similarities", "PROBLEM", 198, 229], ["pandemic influenza strains", "PROBLEM", 258, 284], ["high", "OBSERVATION_MODIFIER", 198, 202], ["percentage", "OBSERVATION_MODIFIER", 203, 213]]], ["The average percentage of identity was 99.7% for both HA and NA genes.", [["HA and NA genes", "DNA", 54, 69], ["identity", "TEST", 26, 34], ["average", "OBSERVATION_MODIFIER", 4, 11], ["percentage", "OBSERVATION_MODIFIER", 12, 22]]], ["Thus, in this period of pandemic circulation, both genes did not segregate into different clusters, but on the contrary showed a constant and stable evolution.INTRODUCTIONThe high percentages of nucleotide identity were in accordance with the single clustering of all 2009-2010 strains in the phylogenetic tree of HA and NA genes (Fig. 2) , without temporal or geographical distribution.", [["nucleotide", "CHEMICAL", 195, 205], ["nucleotide", "CHEMICAL", 195, 205], ["HA and NA genes", "DNA", 314, 329], ["pandemic circulation", "PROBLEM", 24, 44], ["nucleotide identity", "PROBLEM", 195, 214], ["HA", "PROBLEM", 314, 316], ["stable", "OBSERVATION_MODIFIER", 142, 148], ["high", "OBSERVATION_MODIFIER", 175, 179], ["percentages", "OBSERVATION_MODIFIER", 180, 191], ["tree", "ANATOMY_MODIFIER", 306, 310], ["without", "UNCERTAINTY", 341, 348], ["temporal", "ANATOMY_MODIFIER", 349, 357], ["geographical distribution", "OBSERVATION", 361, 386]]], ["It is interesting to note that the overall genetic diversity among 2009 H1N1pdm was less than typically observed among seasonal influenza.", [["H1N1pdm", "DISEASE", 72, 79], ["influenza", "DISEASE", 128, 137], ["seasonal influenza", "PROBLEM", 119, 137], ["influenza", "OBSERVATION", 128, 137]]], ["This is in accordance with its short period of time of circulation in humans [13] .", [["humans", "ORGANISM", 70, 76], ["humans", "SPECIES", 70, 76], ["humans", "SPECIES", 70, 76]]], ["The single clustering of 2009 H1N1pdm observed in this report, however, is in contrast with other studies [14] , in which the authors observe differences by using small datasets of sequences.", [["H1N1pdm", "DISEASE", 30, 37], ["other studies", "TEST", 92, 105], ["small datasets of sequences", "TEST", 163, 190]]], ["The single clustering of 2009 H1N1pdm, furthermore, agrees with serological data in which it was observed that antigenically, the new pandemic viruses were all similar [6] , and thus not requiring a new update of the vaccine (strain A/California/07/2009) until now.INTRODUCTIONGiven that 2009 H1N1pdm constituted a homogeneous phylogenetic group, it was hypothesized that the diversity in nucleotide sequences localized (in average) in the 0.3% of differences within each analyzed gene.", [["pandemic", "DISEASE", 134, 142], ["H1N1pdm", "DISEASE", 293, 300], ["nucleotide", "CHEMICAL", 389, 399], ["nucleotide", "CHEMICAL", 389, 399], ["A/California/07/2009", "SPECIES", 233, 253], ["serological data", "TEST", 64, 80], ["the new pandemic viruses", "PROBLEM", 126, 150], ["the vaccine", "TREATMENT", 213, 224], ["the diversity in nucleotide sequences", "PROBLEM", 372, 409]]], ["Taking into account the complete CDS for HA and NA genes, this percentage of differences constitutes approximately four to five nucleotide random variations among circulating strains.INTRODUCTIONCalculation of average d N /d S rates of evolution showed that both HA and NA genes evolved through negative (purifying) selection (Table 1) , with d N /d S values of 0.2762 and 0.1939, respectively.", [["nucleotide", "CHEMICAL", 128, 138], ["NA", "CHEMICAL", 270, 272], ["nucleotide", "CHEMICAL", 128, 138], ["CDS", "DNA", 33, 36], ["HA and NA genes", "DNA", 41, 56], ["HA and NA genes", "DNA", 263, 278], ["HA", "PROBLEM", 41, 43], ["NA genes", "PROBLEM", 48, 56], ["circulating strains", "PROBLEM", 163, 182], ["average d N /d S rates", "TEST", 210, 232], ["both HA and NA genes", "PROBLEM", 258, 278], ["d N /d S values", "TEST", 343, 358]]], ["Even though in general, both genes underwent negative selection, some positions can evolve through positive selection.", [["negative", "OBSERVATION", 45, 53]]], ["For example, an early study showed that two sites involved in receptor binding specificity of HA (220 and 278) were under positive selection, and these sites were not found in swine or seasonal H1N1 viruses [15] .", [["HA", "GENE_OR_GENE_PRODUCT", 94, 96], ["swine", "ORGANISM", 176, 181], ["seasonal H1N1 viruses", "ORGANISM", 185, 206], ["swine", "SPECIES", 176, 181], ["swine", "SPECIES", 176, 181], ["seasonal H1N1 viruses", "SPECIES", 185, 206], ["an early study", "TEST", 13, 27], ["HA", "PROBLEM", 94, 96], ["seasonal H1N1 viruses", "PROBLEM", 185, 206]]], ["Thus, changes in receptor binding sites could lead to alterations in receptor binding specificities.INTRODUCTIONIn other viruses such as SARS-CoV, it was observed that they can develop through positive selection through the Fig. (1) .", [["SARS", "DISEASE", 137, 141], ["SARS-CoV", "ORGANISM", 137, 145], ["SARS-CoV", "SPECIES", 137, 145], ["changes in receptor binding sites", "PROBLEM", 6, 39], ["alterations in receptor binding specificities", "PROBLEM", 54, 99], ["other viruses", "PROBLEM", 115, 128], ["viruses", "OBSERVATION", 121, 128]]], ["Pairwise identity frequencies for (a) Hemagglutinin and (b) Neuraminidase genes, respectively. cross-species transmission in early epidemics, and negative selection during late epidemics [16] .", [["(b) Neuraminidase", "GENE_OR_GENE_PRODUCT", 56, 73], ["Hemagglutinin and (b) Neuraminidase genes", "DNA", 38, 79], ["a) Hemagglutinin and (b) Neuraminidase genes", "TREATMENT", 35, 79]]], ["It is possible that the same mechanism was the driven force of evolution of 2009INTRODUCTIONH1N1pdm, with positive selection at least during crossspecies transmission.", [["2009INTRODUCTIONH1N1pdm", "PROTEIN", 76, 99]]], ["A number of different amino acid mutations that could confer new functionalities to the new virus were reported worldwide, including those related to increased pathogenicity or antiviral resistance ( Table 2) .", [["amino acid", "CHEMICAL", 22, 32], ["amino acid", "CHEMICAL", 22, 32], ["amino acid", "AMINO_ACID", 22, 32], ["different amino acid mutations", "TREATMENT", 12, 42], ["the new virus", "PROBLEM", 84, 97], ["increased pathogenicity", "PROBLEM", 150, 173], ["antiviral resistance", "PROBLEM", 177, 197], ["acid mutations", "OBSERVATION", 28, 42], ["increased", "OBSERVATION_MODIFIER", 150, 159], ["pathogenicity", "OBSERVATION", 160, 173], ["antiviral resistance", "OBSERVATION", 177, 197]]], ["Polymorphism at position 239 in HA has been associated with severe clinical outcomes, especially in immunocompromised patients; in particular, substitution 239G was found to correlate with fatal outcomes in different countries [17, 18] .", [["patients", "ORGANISM", 118, 126], ["patients", "SPECIES", 118, 126], ["Polymorphism at position", "PROBLEM", 0, 24], ["HA", "PROBLEM", 32, 34], ["severe clinical outcomes", "PROBLEM", 60, 84], ["substitution", "TREATMENT", 143, 155], ["severe", "OBSERVATION_MODIFIER", 60, 66]]], ["Furthermore, this mutation can arise de novo from wildtype (D239) virus in the same patient throughout the disease course [19] .", [["wildtype (D239) virus", "ORGANISM", 50, 71], ["patient", "ORGANISM", 84, 91], ["patient", "SPECIES", 84, 91], ["this mutation", "PROBLEM", 13, 26], ["wildtype (D239) virus", "TREATMENT", 50, 71]]], ["Mutation at position 239 can induce alterations in the receptor binding site, and 239G mutants bind a broader range of 2-3-linked sialyl receptors sequences expressed on cells from the lower respiratory tract, which suggested that its presence could be responsible for the exacerbation of disease [20] .", [["cells", "ANATOMY", 170, 175], ["lower respiratory tract", "ANATOMY", 185, 208], ["sialyl", "CHEMICAL", 130, 136], ["2-3-linked sialyl receptors", "SIMPLE_CHEMICAL", 119, 146], ["cells", "CELL", 170, 175], ["lower respiratory", "ORGANISM_SUBDIVISION", 185, 202], ["tract", "ORGANISM_SUBDIVISION", 203, 208], ["receptor binding site", "DNA", 55, 76], ["239G mutants", "PROTEIN", 82, 94], ["2-3-linked sialyl receptors sequences", "DNA", 119, 156], ["Mutation at position", "PROBLEM", 0, 20], ["alterations in the receptor binding site", "PROBLEM", 36, 76], ["sialyl receptors sequences", "TREATMENT", 130, 156], ["the exacerbation of disease", "PROBLEM", 269, 296], ["lower", "ANATOMY_MODIFIER", 185, 190], ["respiratory tract", "ANATOMY", 191, 208]]], ["Mutants 239E target mainly non-ciliated cells.", [["cells", "ANATOMY", 40, 45], ["cells", "CELL", 40, 45], ["239E", "PROTEIN", 8, 12], ["non-ciliated cells", "CELL_TYPE", 27, 45], ["non-ciliated cells", "OBSERVATION", 27, 45]]], ["We found no significant difference between sequences bearing mutations 239G (2.6%) and 239E (5.5%).", [["sequences bearing mutations", "TEST", 43, 70], ["no", "UNCERTAINTY", 9, 11], ["significant", "OBSERVATION_MODIFIER", 12, 23]]], ["The low percentage of global circulation of mutants 239G found in this study is in accordance with its lower potential to transmit to other individuals [21] .INTRODUCTIONPositions 239 and 220 are localized within the HA antigenic site called Ca.", [["Ca", "CHEMICAL", 242, 244], ["Ca", "CHEMICAL", 242, 244], ["mutants 239G", "PROTEIN", 44, 56], ["HA antigenic site", "DNA", 217, 234], ["this study", "TEST", 66, 76], ["INTRODUCTIONPositions", "TEST", 158, 179], ["low", "OBSERVATION_MODIFIER", 4, 7], ["percentage", "OBSERVATION_MODIFIER", 8, 18], ["global", "OBSERVATION_MODIFIER", 22, 28], ["circulation", "OBSERVATION_MODIFIER", 29, 40], ["Ca", "OBSERVATION", 242, 244]]], ["The amino acid S220, though not exposed to the surface, is localized in the receptor binding domain (RBD), and its change could affect the transmissibility and infectivity of H1N1 in humans.", [["surface", "ANATOMY", 47, 54], ["amino acid", "CHEMICAL", 4, 14], ["H1N1", "DISEASE", 175, 179], ["amino acid", "CHEMICAL", 4, 14], ["amino acid", "AMINO_ACID", 4, 14], ["S220", "AMINO_ACID", 15, 19], ["surface", "CELLULAR_COMPONENT", 47, 54], ["humans", "ORGANISM", 183, 189], ["amino acid S220", "PROTEIN", 4, 19], ["receptor binding domain", "PROTEIN", 76, 99], ["RBD", "PROTEIN", 101, 104], ["humans", "SPECIES", 183, 189], ["humans", "SPECIES", 183, 189], ["The amino acid", "TEST", 0, 14], ["H1N1", "PROBLEM", 175, 179], ["surface", "OBSERVATION_MODIFIER", 47, 54]]], ["The fixed mutation, S220T, has been found at high percentage (76.7%) in this study.", [["The fixed mutation", "PROBLEM", 0, 18], ["this study", "TEST", 72, 82], ["fixed", "OBSERVATION_MODIFIER", 4, 9], ["mutation", "OBSERVATION", 10, 18]]], ["To test whether change 220T could contribute to antigenic drift, it would be interesting to compare its antigenic profile against a wildtype isolate (S220).", [["S220", "CANCER", 150, 154], ["antigenic drift", "PROBLEM", 48, 63], ["antigenic drift", "OBSERVATION", 48, 63]]], ["This mutation, probably, has become fixed in all pandemic strains through optimization of viral fitness, rather than immune selection or adaptation to the host.", [["This mutation", "PROBLEM", 0, 13], ["all pandemic strains", "PROBLEM", 45, 65], ["viral fitness", "PROBLEM", 90, 103], ["immune selection", "TREATMENT", 117, 133], ["fixed", "OBSERVATION_MODIFIER", 36, 41], ["viral fitness", "OBSERVATION", 90, 103]]], ["Substitution S101N has been proposed previously as a reversion to the seasonal H1N1 residue 101N and thus possibly an adaptation to the human host, being found in some studies at high frequencies.", [["S101N", "CHEMICAL", 13, 18], ["S101N", "GENE_OR_GENE_PRODUCT", 13, 18], ["human", "ORGANISM", 136, 141], ["S101N", "PROTEIN", 13, 18], ["human", "SPECIES", 136, 141], ["human", "SPECIES", 136, 141], ["Substitution S101N", "TREATMENT", 0, 18], ["the seasonal H1N1 residue", "PROBLEM", 66, 91]]], ["Its global impact, however, is controvertible because it was found in only 0.2% of our sequences.", [["our sequences", "TEST", 83, 96], ["global", "OBSERVATION_MODIFIER", 4, 10], ["impact", "OBSERVATION_MODIFIER", 11, 17]]], ["Substitution E391K, found at 15.6% in our study, has been identified as part of a highly conserved epitope in the 1918 H1N1 virus with a possible role in membrane fusion [22] .", [["membrane", "ANATOMY", 154, 162], ["E391K", "CHEMICAL", 13, 18], ["1918 H1N1 virus", "ORGANISM", 114, 129], ["membrane", "CELLULAR_COMPONENT", 154, 162], ["H1N1 virus", "SPECIES", 119, 129], ["1918 H1N1 virus", "SPECIES", 114, 129], ["our study", "TEST", 38, 47], ["H1N1 virus", "PROBLEM", 119, 129], ["membrane fusion", "TREATMENT", 154, 169], ["membrane fusion", "OBSERVATION", 154, 169]]], ["Another proximal substitution found in other studies, N387H, was found in only 1.7% of our sequences.INTRODUCTIONIn the NA gene, it was showed that mutations V106I and N248D were present in samples at increasing numbers through early pandemic month (April to December 2009) [23] .", [["samples", "ANATOMY", 190, 197], ["V106I", "GENE_OR_GENE_PRODUCT", 158, 163], ["N248D", "GENE_OR_GENE_PRODUCT", 168, 173], ["samples", "CANCER", 190, 197], ["NA gene", "DNA", 120, 127], ["Another proximal substitution", "PROBLEM", 0, 29], ["other studies", "TEST", 39, 52], ["our sequences", "TEST", 87, 100], ["mutations V106I", "PROBLEM", 148, 163], ["proximal", "OBSERVATION_MODIFIER", 8, 16], ["substitution", "OBSERVATION", 17, 29]]], ["Change 106I was present in the 20th century cases of H1N1 (in 1918 [pandemic] , and 1977), as well as 248D (in 1977).", [["H1N1", "DISEASE", 53, 57], ["H1N1", "PROBLEM", 53, 57]]], ["Since residue at position 248 is located at the drug target domain (DTD) region, as residue 275, it could potentially affect the sensitivity to NA inhibitors.", [["NA", "CHEMICAL", 144, 146], ["position 248", "AMINO_ACID", 17, 29], ["residue 275", "AMINO_ACID", 84, 95], ["NA inhibitors", "SIMPLE_CHEMICAL", 144, 157], ["drug target domain", "PROTEIN", 48, 66], ["DTD", "PROTEIN", 68, 71], ["NA inhibitors", "TREATMENT", 144, 157]]], ["Another substitution of possible interest in NA sequences is D199N, which was previously associated with an increase in oseltamivir resistance in both seasonal and H5N1 virus strains [24] .", [["oseltamivir", "CHEMICAL", 120, 131], ["oseltamivir", "CHEMICAL", 120, 131], ["oseltamivir", "SIMPLE_CHEMICAL", 120, 131], ["H5N1 virus", "ORGANISM", 164, 174], ["NA sequences", "DNA", 45, 57], ["H5N1 virus", "SPECIES", 164, 174], ["H5N1 virus", "SPECIES", 164, 174], ["NA sequences", "TEST", 45, 57], ["oseltamivir resistance", "TREATMENT", 120, 142], ["both seasonal and H5N1 virus strains", "PROBLEM", 146, 182], ["increase", "OBSERVATION_MODIFIER", 108, 116], ["oseltamivir resistance", "OBSERVATION", 120, 142]]], ["We found, however, only 4 out of 1273 NA sequences (0.3%) containing this change.", [["NA sequences", "DNA", 38, 50], ["NA sequences", "TEST", 38, 50]]], ["The rare substitution I223R, which was reported in association with resistance to oseltamivir, zanamivir, and peramivir [25] , was also found in only 2 out of 1273 NA sequences (0.2%).", [["oseltamivir", "CHEMICAL", 82, 93], ["zanamivir", "CHEMICAL", 95, 104], ["peramivir", "CHEMICAL", 110, 119], ["oseltamivir", "CHEMICAL", 82, 93], ["zanamivir", "CHEMICAL", 95, 104], ["peramivir", "CHEMICAL", 110, 119], ["oseltamivir", "SIMPLE_CHEMICAL", 82, 93], ["zanamivir", "SIMPLE_CHEMICAL", 95, 104], ["peramivir [25]", "SIMPLE_CHEMICAL", 110, 124], ["oseltamivir", "TREATMENT", 82, 93], ["zanamivir", "TREATMENT", 95, 104], ["peramivir", "TREATMENT", 110, 119], ["NA sequences", "TEST", 164, 176], ["rare", "OBSERVATION_MODIFIER", 4, 8], ["substitution", "OBSERVATION", 9, 21]]], ["Substitution H275Y has been related to oseltamivir resistance, especially in immunocompromised or severely ill persons [26] .", [["H275Y", "CHEMICAL", 13, 18], ["oseltamivir", "CHEMICAL", 39, 50], ["immunocompromised or severely ill", "DISEASE", 77, 110], ["oseltamivir", "CHEMICAL", 39, 50], ["H275Y", "GENE_OR_GENE_PRODUCT", 13, 18], ["oseltamivir", "SIMPLE_CHEMICAL", 39, 50], ["persons", "SPECIES", 111, 118], ["oseltamivir resistance", "PROBLEM", 39, 61], ["oseltamivir resistance", "OBSERVATION", 39, 61]]], ["In our study, we found 2% of sequences containing this change.INTRODUCTIONIn conclusion, the stable evolution of 2009 H1N1pdm offers an opportunity to control its spread and prevent infections.", [["H1N1pdm", "DISEASE", 118, 125], ["infections", "DISEASE", 182, 192], ["our study", "TEST", 3, 12], ["this change", "PROBLEM", 50, 61], ["infections", "PROBLEM", 182, 192], ["stable", "OBSERVATION_MODIFIER", 93, 99], ["infections", "OBSERVATION", 182, 192]]], ["Reports about new mutations, however, will still be important if those changes can confer an enhanced transmissibility or resistance to drugs.", [["new mutations", "PROBLEM", 14, 27]]], ["Furthermore, a continuous surveillance by public health authorities will be critical to monitor the appearance of new influenza variants, especially in animal reservoirs such as swine and birds, in order to prevent the potential animal-human transmission of viruses with pandemic potential.ACKNOWLEDGEMENTThis work (project code: INV11) was supported by the Consejo Nacional de Ciencia y Tecnolog\u00eda (CONACYT) Programa de Apoyo al Desarrollo de la Ciencia, Tecnolog\u00eda e Innovaci\u00f3n en Paraguay (BID 1698/OC-PR).CONFLICT OF INTERESTDeclared none.SUPPLEMENTARY MATERIALSupplementary material is available on the publisher's web site along with the published article.", [["influenza", "DISEASE", 118, 127], ["pandemic", "DISEASE", 271, 279], ["SUPPLEMENTARY", "DISEASE", 543, 556], ["human", "ORGANISM", 236, 241], ["PR", "PROTEIN", 505, 507], ["swine", "SPECIES", 178, 183], ["human", "SPECIES", 236, 241], ["swine", "SPECIES", 178, 183], ["human", "SPECIES", 236, 241], ["new influenza variants", "PROBLEM", 114, 136], ["SUPPLEMENTARY MATERIALSupplementary material", "TREATMENT", 543, 587], ["new", "OBSERVATION_MODIFIER", 114, 117], ["influenza variants", "OBSERVATION", 118, 136]]]], "01c95cf315d321462af88216191620030ea50439": [["IntroductionCanine parvovirus (CPV) like other parvoviruses contains a linear 5 kilobase (kb) single stranded DNA (ss DNA).", [["IntroductionCanine parvovirus", "DISEASE", 0, 29], ["IntroductionCanine parvovirus", "ORGANISM", 0, 29], ["CPV", "ORGANISM", 31, 34], ["DNA", "CELLULAR_COMPONENT", 110, 113], ["DNA", "CELLULAR_COMPONENT", 118, 121], ["linear 5 kilobase (kb) single stranded DNA", "DNA", 71, 113], ["ss DNA", "DNA", 115, 121], ["IntroductionCanine parvovirus", "SPECIES", 0, 29], ["CPV", "SPECIES", 31, 34], ["IntroductionCanine parvovirus (CPV)", "TREATMENT", 0, 35], ["other parvoviruses", "PROBLEM", 41, 59], ["a linear 5 kilobase (kb", "TREATMENT", 69, 92], ["single stranded DNA", "PROBLEM", 94, 113]]], ["The viral genome encodes two nonoverlapping transcription units 130].", [["viral genome", "DNA", 4, 16], ["The viral genome encodes", "TREATMENT", 0, 24], ["viral genome", "OBSERVATION", 4, 16]]], ["When replication occurs, DNA is converted into double stranded replicative forms (RF) .", [["DNA", "CELLULAR_COMPONENT", 25, 28], ["DNA", "PROBLEM", 25, 28]]], ["Restriction sites have been mapped [22] on the genome and the nucleotide sequence has been determined 1 -30, 32] .IntroductionCanine parvovirus, in spite of vaccination, remains an important cause of disease and is often implicated in fatal disease in young puppies.", [["Canine parvovirus", "DISEASE", 126, 143], ["nucleotide", "CHEMICAL", 62, 72], ["genome", "CELLULAR_COMPONENT", 47, 53], ["Canine parvovirus", "ORGANISM", 126, 143], ["puppies", "ORGANISM_SUBDIVISION", 258, 265], ["nucleotide sequence", "DNA", 62, 81], ["Canine parvovirus", "SPECIES", 126, 143], ["Canine parvovirus", "SPECIES", 126, 143], ["Restriction sites", "PROBLEM", 0, 17], ["the nucleotide sequence", "TEST", 58, 81], ["IntroductionCanine parvovirus", "PROBLEM", 114, 143], ["vaccination", "TREATMENT", 157, 168], ["disease", "PROBLEM", 200, 207], ["fatal disease in young puppies", "PROBLEM", 235, 265], ["parvovirus", "OBSERVATION", 133, 143], ["disease", "OBSERVATION", 200, 207], ["fatal", "OBSERVATION_MODIFIER", 235, 240], ["disease", "OBSERVATION", 241, 248]]], ["CPV diagnosis is best achieved with hemagglutination test on faeces or by the detection of histological changes in gut mucosa 1, 7, 24, 28] .", [["faeces", "ANATOMY", 61, 67], ["gut mucosa", "ANATOMY", 115, 125], ["faeces", "ORGANISM_SUBSTANCE", 61, 67], ["gut mucosa", "MULTI-TISSUE_STRUCTURE", 115, 125], ["CPV", "SPECIES", 0, 3], ["hemagglutination test", "TEST", 36, 57], ["histological changes in gut mucosa", "PROBLEM", 91, 125], ["gut mucosa", "ANATOMY", 115, 125]]], ["Alternatively, virus can be isolated in cell culture from various organs, but this method is reported to be much less sensitive because of the high lytic properties of the intestinal content.", [["cell culture", "ANATOMY", 40, 52], ["organs", "ANATOMY", 66, 72], ["intestinal", "ANATOMY", 172, 182], ["cell culture", "CELL", 40, 52], ["organs", "ORGAN", 66, 72], ["intestinal", "ORGAN", 172, 182], ["virus", "PROBLEM", 15, 20], ["cell culture", "TEST", 40, 52], ["this method", "TEST", 78, 89], ["high", "OBSERVATION_MODIFIER", 143, 147], ["lytic", "OBSERVATION", 148, 153], ["intestinal", "ANATOMY", 172, 182], ["content", "OBSERVATION", 183, 190]]], ["So, even if tests are available CPV diagnosis may be difficult in some cases.IntroductionA sensitive CPV diagnosis test based on viral nucleic acid hybridization has been developed.", [["nucleic acid", "CHEMICAL", 135, 147], ["CPV", "SPECIES", 32, 35], ["CPV", "SPECIES", 101, 104], ["tests", "TEST", 12, 17], ["CPV diagnosis", "TEST", 32, 45], ["IntroductionA sensitive CPV diagnosis test", "TEST", 77, 119], ["viral nucleic acid hybridization", "PROBLEM", 129, 161]]], ["The Eco RI-Pst I restriction fragment of the CPV replicative form DNA has been cloned into the multiple cloning site of the pT7T3 18 U plasmid.", [["Eco RI", "GENE_OR_GENE_PRODUCT", 4, 10], ["Pst I", "GENE_OR_GENE_PRODUCT", 11, 16], ["DNA", "CELLULAR_COMPONENT", 66, 69], ["Eco RI-Pst I restriction fragment", "DNA", 4, 37], ["CPV replicative form DNA", "DNA", 45, 69], ["multiple cloning site", "DNA", 95, 116], ["pT7T3 18 U plasmid", "DNA", 124, 142], ["CPV", "SPECIES", 45, 48], ["The Eco RI", "TEST", 0, 10], ["Pst I restriction fragment", "PROBLEM", 11, 37], ["the CPV replicative form DNA", "PROBLEM", 41, 69], ["U plasmid", "TREATMENT", 133, 142], ["fragment", "OBSERVATION_MODIFIER", 29, 37], ["CPV replicative", "OBSERVATION", 45, 60], ["multiple", "OBSERVATION_MODIFIER", 95, 103]]], ["Viral nucleic acid hybridization was realized using radioactively labelled DNA or RNA probes and also a biotin labelled DNA probe.", [["nucleic acid", "CHEMICAL", 6, 18], ["biotin", "CHEMICAL", 104, 110], ["biotin", "CHEMICAL", 104, 110], ["DNA", "CELLULAR_COMPONENT", 75, 78], ["biotin", "SIMPLE_CHEMICAL", 104, 110], ["DNA", "CELLULAR_COMPONENT", 120, 123], ["radioactively labelled DNA", "DNA", 52, 78], ["RNA probes", "RNA", 82, 92], ["biotin labelled DNA probe", "DNA", 104, 129], ["Viral nucleic acid hybridization", "PROBLEM", 0, 32], ["radioactively labelled DNA", "TREATMENT", 52, 78], ["RNA probes", "TREATMENT", 82, 92], ["a biotin labelled DNA probe", "TREATMENT", 102, 129], ["nucleic", "OBSERVATION", 6, 13], ["acid hybridization", "OBSERVATION", 14, 32]]], ["The biotin labelled probe was found to be 10 fold less sensitive.", [["biotin", "CHEMICAL", 4, 10], ["biotin", "CHEMICAL", 4, 10], ["biotin", "SIMPLE_CHEMICAL", 4, 10], ["The biotin labelled probe", "TEST", 0, 25]]], ["The cloned DNA was sequenced and compared to the previously described CPV sequences.", [["DNA", "CELLULAR_COMPONENT", 11, 14], ["CPV", "ORGANISM", 70, 73], ["cloned DNA", "DNA", 4, 14], ["CPV sequences", "DNA", 70, 83], ["CPV", "SPECIES", 70, 73], ["The cloned DNA", "PROBLEM", 0, 14]]], ["Short deletion and point mutations were observed, which emphasised the high variability of C terminal region of the non structural (NS 1) protein gene.Cells and virus strainCells used for virus propagation were freshly seeded Crandell feline kidney cells maintained with Eagles's minimum essential medium supplemented with 10% foetal bovine serum.", [["Cells", "ANATOMY", 151, 156], ["kidney cells", "ANATOMY", 242, 254], ["serum", "ANATOMY", 341, 346], ["C", "CHEMICAL", 91, 92], ["non structural (NS 1", "GENE_OR_GENE_PRODUCT", 116, 136], ["Cells", "CELL", 151, 156], ["virus strainCells", "ORGANISM", 161, 178], ["feline", "ORGANISM", 235, 241], ["kidney cells", "CELL", 242, 254], ["foetal", "ORGANISM", 327, 333], ["bovine", "ORGANISM", 334, 340], ["serum", "ORGANISM_SUBSTANCE", 341, 346], ["C terminal region", "DNA", 91, 108], ["non structural (NS 1) protein gene", "DNA", 116, 150], ["Crandell feline kidney cells", "CELL_LINE", 226, 254], ["feline", "SPECIES", 235, 241], ["bovine", "SPECIES", 334, 340], ["bovine", "SPECIES", 334, 340], ["Short deletion", "PROBLEM", 0, 14], ["point mutations", "PROBLEM", 19, 34], ["Cells", "TEST", 151, 156], ["virus strainCells", "TREATMENT", 161, 178], ["virus propagation", "TREATMENT", 188, 205], ["10% foetal bovine serum", "TREATMENT", 323, 346], ["kidney", "ANATOMY", 242, 248], ["cells", "OBSERVATION", 249, 254]]], ["The CPV strain used in the present study was derived from the Carmichael strain (CPVb) partially sequenced at passage 88 [8, 32] .", [["CPV", "ORGANISM", 4, 7], ["Carmichael strain", "ORGANISM", 62, 79], ["CPVb", "CANCER", 81, 85], ["CPV", "SPECIES", 4, 7], ["The CPV strain", "PROBLEM", 0, 14], ["the present study", "TEST", 23, 40], ["CPV strain", "OBSERVATION", 4, 14]]], ["It was obtained from a commercial vaccine at passage 108 and six additional passages in cell culture were performed before DNA cloning.", [["cell", "ANATOMY", 88, 92], ["cell", "CELL", 88, 92], ["DNA", "CELLULAR_COMPONENT", 123, 126], ["a commercial vaccine", "TREATMENT", 21, 41], ["cell culture", "TEST", 88, 100]]], ["Passage 108 and passage 114 were further designated as CPV-b 108 and CPVb 114.", [["CPVb 114", "CELL", 69, 77], ["CPVb 114", "DNA", 69, 77], ["CPV-b 108", "SPECIES", 55, 64], ["Passage", "TEST", 0, 7], ["CPV", "TEST", 55, 58], ["CPVb", "TEST", 69, 73]]], ["Feline panleukopenia virus (FPLV), porcine parvovirus, mink aleutian disease virus (Gorham strain) and Derzsy goose virus (kindly supplied by V. Marius, Laboratoire Central de Recherches Avicole et Porcine, Ploufragan) were used to test the probe specificity.Clinical specimensOrgans and faeces were collected from diseased puppies with parvovirus-related symptoms.", [["specimensOrgans", "ANATOMY", 268, 283], ["faeces", "ANATOMY", 288, 294], ["Feline panleukopenia", "DISEASE", 0, 20], ["porcine parvovirus", "DISEASE", 35, 53], ["aleutian disease", "DISEASE", 60, 76], ["parvovirus-related symptoms", "DISEASE", 337, 364], ["Feline panleukopenia virus", "ORGANISM", 0, 26], ["FPLV", "ORGANISM", 28, 32], ["porcine parvovirus", "ORGANISM", 35, 53], ["mink aleutian disease virus", "ORGANISM", 55, 82], ["Gorham strain", "ORGANISM", 84, 97], ["Derzsy goose virus", "ORGANISM", 103, 121], ["specimensOrgans", "CANCER", 268, 283], ["faeces", "ORGANISM_SUBSTANCE", 288, 294], ["puppies", "ORGANISM_SUBDIVISION", 324, 331], ["parvovirus", "ORGANISM", 337, 347], ["Feline panleukopenia virus", "SPECIES", 0, 26], ["porcine parvovirus", "SPECIES", 35, 53], ["mink aleutian disease virus", "SPECIES", 55, 82], ["Derzsy goose virus", "SPECIES", 103, 121], ["Porcine", "SPECIES", 198, 205], ["Feline panleukopenia virus", "SPECIES", 0, 26], ["FPLV", "SPECIES", 28, 32], ["porcine parvovirus", "SPECIES", 35, 53], ["mink aleutian disease virus", "SPECIES", 55, 82], ["Derzsy goose virus", "SPECIES", 103, 121], ["Feline panleukopenia virus (FPLV)", "PROBLEM", 0, 33], ["porcine parvovirus", "PROBLEM", 35, 53], ["mink aleutian disease virus", "PROBLEM", 55, 82], ["Gorham strain)", "PROBLEM", 84, 98], ["Derzsy goose virus", "PROBLEM", 103, 121], ["Laboratoire Central de Recherches Avicole et Porcine, Ploufragan)", "TREATMENT", 153, 218], ["Clinical specimensOrgans", "TEST", 259, 283], ["diseased puppies", "PROBLEM", 315, 331], ["parvovirus", "PROBLEM", 337, 347], ["related symptoms", "PROBLEM", 348, 364], ["porcine parvovirus", "OBSERVATION", 35, 53], ["aleutian disease", "OBSERVATION", 60, 76], ["parvovirus", "OBSERVATION", 337, 347]]], ["Organs from 3 kittens with panleukopenia-like symptoms were also collected and included in this study.", [["Organs", "ANATOMY", 0, 6], ["panleukopenia", "DISEASE", 27, 40], ["Organs", "ORGAN", 0, 6], ["kittens", "ORGANISM", 14, 21], ["panleukopenia", "PROBLEM", 27, 40], ["symptoms", "PROBLEM", 46, 54], ["this study", "TEST", 91, 101]]], ["Histological analysis or hemagglutination test on faeces were performed on an aliquot of each sample.", [["sample", "ANATOMY", 94, 100], ["faeces", "ORGANISM_SUBSTANCE", 50, 56], ["Histological analysis", "TEST", 0, 21], ["hemagglutination test on faeces", "TEST", 25, 56]]], ["Samples were then stored at -2 0 \u00b0C before being processed.DNA isolationThe replicative form of CPV-b 114 DNA was extracted by a modified Hirt procedure as described by McMaster et al. [14, 21] .", [["Samples", "ANATOMY", 0, 7], ["DNA", "CELLULAR_COMPONENT", 59, 62], ["CPV", "ORGANISM", 96, 99], ["DNA", "CELLULAR_COMPONENT", 106, 109], ["CPV-b 114 DNA", "DNA", 96, 109], ["CPV-b 114", "SPECIES", 96, 105], ["Samples", "TEST", 0, 7], ["DNA isolation", "TREATMENT", 59, 72], ["CPV", "TEST", 96, 99], ["a modified Hirt procedure", "TREATMENT", 127, 152]]], ["Viral single stranded DNA was either prepared from purified viral particles [26] or directly from infected cell supernatants.", [["cell supernatants", "ANATOMY", 107, 124], ["DNA", "CELLULAR_COMPONENT", 22, 25], ["cell", "CELL", 107, 111], ["Viral single stranded DNA", "DNA", 0, 25], ["Viral single stranded DNA", "PROBLEM", 0, 25], ["purified viral particles", "PROBLEM", 51, 75], ["infected cell supernatants", "PROBLEM", 98, 124], ["stranded DNA", "OBSERVATION", 13, 25], ["infected cell supernatants", "OBSERVATION", 98, 124]]], ["Virus was then treated with 0.2% SDS and proteinase K (50 ~tg/ml) for 2 h at 37 \u00b0C, followed by a phenol chloroform extraction and ethanol precipitation.", [["K", "CHEMICAL", 52, 53], ["phenol chloroform", "CHEMICAL", 98, 115], ["ethanol", "CHEMICAL", 131, 138], ["SDS", "CHEMICAL", 33, 36], ["phenol chloroform", "CHEMICAL", 98, 115], ["ethanol", "CHEMICAL", 131, 138], ["Virus", "ORGANISM", 0, 5], ["proteinase K", "GENE_OR_GENE_PRODUCT", 41, 53], ["phenol", "SIMPLE_CHEMICAL", 98, 104], ["ethanol", "SIMPLE_CHEMICAL", 131, 138], ["Virus", "PROBLEM", 0, 5], ["proteinase K", "TEST", 41, 53], ["a phenol chloroform extraction", "TREATMENT", 96, 126], ["ethanol precipitation", "TREATMENT", 131, 152]]], ["Viral DNA was extracted from organs and faeces of diseased animals as described by Orth [25] .", [["organs", "ANATOMY", 29, 35], ["faeces", "ANATOMY", 40, 46], ["Viral", "ORGANISM", 0, 5], ["DNA", "CELLULAR_COMPONENT", 6, 9], ["organs", "ORGAN", 29, 35], ["faeces", "ORGANISM_SUBDIVISION", 40, 46], ["Viral DNA", "PROBLEM", 0, 9], ["diseased animals", "PROBLEM", 50, 66], ["DNA", "OBSERVATION", 6, 9], ["diseased", "OBSERVATION", 50, 58]]], ["Gut, spleen and faeces were minced and left in lysis buffer (10 mM Tris pH 8, 100 mM NaC1, 50 mM EDTA, SDS 0.5 %) for 1 h at room temperature.", [["Gut", "ANATOMY", 0, 3], ["spleen", "ANATOMY", 5, 11], ["faeces", "ANATOMY", 16, 22], ["NaC1", "CHEMICAL", 85, 89], ["NaC1", "CHEMICAL", 85, 89], ["EDTA", "CHEMICAL", 97, 101], ["Gut", "MULTI-TISSUE_STRUCTURE", 0, 3], ["spleen", "ORGAN", 5, 11], ["faeces", "ORGANISM_SUBSTANCE", 16, 22], ["mM Tris pH", "TEST", 64, 74], ["NaC1", "TEST", 85, 89], ["EDTA", "TEST", 97, 101], ["SDS", "TEST", 103, 106], ["spleen", "ANATOMY", 5, 11], ["faeces", "OBSERVATION", 16, 22], ["left", "ANATOMY_MODIFIER", 39, 43]]], ["Proteinase K was added (1001.tg/ml) and samples were incubated for 2 h at 37 \u00b0C. After clarification, the NaC1 concentration of the supernatant was adjusted to 1 M and mixtures were kept on ice overnight.", [["samples", "ANATOMY", 40, 47], ["supernatant", "ANATOMY", 132, 143], ["K", "CHEMICAL", 11, 12], ["NaC1", "CHEMICAL", 106, 110], ["NaC1", "CHEMICAL", 106, 110], ["Proteinase K", "GENE_OR_GENE_PRODUCT", 0, 12], ["NaC1", "SIMPLE_CHEMICAL", 106, 110], ["NaC1", "PROTEIN", 106, 110], ["Proteinase K", "TEST", 0, 12], ["the NaC1 concentration", "TREATMENT", 102, 124], ["the supernatant", "TREATMENT", 128, 143], ["concentration", "OBSERVATION_MODIFIER", 111, 124]]], ["The supernatant was centrifuged for 1 h at 10,000 rpm and treated with an equal volume of phenol for 1 h at room temperature.", [["supernatant", "ANATOMY", 4, 15], ["phenol", "CHEMICAL", 90, 96], ["phenol", "CHEMICAL", 90, 96], ["phenol", "SIMPLE_CHEMICAL", 90, 96], ["an equal volume of phenol", "TREATMENT", 71, 96]]], ["It was then treated by chloroform and precipitated by ethanol.", [["chloroform", "CHEMICAL", 23, 33], ["ethanol", "CHEMICAL", 54, 61], ["chloroform", "CHEMICAL", 23, 33], ["ethanol", "CHEMICAL", 54, 61], ["chloroform", "SIMPLE_CHEMICAL", 23, 33], ["ethanol", "SIMPLE_CHEMICAL", 54, 61]]], ["The DNA pellet was suspended in TE with RNase (20 lag/ml) for 30 min at 37 \u00b0C, and 50 gg of this treated DNA were spotted onto a nitrocellulose filter after denaturation by sodium hydroxide.DNA isolationPartial DNA cloning and sequencing of a canine parvovirus vaccine strain 259 DNA cloning DNA was digested with EcoRI and PstI (Boehringer) and ligated into the pT7T3 18U plasmid (Pharmacia).", [["sodium hydroxide", "CHEMICAL", 173, 189], ["nitrocellulose", "CHEMICAL", 129, 143], ["sodium hydroxide", "CHEMICAL", 173, 189], ["DNA", "CELLULAR_COMPONENT", 4, 7], ["RNase", "GENE_OR_GENE_PRODUCT", 40, 45], ["DNA", "CELLULAR_COMPONENT", 105, 108], ["sodium hydroxide", "SIMPLE_CHEMICAL", 173, 189], ["DNA", "CELLULAR_COMPONENT", 190, 193], ["DNA", "CELLULAR_COMPONENT", 211, 214], ["canine parvovirus", "ORGANISM", 243, 260], ["DNA", "CELLULAR_COMPONENT", 280, 283], ["DNA", "CELLULAR_COMPONENT", 292, 295], ["EcoRI", "GENE_OR_GENE_PRODUCT", 314, 319], ["PstI", "GENE_OR_GENE_PRODUCT", 324, 328], ["RNase", "PROTEIN", 40, 45], ["canine parvovirus vaccine strain 259 DNA cloning DNA", "DNA", 243, 295], ["EcoRI", "DNA", 314, 319], ["PstI", "DNA", 324, 328], ["pT7T3 18U plasmid", "DNA", 363, 380], ["canine parvovirus vaccine", "SPECIES", 243, 268], ["canine parvovirus vaccine strain 259", "SPECIES", 243, 279], ["The DNA pellet", "TREATMENT", 0, 14], ["a nitrocellulose filter", "TREATMENT", 127, 150], ["sodium hydroxide", "TREATMENT", 173, 189], ["DNA isolationPartial DNA cloning", "TREATMENT", 190, 222], ["a canine parvovirus vaccine strain", "TREATMENT", 241, 275], ["DNA cloning DNA", "PROBLEM", 280, 295], ["EcoRI and PstI (Boehringer)", "TREATMENT", 314, 341], ["plasmid (Pharmacia", "TREATMENT", 373, 391], ["DNA pellet", "OBSERVATION", 4, 14]]], ["Eseherichia coli NM 522 was transformed with the recombined plasmid as described by Hanahan [13] .", [["plasmid", "ANATOMY", 60, 67], ["Eseherichia coli", "ORGANISM", 0, 16], ["recombined plasmid", "DNA", 49, 67], ["Eseherichia coli", "SPECIES", 0, 16], ["Eseherichia coli", "SPECIES", 0, 16], ["Eseherichia coli NM", "PROBLEM", 0, 19], ["the recombined plasmid", "TREATMENT", 45, 67]]], ["Recombinants were identified by in situ hybridization of white colony replicas with a radioactive labelled viral probe obtained from purified virions.", [["virions", "ANATOMY", 142, 149], ["a radioactive labelled viral probe", "TREATMENT", 84, 118]]], ["The hybridization procedure was performed as described by Maniatis etal.", [["The hybridization procedure", "TREATMENT", 0, 27]]], ["Recombinant plasmid DNA was also further analyzed by agar gel electrophoresis after digestion with Eco RI and Pst I or with Hind III.DNA isolationDNA sequencing M 13 dideoxynucleotide sequencing was carried out as already described [5] .", [["plasmid", "ANATOMY", 12, 19], ["DNA", "CELLULAR_COMPONENT", 20, 23], ["Eco RI", "GENE_OR_GENE_PRODUCT", 99, 105], ["Pst I", "GENE_OR_GENE_PRODUCT", 110, 115], ["Hind III", "GENE_OR_GENE_PRODUCT", 124, 132], ["DNA", "CELLULAR_COMPONENT", 133, 136], ["Recombinant plasmid DNA", "DNA", 0, 23], ["Eco RI", "PROTEIN", 99, 105], ["Pst I", "DNA", 110, 115], ["Hind III", "DNA", 124, 132], ["Pst I", "SPECIES", 110, 115], ["Recombinant plasmid DNA", "TREATMENT", 0, 23], ["agar gel electrophoresis", "TEST", 53, 77], ["Eco RI", "TREATMENT", 99, 105], ["Hind III", "TREATMENT", 124, 132], ["DNA isolationDNA sequencing M", "TREATMENT", 133, 162], ["dideoxynucleotide sequencing", "TREATMENT", 166, 194], ["plasmid DNA", "OBSERVATION", 12, 23]]], ["For direct sequencing of denatured plasmid DNA, we used synthetic primers (Biosearch 8600 apparatus) [17] with the Sequenase Kit (USB).", [["plasmid", "ANATOMY", 35, 42], ["DNA", "CELLULAR_COMPONENT", 43, 46], ["denatured plasmid DNA", "DNA", 25, 46], ["denatured plasmid DNA", "PROBLEM", 25, 46], ["synthetic primers", "TREATMENT", 56, 73]]], ["Sequence data were analyzed by using the Microgenie (Beckman, 1988) and PC Gene (Intellegenetics, 1990) computer programs.HybridizationHybridization were carried out overnight at 420C in 50% formamide, 5 x SSC (1 x SSC: 150mM sodium chloride, 15 mM sodium citrate), 1 x Denhardt's solution (Denhardt's solution: 1% polyvinyl pyrrolidone, 1% Ficoll, 1% bovine serum albumin), 0.5% SDS and 10 gg/ml of sonicated calf thymus DNA (Sigma).", [["serum", "ANATOMY", 359, 364], ["thymus", "ANATOMY", 415, 421], ["formamide", "CHEMICAL", 191, 200], ["sodium chloride", "CHEMICAL", 226, 241], ["sodium citrate", "CHEMICAL", 249, 263], ["polyvinyl pyrrolidone", "CHEMICAL", 315, 336], ["formamide", "CHEMICAL", 191, 200], ["sodium chloride", "CHEMICAL", 226, 241], ["sodium citrate", "CHEMICAL", 249, 263], ["polyvinyl pyrrolidone", "CHEMICAL", 315, 336], ["formamide", "SIMPLE_CHEMICAL", 191, 200], ["sodium chloride", "SIMPLE_CHEMICAL", 226, 241], ["sodium citrate", "SIMPLE_CHEMICAL", 249, 263], ["Denhardt", "SIMPLE_CHEMICAL", 270, 278], ["Denhardt", "SIMPLE_CHEMICAL", 291, 299], ["polyvinyl pyrrolidone", "SIMPLE_CHEMICAL", 315, 336], ["Ficoll", "SIMPLE_CHEMICAL", 341, 347], ["bovine", "ORGANISM", 352, 358], ["serum", "ORGANISM_SUBSTANCE", 359, 364], ["albumin", "SIMPLE_CHEMICAL", 365, 372], ["calf", "ORGANISM", 410, 414], ["thymus DNA", "ORGANISM_SUBSTANCE", 415, 425], ["bovine", "SPECIES", 352, 358], ["calf", "SPECIES", 410, 414], ["Sequence data", "TEST", 0, 13], ["HybridizationHybridization", "TREATMENT", 122, 148], ["formamide", "TREATMENT", 191, 200], ["sodium chloride", "TREATMENT", 226, 241], ["15 mM sodium citrate)", "TREATMENT", 243, 264], ["1 x Denhardt's solution", "TREATMENT", 266, 289], ["Denhardt's solution", "TREATMENT", 291, 310], ["1% polyvinyl pyrrolidone", "TREATMENT", 312, 336], ["1% Ficoll", "TREATMENT", 338, 347], ["1% bovine serum albumin", "TREATMENT", 349, 372], ["calf thymus", "ANATOMY", 410, 421]]], ["10% dextran sulfate was also added for biotinylated probe.", [["dextran sulfate", "CHEMICAL", 4, 19], ["sulfate", "CHEMICAL", 12, 19], ["dextran sulfate", "SIMPLE_CHEMICAL", 4, 19], ["10% dextran sulfate", "TREATMENT", 0, 19], ["biotinylated probe", "TREATMENT", 39, 57]]], ["Filters were washed twice in 0.1% SSC, 0.1% SDS for 1 h at 42 \u00b0C. Radioactive filters were exposed to X-ray film (Kodak XAR) at -7 0 \u00b0C for 12 h.", [["Filters", "TREATMENT", 0, 7], ["Radioactive filters", "TREATMENT", 66, 85], ["X-ray film", "TEST", 102, 112], ["Kodak XAR", "TEST", 114, 123]]], ["Biotin labelled probe was detected with streptavidin-alkaline phosphatase conjugate (BRL).", [["Biotin", "CHEMICAL", 0, 6], ["Biotin", "SIMPLE_CHEMICAL", 0, 6], ["streptavidin-alkaline phosphatase conjugate", "SIMPLE_CHEMICAL", 40, 83], ["streptavidin", "PROTEIN", 40, 52], ["alkaline phosphatase conjugate", "PROTEIN", 53, 83], ["Biotin labelled probe", "TEST", 0, 21], ["streptavidin", "TEST", 40, 52]]], ["After 260 M. Remond etal. incubation with a luminescent substrate, PPD (4 methoxy 4-3-phosphate phenyl spiro 1-2-dioxetane 3.2' adamantan), as recommended by the supplier (Photogene-BRL), light emission was detected by autoradiography for 5 rain on X-ray film.CP V-DNA cloning and sequencingEight recombinant clones containing CPV sequences were selected by colony hybridization, Six clones contained an insert of the 2 kb; as expected the other two contained 1.5 kb and 1.3 kb inserts.", [["PPD", "CHEMICAL", 67, 70], ["4 methoxy 4-3-phosphate phenyl spiro 1-2-dioxetane", "CHEMICAL", 72, 122], ["PPD", "CHEMICAL", 67, 70], ["4 methoxy 4-3-phosphate phenyl spiro 1-2-dioxetane", "CHEMICAL", 72, 122], ["PPD", "SIMPLE_CHEMICAL", 67, 70], ["4 methoxy 4-3-phosphate phenyl spiro 1-2-dioxetane 3.2' adamantan", "SIMPLE_CHEMICAL", 72, 137], ["DNA", "CELLULAR_COMPONENT", 265, 268], ["CPV", "ORGANISM", 327, 330], ["CPV sequences", "DNA", 327, 340], ["1.5 kb and 1.3 kb inserts", "DNA", 460, 485], ["CPV", "SPECIES", 327, 330], ["a luminescent substrate, PPD (4 methoxy", "TREATMENT", 42, 81], ["phosphate phenyl spiro", "TREATMENT", 86, 108], ["dioxetane", "TREATMENT", 113, 122], ["light emission", "TEST", 188, 202], ["X-ray film", "TEST", 249, 259], ["CP V", "PROBLEM", 260, 264], ["DNA cloning", "TREATMENT", 265, 276], ["Eight recombinant clones", "TREATMENT", 291, 315], ["CPV sequences", "TEST", 327, 340], ["an insert of the 2 kb", "TREATMENT", 401, 422], ["1.5 kb and 1.3 kb inserts", "TREATMENT", 460, 485]]], ["All clones hybridized with purified viralG[E] G[E] G[E] G[E] C~[R]Partial DNA cloning and sequencing of a canine parvovirus vaccine strainG[E] G[E] G[E] G[E] C~[R]It is noteworthy that sequence analysis of Hind III fragment allowed differentiation between the four CPV strains a See [20] b Reversions c Consistent differences between CPV-b 114 and the other CP\u00a5 strains d Unique difference between CPV-N and CPV Parrish del Deletion nc Non coding nd Not done In brackets, amino acids probe after restriction enzyme digestion and Southern transfer.", [["amino acids", "CHEMICAL", 472, 483], ["amino acids", "CHEMICAL", 472, 483], ["E] G[E] G[E] C", "SIMPLE_CHEMICAL", 48, 62], ["DNA", "CELLULAR_COMPONENT", 74, 77], ["canine parvovirus", "ORGANISM", 106, 123], ["E] G[E] G[E] G[E] C", "SIMPLE_CHEMICAL", 140, 159], ["Hind III", "GENE_OR_GENE_PRODUCT", 206, 214], ["CPV", "ORGANISM", 265, 268], ["CPV", "ORGANISM", 398, 401], ["CPV", "ORGANISM", 408, 411], ["amino acids", "AMINO_ACID", 472, 483], ["Hind III fragment", "DNA", 206, 223], ["canine parvovirus vaccine", "SPECIES", 106, 131], ["canine parvovirus", "SPECIES", 106, 123], ["CPV", "SPECIES", 265, 268], ["CPV-b 114", "SPECIES", 334, 343], ["CPV", "SPECIES", 398, 401], ["CPV", "SPECIES", 408, 411], ["All clones", "TEST", 0, 10], ["viralG", "TEST", 36, 42], ["G", "TEST", 46, 47], ["G", "TEST", 51, 52], ["G", "TEST", 56, 57], ["E", "TEST", 58, 59], ["C", "TEST", 61, 62], ["Partial DNA cloning", "TEST", 66, 85], ["sequencing", "TEST", 90, 100], ["a canine parvovirus vaccine", "TEST", 104, 131], ["strainG", "TEST", 132, 139], ["E", "TEST", 140, 141], ["G", "TEST", 143, 144], ["E", "TEST", 145, 146], ["G", "TEST", 148, 149], ["E", "TEST", 150, 151], ["G", "TEST", 153, 154], ["C", "TEST", 158, 159], ["Hind III fragment", "PROBLEM", 206, 223], ["CPV", "TEST", 334, 337], ["the other CP", "PROBLEM", 348, 360], ["CPV", "TEST", 398, 401], ["CPV Parrish del Deletion nc", "TREATMENT", 408, 435], ["amino acids probe", "TREATMENT", 472, 489], ["restriction enzyme digestion", "PROBLEM", 496, 524]]], ["As predicted from previously sequenced CPV [30] , digestion of the six 2kb recombinant plasmids with Hind Ill yielded the predicted 660 bp fragment (Fig. 1) .", [["plasmids", "ANATOMY", 87, 95], ["Hind", "GENE_OR_GENE_PRODUCT", 101, 105], ["2kb recombinant plasmids", "DNA", 71, 95], ["Hind Ill", "DNA", 101, 109], ["660 bp fragment", "DNA", 132, 147], ["CPV", "SPECIES", 39, 42], ["the six 2kb recombinant plasmids", "TREATMENT", 63, 95], ["Hind Ill", "PROBLEM", 101, 109], ["fragment", "OBSERVATION_MODIFIER", 139, 147]]], ["The sequence of both strands of cloned DNA was determined for three different plasmids after subcloning into the M 13 phage.", [["plasmids", "ANATOMY", 78, 86], ["DNA", "CELLULAR_COMPONENT", 39, 42], ["cloned DNA", "DNA", 32, 42], ["plasmids", "DNA", 78, 86], ["M 13 phage", "CELL_LINE", 113, 123], ["cloned DNA", "PROBLEM", 32, 42], ["three different plasmids", "TREATMENT", 62, 86]]], ["The resulting 1947 nucleotide sequence represented about 37% of the CPV genome.", [["nucleotide", "CHEMICAL", 19, 29], ["nucleotide", "CHEMICAL", 19, 29], ["CPV", "ORGANISM", 68, 71], ["1947 nucleotide sequence", "DNA", 14, 38], ["CPV genome", "DNA", 68, 78], ["CPV", "SPECIES", 68, 71], ["nucleotide sequence", "TEST", 19, 38], ["CPV genome", "OBSERVATION", 68, 78]]], ["As expected, it included parts of two major open reading frames (ORFs) which are in the same phase corresponding to the 3' end of NSI gene and the first 785 nucleotides of the VP 1/VP 2 gene (Fig. 1 ) [30] .G[E] G[E] G[E] G[E] C~[R]Comparison of this sequence with that of three other CPV strains [27, 30, 32] and one FPLV strain [20] revealed point mutations between the different isolates (Table 1) .", [["nucleotides", "CHEMICAL", 157, 168], ["G[E] G[E] G[E] G[E] C", "CHEMICAL", 207, 228], ["3' end", "CELLULAR_COMPONENT", 120, 126], ["VP 1", "GENE_OR_GENE_PRODUCT", 176, 180], ["VP 2", "GENE_OR_GENE_PRODUCT", 181, 185], ["G[E] G[E] G[E] G[E] C", "SIMPLE_CHEMICAL", 207, 228], ["open reading frames", "DNA", 44, 63], ["ORFs", "DNA", 65, 69], ["3' end", "DNA", 120, 126], ["NSI gene", "DNA", 130, 138], ["VP 1/VP 2 gene", "DNA", 176, 190], ["the VP", "TEST", 172, 178], ["G[E] G[E] G[E] G[E] C", "TEST", 207, 228], ["this sequence", "TEST", 246, 259], ["CPV strains", "TEST", 285, 296], ["one FPLV strain", "PROBLEM", 314, 329], ["point mutations", "PROBLEM", 344, 359]]], ["Furthermore, a 15 nucleotides deletion, located in the NS 1 gene, and extending from nucleotide 2040 to nucleotide 2056 of the Norden CPVs strain (CPV-N) sequence [30] was observed in the cloned DNA.", [["nucleotide", "CHEMICAL", 85, 95], ["nucleotide", "CHEMICAL", 104, 114], ["nucleotide", "CHEMICAL", 85, 95], ["nucleotide", "CHEMICAL", 104, 114], ["NS 1", "GENE_OR_GENE_PRODUCT", 55, 59], ["CPV-N)", "GENE_OR_GENE_PRODUCT", 147, 153], ["DNA", "CELLULAR_COMPONENT", 195, 198], ["15 nucleotides deletion", "DNA", 15, 38], ["NS 1 gene", "DNA", 55, 64], ["nucleotide 2056", "DNA", 104, 119], ["Norden CPVs strain (CPV-N) sequence", "DNA", 127, 162], ["cloned DNA", "DNA", 188, 198], ["a 15 nucleotides deletion", "PROBLEM", 13, 38], ["the Norden CPVs strain", "TREATMENT", 123, 145]]], ["To elucidate whether the deletion observed was originally in the vaccine or was generated by cell culture passages in our laboratory, DNA sequence was determined on CPV-b 108 after PCR amplification of a 1000 bp fragment including the deleted region and the two H i n d I I I restriction sites (Fig. 1) .", [["cell", "ANATOMY", 93, 97], ["cell", "CELL", 93, 97], ["DNA", "CELLULAR_COMPONENT", 134, 137], ["DNA sequence", "DNA", 134, 146], ["1000 bp fragment", "DNA", 204, 220], ["H i n d I I I restriction sites", "DNA", 262, 293], ["CPV-b 108", "SPECIES", 165, 174], ["the deletion", "PROBLEM", 21, 33], ["DNA sequence", "TEST", 134, 146], ["CPV", "TEST", 165, 168], ["PCR amplification", "TEST", 181, 198], ["a 1000 bp fragment", "TREATMENT", 202, 220], ["the deleted region", "TREATMENT", 231, 249], ["the two H i n d I I I restriction sites", "TREATMENT", 254, 293]]], ["PCR amplification products were then cleaved with Hind III, cloned in pT7T 318U and sequenced.", [["Hind III", "GENE_OR_GENE_PRODUCT", 50, 58], ["pT7T 318U", "CELL", 70, 79], ["Hind III", "PROTEIN", 50, 58], ["pT7T 318U", "DNA", 70, 79], ["PCR amplification products", "TREATMENT", 0, 26], ["Hind III", "TREATMENT", 50, 58]]], ["The presence of the deletion in the original vaccine was thus confirmed.", [["the deletion", "PROBLEM", 16, 28], ["the original vaccine", "TREATMENT", 32, 52], ["deletion", "OBSERVATION", 20, 28]]], ["Consequently, the modified NS 1 gene did not alter viral replication in cell culture as CPV-b 108 could be multiplied without loss of infectivity.", [["cell", "ANATOMY", 72, 76], ["NS 1", "GENE_OR_GENE_PRODUCT", 27, 31], ["cell", "CELL", 72, 76], ["CPV-b 108", "ORGANISM", 88, 97], ["NS 1 gene", "DNA", 27, 36], ["CPV-b 108", "SPECIES", 88, 97], ["the modified NS 1 gene", "TREATMENT", 14, 36], ["cell culture", "TEST", 72, 84], ["CPV", "TEST", 88, 91], ["loss of infectivity", "PROBLEM", 126, 145], ["infectivity", "OBSERVATION", 134, 145]]], ["Application of 32p labelled DNA or RNA probe for routine diagnosis DNA from various organs of dogs and cats was extracted, spotted onto nitrocellulose and assayed with probes.", [["organs", "ANATOMY", 84, 90], ["nitrocellulose", "CHEMICAL", 136, 150], ["DNA", "CELLULAR_COMPONENT", 28, 31], ["DNA", "CELLULAR_COMPONENT", 67, 70], ["organs", "ORGAN", 84, 90], ["dogs", "ORGANISM", 94, 98], ["cats", "ORGANISM", 103, 107], ["32p labelled DNA", "DNA", 15, 31], ["dogs", "SPECIES", 94, 98], ["cats", "SPECIES", 103, 107], ["32p labelled DNA", "TREATMENT", 15, 31], ["RNA probe", "TREATMENT", 35, 44], ["routine diagnosis DNA", "TEST", 49, 70], ["various organs of dogs", "PROBLEM", 76, 98], ["nitrocellulose", "TREATMENT", 136, 150]]], ["Samples came from animals which died of parvovirus infection as could be deduced from histological examinations, expected for three of them which were classified as \"suspect\"and one gut sample taken from a puppy suffering from distemper which was chosen as a negative control.", [["gut sample", "ANATOMY", 182, 192], ["parvovirus infection", "DISEASE", 40, 60], ["distemper", "DISEASE", 227, 236], ["parvovirus", "ORGANISM", 40, 50], ["gut", "ORGANISM_SUBDIVISION", 182, 185], ["distemper", "ORGANISM", 227, 236], ["parvovirus", "SPECIES", 40, 50], ["Samples", "TEST", 0, 7], ["parvovirus infection", "PROBLEM", 40, 60], ["histological examinations", "TEST", 86, 111], ["distemper", "PROBLEM", 227, 236], ["parvovirus infection", "OBSERVATION", 40, 60]]], ["Out of 15 gut samples from diseased dogs, 13 were positive with DNA or RNA probes.", [["gut samples", "ANATOMY", 10, 21], ["gut samples", "CANCER", 10, 21], ["dogs", "ORGANISM", 36, 40], ["DNA", "CELLULAR_COMPONENT", 64, 67], ["RNA probes", "RNA", 71, 81], ["dogs", "SPECIES", 36, 40], ["diseased dogs", "TEST", 27, 40], ["DNA or RNA probes", "PROBLEM", 64, 81], ["diseased", "OBSERVATION", 27, 35]]], ["Two spleen extracts were tested: only one hybridized.", [["spleen extracts", "ANATOMY", 4, 19], ["spleen extracts", "ORGANISM_SUBSTANCE", 4, 19], ["spleen", "ANATOMY", 4, 10]]], ["Four faecal extracts which showed specific hemagglutinating properties hybridized strongly and the fifth one from a suspect dog was negative.", [["extracts", "ANATOMY", 12, 20], ["faecal extracts", "ORGANISM_SUBSTANCE", 5, 20], ["dog", "ORGANISM", 124, 127], ["dog", "SPECIES", 124, 127], ["dog", "SPECIES", 124, 127], ["Four faecal extracts", "TEST", 0, 20], ["specific hemagglutinating properties hybridized", "PROBLEM", 34, 81], ["a suspect dog", "TEST", 114, 127], ["hemagglutinating properties", "OBSERVATION", 43, 70]]], ["Two samples for panleukopenia diagnosis, one from the gut and the other, a mixture of spleen and kidney, did not hybridize.", [["samples", "ANATOMY", 4, 11], ["gut", "ANATOMY", 54, 57], ["spleen", "ANATOMY", 86, 92], ["kidney", "ANATOMY", 97, 103], ["panleukopenia", "DISEASE", 16, 29], ["gut", "ORGANISM_SUBDIVISION", 54, 57], ["spleen", "ORGAN", 86, 92], ["kidney", "ORGAN", 97, 103], ["Two samples", "TEST", 0, 11], ["panleukopenia diagnosis", "TEST", 16, 39], ["gut", "ANATOMY", 54, 57], ["spleen", "ANATOMY", 86, 92], ["kidney", "ANATOMY", 97, 103]]], ["Results presented with the DNA probe in Fig. 3 were identical with the RNA probe (data not shown).Biotinylated probeTwofold dilutions of purified CPV-DNA were spotted in duplicate and assayed respectively with 32p labelled DNA probe and biotin labelled probe in order to determine the sensitivity of the non-radioactive probe.", [["biotin", "CHEMICAL", 237, 243], ["biotin", "CHEMICAL", 237, 243], ["DNA", "CELLULAR_COMPONENT", 27, 30], ["CPV", "ORGANISM", 146, 149], ["DNA", "CELLULAR_COMPONENT", 150, 153], ["DNA", "CELLULAR_COMPONENT", 223, 226], ["biotin", "SIMPLE_CHEMICAL", 237, 243], ["DNA probe", "DNA", 27, 36], ["RNA probe", "DNA", 71, 80], ["purified CPV-DNA", "DNA", 137, 153], ["32p labelled DNA probe", "DNA", 210, 232], ["CPV", "SPECIES", 146, 149], ["the DNA probe", "TREATMENT", 23, 36], ["the RNA probe", "TEST", 67, 80], ["Biotinylated probeTwofold dilutions", "TREATMENT", 98, 133], ["purified CPV", "TEST", 137, 149], ["32p labelled DNA probe", "TEST", 210, 232], ["biotin labelled probe", "TREATMENT", 237, 258], ["the non-radioactive probe", "TREATMENT", 300, 325], ["non-radioactive probe", "OBSERVATION", 304, 325]]], ["Results are shown inDiscussionThe vaccine strain used in this study was derived from the Carmichael strain (Fig. 5) .", [["The vaccine strain", "TREATMENT", 30, 48], ["this study", "TEST", 57, 67]]], ["It underwent 26 additional passages in cell culture (CPV-b 114) before being cloned and sequenced.", [["cell", "ANATOMY", 39, 43], ["cell culture", "CELL", 39, 51], ["CPV-b 114", "SPECIES", 53, 62], ["cell culture", "TEST", 39, 51], ["CPV", "TEST", 53, 56]]], ["Eco RI and Pst I sites were chosen because they are perfectly conserved among different isolates of CPV and FPLV [20] .DiscussionMoreover, the Eco RI-Pst I fragment covered partially non-structural protein genes which present a strong homology between some members of the family Parvoviridae, allowing its use for diagnosis of related diseases [-37] .DiscussionComparison with the previously published sequence of CPV-b strain [32] showed a high rate of point mutations and one deletion which could have been generated by cell culture passages.DiscussionThis result emphasises the high variability of the CPV genome and sequence comparison was further investigated on three other CPV strains [27, 30, 32] and one FPLV strain [20] .", [["cell", "ANATOMY", 522, 526], ["Eco RI", "GENE_OR_GENE_PRODUCT", 0, 6], ["Pst I", "GENE_OR_GENE_PRODUCT", 11, 16], ["CPV", "ORGANISM", 100, 103], ["Pst I", "GENE_OR_GENE_PRODUCT", 150, 155], ["CPV-b strain", "ORGANISM", 414, 426], ["cell", "CELL", 522, 526], ["Eco RI and Pst I sites", "DNA", 0, 22], ["Eco RI-Pst I fragment", "DNA", 143, 164], ["non-structural protein genes", "DNA", 183, 211], ["CPV genome", "DNA", 605, 615], ["CPV", "SPECIES", 100, 103], ["CPV-b strain", "SPECIES", 414, 426], ["CPV", "SPECIES", 605, 608], ["CPV", "SPECIES", 680, 683], ["Eco RI", "TREATMENT", 0, 6], ["Pst I sites", "TREATMENT", 11, 22], ["the Eco RI", "TEST", 139, 149], ["Pst I fragment", "PROBLEM", 150, 164], ["partially non-structural protein genes", "PROBLEM", 173, 211], ["Parvoviridae", "TREATMENT", 279, 291], ["related diseases", "PROBLEM", 327, 343], ["CPV", "TEST", 414, 417], ["a high rate of point mutations", "PROBLEM", 439, 469], ["one deletion", "PROBLEM", 474, 486], ["cell culture passages", "TEST", 522, 543], ["non-structural protein genes", "OBSERVATION", 183, 211]]], ["22 point mutations were observed between the different CPV sequences and 15 between CPV-b 108 and FPLV (Table 1) .Discussion10 reversions appeared in CPV-b 108 strain; the 10 nucleotidic changes were only observed in CPV-b at passage 88, compared to FPLV and no longer existed in the partially sequenced DNA of CPV-b 108.", [["CPV-b", "GENE_OR_GENE_PRODUCT", 217, 222], ["FPLV", "CANCER", 250, 254], ["DNA", "CELLULAR_COMPONENT", 304, 307], ["CPV-b 108", "ORGANISM", 311, 320], ["CPV sequences", "DNA", 55, 68], ["CPV-b 108", "DNA", 311, 320], ["CPV", "SPECIES", 55, 58], ["CPV-b 108", "SPECIES", 84, 93], ["CPV-b 108 strain", "SPECIES", 150, 166], ["CPV", "SPECIES", 217, 220], ["FPLV", "SPECIES", 250, 254], ["CPV-b 108", "SPECIES", 311, 320], ["22 point mutations", "PROBLEM", 0, 18], ["the different CPV sequences", "TEST", 41, 68], ["CPV", "TEST", 84, 87], ["CPV", "TEST", 150, 153], ["CPV", "TEST", 311, 314], ["no longer", "UNCERTAINTY", 259, 268]]], ["By contrast, no changes were observed in regulatory regions (polyadenylation sites, P38 and P45 promoters, potential splicing sites).DiscussionMost of the coding mutations appeared in the C terminal part of NS 1 ( Table 1 ) and this is in contrast with the results published for Minute virus of mice [2] .", [["P38", "GENE_OR_GENE_PRODUCT", 84, 87], ["P45", "GENE_OR_GENE_PRODUCT", 92, 95], ["NS 1", "GENE_OR_GENE_PRODUCT", 207, 211], ["Table 1", "GENE_OR_GENE_PRODUCT", 214, 221], ["Minute virus", "ORGANISM", 279, 291], ["mice", "ORGANISM", 295, 299], ["regulatory regions", "DNA", 41, 59], ["polyadenylation sites", "DNA", 61, 82], ["P38 and P45 promoters", "DNA", 84, 105], ["potential splicing sites", "DNA", 107, 131], ["NS 1", "DNA", 207, 211], ["mice", "SPECIES", 295, 299], ["mice", "SPECIES", 295, 299], ["polyadenylation sites", "TREATMENT", 61, 82], ["P38 and P45 promoters", "TREATMENT", 84, 105], ["potential splicing sites", "PROBLEM", 107, 131], ["the coding mutations", "PROBLEM", 151, 171], ["splicing sites", "OBSERVATION", 117, 131]]], ["The short deletion observed in CPV-b 108 and CPV-b 114 was also located in this part of the NS 1 gene.", [["CPV-b 108", "GENE_OR_GENE_PRODUCT", 31, 40], ["CPV-b 114", "GENE_OR_GENE_PRODUCT", 45, 54], ["NS 1", "GENE_OR_GENE_PRODUCT", 92, 96], ["CPV-b 114", "DNA", 45, 54], ["NS 1 gene", "DNA", 92, 101], ["CPV-b 108", "SPECIES", 31, 40], ["CPV-b 114", "SPECIES", 45, 54], ["The short deletion", "PROBLEM", 0, 18], ["CPV", "TEST", 31, 34], ["CPV", "TEST", 45, 48], ["short", "OBSERVATION_MODIFIER", 4, 9]]], ["Short deletions often appeared in the noncoding part of the genome but were never described in the parvovirus NS 1 gene.", [["genome", "CELLULAR_COMPONENT", 60, 66], ["parvovirus NS 1", "GENE_OR_GENE_PRODUCT", 99, 114], ["parvovirus NS 1 gene", "DNA", 99, 119], ["parvovirus NS 1", "SPECIES", 99, 114], ["Short deletions", "PROBLEM", 0, 15], ["the parvovirus NS", "TREATMENT", 95, 112]]], ["This deletion, located 45 bases downstream of the P 38 promoter did not 266 M. Remond et al.C P V Parrish PEDWMiMLQPD S Y I E M M A Q P G G E N L L K N T L E I C T L T L A R T K T A F E L I L E K A M u r i n e minute virus (Astel]) P E D W M M M Q P D S Y I E M M A Q P G G E N L L K N T L E I C T L T L A R T K T A F D L I L E K A 348 M u r i n e minute virus (Sah]i) P E D M M M Q P D S Y I E M M A Q P G G E N L L K N T L E I C T L T L A R T K T A F D L I L E KR I F A F H G W N Y V K V C H A I C C V L N R Q G G K R N T V L F H 398 ET S K L T N F S L P D T R T C K I F A F H G W N Y V K V C H A I C C V L N R Q G G K R N T V L F H 447 E T S K L A N F S M A S T R T C R I F A E H G W N Y I K V C H A I C C V L N R Q G G K R N T V L F H 398 K P S M L P T F N I S N T R T C K I F S M H N W N Y I K C C H A I T C V L N R Q G G K R N T I L F H 397 D N T K L T N F D L A N S R T C Q I F R M H G W N W I K V C H A I A C V L N R Q G G K R N T V L F H 123 F E Q V M ---C I K D N K I V K L L L C Q N Y D P L L V G Q H V L K W I D K K C G K K N T L W F Y 327 A P H Y D ---C -Q G N L V F K L L N L Q G Y N P W Q V G H W L V M M L S K K T G K R N S T L F YG P A S T G K S I I A Q A I A Q A V G N V G C Y N A A N V } ~P A S T G K S I I A Q A I A Q A V G N V G C Y N A A N V } G P A S T G K S I I A Q A I A Q A V G N V G C Y N A A N V } S P A S T G K S I I A Q A I A Q A V G N V G C Y N A A N V } G P A S T G K S I I A Q A I A Q A V G N V G C Y N A A N V } ~P A S T G K S I I A Q H I A N L V G N V G C Y N A A N V } S P A S T G K S I I A Q A I A Q A V G N V G C Y N A A N V } ~P P S T G K r N L A M A I A K S V P V Y G M %~W N N E } S P A S T G N P N L A K A I C HFPFNI~PNKNILWWEECIMT 359 alter the reading frame and defined a genetic marker for this vaccine strain.", [["K", "CHEMICAL", 1457, 1458], ["C", "CHEMICAL", 92, 93], ["H Y D ---C -Q", "CHEMICAL", 1056, 1069], ["N N E", "CHEMICAL", 1614, 1619], ["45 bases downstream", "DNA", 23, 42], ["P 38 promoter", "DNA", 50, 63], ["PNKNILWWEECIMT 359", "DNA", 1659, 1677], ["reading frame", "DNA", 1688, 1701], ["This deletion", "PROBLEM", 0, 13], ["T", "TEST", 162, 163], ["K", "TEST", 176, 177], ["K", "TEST", 194, 195], ["A", "TEST", 196, 197], ["u", "TEST", 200, 201], ["virus", "TEST", 217, 222], ["Astel", "TEST", 224, 229], ["G", "TEST", 272, 273], ["K", "TEST", 282, 283], ["T", "TEST", 286, 287], ["C", "TEST", 294, 295], ["T", "TEST", 296, 297], ["T", "TEST", 300, 301], ["K", "TEST", 310, 311], ["A", "TEST", 330, 331], ["u", "TEST", 338, 339], ["virus", "TEST", 355, 360], ["Sah", "TEST", 362, 365], ["G", "TEST", 407, 408], ["K", "TEST", 417, 418], ["T", "TEST", 421, 422], ["C", "TEST", 429, 430], ["T", "TEST", 431, 432], ["T", "TEST", 435, 436], ["A", "TEST", 439, 440], ["K", "TEST", 445, 446], ["D", "TEST", 453, 454], ["KR I", "TEST", 463, 467], ["V", "TEST", 488, 489], ["H", "TEST", 492, 493], ["A", "TEST", 494, 495], ["C", "TEST", 498, 499], ["V", "TEST", 502, 503], ["Q", "TEST", 510, 511], ["G", "TEST", 512, 513], ["G", "TEST", 514, 515], ["K", "TEST", 516, 517], ["V", "TEST", 524, 525], ["H", "TEST", 530, 531], ["ET S", "TEST", 536, 540], ["K", "TEST", 541, 542], ["T", "TEST", 545, 546], ["S", "TEST", 551, 552], ["D", "TEST", 557, 558], ["T", "TEST", 559, 560], ["T", "TEST", 563, 564], ["K", "TEST", 567, 568], ["A", "TEST", 573, 574], ["G", "TEST", 579, 580], ["K", "TEST", 589, 590], ["V", "TEST", 591, 592], ["C", "TEST", 593, 594], ["H", "TEST", 595, 596], ["A", "TEST", 597, 598], ["C", "TEST", 601, 602], ["V", "TEST", 605, 606], ["Q", "TEST", 613, 614], ["G", "TEST", 615, 616], ["G", "TEST", 617, 618], ["K", "TEST", 619, 620], ["V", "TEST", 627, 628], ["H", "TEST", 633, 634], ["T", "TEST", 641, 642], ["S", "TEST", 643, 644], ["K", "TEST", 645, 646], ["A S", "TEST", 659, 662], ["K V", "TEST", 693, 696], ["C", "TEST", 697, 698], ["H", "TEST", 699, 700], ["A", "TEST", 701, 702], ["C", "TEST", 705, 706], ["V", "TEST", 709, 710], ["Q", "TEST", 717, 718], ["G", "TEST", 719, 720], ["G", "TEST", 721, 722], ["K", "TEST", 723, 724], ["T", "TEST", 729, 730], ["V", "TEST", 731, 732], ["H", "TEST", 737, 738], ["K", "TEST", 743, 744], ["S", "TEST", 747, 748], ["M", "TEST", 749, 750], ["S", "TEST", 763, 764], ["T", "TEST", 767, 768], ["T", "TEST", 771, 772], ["C", "TEST", 773, 774], ["K", "TEST", 775, 776], ["S", "TEST", 781, 782], ["M", "TEST", 783, 784], ["H", "TEST", 785, 786], ["W", "TEST", 789, 790], ["Y", "TEST", 793, 794], ["K", "TEST", 797, 798], ["C", "TEST", 799, 800], ["C", "TEST", 801, 802], ["H", "TEST", 803, 804], ["A", "TEST", 805, 806], ["I", "TEST", 807, 808], ["T", "TEST", 809, 810], ["C", "TEST", 811, 812], ["V", "TEST", 813, 814], ["N", "TEST", 817, 818], ["G", "TEST", 823, 824], ["G", "TEST", 825, 826], ["K", "TEST", 827, 828], ["T", "TEST", 833, 834], ["H", "TEST", 841, 842], ["D", "TEST", 847, 848], ["N", "TEST", 849, 850], ["T", "TEST", 851, 852], ["K", "TEST", 853, 854], ["T", "TEST", 857, 858], ["N", "TEST", 859, 860], ["D", "TEST", 863, 864], ["S", "TEST", 871, 872], ["G", "TEST", 891, 892], ["V", "TEST", 903, 904], ["C", "TEST", 905, 906], ["A", "TEST", 909, 910], ["A", "TEST", 913, 914], ["V", "TEST", 917, 918], ["G", "TEST", 927, 928], ["G", "TEST", 929, 930], ["K", "TEST", 931, 932], ["V", "TEST", 939, 940], ["L F H", "TEST", 941, 946], ["E", "TEST", 953, 954], ["V M", "TEST", 957, 960], ["D", "TEST", 970, 971], ["K", "TEST", 974, 975], ["I", "TEST", 976, 977], ["V", "TEST", 978, 979], ["K", "TEST", 980, 981], ["L", "TEST", 982, 983], ["L", "TEST", 984, 985], ["L", "TEST", 986, 987], ["C", "TEST", 988, 989], ["Q", "TEST", 990, 991], ["Y", "TEST", 994, 995], ["D", "TEST", 996, 997], ["P", "TEST", 998, 999], ["L L V G Q H V", "TEST", 1000, 1013], ["K", "TEST", 1016, 1017], ["W I", "TEST", 1018, 1021], ["D", "TEST", 1022, 1023], ["K", "TEST", 1024, 1025], ["K", "TEST", 1026, 1027], ["C", "TEST", 1028, 1029], ["G", "TEST", 1030, 1031], ["K", "TEST", 1032, 1033], ["K", "TEST", 1034, 1035], ["N", "TEST", 1036, 1037], ["T", "TEST", 1038, 1039], ["L W F Y", "TEST", 1040, 1047], ["A", "TEST", 1052, 1053], ["D", "TEST", 1060, 1061], ["---C", "TEST", 1062, 1066], ["G", "TEST", 1070, 1071], ["K", "TEST", 1080, 1081], ["W", "TEST", 1100, 1101], ["Q V G H W L V M M", "TEST", 1102, 1119], ["L S", "TEST", 1120, 1123], ["K", "TEST", 1124, 1125], ["K", "TEST", 1126, 1127], ["T", "TEST", 1128, 1129], ["G", "TEST", 1130, 1131], ["K", "TEST", 1132, 1133], ["R", "TEST", 1134, 1135], ["S", "TEST", 1138, 1139], ["K S", "TEST", 1159, 1162], ["G", "TEST", 1183, 1184], ["A S T G K S", "TEST", 1210, 1221], ["G", "TEST", 1242, 1243], ["K S", "TEST", 1278, 1281], ["G", "TEST", 1302, 1303], ["V", "TEST", 1306, 1307], ["G", "TEST", 1308, 1309], ["C", "TEST", 1310, 1311], ["V", "TEST", 1322, 1323], ["A S", "TEST", 1330, 1333], ["K S", "TEST", 1338, 1341], ["G", "TEST", 1362, 1363], ["V", "TEST", 1366, 1367], ["G", "TEST", 1368, 1369], ["C", "TEST", 1370, 1371], ["V", "TEST", 1382, 1383], ["G", "TEST", 1386, 1387], ["A S", "TEST", 1390, 1393], ["K S", "TEST", 1398, 1401], ["G", "TEST", 1422, 1423], ["V", "TEST", 1426, 1427], ["G", "TEST", 1428, 1429], ["C", "TEST", 1430, 1431], ["A", "TEST", 1436, 1437], ["V", "TEST", 1442, 1443], ["A S", "TEST", 1449, 1452], ["K S", "TEST", 1457, 1460], ["V", "TEST", 1479, 1480], ["G", "TEST", 1481, 1482], ["V", "TEST", 1485, 1486], ["G", "TEST", 1487, 1488], ["C", "TEST", 1489, 1490], ["A", "TEST", 1495, 1496], ["V", "TEST", 1501, 1502], ["} S", "TEST", 1503, 1506], ["A S", "TEST", 1509, 1512], ["K S", "TEST", 1517, 1520], ["G", "TEST", 1541, 1542], ["V", "TEST", 1545, 1546], ["G", "TEST", 1547, 1548], ["C", "TEST", 1549, 1550], ["A", "TEST", 1555, 1556], ["V", "TEST", 1561, 1562], ["}", "TEST", 1563, 1564], ["S", "TEST", 1570, 1571], ["G", "TEST", 1574, 1575], ["K", "TEST", 1576, 1577], ["K S", "TEST", 1594, 1597], ["V", "TEST", 1598, 1599], ["V", "TEST", 1602, 1603], ["Y", "TEST", 1604, 1605], ["G", "TEST", 1606, 1607], ["E", "TEST", 1618, 1619], ["A S", "TEST", 1626, 1629], ["G", "TEST", 1632, 1633], ["P", "TEST", 1636, 1637], ["A K", "TEST", 1642, 1645], ["A I", "TEST", 1646, 1649], ["HFPFNI", "TEST", 1652, 1658], ["PNKNILWWEECIMT", "TEST", 1659, 1673], ["a genetic marker", "TEST", 1714, 1730], ["this vaccine strain", "PROBLEM", 1735, 1754], ["V M", "ANATOMY_MODIFIER", 957, 960], ["---C", "ANATOMY_MODIFIER", 961, 965]]], ["The N terminal part of the NS 1 gene appeared more conserved in the analyzed sequences.", [["N", "CHEMICAL", 4, 5], ["NS 1", "GENE_OR_GENE_PRODUCT", 27, 31], ["N terminal part", "PROTEIN", 4, 19], ["NS 1 gene", "DNA", 27, 36], ["terminal", "OBSERVATION_MODIFIER", 6, 14]]], ["Furthermore, the alignment of NS 1 protein sequences from different parvovirus allowed identification of a highly conserved sequence already de-scribed as a homologous domain of proteins which used purines nucleotides (Fig. 6 ) [1] .", [["purines", "CHEMICAL", 198, 205], ["purines nucleotides", "CHEMICAL", 198, 217], ["NS 1", "GENE_OR_GENE_PRODUCT", 30, 34], ["NS 1 protein sequences", "DNA", 30, 52], ["the alignment of NS 1 protein sequences", "TEST", 13, 52], ["different parvovirus", "PROBLEM", 58, 78], ["a highly conserved sequence", "PROBLEM", 105, 132], ["a homologous domain of proteins", "PROBLEM", 155, 186], ["purines nucleotides", "TREATMENT", 198, 217]]], ["The 2 kb insert has been used as probe on CPV and other parvoviruses available in the laboratory for cross-hybridization in order to measure to what extent the probe could be useful for other parvoviruses.", [["parvoviruses", "ORGANISM", 192, 204], ["2 kb insert", "DNA", 4, 15], ["CPV", "SPECIES", 42, 45], ["The 2 kb insert", "TREATMENT", 0, 15], ["CPV", "TREATMENT", 42, 45], ["other parvoviruses", "PROBLEM", 50, 68], ["cross-hybridization", "TREATMENT", 101, 120], ["other parvoviruses", "PROBLEM", 186, 204]]], ["CPV and FPLV are closely related but the sensitivity of the probe for FPLV is one hundred fold lower as measured by the difference in titer of the infectious particles detected.G Q Q V N Q F K A I C S G Q T I R I D Q K G K G S K Q I E P T P V I M T T N E N I T I V R I G C E E 499 G Q Q V N Q F K A I C S G Q T I R I D Q K G K G S K Q I E P T P V I M T T N E N I T I V R I G C E E 499 G Q Q V N Q F K A I C S G Q T I R I D Q K G K G S K Q I E P T P V I M T T N E N I T V V R I G C E EThe sensitivity of the DNA CPV probe on homologous DNA is comparable to that reported for other viruses: herpesvirus [18] , adenovirus [12] and, rotavirus [10] .", [["CPV", "ORGANISM", 0, 3], ["FPLV", "CANCER", 8, 12], ["DNA", "CELLULAR_COMPONENT", 507, 510], ["DNA", "CELLULAR_COMPONENT", 535, 538], ["herpesvirus [18]", "ORGANISM", 589, 605], ["adenovirus", "ORGANISM", 608, 618], ["DNA CPV probe", "DNA", 507, 520], ["homologous DNA", "DNA", 524, 538], ["CPV", "SPECIES", 0, 3], ["CPV", "SPECIES", 511, 514], ["CPV", "TEST", 0, 3], ["FPLV", "TREATMENT", 8, 12], ["FPLV", "TEST", 70, 74], ["the infectious particles", "PROBLEM", 143, 167], ["D", "TEST", 213, 214], ["K", "TEST", 217, 218], ["G", "TEST", 219, 220], ["K", "TEST", 221, 222], ["G", "TEST", 223, 224], ["K", "TEST", 227, 228], ["V R I G C E E", "TEST", 263, 276], ["V N Q F K", "TEST", 287, 296], ["A I C S", "TEST", 297, 304], ["G", "TEST", 305, 306], ["T I", "TEST", 309, 312], ["I", "TEST", 315, 316], ["D", "TEST", 317, 318], ["Q", "TEST", 319, 320], ["K", "TEST", 321, 322], ["G", "TEST", 323, 324], ["K", "TEST", 325, 326], ["G S", "TEST", 327, 330], ["K", "TEST", 331, 332], ["I", "TEST", 335, 336], ["E", "TEST", 337, 338], ["P", "TEST", 339, 340], ["T", "TEST", 341, 342], ["P", "TEST", 343, 344], ["V I", "TEST", 345, 348], ["M", "TEST", 349, 350], ["T", "TEST", 351, 352], ["T", "TEST", 353, 354], ["N", "TEST", 355, 356], ["E", "TEST", 357, 358], ["I", "TEST", 361, 362], ["T", "TEST", 363, 364], ["I", "TEST", 365, 366], ["V", "TEST", 367, 368], ["I", "TEST", 371, 372], ["G", "TEST", 373, 374], ["C", "TEST", 375, 376], ["E", "TEST", 377, 378], ["E", "TEST", 379, 380], ["G", "TEST", 385, 386], ["V N", "TEST", 391, 394], ["Q F", "TEST", 395, 398], ["K", "TEST", 399, 400], ["A I", "TEST", 401, 404], ["C", "TEST", 405, 406], ["S", "TEST", 407, 408], ["G", "TEST", 409, 410], ["T I", "TEST", 413, 416], ["I", "TEST", 419, 420], ["D", "TEST", 421, 422], ["Q", "TEST", 423, 424], ["K", "TEST", 425, 426], ["G", "TEST", 427, 428], ["K", "TEST", 429, 430], ["G", "TEST", 431, 432], ["S", "TEST", 433, 434], ["K", "TEST", 435, 436], ["Q", "TEST", 437, 438], ["I", "TEST", 439, 440], ["E", "TEST", 441, 442], ["P", "TEST", 443, 444], ["T", "TEST", 445, 446], ["P", "TEST", 447, 448], ["V I", "TEST", 449, 452], ["T", "TEST", 455, 456], ["T", "TEST", 457, 458], ["E", "TEST", 461, 462], ["T", "TEST", 467, 468], ["V", "TEST", 469, 470], ["V", "TEST", 471, 472], ["I G", "TEST", 475, 478], ["C", "TEST", 479, 480], ["E", "TEST", 481, 482], ["EThe", "TEST", 483, 487], ["sensitivity", "TEST", 488, 499], ["the DNA CPV probe", "TEST", 503, 520], ["homologous DNA", "PROBLEM", 524, 538], ["other viruses", "PROBLEM", 574, 587], ["herpesvirus", "PROBLEM", 589, 600], ["adenovirus", "TREATMENT", 608, 618], ["rotavirus", "TREATMENT", 629, 638], ["infectious", "OBSERVATION", 147, 157]]], ["Probes for viruses in the family Parvoviridae have only been reported for the human B 19 parvovirus [4, 34] with higher sensitivity in terms of quantity of target DNA detected but the number of infectious particles detected is of the same order.", [["Probes", "GENE_OR_GENE_PRODUCT", 0, 6], ["Parvoviridae", "GENE_OR_GENE_PRODUCT", 33, 45], ["human B 19 parvovirus", "ORGANISM", 78, 99], ["DNA", "CELLULAR_COMPONENT", 163, 166], ["human", "SPECIES", 78, 83], ["B 19 parvovirus", "SPECIES", 84, 99], ["human B 19 parvovirus", "SPECIES", 78, 99], ["viruses", "PROBLEM", 11, 18], ["Parvoviridae", "TREATMENT", 33, 45], ["higher sensitivity", "PROBLEM", 113, 131], ["target DNA", "PROBLEM", 156, 166], ["infectious particles", "PROBLEM", 194, 214], ["target DNA", "OBSERVATION", 156, 166], ["infectious", "OBSERVATION", 194, 204]]], ["In fact, there is a discrepancy between the number of infectious particles detected (104s CCIDs0) and the quantity of purified DNA spotted and detected: 0.3 ng DNA correspond to 10 s viral particles.", [["DNA", "CELLULAR_COMPONENT", 127, 130], ["DNA", "CELLULAR_COMPONENT", 160, 163], ["a discrepancy", "PROBLEM", 18, 31], ["infectious particles", "PROBLEM", 54, 74], ["purified DNA spotted", "PROBLEM", 118, 138], ["ng DNA", "PROBLEM", 157, 163], ["discrepancy", "OBSERVATION", 20, 31], ["number", "OBSERVATION_MODIFIER", 44, 50], ["infectious", "OBSERVATION_MODIFIER", 54, 64], ["particles", "OBSERVATION_MODIFIER", 65, 74], ["DNA spotted", "OBSERVATION", 127, 138]]], ["This may be explained by the production of defective DNA genomes and/or a greater number of RF copies in the supernatants of infected cell culture which cannot be measured in terms of infectivity.", [["supernatants", "ANATOMY", 109, 121], ["cell culture", "ANATOMY", 134, 146], ["DNA", "CELLULAR_COMPONENT", 53, 56], ["cell culture", "CELL", 134, 146], ["DNA genomes", "DNA", 53, 64], ["RF copies", "DNA", 92, 101], ["infected cell culture", "CELL_LINE", 125, 146], ["defective DNA genomes", "PROBLEM", 43, 64], ["RF copies", "PROBLEM", 92, 101], ["infected cell culture", "TEST", 125, 146], ["infectivity", "PROBLEM", 184, 195], ["may be explained", "UNCERTAINTY", 5, 21], ["defective DNA genomes", "OBSERVATION", 43, 64], ["infected cell culture", "OBSERVATION", 125, 146], ["infectivity", "OBSERVATION", 184, 195]]], ["RNA probes have been developped to overcome any background due to hybridization of the plasmid with bacteria present in stools and gut contents but we did not encounter such difficulty.", [["plasmid", "ANATOMY", 87, 94], ["stools", "ANATOMY", 120, 126], ["gut", "ANATOMY", 131, 134], ["stools", "ORGANISM_SUBDIVISION", 120, 126], ["gut", "ORGANISM_SUBDIVISION", 131, 134], ["plasmid", "DNA", 87, 94], ["RNA probes", "TEST", 0, 10], ["any background", "PROBLEM", 44, 58], ["hybridization of the plasmid", "PROBLEM", 66, 94], ["bacteria", "PROBLEM", 100, 108], ["stools and gut contents", "PROBLEM", 120, 143], ["bacteria", "OBSERVATION", 100, 108], ["stools", "OBSERVATION", 120, 126]]], ["Although RNA probes have been shown to offer up to tenfold more sensitivity than DNA probes, at least on RNA viruses such as enterovirus [15] and on DNA viruses such as B 19 parvovirus [34] , the results obtained in our study did not demonstrate any difference in the sensitivity and specificity of the two types of probes.G Q Q V N Q F K A I C S G Q T I R I D Q K G K G S K Q I E P T P V I M T T N E N I T I V R I G C E E 499 G Q Q V N Q F K A I C S G Q T I R I D Q K G K G S K Q I E P T P V I M T T N E N I T I V R I G C E E 499 G Q Q V N Q F K A I C S G Q T I R I D Q K G K G S K Q I E P T P V I M T T N E N I T V V R I G C E EData presented on clinical samples demonstrated that CPV nucleic acid probes were effective for diagnosis of parvovirus disease even on specimens which had been stored under unappropriate conditions.", [["specimens", "ANATOMY", 766, 775], ["nucleic acid", "CHEMICAL", 687, 699], ["parvovirus disease", "DISEASE", 739, 757], ["DNA", "CELLULAR_COMPONENT", 81, 84], ["enterovirus [15", "ORGANISM", 125, 140], ["DNA", "CELLULAR_COMPONENT", 149, 152], ["B 19 parvovirus", "ORGANISM", 169, 184], ["parvovirus", "ORGANISM", 739, 749], ["DNA probes", "DNA", 81, 91], ["B 19 parvovirus", "SPECIES", 169, 184], ["B 19 parvovirus", "SPECIES", 169, 184], ["CPV", "SPECIES", 683, 686], ["RNA probes", "TEST", 9, 19], ["DNA probes", "TEST", 81, 91], ["RNA viruses", "PROBLEM", 105, 116], ["enterovirus", "PROBLEM", 125, 136], ["DNA viruses", "PROBLEM", 149, 160], ["our study", "TEST", 216, 225], ["the sensitivity", "TEST", 264, 279], ["D", "TEST", 359, 360], ["K", "TEST", 363, 364], ["G", "TEST", 365, 366], ["K", "TEST", 367, 368], ["G", "TEST", 369, 370], ["K", "TEST", 373, 374], ["R I G C E E", "TEST", 411, 422], ["V N Q F K", "TEST", 433, 442], ["A I C S", "TEST", 443, 450], ["G", "TEST", 451, 452], ["T I", "TEST", 455, 458], ["I", "TEST", 461, 462], ["D", "TEST", 463, 464], ["Q", "TEST", 465, 466], ["K", "TEST", 467, 468], ["G", "TEST", 469, 470], ["K", "TEST", 471, 472], ["G", "TEST", 473, 474], ["S", "TEST", 475, 476], ["K", "TEST", 477, 478], ["I", "TEST", 481, 482], ["E", "TEST", 483, 484], ["P", "TEST", 485, 486], ["T", "TEST", 487, 488], ["P", "TEST", 489, 490], ["V", "TEST", 491, 492], ["M", "TEST", 495, 496], ["T", "TEST", 497, 498], ["T", "TEST", 499, 500], ["N", "TEST", 501, 502], ["E", "TEST", 503, 504], ["I", "TEST", 507, 508], ["T", "TEST", 509, 510], ["I", "TEST", 511, 512], ["V", "TEST", 513, 514], ["G", "TEST", 519, 520], ["C", "TEST", 521, 522], ["E", "TEST", 523, 524], ["E", "TEST", 525, 526], ["G", "TEST", 531, 532], ["V", "TEST", 537, 538], ["N", "TEST", 539, 540], ["F", "TEST", 543, 544], ["K", "TEST", 545, 546], ["A I", "TEST", 547, 550], ["C", "TEST", 551, 552], ["S", "TEST", 553, 554], ["G", "TEST", 555, 556], ["T", "TEST", 559, 560], ["I", "TEST", 561, 562], ["R", "TEST", 563, 564], ["I", "TEST", 565, 566], ["D", "TEST", 567, 568], ["Q", "TEST", 569, 570], ["K", "TEST", 571, 572], ["G", "TEST", 573, 574], ["K", "TEST", 575, 576], ["G", "TEST", 577, 578], ["S", "TEST", 579, 580], ["K", "TEST", 581, 582], ["Q", "TEST", 583, 584], ["I", "TEST", 585, 586], ["E", "TEST", 587, 588], ["P", "TEST", 589, 590], ["T", "TEST", 591, 592], ["P", "TEST", 593, 594], ["V", "TEST", 595, 596], ["I", "TEST", 597, 598], ["M", "TEST", 599, 600], ["T", "TEST", 601, 602], ["T", "TEST", 603, 604], ["E", "TEST", 607, 608], ["T", "TEST", 613, 614], ["V V", "TEST", 615, 618], ["I G", "TEST", 621, 624], ["E EData", "TEST", 627, 634], ["clinical samples", "TEST", 648, 664], ["CPV nucleic acid probes", "TEST", 683, 706], ["parvovirus disease", "PROBLEM", 739, 757], ["specimens", "TEST", 766, 775], ["parvovirus disease", "OBSERVATION", 739, 757]]], ["We plan to simplify DNA extraction and to use this probe in combination with PCR to improve the sensitivity of the test.", [["DNA", "CELLULAR_COMPONENT", 20, 23], ["DNA extraction", "TREATMENT", 20, 34], ["this probe", "TREATMENT", 46, 56], ["PCR", "TREATMENT", 77, 80], ["the test", "TEST", 111, 119]]]], "4e99cf738efa156d1ff89926ad93dd674155320e": [["Available online at ScienceDirect www.sciencedirect.com CORRESPONDENCE Pre-and post-operative screening in limited-term elective cancer surgery patients during the COVID-19 pandemic Dear Editor, we read with great interest ''Strategy for the practice of digestive and oncological surgery during the Covid-19 epidemic'' by Tuech et al. [1] .", [["cancer", "ANATOMY", 129, 135], ["digestive", "ANATOMY", 254, 263], ["cancer", "DISEASE", 129, 135], ["cancer", "CANCER", 129, 135], ["patients", "ORGANISM", 144, 152], ["digestive", "ORGAN", 254, 263], ["patients", "SPECIES", 144, 152], ["Pre-and post-operative screening", "TEST", 71, 103], ["limited-term elective cancer surgery", "TREATMENT", 107, 143], ["digestive and oncological surgery", "TREATMENT", 254, 287], ["the Covid", "TEST", 295, 304], ["cancer", "OBSERVATION", 129, 135]]], ["Authors introduced a very comprehensive analysis on elective surgery for digestive cancer during COVID-19 pandemic [1] .", [["digestive cancer", "ANATOMY", 73, 89], ["digestive cancer", "DISEASE", 73, 89], ["digestive cancer", "CANCER", 73, 89], ["elective surgery", "TREATMENT", 52, 68], ["digestive cancer", "PROBLEM", 73, 89], ["COVID", "TEST", 97, 102], ["cancer", "OBSERVATION", 83, 89]]], ["In particular, they highlighted both broad and specific strategies (esophagogastric, hepato-bilio-pancreatic and colorectal surgery) for intraoperative and postoperative care of ''surgical environment'' [1] .", [["esophagogastric", "ANATOMY", 68, 83], ["hepato", "ANATOMY", 85, 91], ["pancreatic", "ANATOMY", 98, 108], ["colorectal", "ANATOMY", 113, 123], ["esophagogastric", "MULTI-TISSUE_STRUCTURE", 68, 83], ["pancreatic", "MULTI-TISSUE_STRUCTURE", 98, 108], ["colorectal", "MULTI-TISSUE_STRUCTURE", 113, 123], ["pancreatic and colorectal surgery", "TREATMENT", 98, 131], ["intraoperative and postoperative care of ''surgical environment", "TREATMENT", 137, 200], ["esophagogastric", "ANATOMY", 68, 83], ["pancreatic", "ANATOMY", 98, 108], ["colorectal", "ANATOMY", 113, 123]]]]}